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Abstract 
 
Streptococcus pneumoniae is a prevalent etiological agent of diseases and a common 
colonizer. During pneumococcal colonization, adaptation and evolution of the 
organism is thought to occur by horizontal gene transfer. Heterogeneity in distribution 
of genes between strains contributes to the global supragenome pool greater than the 
genome of any single strain. Co-colonization of multiple strains, therefore, enables an 
organism to expand its supragenome and hence its adaptive potential.  
 
In this study, the development and design of a single primer-pair PCR- and sequence-
based serotyping (sequetyping) method for surveillance of prevalent serotypes is 
presented. Serotypes including those covered in the latest conjugate vaccines were 
identified at least to the serogroup level. This method thus shows promise in its 
application in routine determination of prevalent serotypes. 
 
The sequetyping method was applied to perform a systematic analysis of 
characterizing pneumococci isolated from healthy Tanzanian children in an attempt to 
determine phenotypic and genotypic diversities (multilocus sequence typing) within 
colonization events. Through this work evidence is presented to support that previous 
studies analyzing serotype diversity alone is an underestimate of true strain diversity 
during co-colonization events.  
 
Determination of competence peptide allelic variants revealed significant differences 
in proportions of pherotypes in two geographical locations. The majority of co-
 4 
colonization events showed multiple pherotypes, indicating that co-colonization 
events may provide an optimal condition for genetic exchanges. 
 
Intra-serotype variations in the capsular gene cpsB were observed and the difference 
of this variation between serotypes. Nucleotide differences were mapped to specific 
domains of the CpsB protein, which may affect the enzymatic activity of this 
regulatory protein. 
 
Sequencing comC from presumptive strains of S. pseudopneumoniae revealed that 
comC6.1 is a common pherotype of this organism. It is proposed that this gene may 
be a potential target for differentiation between S. pseudopneumoniae from S. 
pneumoniae and other streptococcal species. 
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CHAPTER ONE: General Introduction 
 
 
1.1 The Organism 
1.1.1 History 
Streptococcus pneumoniae was first isolated in 1880 when George Miller Sternberg 
inoculated his own saliva into a rabbit and isolated diplococci in its blood, followed 
by Louis Pasteur’s discovery of the same organism few months later in blood after 
inoculating a rabbit with saliva from a child who died of rabies (Watson et al. 1993). 
Pasteur named the organism Microbe septicemique du salive and Sternberg termed the 
organism Micrococcus pasteuri. The organism was later known as Diplococcus 
pneumoniae as isolates from pneumonia appeared as pairs. Its current scientific name, 
Streptococcus pneumoniae, was adopted based on the chain-like growth of 
pneumococci in liquid media (Diebel & Seeley 1974). The history of S. pneumoniae 
is reviewed in numerous publications (Austrian 1981; Watson et al. 1993; Watson & 
Musher 1999; López 2006). 
 
Some of the most profound biological principles and inventions were tested and 
proven using the pneumococcus, such as invention of Gram staining, the concept of 
opsonisation, the discovery of polysaccharides as possible antigenic substances, and 
the discovery of penicillin-binding proteins
11
 (Section 1.3.2). The greatest scientific 
discovery of the 20
th
 century where the pneumococcus was tested was perhaps the 
transforming principle, which proved DNA to be the hereditary material (see below). 
 
1.1.2 The Transformation Principle 
Frederick Griffith identified a live rough (R) and smooth (S) form of pneumococcus, 
where only the latter expressed the virulent polysaccharide capsule (Griffith 1928).  
When a live, avirulent R strain was injected subcutaneously with a heat-killed 
pathogenic S strain into mice, he found that the R strain had “transformed” to express 
the same capsule type as the heat-killed strain. Oswald Avery, Colin MacLeod, and 
Maclyn McCarty (Avery, Macleod & McCarty 1944) continued this work and 
                                                        
11
 PBPs are also expressed in species of Neisseria spp., Escherichia spp., Staphylococcus aureus, 
Pseudomonas aeruginosa, Haemophilus influenzae, etc. (Georgopapadakou 1993). 
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provided evidence concluding that the active transforming material was DNA and not 
protein. This landmark discovery paved way for a plethora a studies understanding 
DNA and genes, and consequently to the rapid advances in molecular biology. 
 
1.1.3 Bacteriology and Microbiology  
1.1.3.1 Growth Conditions and Characteristics of Streptococci 
Members of the Streptococcus genus belong to the Firmicutes phylum, 
Lactobacillales order, and Streptococcaceae family. They are Gram-positive 
facultative anaerobe mainly seen in pairs and chains. They are non-spore forming and 
non-motile. They generate lactic acid from glucose fermentation. They are catalase-
negative, and the addition of exogenous catalase in growth media is required to 
neutralise the toxic effects of hydrogen peroxide synthesized by the organism. Growth 
is optimal on agar supplemented with blood in at 35-37°C when supplied with 5% 
CO2. They undergo either α-, β-, or γ- haemolysis
12
. Members of the Streptococcus 
genus, classified by their groups, are indicated in Table 1.1. 
  
                                                        
12
  α-haemolysis is the reduction of haemoglobin to methemoglobin by hydrogen peroxide, β-
haemolysis is the breakdown of red blood cells, γ-haemolysis is non-haemolytic. The Mitis group 
of Streptococci, including S. pneumoniae, is α-haemolytic. 
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Table 1.1 Members of the Streptococcus genus, divided by genus subgroups 
Group Species 
Mitis Streptococcus pneumoniae 
Streptococcus mitis 
Streptococcus oralis 
Streptococcus pseudopneumoniae 
Streptococcus infantis 
Streptococcus cristatus 
Streptococcus gordonii 
Streptococcus sangiunis 
 
Pyogenic Streptococcus pyogenes 
Streptococcus agalactiae 
Streptococcus dysgalactiae 
Streptococcus iniae 
Streptococcus uberis 
Streptococcus equi 
 
Anginosus Streptococcus anginosus 
Streptococcus intermedius 
Streptococcus constellatus 
 
Salivarius Streptococcus salivarius 
Streptococcus thermophilus 
Streptococcus vestibularius 
 
Bovis Streptococcus bovis 
Streptococcus gallolyticus 
Streptococcus infantarius 
Streptococcus equinus 
 
Mutans Streptococcus mutans 
Streptococcus sobrinus 
Streptococcus downeii 
Streptococcus rattus 
Streptococcus cricetus 
 
 
1.1.3.2 Phenotypic Pneumococcal Identification 
S. pneumoniae is in the Mitis group of streptococci with a cell diameter of 0.5 – 1.25 
μm, and its colonies have a glistening and mucoid appearance on blood agar plates 
(Kawamura et al. 1995). Depression at the centre of colonies (draughtsman’s shape) 
can be seen due to autolysis during stationary phase. Blood agar plates containing 
gentamicin may be used for selection of pneumococci from naso-/oropharyngeal 
samples where other organisms may be in abundance (Sondag et al. 1977; Dilworth et 
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al. 1975; Dudley et al. 2001). Most pneumococci express one of 93 structurally 
variable polysaccharide capsules (Section 1.1.4.1), which are differentiated by 
serological and DNA-based methods (Chapter 3). 
 
The pneumococcus is differentiated from other related (viridans) streptococci by α-
haemolysis, colony morphology, optochin (ethylhydrocuprein hydrochloride) 
sensitivity, bile (deoxycholic acid) solubility, and agglutination with capsular-specific 
antibodies. Pneumococci are generally optochin-sensitive and bile-soluble. However, 
optochin-resistant pneumococci (Pikis et al. 2001; Ing et al. 2012), optochin-sensitive 
viridans streptococci (Borek et al. 1997; Balsalobre et al. 2006) and bile-soluble 
viridans streptococci (Messmer, Black & Facklam 1995) complicate conventional 
classification. This is further aggravated with the recent identification of 
Streptococcus pseudopneumoniae (Chapter 7), a species that is bile-insoluble and 
acapsulate, but is optochin-resistant in presence of increased (5%) CO2 and optochin-
sensitive in ambient air (Arbique et al. 2004). Biochemical tests such as the Rapid 
ID32 Strep System and the API Rapid Strep Test (bioMerieux) have been used for 
species differentiation, however results are inconclusive and additional tests are often 
required to confirm species identity (Freney et al. 1992; Kikuchi et al. 1995; Arbique 
et al. 2004). 
 
1.1.3.3 Genetic Pneumococcal Differentiation from Viridans Streptococci 
S. pneumoniae shares 99% 16S rRNA sequence similarity with S. mitis and S. 
pseudopneumoniae (Kawamura et al. 1995; Arbique et al. 2004), However, recent 
reports suggest that internal species-specific signature sequences of the 16S rRNA 
gene can distinguish these species (El Aila et al. 2010). Autolysin and pneumolysin 
were thought to be exclusive pneumococcal virulence factors. However, viridans 
streptococci with lytA and ply homologues have been detected (Whatmore et al. 2000; 
Neeleman et al. 2004; Jefferies et al. 2007a; Johnston et al. 2010). DNA-based 
differentiation methods include sequence analysis of housekeeping genes (Kawamura 
et al. 1999; Hanage et al. 2005; Kilian et al. 2008). Other genetic targets for species 
differentiation include Spn9802, Spn9828, cpsA, recA, and psaA (Suzuki et al. 2005; 
El Aila et al. 2010; Park et al. 2010; Sistek et al. 2011). Correct identification of 
streptococcal species is important, as misidentification of pneumococci based on 
optochin sensitivity, bile solubility, and non-specific markers potentially leads to an 
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overestimation of prevalence in pneumococcal antibiotic-resistance and hence 
incorrect use of antibiotics and obscures the pathogenic potentials of viridans 
streptococci (Wester et al. 2002; Neeleman et al. 2004).  
 
1.1.4 Cellular Components 
The pneumococcus expresses a polysaccharide capsule on its outermost layer, 
followed by a peptidoglycan cell wall containing teichoic and lipoteichoic acids (TA 
and LTAs). Pneumococcal surface proteins are bound to the cell surface either via the 
choline residues on TAs and LTAs, peptidoglycan chains, or cell membrane (Fig. 
1.1). Other major proteins may be cytoplasmic. Selected cellular structures are 
described below. 
 
 
Fig. 1.1. Pneumococcal virulence and colonization factors. Representatives of 
surface proteins indicated based on their method of association to cell wall (metal-
binding, LPxTG-motif cell wall associated, choline-binding proteins). Additional 
proteins from each of these types are described below, as well as the cytoplasmic 
pneumolysin, and cell-surface carbohydrate moieties (LTA/TA, capsule). Figure from 
Kadioglu et al. (Kadioglu et al. 2008) with permission granted from Nature 
Publishing Group via RightsLink Copyright Clearance Center. 
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1.1.4.1 Polysaccharide Capsule  
The capsule is a high molecular mass complex of oligosaccharide repeating units 
covalently linked to the peptidoglycan layer (Sørensen et al. 1990). The thickness of 
the capsule ranges from 200-400 nm. The capsule has been considered as the sine qua 
non of virulence, and strains with defects in capsular production are either avirulent or 
attenuated in infection and colonization models (Watson & Musher 1990; Bender & 
Yother 2001; Hardy et al. 2001; Magee & Yother 2001; Morona et al. 2004; Nelson 
et al. 2007b). The polysaccharide allows the organism to evade complement-mediated 
opsonophagocytosis and removal from the mucosal surface (Kim et al. 1999; Nelson 
et al. 2007b; Hyams et al. 2010), and strains with higher levels of capsule expression 
are more resistant to phagocytosis (Weinberger et al. 2009). Acapsulate strains rarely 
cause diseases except in cases of conjunctivitis (Section 1.2.1). The presence of the 
capsule may also affect differential expression of immunomodulatory genes by the 
host epithelium during attachment, thereby affecting the host response (Bootsma, 
Egmont-Petersen & Hermans 2007). The regulation of capsule production has been 
shown to be crucial for pneumococcal survival within the host; full encapsulation 
appears to be beneficial for systemic virulence, while reduced expression of capsular 
polysaccharide aids adherence and biofilm formation (Magee & Yother 2001; 
Hammerschmidt et al. 2005; Moscoso, García & López 2006).  
 
The pneumococcus undergoes phase variation between opaque and transparent forms 
varying in opacity and colony morphology, with a frequency ranging from 10
-3
 to 10
-6
 
depending on the strain (Weiser et al. 1994). Opaque variants produce up to 5.6 times 
more CPS than transparent variants, while transparent variants were reported to 
produce up to 3.8 times more teichoic acid (Kim & Weiser 1998). Transparent 
variants are more efficient in stable colonization and clonal expansion in the 
nasopharynx in infant rats, while opaque variants are frequently associated with 
systemic diseases.  
 
1.1.4.1.1 Capsule Biochemistry 
Ninety-three serotypes have thus far been identified (Calix & Nahm 2010). Serotypes 
can be categorized by two systems; the American system ranks serotypes by order of 
discovery, while the more common Danish system groups cross-reactive serotypes 
into serogroups. Under the Danish system, forty-six serotypes/groups are numbered 
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from 1 to 48 (numbers 26 and 30 not used) based on their structural properties and 
immunogenicity. Serotypes can be differentiated and identified by type-specific anti-
capsular rabbit antibodies (Chapter 3). Cross-reactive serotypes are categorized into a 
serogroup and given a letter (e.g. serotypes 6A, 6B, 6C, 6D within serogroup 6). The 
primary structures of the capsule vary between serotypes by the types and number of 
monosaccharides present, the monosaccharide sequences and ring sizes, glycosidic 
linkage configurations, and non-sugar elements (Kamerling 2000). Most serotypes 
have negatively charged capsules due to the presence of acidic sugars, pyruvate 
and/or phosphate groups. Serotypes 7F, 7A, 14, 33F 37 have no net charge. Serotype 
1 has a zwitterionic charge containing positive and negative charges on the backbone 
substituents.  
 
The chemical structure of each capsular serotype may be associated with their ability 
to colonize the host; Weinberger et al. (Weinberger et al. 2009) demonstrated that 
serotypes with fewer number of carbon repeats (e.g. 6A, 6B, 19F, 23F) produce more 
capsules, are more resistant to neutrophil-mediated phagocytosis, and are more 
prevalent in carriage. The authors also predict that analysing capsule structures can 
also assist in predicting which serotypes will be involved in serotype replacement 
(Weinberger et al. 2009). 
 
Capsule enzymes are termed either by the Wzy system (based on homologues of E. 
coli), or by Cps (capsular polysaccharide synthesis) followed by a letter based on the 
order of the enzyme/gene from 5’ to 3’. Table 1.2 shows the proteins of the cps 
operon and the corresponding names in the Wzy nomenclature system based on the 
genetic structure of serotype 19F (Muñoz, Mollerach & López 1997; Bentley et al. 
2006). 
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Table 1.2. Capsular polysaccharide proteins of serotype 19F based on Wzy and 
Cps nomenclatures 
 
Biological Role Wzy Nomenclature Cps Nomenclature 
Regulatory Wzg CpsA 
 Wzh CpsB 
 Wzd CpsC 
 Wze CpsD 
Initial transferase WchA CpsE 
Glycosyl transferase WchO CpsF 
 WchP CpsG 
 WchQ CpsH 
Polymerase Wzy CpsI 
Flippase Wzx CpsJ 
Sugar biosynthesis MnaA CpsK 
 RmlA CpsL 
 RmlC CpsM 
 RmlB CpsN 
 RmlD CpsO 
 
 
1.1.4.1.2 Capsule Assembly 
All serotypes except 3 and 37 follow the Wzy-dependent (Block-Type) capsular 
synthesis pathway (Fig. 1.2), a fashion similar to capsule production in other 
streptococci and staphylococci, as well as lipopolysaccharide O-antigen synthesis in 
Group 1 Escherichia coli (Whitfield & Paiment 2003; Yother 2011). For these 
serotypes, biosynthesis of nucleotide-sugar is initiated in the cytoplasm and is 
transferred to the undecaprenyl phosphate lipid acceptor, catalyzed by initial 
glycosyltransferases (Kolkman, van der Zeijst & Nuijten 1998; Yother 2004; Cartee 
et al. 2005). Extension of the repeating unit is catalyzed by additional membrane-
associated glycosyltransferases (Aanensen et al. 2007). The repeat unit transporter, 
also known as the flippase (Wzx), then translocates the repeat unit from the 
cytoplasmic to the periplasm, followed by the polymerization (by Wzy polymerase) 
of the repeating units to form a lipid-linked polysaccharide capsule. Lastly, 
information regarding the release of the capsule from the lipid layer and attachment to 
cell wall remains elusive, but may involve CpsC (Wzd) and CpsD (Wze) (Morona, 
Morona & Paton 2006).  
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Fig. 1.2. Capsule assembly via Wzy-dependent mechanism. Diagram depicts 
assembly process for serotype 9A. Capsule assembly is as follows: 1) the 
biosynthesis of non-housekeeping sugars by proteins encoded by genes in the 
3’ end of the operon, 2) the transfer of first sugar of the repeat unit onto a 
lipid-linked anchor, mediated by the initial glycosyltransferase (WchA in 
serotype 9A), 3) the addition of subsequent saccharides to form a repeating 
unit mediated by additional glycosyltransferases, 4) the transfer of repeating 
unit from the cytoplasmic space to the periplasm, mediated by flippase Wzx, 
5) the polymerization of repeating units by polymerase Wzy, 6) the attachment 
of capsule polymer to the peptidoglycan via Wzd/Wze complex. Figure from 
Aanensen et al. (Aanensen et al. 2007). Journal of Bacteriology authorizes the 
reuse of journal material including figure shown for academic purposes. 
 
  
 31 
Serotypes 3 and 37 use the synthase-dependent synthesis pathway. For serotype 3, 
synthesis is initiated by linking glucose (Glc) and glucuronic acid (GlcUA) to form 
the capsule polymer by a membrane-associated glucosyltransferase (synthase) 
encoded by cps3S (Llull et al. 1999; Cartee et al. 2000) (Fig. 1.3). The synthesis of 
the serotype 37 glucose homopolymer capsule is mediated by a single β-
glucosyltransferase encoded by the tts gene located outside the cps locus (Llull et al. 
1999). 
 
Fig. 1.3. Biochemical pathway of capsule assembly via synthase-dependent 
mechanism (serotype 3). Pathway illustrated for synthesis of serotype 3 capsule. 
Figure from Denapaite and Hakenbeck (Denapaite & Hakenbeck 2011). PLoS grants 
unrestricted use of contents including figure shown. 
 
 
1.1.4.1.3 Genetic Structure of cps Loci for Wzy-Dependent Pathway Serotypes 
Most genes required for capsule synthesis are within the capsule polysaccharide 
synthesis (cps) operon (Fig. 1.2) (Bentley et al. 2006). The operon is located in the 
same chromosomal region in different serotypes, and ranges from 10 kb (serotype 3) 
to 30 kb (serotype 38). In all serotypes, cps is flanked by dexB in 5’ end and aliA in 
the 3’ end, neither of which participates in capsule synthesis. The 5’ end of the locus, 
encoding cpsA, cpsB, cpsC, and cpsD, are conserved in all serotypes and is involved 
in capsule production regulation and perhaps attachment of capsule to the cell wall. 
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The next gene is cpsE encoding the initial glycosyltransferase, catalyzing the transfer 
of glucose-1-phosphate to the lipid-linked undecaprenyl-phosphate moiety in most 
serotypes that contains glucose in their capsules. The central region of the locus 
encodes specific enzymes required for the transfer of sugar constituents of a repeating 
unit. Within this region, the flippase (wzx) and polymerase (wzy) genes mediate the 
export and polymerization of the repeating units at the extracellular space. The 
diversity of gene sequences and gene content in this region is a reflection the 
enzymes’ specificities for substrates that constitute the capsule. Genes at the 3’ end of 
the locus encodes for proteins required for non-housekeeping capsule sugar 
biosynthesis. Housekeeping sugars present in the capsule are present elsewhere in the 
chromosome (Jiang, Wang & Reeves 2001; Bentley et al. 2006).  
 
The locus contains a functional conserved promoter immediately upstream of cpsA. 
The operon is transcribed as a single unit, with the transcriptional start site eight 
nucleotides after the -10 consensus region of the promoter (Muñoz, Mollerach & 
López 1997; Llull et al. 1998). Transposase sequences are present between cps genes 
and dexB/aliA that may be involved with serotype switching (Section 1.4.4). In 
serotypes 25A, 25F, and 38, the rearrangement of the 5’ genes is associated with the 
presence of transposase genes between cpsCD and cpsAB (Muñoz, Mollerach & 
López 1997; Mavroidi et al. 2007). Cryptic synthesis genes for a particular 
monosaccharide may be present even though the monosaccharide is not expressed on 
the capsule; ORFs coding for dTDP-rhamnose synthesis have been found in serotype 
1, a serotype that does not have rhamnose in its capsule (Muñoz, Mollerach & López 
1997).  
 
Genes with genetic similarity to the pneumococcal capsulation loci have also been 
detected in other capsulated streptococci such as S. agalactiae, S. mitis, S. oralis, S. 
suis, and S. thermophilus (Smith et al. 1999; Cieslewicz et al. 2001; Mavroidi et al. 
2007; Rukke, Hegna & Petersen 2012).  
 
1.1.4.1.4 Genetic Structure of cps Loci for Synthase-Dependent Pathway Serotypes 
Dillard et al. (Dillard & Yother 1994; Dillard, Vandersea & Yother 1995) reported the 
serotype-specific genes cps3D, cps3S, and cps3U (or cap3A, cap3B, and cap3C, 
respectively, according to Arrucubieta et al. (Arrecubieta, López & García 1994; 
 33 
Arrecubieta, Garcia & López 1995) (Fig. 1.4). The cap3ABC genes are not to be 
confused with the regulatory genes cpsABC of other serotypes as cap3A, cap3B and 
cap3C are serotype-specific genes required for capsule polymerization. A promoter is 
located upstream of cpsD. Further upstream are sequences similar to that of regulatory 
genes of other serotypes, however deletions are present in this region, and these 
pseudogenes are not transcribed in serotype 3 (Arrecubieta, Garcia & López 1995). 
The first 3 genes appear to be transcribed as a single unit, but only cpsD and cpsS in 
this operon has been shown to be required for encapsulation (Arrecubieta, Garcia & 
López 1995). Also, cpsD-knockout strains were able to express serotype 3 capsules if 
UDP-Glc and UDP-GlcA were supplied in vitro (Dillard, Vandersea & Yother 1995).  
 
 
Fig. 1.4 Genetic organization of cps in serotype 3. The genes ugd (glucose 
dehydrogenase) wchE (glycosyltransferase), galU (pyrophosphorylase), and pgm 
(phosphoglucomutase) are cpsD, cpsS, cpsU, and cpsM respectively by the cps 
nomenclature. All upstream genes except for wzd contain mutations (i.e. pseudogene) 
and are not expressed. Transposase genes indicated as tnp. Figure from Bentley et al. 
(Bentley et al. 2006). PLoS grants unrestricted use of contents including figure above 
for academic purposes. 
  
The cps of serotype 37 is not required for capsule production. Instead, capsule 
synthesis in this serotype requires a single tts gene located outside the cps locus (Llull 
et al. 1999). Between dexB and aliA in serotype 37 is a cryptic cps33f locus, 
containing multiple mutations inactivating cps37B, cps37E, cps37N, and cps37O.  
 
1.1.4.2 Cell Wall 
The pneumococcal cell wall, found below the capsule polysaccharide, is a complex 
cellular layer containing a dense network of peptidoglycan (murein), teichoic acid 
(TA), and lipoteichoic acid (LTA) (Fig. 1.5). TA and LTA are decorated with 
phosphrylocholine (PCho) residues acting as anchoring sites for choline-binding 
proteins (CBP) (see below).  
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Fig. 1.5. Schematic diagram of pneumococcal cell wall components. Figure from 
Di Guilmi and Dessen (Di Guilmi & Dessen 2002) with permission granted from 
Nature Publishing Group via RightsLink Copyright Clearance Center. 
 
 
1.1.4.3 Peptidoglycan 
Peptidoglycan, sometimes referred to murein, is a multi-layered network of glycan 
strands interconnected by short peptide chains. A typical glycan strand consists of 
alternating N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) 
residues. Up to 80% of the GlcNAc may be deacetylated by a deacetylase (PdgA), 
forming glucosamine. PdgA has been shown to play a role in resistance to lysozyme-
mediated degradation of the cell wall by the host (Vollmer & Tomasz 2000). 
 
Peptidoglycan in S. pneumoniae has cross-linked short peptide chains connected via 
the MurNAc residue and the terminal alanine residues of the stem peptide. There are 
18 different stem muropeptide chains found highly conserved in pneumococcus of 
different serotypes, geographical origin, and isolation date (Severin & Tomasz 1996). 
Differences in proportions of these stem peptide compositions between strains may be 
due to concentrations of various amino acids in growth medium, or amino acid 
substitutions in PBP active sites associated with nonsusceptibility to penicillin 
(Section 1.3.2). 
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1.1.4.4 Teichoic Acid (TA) and Lipoteichoic Acid (LTA) 
TA, also known as C-polysaccharide, is covalently linked to N-acetylmuramyl 
residues of peptidoglycan via a phosphodiester bond. LTA, also known as F-antigen, 
is uniformly distributed around the cell wall, anchored to the plasma membrane by the 
fatty acid component of the molecule (Fischer 2000). TA and LTA have identical 
repeating units, are complex in chemical structure, and contain choline acting as 
anchor for a wide array of pneumococcal surface proteins (see below). TA and LTA 
are common pneumococcal antigens, with positive reaction to anti-C-polysaccharide 
antiserum in 90 different capsular serotypes (Sørensen & Henrichsen 1987; 
Henrichsen 1995). A schematic representation of LTA and TA is provided in Fig. 1.6.  
 
 
 
 
Fig 1.6. Structures of TA and LTA. LTA and TA (indicated here as WTA for wall 
teichoic acid) have identical repeating units. The repeating units (RU) are identical in 
both TA and LTA. In TA, the RU is linked to the peptidoglycan via the MurNAc, 
while in LTA the RU is linked to a fatty acid component (lipid anchor). Figure from 
Denapaite et al. (Denapaite et al. 2012). 
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1.1.4.5 Phosphorylcholine 
The pneumococcal cell wall contains phosphorylcholine (PCho) covalently linked to 
TAs and LTAs. PCho was first found to be associated with pneumococcal cell wall in 
1967 (Tomasz 1967), and since then it had been discovered in other bacterial species 
including nasopharyngeal colonizers S. mitis, S. oralis, Neisseria meningitidis, and 
Haemophilus influenzae (Weiser et al. 1998a; Weiser et al. 1998b). PCho promotes 
colonization and invasion by anchoring an array of choline-binding proteins (CBPs), 
many of which are virulence factors and adhesins crucial for pathogenicity and 
attachment (Reviewed in Jedrzejas 2004). PCho also directly binds to the platelet-
activating factor receptor (PAFr) of stimulated host epithelial cells, playing a role in 
pneumococcal transcytosis through host cells during disease progression (Cundell et 
al. 1995; Ring, Weiser & Tuomanen 1998). 
 
Mutants lacking choline uptake mechanisms showed marked reduction in adherence 
to nasopharyngeal epithelial cells, as well as deficiencies in colonization and invasion 
in mice (Tomasz 1968; Kharat & Tomasz 2006). In addition, mutants growing in 
choline-free medium appear as long chains and are resistant to autolysis, bile-
insoluble, and genetically incompetent.  
 
1.1.5 Pneumococcal Proteins 
S. pneumoniae expresses numerous proteins crucial to colonization and virulence. 
Some, if not all, of these proteins are crucial in the pathogenicity of the organism, and 
are hence considered as virulence factors. Such virulence factors are reviewed in 
several reports (Gillespie & Balakrishnan 2000; Jedrzejas 2001; Jedrzejas 2004; 
Kadioglu et al. 2008; Mitchell & Mitchell 2010). The proteins have been organized in 
this section based on localization with respect to the cell: 1) cytoplasmic proteins, 2) 
choline-binding proteins (CBPs) associate with TA/LTA phosphorylcholine 
residues via non-covalent interactions, 3) peptidoglycan-associated proteins anchor 
to peptidoglycan via its LPxTG motif, and 4) lipoproteins. In addition, some 
pneumococcal proteins are anchored to the cell surface via yet unknown mechanisms. 
 
1.1.5.1 Cytoplasmic Protein - Pneumolysin 
The 471-amino acid, 52.8-kDa thiol-activated toxin binds to the host cholesterol 
receptor and subsequently forms an oligomeric pore (Morgan et al. 1994; Rossjohn et 
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al. 1998). Pneumolysin has been shown to damage the blood-brain barrier disrupting 
the integrity of microendothelial cells (Zysk et al. 2001). Pneumolysin activates 
phospholipase A2 in endothelial cells, releasing cytolytic free fatty acids and 
lysophosphatides to induce inflammation (Rubins et al. 1994). Pneumolysin-deficient 
strains are attenuated in animal models of infection (Berry & Paton 2000; Wellmer et 
al. 2002), but animal studies provide conflicting observations regarding 
pneumolysin’s role in colonization (Rubins et al. 1998; Kadioglu et al. 2002; van 
Rossum, Lysenko & Weiser 2005). Expression of pneumolysin may promote bacterial 
clearance from the nasopharynx in mice (van Rossum, Lysenko & Weiser 2005), and 
pneumolysin-deficient strains had higher bacterial count and longer duration of 
carriage in the nasopharynx (Rubins et al. 1998). However, one other work showed 
that pneumolysin expression was associated with higher bacterial count in the 
nasopharynx of mice (Kadioglu et al. 2002), however these studies employed strains 
of different serotypes and genetic backgrounds. 
 
At high concentrations (1 μg/mL), pneumolysin is capable of activating the classical 
complement pathway, depleting complement components during infection (Paton, 
Rowan-Kelly & Ferrante 1984; Mitchell et al. 1991; Alcantara, Preheim & Gentry-
Nielsen 2001). In nano-molar concentrations, purified pneumolysin impedes the 
respiratory burst of polymorphonuclear leukocytes (PMNLs), reducing antimicrobial 
activity (Paton & Ferrante 1983). Additionally, pneumolysin significantly stimulates 
the production of cytokines and nitric oxide in monocytes (Houldsworth, Andrew & 
Mitchell 1994)) and macrophages (Braun et al. 1999) in vitro, respectively. Allelic 
variants with differing hemolytic activity have been detected, and those with lowered 
activity were associated with strains causing IPD (ST306 of serotype 1 and ST53 of 
serotype 8) (Lock et al. 1996; Kirkham et al. 2006; Jefferies et al. 2007b; Jefferies et 
al. 2010b; Harvey et al. 2011). 
  
Initial data supported the hypothesis that the release of pneumolysin is dependent on 
autolysin (Berry et al. 1989). However, the release of pneumolysin with inactivated 
autolysin and lytA-deletion suggests that additional, autolysin-independent 
mechanisms potentiate pneumolysin release (Balachandran et al. 2001).  
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1.1.5.2 Choline-Binding Proteins 
1.1.5.2.1 Autolysins (LytA, LytB, LytC) 
The autolysins form a group of murein hydrolases, cleaving covalent bonds of the 
peptidoglycan (Table 1.3). Pneumococcal autolysis is mediated by these proteins 
during stationary phase and upon deoxycholate (bile) and β-lactam exposure (López, 
Ronda & Garcia 1990). Autolysis is also fundamental to cell division (García et al. 
1999b). The pneumococcus has three autolysins, LytA (N-acetyl-muramyl-L-alanine 
amidase), LytB (glucosaminidase) and LytC (lysozyme), with LytA being the best 
characterized. All three autolysins have been shown to be important for biofilm 
formation, as mutants lacking these genes showed up to 50% reduction in biofilm 
formation and reduced colonization in a rat model (Moscoso, García & López 2006). 
LytA and LytC are two of the three main lytic enzymes shown to be important in 
competence-mediated fratricide, along with CbpD (Guiral et al. 2005; Eldholm et al. 
2009). While insertion-inactivation of lytA alone had little effect in release of 
cytoplasmic enzymes following competence activation, double and triple mutants 
with mutations in lytC and cbpD had minimal if any competence-mediated cell lysis. 
 
Table 1.3. Biological role, size, and amino acid length of pneumococcal autolysin 
proteins 
 
 LytA LytB LytC 
Biological Role Acetylmuramidase Glucosaminidase Lysozyme 
Size (kDa) 36.5 76.4 58.7 
Length (aa
a
) 318 658 501 
 
a 
aa: amino acid 
 
 
1.1.5.2.1.1 LytA 
LytA cleaves the N-acetylmuramyl-L-alanine bond linking the cell wall peptidoglycan 
and the peptide chain.  Autolysin is first synthesized as the inactive form and is 
activated during stationary phase or by penicillin, and its enzymatic activity is 
dependent on the presence of choline (Tomasz & Westphal 1971). Mutants with 
disrupted lytA are resistant to lysis in stationary phase, or when exposed to 
deoxycholate or penicillin (Tomasz, Moreillon & Pozzi 1988). Autolysin contributes 
to pneumococcal virulence by facilitating the release of pneumolysin and cell wall 
components that induce pro-inflammatory host responses (Tuomanen et al. 1985; 
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Berry et al. 1989; Martner et al. 2008). Autolysin-negative mutants have been 
associated with reduced virulence in numerous animal models. Extended host survival 
time, rapid bacterial clearance, and increased LD50 were observed in infection models 
using mutated strains (Berry et al. 1989; Berry, Paton & Hansman 1992; Canvin et al. 
1995; Berry & Paton 2000). 
 
1.1.5.2.1.2 LytB and LytC 
For LytB and LytC, the choline-binding and the catalytic domains are in the N- and 
C-termini, respectively, which is opposite to other CBPs (García et al. 1999a). LytB is 
an endo-β-N-acetylglucosaminidase responsible for cell wall hydrolysis during cell 
separation (De Las Rivas et al. 2002). Pneumococci with non-functional LytB or 
LytC result in reduced ability to colonize the nasopharynx of infant rats (Gosink et al. 
2000). 
 
1.1.5.2.2 Phosphorylcholine Esterase (Pce) 
Pce (also known as CbpE) is a 69.4 kDa protein with 602 amino acid residues that 
removes PCho from TAs and LTAs (Vollmer & Tomasz 2001). Insertion duplication 
mutagenesis of pce decreased pneumococcal adherence to Detroit nasopharyngeal cell 
line in vitro and reduction in colonization in an infant rat model (Gosink et al. 2000). 
The activity of Pce in regulating PCho abundance in TA and LTA may modulate 
ability for pneumococci to adhere to host cells, as well as the ability for C-reactive 
protein (which binds to pneumococcal PCho) to recognize presence of the organism. 
 
1.1.5.2.3 Pneumococcal Surface Protein A (PspA) 
The 84-kDa protein impedes complement activation by affecting C3b deposition onto 
the cell surface (Tu et al. 1999). In carriage, PspA interacts with lactoferrin, a host 
protein thought to exert its bactericidal property by binding to iron, thereby limiting 
its concentration for bacterial acquisition (Hammerschmidt et al. 1999). Shaper et al. 
(Shaper et al. 2004) has shown that PspA on the surface as well as extracellular PspA 
can prevent apolactoferrin (lactoferrin without iron)-mediated bacterial killing, and 
hypothesized that PspA may block the active site of lactoferrin to prevent the host 
uptake of iron by the host glycoprotein. 
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PspA contains an N-terminal signal sequence followed by a region coding for a 
mature protein with four domains: a positively-charged α-helical N-terminal domain 
to stabilize the capsular negative charge, a proline-rich domain, a choline-binding 
domain (CBD), and a hydrophobic C-terminal tail (Yother & Briles 1992). Sequence 
diversity greater than 20% in pspA is found between strains, especially in the α-helical 
region, possibly as a result of horizontal gene transfer (HGT) (Hollingshead, Becker 
& Briles 2000). These variations are grouped into three allelic families and six sub-
clades (Family 1: clades 1 and 2, family 2: clades 3, 4, and 5, family 3: clade 6). 
However, homologous and recombinant forms of PspA from multiple strains are able 
to provide cross-protection in mice against pneumococcal infections by different 
PspA families and capsular serotypes (Briles et al. 2000b; Moreno et al. 2010). 
Sequence variation in the lactoferrin-binding α-helical region between pneumococci 
is associated with differences in lactoferrin binding (Håkansson et al. 2001; Ren et al. 
2003). 
 
1.1.5.2.4 Pneumococcal Surface Protein C (PspC) 
PspC is a multifunctional protein known as CbpA (choline-binding protein A), and 
SpsA (poly Ig receptor-binding protein). PspC contains four domains: the signal 
leader sequence, N-terminal variable region, a proline-rich sequence, and a C-terminal 
choline-binding region (CBR). PspC shares homology to PspA in only the proline-
rich and C-terminal regions (Hammerschmidt 2007). Similar to pspA, pspC exhibits 
extensive sequence diversity between strains, and while most strains contain CBD at 
its C-terminal, some encode an LPXTG cell wall-binding motif mediating cell 
anchorage (Iannelli, Oggioni & Pozzi 2002).  
 
PspC is also termed SpsA as it binds to the human secretory IgA via its N-terminal 
region for transcytosis and invasion across the epithelium (Hammerschmidt et al. 
1997; Zhang et al. 2000). Another name for PspC is CbpA (choline-binding protein 
A), binding to the laminin receptor in the activated vascular endothelium of the blood-
brain barrier to invade into the meninges (Orihuela et al. 2009). Additionally, PspC 
also binds to factor H preventing evasion from the alternative complement pathway 
(Dave et al. 2001). Antiserum of rabbits immunized with PspC cross-react with PspC 
as well as PspA in vitro and in a mouse challenge model (Brooks-Walter, Briles & 
Hollingshead 1999). The authors hypothesized that cross-reactivity was mediated by 
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the presence of the proline-rich regions in both proteins (Brooks-Walter, Briles & 
Hollingshead 1999).  
 
1.1.5.2.5 Choline-Binding Protein D (CbpD) 
CbpD is a 50-kDa murein hydrolase containing an N-terminal CHAP domain, two 
SH3 domains, and a C-terminal CBD. Mutants with defective CbpD showed reduced 
colonization and lung infection in rats and mice, respectively (Gosink et al. 2000; 
Hava 2002). The gene cbpD was identified as a late-competence-induced gene 
(Peterson et al. 2004), and CbpD subsequently was found to be involved in 
competence-mediated fratricide (Chapter 5). CbpD is thought to activate the lytic 
effects of autolysins LytA and LytC to exert their effects on fratricide (Eldholm et al. 
2009). The SH3 domains bind to the peptidoglycan, while intriguingly its CBD 
selectively binds to the poles of target cells; these two interactions were demonstrated 
to be required for fratricide (Eldholm et al. 2010). CbpD, possibly through its CHAP 
domain may also mediate clumping observed between competent and non-competent 
cells in the presence of acid, in a yet unknown mechanism related to the release of 
DNA during fratricide (Håvarstein et al. 2006b). 
 
1.1.5.3 Lipoproteins 
1.1.5.3.1 Pneumococcal Surface Adhesin A (PsaA) 
PsaA is a 37-kDa species-specific protein (Russell et al. 1990). It was initially 
postulated to be an adhesin, mainly due to its homology to lipoproteins SsaB and 
FimA in Streptococcus sanguinis and Streptococcus parasanguinis, respectively 
(Sampson et al. 1994). Exposure to anti-PsaA antibodies reduced adhesion of 
pneumococci of different serotypes to host epithelial cells in vitro (Romero-Steiner et 
al. 2003). Mutations in psaA also showed reduced ability to colonize the nasopharynx 
and infect the lungs and middle ear of mice, and a 10,000-fold increase in LD50 when 
infected intraperitoneally into mice (Berry & Paton 1996; Marra et al. 2002; 
McAllister et al. 2004). 
 
PsaA was subsequently found to be an ABC transporter lipoprotein of the manganese 
permease complex, encoded by psaA found in a locus which also contains genes 
encoding for an ATP-binding cassette (psaB), transmembrane protein (psaC), and a 
thiol peroxidase (psaD) (McAllister et al. 2004). Mutagenesis of psa genes results in 
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lowered Mn
2+
 uptake and reduced growth in vitro unless supplemented with the ion 
(Marra et al. 2002). In addition, PsaA is also suggested to play a crucial role in 
pneumococcal survival in response to oxidative stress, as mutants lacking PsaA 
exhibited increased cell death in presence of H2O2 compared to wild-type (Tseng et 
al. 2002). 
 
1.1.5.3.2 Pneumococcal Iron Acquisition and Uptake Transporters (PiaA, PiuA, PitA) 
Three proteins, PiuA (34 kDa), PiaA (42 kDa), and PitA (37 kDa), have been 
suggested to play roles in iron acquisition and uptake (Brown et al. 2001; Brown et al. 
2002; Whalan et al. 2005). These proteins are encoded by three unlinked genes, piuA 
(previously known as pit1A), piaA (previously known as pit2A), and pitA. They 
encode homologues of ATP-binding cassette (ABC) iron transporter of gram-negative 
organisms and are found in the pneumococci of different serotypes as well as 
members of S. mitis and S. oralis (Brown et al. 2001; Brown, Gilliland & Holden 
2001; Brown et al. 2002; Whalan et al. 2006). Each of these transporter genes are part 
of their respective operon each encoding a putative ATPase, the iron receptor, and 
two genes coding for transmembrane permease proteins. Mutation to one of the three 
loci results in modest reduction in virulence, while disruption to two or all loci 
contributed to reduced growth in iron-depleting environment, reduced sensitivity to 
streptonigrin
13
, and attenuation of virulence in a murine pulmonary and systemic 
model. The piaA locus is located in a pathogenicity island resembling a gram-negative 
source with a reduced G+C content (32.0% compared to ~40.0% in pneumococcal 
genome) over a length of more than 27 kb, suggesting horizontal acquisition from 
other species. Immunization with antibodies specific to PiuA and PiaA enhanced 
opsonophagocytosis by neutrophils in vitro and enhanced survival of mice from 
systemic and lung infections (Brown et al. 2001).  
 
1.1.5.4 Peptidoglycan-Associated Proteins 
1.1.5.4.1 Neuraminidase (NanA, NanB, NanC) 
The neuraminidase group comprises of NanA (~115kDa), NanB (~75kDa), and NanC 
(~82kDa), each containing an N-terminal signal sequence, followed by a lectin-
binding domain, and an active site domain. In addition NanA also contains a C-
                                                        
13
 The activity of streptonigrin is dependent on the presence of iron (Yeowell & White 1982).  
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terminal LXPTG motif for cell wall adhesion. They cleave sialic acid residues of 
mucin, glycolipids, glycoproteins, and oligosaccharides. Furthermore, NanA was 
shown to desialate residues on secretory component, lactoferrin, and IgA2, thereby 
preventing host clearance and increasing survival on the mucosal surface (King et al. 
2004). NanA also removes sugar residues of H. influenzae and N. meningitidis. This is 
considered as a means of interspecies competition, as removal of these residues 
confers vulnerability to complement-mediated killing (Shakhnovich, King & Weiser 
2002). Most pneumococci contain both nanA and nanB genes, and nanC is present in 
some isolates (Pettigrew et al. 2006). Pneumococcal neuraminidase exhibits intra-
species variation, possibly through HGT with viridans streptococci as well as point 
mutations (King, Whatmore & Dowson 2005). In addition, NanA homologues have 
been identified in members of S. mitis and S. pseudopneumoniae (Johnson et al. 
2010). 
 
Transparent phase variants as well as biofilm cells are associated with increased 
expression of nanA compared to the opaque type (King et al. 2004), and biofilm 
formation was reduced in pneumococci with nanA mutation or pneumococci treated 
with neuraminidase inhibitors. (Parker et al. 2009). mRNA levels of nanA and nanB 
were also higher in biofilm cells compared to planktonic cells (Oggioni et al. 2006).   
 
Pneumococci with defective NanA and NanB resulted in early clearance of 
pneumococci from the nasopharynx, trachea and lungs, as well as failure to grow in 
blood in a mouse model of infection following intranasal and intravenous infections 
(Manco et al. 2006). The virulence and pathogenicity of NanC has yet to be 
elucidated, but Pettigrew et al. (Pettigrew et al. 2006) reported that pneumococci with 
nanC are more likely to be detected in CSF compared to nasopharynx.  
 
1.1.5.4.2 IgA1 Protease 
IgA1 protease, encoded by iga, is a 200-kDa metalloprotease that cleaves the bond 
between Pro-227 and Thr-228 in the hinge region of IgA1 (Kilian & Holmgren 1981; 
Poulsen, Reinholdt & Kilian 1996; Wani et al. 1996). The cleavage of IgA1 by the 
protease enhances adherence to respiratory epithelial cells in vitro, probably by 
altering surface electrochemical properties of the pneumococci (the cationic, 
hydrophobic properties of F’ab cleaved fragments counteract the anionic, hydrophilic 
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properties of the pneumococcal capsule) and by enhancing PCho binding to PAFr 
(Weiser et al. 2003). As IgA is the most common immunoglobulin class on mucosal 
surfaces, and over 90% of IgA is of the IgA1 subclass, the IgA1 protease represents a 
major colonization factor in the nasopharynx and virulence factor during mucosal 
infections, allowing the organism to exploit this predominant host immune component 
for survival. 
 
1.1.5.4.3 Hyaluronate Lyase (Hyl) 
Hyl is a 107-kDa protein found both anchored to the peptidoglycan and released into 
extracellular space by S. pneumoniae. It cleaves hyaluronic acid, a key 
glycosaminoglycan component of the extracellular matrix (ECM) of host mucosal 
surfaces (Berry et al. 1994; Hammerschmidt 2007). Hyl contains an N-terminal 
domain, a carbohydrate adhesion domain, a spacer domain, and the C-terminal 
LXPTG anchor domain. Fragmented hyaluronan stimulates the production of pro-
inflammatory cytokines, thus Hyl activity may play a role in pathogenicity of 
pneumococcal pneumonia due to the activation and maintenance of the inflammatory 
response (McKee et al. 1996). In addition, Hyl activity may be associated with cases 
of meningitis, as one study demonstrated the expression of Hyl in all pneumococci 
isolated from cases of meningitis, compared to 11.5% pneumococci expressing Hyl in 
the nasopharynx (Kostyukova et al. 1995). A recent study has showed that Hyl may 
allow the pneumococcus to use hyaluronic acid from host as well as respiratory tract 
colonizers as a carbon source for growth (Marion et al. 2012). 
 
1.1.5.4.4 Pilus Structures 
Pilus-like structures have recently been detected in pneumococci (Barocchi et al. 
2006; Bagnoli et al. 2008; Donati et al. 2010) and other members of the Mitis group 
(Zähner et al. 2011). The structures are composed of polymers of LPXTG motifs 
covalently linked together by the sortase enzyme, which mediate the covalent linkage 
of LPXTG motif-containing proteins to the cell wall. The genes required for 
pneumococcal pilus synthesis were mapped to the rlrA islet, flanked by IS1167 
containing seven genes including rlrA regulator, the LPXTG-containing proteins 
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encoded by rrgA, rrgB, rrgC, and the sortase
14
 genes srtB, srtC, and srtD (Barocchi et 
al. 2006).  
 
Expression of rlrA islet was associated with increased adherence to epithelial cells in 
vitro (Barocchi et al. 2006; Nelson et al. 2007a), and rra mutants were associated 
with reduction in biofilm formation (Muñoz-Elías, Marcano & Camilli 2008). Mice 
infected intranasally with mutants lacking RrgA had lower concentration of bacteria 
in the nasopharynx and higher survival rate compared to wild type strains. A second 
pilus islet (PI-2) was identified in the pneumococcus (Bagnoli et al. 2008), with a 
similar genetic structure to the rlrA islet (PI-1) (Fig. 1.7).  
 
 
 
Fig. 1.7. Genetic organization of genes encoding pilus structures (A) PI-2 and (B) 
PI-1. The functions of proteins/genetic elements encoded by these genes are 
differentiated by colour groups. The comparison of strains TIGR4 and INV104 
highlights the differentiatial distribution of these pili in pneumococci. Comparison of 
presence/absence of the two pili in additional pneumococci is described in another 
study (Donati et al, 2010). Figure from Bagnoli et al. (Bagnoli et al. 2008). Journal of 
Bacteriology authorizes the reuse of journal material including figure shown for 
academic purposes.  
 
 
 
 
 
                                                        
14
  Sortases are transpeptidases which are crucial in the assembly of pili components and has been 
shown to anchor pili onto cell wall of Corynebacterium diphtheriae (Swaminathan et al. 2007). 
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1.1.5.5 Other Surface-Attached Proteins - Pneumococcal Adhesion and Virulence  
A (PavA) 
PavA (62 kDa) is a 551-aa polypeptide mediating pneumococcal binding to host 
fibronectin, and may play roles in pneumococcal adhesion to host tissues and 
indirectly mediates virulence. The requirement of PavA in adhesion was clearly 
demonstrated in cell culture infection studies, where pavA-knockout mutants 
exhibited reduced adherence and invasion of epithelial and endothelial cells (Pracht et 
al. 2005). Also, mice infected with pavA-deficient mutants had reduced mortality in 
models of pneumonia and sepsis (Lau et al. 2001; Pracht et al. 2005), septicaemia 
(Holmes et al. 2001), and meningitis (Pracht et al. 2005). In addition, mutants with 
deficient pavA were cleared from the nasopharynx more rapidly, and were unable to 
translocate to the bloodstream from the lungs following intranasal challenge 
(Kadioglu et al. 2010).  
 
1.1.5.6 Concluding Remarks for Pneumococcal Proteins 
While the capsule has long been recognized as a major virulence factor of the 
pneumococcus, additional proteins, whether cytosolic, extracellular, or surface-
associated, also contribute to virulence and pathogenicity. Furthermore, the majority 
of these factors have important roles in colonization. As the human nasopharynx is 
the most predominant ecological niche, it is possible that these factors have evolved 
and adapted to better adapt during colonization, and in relatively rare cases of 
infection, these factors also mediate virulence in order to survive in the host.  
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1.2 Pneumococcal Diseases 
The World Health Organization estimates that pneumococcal diseases account for 1.6 
million deaths worldwide per year, with the majority of which occur in children under 
the age of 5 years and the elderly (World Health Organization 2007). The ten 
countries with the highest mortality rates from invasive pneumococcal diseases (all in 
Asia and Africa) constitute over 60% of all pneumococcal deaths in children (O'Brien 
et al. 2009). The pneumococcus commonly causes relatively mild diseases such as 
otitis media and sinusitis, and more severe clinical manifestations such as pneumonia. 
The pneumococcus also causes infections in normally-sterile sites, leading to invasive 
diseases such as septicaemia and meningitis. In addition, the organism occasionally 
causes pyogenic arthritis, osteomyelitis, pyomyositis, necrotizing faciitis, 
endocarditis, pericarditis, peritonitis, paritotis, endophthalmitis, and conjunctivitis 
(Butler 2004). Pneumococcal diseases are usually caused by a small number of 
serotypes; around 20 serotypes cause 70-90% of IPD worldwide, and serotypes 1, 5, 
6A, 6B, 14, 19F, and 23F collectively are responsible for at least 50% of IPD in 
children < 5 years in every continent (Örtqvist 2001; Johnson et al. 2010). A higher 
number of serotypes are responsible for an equal proportion of IPD in Africa and Asia 
than in North America, suggesting a greater diversity of serotypes causing IPD in the 
former two continents (Johnson et al. 2010). 
 
S. pneumoniae enters the bloodstream from the lungs causing septicaemia. Activation 
of host complement system promotes transcytosis through the blood-brain barrier and 
subsequent pneumococcal replication in the brain. Meningitis can also occur in the 
absence of apparent bacteraemia and pneumococcus-positive blood culture; it is 
hypothesized that other infection routes allow bypassing of the bloodstream to cause 
meningitis without septicaemia (Marra & Brigham 2001; Filippidis & Fountas 2009).  
 
1.2.1 Conjunctivitis 
Outbreaks of conjunctivitis frequently involve acapsulate and non-serotypable (NT) 
pneumococci (Shayegani et al. 1982; Smart, Dougall & Girdwood 1987; Carvalho et 
al. 2003; Crum et al. 2004; Haas et al. 2011). Genetic analyses show that most 
pneumococcal conjunctivitis is caused by clonal complexes of related NT strains, 
including clonal complex of ST344, and are genetically diverse based on PFGE and 
MLST (Martin et al. 2003; Crum et al. 2004; Buck et al. 2006; Porat et al. 2006). 
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Fig. 1.8. Pneumococcal diseases and pathogenic route. Pneumococci enter host via 
airborne droplets into the nasopharynx, where they colonize. Local spread from the 
nasopharynx into the middle ear, sinus, and conjunctiva leads to otitis media, 
sinusitis, and conjunctivitis, respectively. From the nasopharynx, pneumococci can 
also be aspired into alveoli leading to pneumonia. Septicaemia can be caused by 
translocation of pneumococci into blood. Further translocation from the blood to the 
meninges can cause meningitis, however some studies hypothesize that pneumococci 
can cause meningitis without septicaemia via other infection routes. Figure modified 
from Bogaert, de Groot and Hermans (Bogaert, de Groot & Hermans 2004). 
 
Some of the NT STs from the conjunctiva are also distinct from NT isolated in other 
anatomical sites. This suggests that loss of capsule alone does not explain these NT 
strains’ likelihood to cause conjunctivitis, and that additional genetic factors 
associated with these distinct STs may play contributing roles in these NT strains 
(Berrón et al. 2005).  
 
1.2.2 Otitis Media (OM) 
OM is the leading cause for visits to doctors among children. Pneumococcus is among 
the leading bacterium responsible for otitis media in both adults and children, 
followed by H. influenzae and M. catarrhalis. High-density population settings such 
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as crowded homes and day-care centres have been shown to be a risk factor 
development of acute OM in child populations (Faden et al. 1997; Paradise et al. 
1997). Otitis media may be more common in indigenous populations such as 
Australian Aboriginals and Native Americans (Leach 1999; Curns et al. 2002). OM is 
the most common infection in children and diagnosis for antibiotic prescription. This 
leads to the rapid emergence of antibiotic-resistant pneumococci worldwide, 
including strains of serotypes not directly targeted by the heptavalent pneumococcal 
conjugate vaccine (Section 1.4.2) (Huebner et al. 2003; Xu et al. 2009; Porat et al. 
2010). Middle ear infections in humans (Hall-Stoodley et al. 2006; Hoa et al. 2009b) 
and chinchillas (Ehrlich et al. 2002; Hoa et al. 2009a; Reid et al. 2009; Weimer et al. 
2010) have been associated with the formation of pneumococcal biofilms (Section 
1.5.9). 
 
1.2.3 Pneumonia 
Pneumonia accounts for nearly 20% of childhood deaths worldwide, and 50% of 
pneumonia cases can be attributed to the pneumococcus, with a case-fatality rate of 
over 10% in Africa (O'Brien et al. 2009; Jambo et al. 2010). In addition to children, 
the elderly and the immunocompromised are also at heightened risk. Pneumococcal 
pneumonia is triggered by the interaction between pneumococcus and the defense 
mechanisms of the lungs, following inhalation of pneumococci into alveolar air 
spaces. Alveolar macrophages are normally efficient in clearing the infection by 
opsonophagocytosis (Gordon et al. 2000). Failure to clear the infection results in 
rapid bacterial proliferation in the alveoli. At high bacterial concentration, alveolar 
macrophages are overwhelmed and phagocytic activity is lowered, with concomitant 
activation of pro-inflammatory cytokines. The development of pneumococcal 
pneumonia in CD1 mice is described in detail in Bergeron et al. (Bergeron et al. 
1998). 
  
1.2.4 Septicaemia/Bacteraemia 
Despite the availability of antibiotics and vaccines, the case-fatality rate of 
pneumococcal bacteremia remains at approximately 20% (Balakrishnan et al. 2000). 
Suspected Cases of bacteremia are usually treated with amoxicillin and third-
generation cephalosporin, however the recent isolation of a serotype 19A strain highly 
resistant to penicillin and ceftriaxone is alarming (Shouval et al. 2010). Nearly 50% 
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of bacteremia fatalities occur at the early onset, therefore rapid diagnosis of 
bacteremia by molecular detection directly on blood samples provides an efficient 
alternative to the conventional blood culture method which is time-consuming 
(Paolucci, Landini & Sambri 2010). Recently, Kadioglu et al. (Kadioglu et al. 2011) 
demonstrated that male mice were more susceptible to sepsis with shorter survival 
time and a more pronounced inflammatory response. 
 
1.2.5 Meningitis 
The pneumococcus is a leading bacterial agent of meningitis in children, with a high 
disease incidence during the dry season (January and February) in the African 
pneumococcal meningitis belt in the sub-Sahara region, with a high proportion of 
cases caused by serotype 1 (Leimkugel et al. 2005; Yaro et al. 2006; Gessner, Mueller 
& Yaro 2010). Mortality rates for meningitis may be as high as nearly 80%, and 
survivors suffer from neurological sequelae such as hearing loss, learning deficits, 
mental retardation, sensory motor deficits, and seizure disorders (Grimwood et al. 
1995; Marra and Brigham 2001). These outcomes are probably due to tissue damage 
inflicted in the brain during the inflammatory process. 
 
Meningitis occurs by the breaching the blood-brain barrier (BBB) and transcytosis 
across into the subarachnoid space. Initial attachment to the brain capillary 
endothelial cells (BMEC) requires CbpA, and the upregulation of host PAFr is 
required for entrance into the subarachnoid space (Ring, Weiser & Tuomanen 1998). 
Increase in PAFr expression is mediated by TNF-α production stimulated by the 
pneumococcal cell wall (Cundell et al. 1995; Freyer et al. 1999). Once inside the 
CNS, bacterial replication occurs and inflammation is induced in this sterile 
environment to cause the pathogenic traits associated with meningitis. 
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1.3 Antibiotic Treatment and Resistance 
1.3.1 β-Lactams 
Twenty years after the introduction of penicillin in 1940, penicillin-nonsusceptible 
pneumococci were first isolated from the sputum of an adult in Australia (Hansman & 
Bullen 1967), and Papua New Guinea (Hansman et al. 1974). Detection of resistant 
isolates from children with systemic diseases in South Africa was also recorded 
(Appelbaum et al. 1977). By the 1990s the majority of pneumococci isolated in 
studies in Spain, Hungary, and South Africa were resistant to penicillin and other β-
lactams, some of which with MICs 1000-fold of susceptible strains (Fenoll et al. 
1991; Marton et al. 1991; Liñares et al. 1992). 
 
The rise in penicillin resistance was associated with the increase in use of β-lactams in 
the early 1990s (Granizo et al. 2000). The emergence of penicillin-nonsusceptible 
pneumococci can be attributed to expansion of resistant clones, many of which 
characterized by the Pneumococcal Molecular Epidemiology Network (Mcgee et al. 
2001) (Fig. 1.9). These resistant clones are associated with serotypes commonly 
found in carriage such as members of serogroups 6 and 19. Conversely, invasive 
serotypes but ones that are rarely detected in carriage (serotype 1) are rarely resistant, 
even in countries where penicillin nonsusceptibility is common, consistent with the 
hypothesis that nonsusceptibility is mainly acquired and transmitted during carriage 
(Yagupsky et al. 1998; Marimon et al. 2009; Fenoll et al. 2010). 
 
1.3.2 Mechanism of β-Lactam Resistance  
Genes encoding β-lactamases have yet to be identified in the pneumococci. Non- 
susceptibility to β-lactam in pneumococci is due to the reduced affinity of the drug to 
the six penicillin-binding proteins (PBPs). These proteins are responsible for the 
cross-linking of peptidoglycan strains. β-lactams bind to the active site region of these 
proteins, inactivating peptidoglycan linking. β-lactam resistance is mediated by 
genetic changes of PBP genes resulting in the reduced affinities of PBPs to the drugs. 
PBPs are classified into 3 groups: high-molecular weight (HMW) class-A proteins 
PBP1a, PBP1b, and PBP2a; HMW class-B proteins PBP2x and PBP2b; and a low-
molecular weight PBP3. Mutations in pbp2b and/or pbp2x confer low-level β-lactam 
resistance, while alterations in pbp1a contribute to higher level of resistance if 
mutations in pbp2b and/or pbp2x are present (Smith & Klugman 1998).  
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Fig. 1.9. Spread of penicillin-nonsusceptible S. pneumoniae. A total of 26 pneumococcal clones non-susceptible to penicillin and other drugs 
have been characterized by the PMEN. These clones are named according to the country where they were first identified, the serotype 
(superscript), and the PMEN clone number in chronological order. These clones are responsible to the spread of drug resistance due to their 
expansion.  
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Resistant isolates contain major sequence blocks with extensive variation in pbp 
genes. Sequence variation of over 20% between resistant and sensitive strains can be 
observed for pbp1a (Martin, Sibold & Hakenbeck 1992), pbp2x (Laible, Spratt & 
Hakenbeck 1991), and pbp2b (Dowson et al. 1989). These variable sequences are 
likely to have been acquired from the related S. mitis and S. oralis (Dowson et al. 
1989; Dowson et al. 1993; Sibold et al. 1994). Recombination between pbp genes can 
occur within the pbp genes or in the flanking regions, as in the case of ddl hitchhiking 
effect with pbp2b and the transformation of cps along with pbp2x and pbp1a (Coffey 
et al. 1999; Enright & Spratt 1999; Trzciński, Thompson & Lipsitch 2004; 
Brueggemann et al. 2007). 
 
Amino acid alterations at the penicillin-targeting active site contribute to changes in 
the peptidoglycan structure. Resistant pneumococci contain a higher proportion of 
hydrophobic branched muropeptides in their cross-linkages, compared to susceptible 
pneumococci containing mainly linear stem peptides (Garcia-Bustos & Tomasz 
1990). A possible explanation for its role in resistance may be that branched peptides 
are more efficient competitors to the PBPs than β-lactams. This suggests that changes 
in penicillin-binding proteins (PBPs) as a result of reduced drug affinity also change 
substrate specificity in murein peptide chain synthesis (Garcia-Bustos & Tomasz 
1990). 
 
1.3.3 Macrolides 
Macrolides inhibit translation by binding to the 23S rRNA of the 50S bacterial 
ribosome subunit. Resistance to macrolides involves 23S rRNA methylation (mainly 
mediated by erm(A), erm(B)), and efflux pump (mef genes). Both classes of genes can 
be found flanked by genes encoding transposable elements (McDougal et al. 1998; 
Gay & Stephens 2001; Croucher et al. 2011). The increase of macrolide resistance in 
some areas may be correlated by increase in macrolide usage (Karlowsky et al. 2009) 
selecting for survival and expansion of strains containing these genetic elements. 
Also, strains containing both mef(A) and erm(B) are associated with multi-drug 
resistance, and are also hyper-recombinant (Lee, Song & Ko 2010). Depending on 
geographical region, macrolide nonsusceptibility rates may be as low as 1% in 
Mozambique to over 90% in Taiwan (Van Bambeke et al. 2007).  
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1.3.4 Fluoroquinolones 
The quinolone is a broad class of antibiotic drugs affecting DNA replication. Most 
quinolones belong to the fluoroquinolone group, containing fluorine in the central 
carbon ring. Quinolones and fluoroquinolones target the GyrA and ParC proteins of 
the DNA gyrase and topoisomerase IV proteins, respectively, which are involved in 
regulating DNA supercoiling. Fluoroquinolones halt the replication fork during DNA 
replication. DNA gyrase is a heterodimer consisting of GyrA and GyrB, and the 
topoisomerases IV is a heterodimer of ParC and ParE. Resistance to fluoroquinolones 
is associated with amino acid substitutions in GyrA, ParC, and ParE (Tankovic et al. 
1996; Perichon, Tankovic & Courvalin 1997). ParC appears to be the primary target 
for quinolones in S. pneumoniae, while additional mutations in gyrA results in higher 
resistance. Mutations in parE and gyrB may also be present, but are not found in all 
strains with quinolone resistance (Bast et al. 2000; Richter et al. 2005). The majority 
of spread is as a result of clonal expansion of nonsusceptible strains, with a small 
proportion from interspecies transfer (Balsalobre et al. 2003; Stanhope et al. 2005). 
High nonsusceptibility rates have been documented in Hong Kong, Sri Lanka, the 
Philippines, and Korea (Song et al. 2004).  
 
1.3.5 Trimethoprim-Sulfamethoxazole (Co-trimoxazole, SXT) 
SXT is mainly used as a first-line antibiotic in developing countries for dual-treatment 
for malaria and pneumonia, mainly because of its low cost and its effectiveness as a 
daily prophylaxis for HIV/AIDS patients (Wiktor et al. 1999; Mermin et al. 2004; 
Hamel et al. 2008). SXT targets dihydrofolate reductase (DHFR) encoded by folA and 
dihydropteroate synthase (DHPS) encoded by folP, respectively. DHFR and DHPS 
are enzymes involved in the folate biosynthesis pathway, required for purines and 
amino acid synthesis.  
 
SXT-nonsusceptible pneumococcus was first isolated from a patient with chronic 
bronchitis in 1972 (Howe & Wilson 1972). Since then, resistance has increased 
rapidly, with nonsusceptibility prevalence well above 50% across continents (Joloba 
et al. 2001; Arifeen et al. 2009). In the laboratory, single amino acid substitutions has 
been shown to mediate non-susceptibility to trimethoprim, namely the leucine 
substitution from isoleucine in amino acid position 100. However, clinical isolates of 
resistance pneumococci are usually associated with multiple substitutions, along with 
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I100L (Adrian & Klugman 1997; Wilén et al. 2009). These additional alterations, 
possibly mediated through mutations or interspecies recombination, may moderate 
affinity of enzyme to the natural substrate in response to the reduced susceptibility to 
the antibiotics. 
 
1.4 Prophylaxis – Pneumococcal Vaccines 
The development of pneumococcal vaccines was prompted by 1) the high mortality 
and morbidity associated with pneumococcal infections despite antibiotic treatment, 
and 2) the rapid emergence of antibiotic non-susceptible pneumococci. Four 
pneumococcal vaccines have been licensed and more are in development. Current 
licensed vaccines target the pneumococcal polysaccharide capsule, providing 
protection from infection of the most commonly encountered serotypes. The 
following sections will describe the 23-valent polysaccharide (PPV23), seven-valent 
(PCV7), and 13-valent (PCV13) conjugate vaccines (Table 1.4). A nine-valent 
(PCV9) vaccine (containing PCV7 serotypes plus 1 and 5) was also effective in 
reducing IPD in a clinical trial in the Gambia (Cutts et al. 2005), however it was not 
developed further because of the expanded valency provided by PCV13. 
 
Table 1.4. Currently licensed pneumococcal vaccines 
  
Vaccine Serotypes Covered Year Licensed 
PPV23 
(Pneumovax) 
1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 
11A, 12F, 14, 15B, 17F, 18C, 19F, 
19A, 20, 22F, 23F, 33F 
 
1983 
PCV7 (Prevnar) 4, 6B, 9V, 14, 18C, 19F, 23F 2000 
 
PCV10 (Synflorix)  1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F 2009 
 
PCV13 (Prevnar 13) 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 
19A, 19F, 23F 
2010 
 
 
1.4.1 PPV23 
The 23-valent pneumococcal polysaccharide vaccine (PPV23) was designed to reduce 
invasive diseases and pneumonia in adults. The vaccine, formulated by Merck, 
containing 25 µg of purified capsular polysaccharide from each of the included 
serotypes. These serotypes covered over 90% and 60% of isolates responsible for 
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invasive diseases in the US in 2000 (Rudolph, 2000). PPV23 is recommended for the 
healthy individuals over the age of 65, and high-risk individuals over the age of 2, 
including asplenic patients, people with chronic renal, heart, lung, liver diseases, 
diabetes mellitus, and the immunocompromised (Melegaro & Edmunds 2004).  
 
The pneumococcal capsule is a T-cell-independent type 2 (TI-2) antigen, binding 
directly to B-cells via its repeating sugar epitopes. Immune response to TI-2 requires 
co-stimulation with CD21, which is expressed at low levels in infants (Rijkers et al. 
1998). PPV23 are thus not immunogenic in children under the age of 2. Antibody 
responses following PPV23 immunization may be transient in other age groups. 
Repeated administration of PPV23 may also cause immune hyporesponsiveness, and 
this state of immune tolerance may stem from memory B cells being exposed to 
excessive amounts of polysaccharide antigens (O'Brien, Hochman & Goldblatt 2007). 
PPV23 also provides limited protection in mucosal infections such as AOM in 
children and pneumonia in the elderly (Douglas & Miles 1984; Jackson et al. 2003). 
These reports demonstrate the sub-optimal efficacy of PPV23 for age groups most 
vulnerable to pneumococcal infections, possibly due to its polysaccharide nature. 
Therefore, the heptavalent pneumococcal conjugated vaccine (PCV7) was introduced 
in an attempt to shift the capsule-targeted immune response to an earlier age (see 
below).  
 
1.4.2 PCV7 
Polysaccharide antigens from each of the seven serotypes in PCV7 are individually 
conjugated to a non-lethal diphtheria toxoid protein (cross-reactive material 197, 
CRM197), which converts the polysaccharide antigen to a T-dependent response 
present in young children. The PCV7 was first introduced in 2000 in the United 
States, recommended for all children aged 2-20 months as well as those aged 2-5 
years with increased risks. By 2008, PCV7 had been licensed for use in more than 
ninety countries. In addition, numerous developing countries have recently been 
approved for the use of PCV7 (World Health Organization 2008). 
 
In the US, PCV7 administration was associated with over 97% reduction in IPDs 
caused by vaccine serotypes (VTs) and 89.1% reduction in IPDs overall in infants 
who received PCV7 (Black et al. 2000). Similar but more modest reductions observed 
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in individuals of other age groups as a result of herd immunity
15
 (Whitney et al. 2003; 
Carter 2006; Miller et al. 2011). Use of PCV7 has also contributed to the decrease of 
IPD caused by antibiotic-nonsusceptible pneumococci in children and adults (Black et 
al. 2004; Hampton et al. 2011). Decreases in IPD by VTs were also seen in high-risk 
groups, such as those over the age of 65, indigenous populations, and HIV-positive 
infants (Klugman et al. 2003; O'Brien et al. 2003; Lexau et al. 2005). Studies also 
documented more modest reductions in otitis media (Eskola et al. 2001; Fireman et 
al. 2003), and pneumonia (Black et al. 2002) cases. 
 
PCV7 was associated with reductions in colonization by VT, with VT carriage rates 
as low as 3% after PCV implementation (Dagan et al. 2002; Huang et al. 2009). The 
protective property of PCV in carriage extends to vaccine-related serotypes; serotype 
6A carriage rate was significantly lower in toddlers who received the nonavalent 
pneumococcal conjugate vaccine (PCV9, contains serotypes in PCV7 in addition to 
serotypes 1 and 5) targeting serotype 6B. The carriage of antibiotic-resistant 
pneumococci was also lowered upon the administration of conjugate vaccines in 
children, as the majority of nonsusceptible strains are of serotypes included in PCV7 
(Dagan et al. 2003).  
 
1.4.3 Serotype Replacement 
Due to limited serotype protective coverage, conjugated vaccines enable serotypes not 
covered in the vaccine to fill up niches previously occupied by VTs, a phenomenon 
termed serotype replacement. Since PCV7 use, serotype 19A
16
 is among the most 
prevalent NVT to cause IPD in the post-vaccine era across continents, with serotypes 
15B/C, 35B, 22F, 6C, 7F, and 11A also common (Singleton et al. 2007; Carvalho et 
al. 2009; Hsu et al. 2009; Huang et al. 2009; Hanage et al. 2010; Hanquet et al. 2010; 
Gladstone et al. 2011a; Miller et al. 2011; Wroe et al. 2011). Replacements have also 
been observed in carriage (Pelton, Loughlin & Marchant 2004; Nahm et al. 2009; 
Tocheva et al. 2010; Tocheva et al. 2011) and AOM (McEllistrem et al. 2003). Rates 
of antibiotic resistance in replacement serotypes are also increasing (Hanage et al. 
2007; Hicks et al. 2007; Simões et al. 2011a). Serotype replacement could be 
                                                        
15
  Herd immunity: protection of non-vaccinated individuals due to the large proportion of vaccinated 
individuals in that transmission of disease-causing organisms is interrupted. 
16
 PCV7 targeting serotype 19F does not provide cross-protection for serotype 19A (Dagan et al. 2002) 
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mediated by the expansion of pre-existing NVT clones and clonal complexes, such as 
that of ST199 and ST320, both in serotype 19A (Hanage et al. 2007; Gladstone et al. 
2011a), and serotype switching, where the cps locus encoding a NVT capsule is 
acquired by a virulent strain of a VT, generating vaccine escape recombinants (see 
below).  
 
The clinical impact of serotype replacement depends on the invasiveness of the 
serotype that is replacing. Host factors, transmission environment (crowded vs. non-
crowded), and vaccination coverage within the host population also contribute to 
serotype replacement as these are variables likely to affect pneumococcal 
transmission between hosts (Long 2005). It must be noted that temporal fluctuations 
in serotype prevalence may take place in the absence of PCVs, as seen carriage in 
Icelandic children (Tomasson, Gudnason & Kristinsson 2005) and IPD in Scotland 
(Jefferies et al. 2010a). However, serotype replacement could be an artifact of 
unmasking
17
 within multiple colonization (Azzari et al. 2008). The effects of serotype 
replacement can be assessed more accurately by using sensitive serotyping methods 
(Chapters 3 and 4).  
 
1.4.4 Serotype Switching 
Serotype switching is the horizontal acquisition of the cps operon, leading to the 
expression of a different capsule. The change of serotype may involve parts of the 
operon (Park et al. 2007) or the entire operon, sometimes including adjacent pbp 
genes (Coffey et al. 1998; Nesin, Ramirez & Tomasz 1998; Brueggemann et al. 2007; 
Pillai, Shahinas & Buzina 2009; Croucher et al. 2011; Golubchik et al. 2012). 
Serotype switching has also been seen in laboratory settings (Kelly, Dillard & Yother 
1994; Trzciński, Thompson & Lipsitch 2004). Other studies infer capsular switching 
as comparison of two strains of different serotypes having identical or highly similar 
genetic properties determined by PFGE, MLST, and antibiotic-resistance and 
virulence genes (Barnes, Whittier & Gilligan 1995; Jefferies et al. 2004; Moore et al. 
2008; Hanage et al. 2011). As different capsule types have varying disease potentials 
(Kelly, Dillard & Yother 1994; Brueggemann et al. 2003; Sandgren et al. 2004), 
serotype switching may significantly change the invasiveness of a pneumococcus. It 
                                                        
17
  Unmasking: NVT may not have increased in prevalence, but are more frequently detected simply 
due to the reduction of VT in carriage.  
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reduces the efficacies of pneumococcal vaccines as recombinants are able to escape 
serotype-specific immune responses. Comparison of serotype, genetic background (by 
MLST), and pbp genes on over 200 international clones provides evidence that 
serotype switching is relatively common compared to horizontal transfer of penicillin-
resistance determinants (Stanhope et al. 2007). 
 
1.4.5 PCV10 
GlaxoSmithKline introduced a 10-valent conjugate vaccine (PCV10) in 2009, 
containing serotypes included in PCV7 in addition to 1, 5, and 7F. Two of the 
serotypes are conjugated to either a tetanus (18C) or a diphtheria (19F) toxoid, while 
the remaining eight serotypes are conjugated to the cell surface protein D of H. 
influenzae. This is thought to confer protection against AOM caused by nontypable H. 
influenzae in addition to IPD (Gladstone et al. 2011).  
 
1.4.6 PCV13 
A 13-valent conjugate vaccine was licensed in 2009 in Chile and 2010 in the United 
States and Europe, covering PCV7 serotypes in addition to serotypes 1, 3, 5, 6A, 7F, 
and 19A (Reviewed in Jefferies et al. 2011). It is estimated that the global vaccine 
coverage of PCV13 exceeds 70% of IPD in children < 5 years, ranging from 74% to 
88% depending on geographical region (Johnson et al. 2010), and the coverage is 
likely to be higher given its cross-protective properties to serotypes 6C and 7A 
(Cooper et al. 2011). Subjects immunized with PCV13 showed higher levels of 
functional IgG (as assessed by opsonophagocytosis assay
18
, OPA) than those 
immunized with PPV23, for at least 12 of the 13 serotypes, except for serotype 4 
(Scott et al. 2007). For serotypes included in PCV7, infant IgG levels were similar to 
that elicited by PCV7, in addition to fold-increases in levels of IgG targeting the extra 
six serotypes not covered in PCV7 (Bryant et al. 2010). The Global Alliance for 
Vaccines and Immunization (GAVI) aimed to provide easier access to PCV13 in 
resource-poor nations. As of 2011, PCV13 has been introduced in developing 
countries of three continents (Nicaragua, Guyana, Yemen, Sierra Leone, Kenya, Mali, 
                                                        
18
  The OPA analyze efficacy of vaccine by assessing antibody’s ability to opsonize bacteria. This is 
an accompaniment to ELISA detection of IgG concentration, because IgG concentration alone does 
not equate presence of functional antibody and thus protection, as seen in the elderly (Romero-
Steiner et al. 1997). 
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Democratic Republic of Congo, Benin, Cameroon, Rwanda, Burundi, Ethiopia, 
Malawi) (Global Alliance for Vaccine and Immunization 2012).  
 
Fig. 1.10. PCV7, PCV10, and PCV13 coverages of serotypes causing IPD in 
children under the age of 5 by continent. Figure taken from Johnson et al. (Johnson 
et al. 2010). PLoS grants unrestricted use of contents including figure above for 
academic purposes. 
 
1.4.7 Protein-Based Vaccines 
The lack of efficacy of PPV23 in infants and the limited serotype coverage of 
conjugate vaccines call for the design of protein-based vaccines. Such vaccines 
should be immunogenic to children under the age of 2, provide protection from 
pneumococci of different serotypes and strains, and reduce cost for its widespread use 
in developing countries.  
 
Protein antigens can be used either as purified protein vaccine or as an adjuvant of 
polysaccharide conjugate vaccines. Potential antigen targets include a purified, non-
cytotoxic variant of Ply (pneumolysoid) that provided protection in mice against 
pneumonia and septicaemia across different serotypes (Alexander et al. 1994; Briles 
et al. 2003; Kirkham et al. 2006; Harvey et al. 2011). Despite the antigenic 
variability, administration of PspA subcutaneously, orally, and nasally, has also been 
shown to confer protection to sepsis and carriage in mice and human challenged with 
pneumococci of different serotypes and PspA types (Talkington et al. 1991; Wu, 
Nahm & Guo 1997; Yamamoto et al. 1997; McCool et al. 2002). The mixture of 
pneumolysoid and PspA immunization may also provide additive protection (Briles et 
al. 2003). For protection against pneumococcal carriage, it has been shown that PsaA 
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immunization is superior to PspA and pneumolysoid, with the mixture of PsaA and 
PspA providing the best protection against carriage (Briles et al. 2000a). Other 
potential vaccine targets include PspC, LytA, PiuA, PiaA, Hyl, and IgA1 protease. 
 
 
1.5 Pneumococcal Colonization 
The human nasopharynx is the predominant ecological niche for the pneumococcus, 
and rarely is the organism found in animals (Whatmore et al. 1999; Chi et al. 2007; 
Denapaite & Hakenbeck 2011). Colonization is required for pneumococcal disease as 
well as dissemination to other hosts. Local spread of pneumococci from the URT can 
result in otitis media and sinusitis, while pneumococci entry into alveolar spaces 
contributes to the development of pneumonia (Reviewed in Bogaert, de Groot & 
Hermans 2004). Serotyping and genetic typing methods reveal that serotypes and 
strains causing diseases overlap those detected in carriage, suggesting that such 
strains colonize the host before causing diseases, but strains colonizing are more 
genetically diverse compared to invasive pneumococci (Gray, Converse & Dillon 
1980; Müller-Graf et al. 1999; Robinson et al. 2001; Brueggemann et al. 2003). Of 
the pneumococci that cause diseases, colonization of the nasopharynx is followed by 
via receptor-mediated uptake and transcytosis, and the entry of submucosal layers 
(Cundell et al. 1995).  
 
1.5.1 Mechanism of Colonization 
Host surface proteins are involved in pneumococcus-host interaction. CBPs may be 
involved in hydrophobic and/or electrostatic interaction with epithelial cells (Swiatlo 
et al. 2002). PspA binds to non-inflamed, resting epithelial cells via its GlcNAc 
receptors, which may be exposed following cleavage of glycolipids, glycoproteins, 
and oligosaccharides by NanA. Local inflammatory response may alter the expression 
of host platelet-activating factor receptor (PAFr).  PCho on TA and LTA acts as an 
anchor for a number of CBPs, but PCho itself may also act as an adhesin, binding to 
host PAFr, facilitating transcytosis during progression from carriage to invasion as 
well as crossing the blood-brain barrier (Cundell et al. 1995; Ring, Weiser & 
Tuomanen 1998). Furthermore, CbpA has been demonstrated to bind to sialic acid 
and lacto-N-neotetraose, known pneumococcal ligands for cytokine-activated 
epithelial host cells (Rosenow et al. 1997). NanA can also alter surface structures of 
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competing co-colonizing bacteria (Section 1.5.7). The result of this is the exposure of 
adhesion factors, modulation of host clearance glycoproteins, reduction of 
competitiveness of co-colonizing species, and a supply of carbon source for growth 
(Tong et al. 1999; Shakhnovich, King & Weiser 2002; King et al. 2004; King, Hippe 
& Weiser 2006).  
 
1.5.2 Age-Related Epidemiology in Carriage 
All individuals are likely to have been colonized by pneumococci at least once, and 
most by two years of age (Gray, Converse & Dillon 1980). Pneumococcal 
colonization is most common in infants under the age of six. Colonization may begin 
as early as four days after birth (Gray, Converse & Dillon 1980), and prevalence 
peaks at the age of one to three years (Bogaert, de Groot & Hermans 2004). Children 
in day care centers have high carriage rates, possibly due to the close contact 
facilitating transmission (Bogaert et al. 2001; Regev-Yochay et al. 2004b; Sá-Leão et 
al. 2008). Colonization prevalence as well as duration of carriage are lower in older 
children and adults (Gray, Converse & Dillon 1980; Hansman et al. 1985; Regev-
Yochay et al. 2004b; Hussain et al. 2005; Chen et al. 2007; Hogberg et al. 2007; 
Abdullahi et al. 2008). In adults, carriage rates are higher in areas of close contacts, 
such as prisons, barracks, dormitories, and nursing homes. Carriage rates in adults 
tend to be low, but may be higher in special populations, disease outbreaks, or when 
living with young children (Grennan et al. ; Nuorti et al. 1998; Flamaing et al. 2010).  
 
1.5.3 Epidemiological Differences in Serotypes during Colonization 
Different serotypes vary in colonization prevalence and duration, and while the 
chemical properties of the capsule may account for such difference, host age, 
geographical location, cohort type, and other factors also play roles in shaping this 
prevalence.  
 
1.5.3.1 Age-Related Differences 
Disparities in prevalent carriage serotypes between different age groups are best 
described when analyzing cross-sectional studies of numerous age groups within a 
single community (Regev-Yochay et al. 2004b; Hussain et al. 2005; Hammitt et al. 
2006; Abdullahi et al. 2008).   While serotypes such as 6B, 6A, and 14 are common in 
children and adults, prevalence of PCV7 serotypes as a group decreases with 
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increasing age. PCV7, in addition to serotypes 6A, 35B, and 23A, are commonly 
found in young children. Prevalence of colonizing PCV7 serotypes decreases in older 
children, and serotypes 3 and 8 and groups 10, 11, 16, 22, and NT serotypes increase 
in prevalence by age until adulthood (Bogaert et al. 2001; Regev-Yochay et al. 
2004b). 
 
1.5.3.2 Geographical Distribution of Different Serotypes 
In general serotypes of the PCV7 are commonly detected across the globe. Serotypes 
6B, 19F, and 23F are among the most prevalent colonizing serotypes across 
continents (Bogaert et al. 2006; Laval et al. 2006). In the pre-PCV7 era, high PCV7 
coverage rates are seen in Europe and North America, and vaccine coverage rates 
may be lower in Asia, Middle East, and Africa (Dagan et al. 1996; Soewignjo et al. 
2001; Hill et al. 2008), as well as in special populations such as the American Natives 
and Australian Aboriginals (Mackenzie et al. 2007; Millar et al. 2009; Mackenzie et 
al. 2010). In addition, prevalence of different serotypes can be seen across different 
countries within a continent (Bogaert, de Groot & Hermans 2004), or different 
cohorts within a country or city (Givon-Lavi et al. 1999; Hill et al. 2006).  
 
1.5.4 Risk Factors for Colonization 
1.5.4.1 Crowding 
Crowded environments represent a reservoir for the rapid transmission of 
pneumococci between individuals in close contact, and pneumococcal disease 
outbreaks tend to occur in these environments. Day care center attendees were 
associated with high carriage rates (Rosén et al. 1984; Dagan et al. 1996; Vives et al. 
1997; Bogaert et al. 2001; Peerbooms & Engelen 2002; Vestrheim et al. 2008a). 
Children are potentially the source of pneumococci in a family setting where 
transmission to mothers and infants occur. The high prescription of antibiotics in 
young children provides a selective pressure for colonization and dissemination of 
antibiotic resistant strains in day care centers (Barnes, Whittier & Gilligan 1995). A 
large-scale longitudinal carriage study conducted in Israeli day-care center children 
revealed pneumococcus-positivity in 77% of cultures, with over half of the isolates 
being resistant to at least one antibiotic (Givon-Lavi et al. 1999).  
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Fig. 1.11. Differences in PCV7 serotype coverage in colonization by geography. Percentages represent proportions of serotypes covered in 
PCV7 in each country. Proportions are based on selected studies of pneumococcal colonization in children (Huebner et al. 1998; Inostroza et al. 
1998; Joloba et al. 2001; Soewignjo et al. 2001; Rey et al. 2002; Lo et al. 2003; Hill et al. 2006; Kellner et al. 2008; Sa-Leao et al. 2009; Cohen 
et al. 2010; Vestrheim et al. 2010; Grivea et al. 2011; Inverarity et al. 2011; Tocheva et al. 2011; Moyo et al. 2012; Scott et al. 2012).  
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Other environments with high population density such as military barracks, prisons, 
and detention camps, also have been associated with high carriage rates (Jousimies-
Somer, Savolainen & Ylikoski 1989; Hoge et al. 1994; Sung et al. 1995). Prior 
hospital admission has also been shown to be a risk factor for pneumococcal 
colonization, especially antibiotic-resistant pneumococci (Huebner et al. 2000b). 
 
1.5.4.2 Socioeconomic Status 
Individuals of lower socioeconomic status may be at risk for pneumococcal 
colonization, possibly due to harsh living conditions, malnutrition, and lack of access 
to health care facilities. Families living in small areas with lack of health care 
facilities and lower educational levels may have higher rates and earlier onset of 
colonization in children (Leach et al. 1994; Sung et al. 1995). However, some of 
these studies also compared cohorts of different cultural backgrounds, and other 
factors such as genetics and ethnicity may affect colonization. St. Sauver et al. (St. 
Sauver et al. 2000) did not identify low level of income as a risk factor for 
colonization, however the study was conducted with the focus of simultaneous 
pneumococcal colonization (Section 1.6). In a recent study conducted on children in 
Belgian day care centers, children from families of lower socioeconomic backgrounds 
showed no significant in pneumococcal colonization rates, but had a higher 
prevalence of penicillin-nonsusceptible pneumococci belonging to vaccine serotypes 
and nontypables (Jourdain et al. 2011).  
 
1.5.4.3 Seasonality 
Colonization rates tend to increase during the winter months for both children and 
adults (Gray, Converse & Dillon 1980; Darboe et al. 2010). A longitudinal study in 
Israel revealed that in children day care settings, winter months are a risk factor for 
carriage of single or multi-resistant pneumococci (Yagupsky et al. 1998). Different 
trends of individual serotype prevalence over a year was observed in another one-year 
longitudinal study in France, where serotype 14 peaked in prevalence in summer 
while 6B was the most prevalent in the winter (Raymond et al. 2000). Rainy months 
in Africa are also associated with a higher prevalence in carriage (Abdullahi et al. 
2008). Authors from that work suggested that rainy seasons promote indoor lifestyles, 
which may enhance horizontal transmission. However, a study in Finland showed a 
fluctuation in prevalence throughout the year, as opposed to an observable increase in 
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carriage prevalence in any specific season, as detected by both nasal swabs and 
aspirates positive for pneumococci (Syrjänen et al. 2001). 
 
1.5.4.4 Virus Infection 
Co-infection with influenza and pneumococcus was associated with increase in 
pneumococcal adherence (Fainstein, Musher & Cate 1980). Action of viral 
neuraminidases potentially releases free sialic acid, which has recently been 
hypothesized to promote biofilm formation in pneumococci. In agreement with this, 
influenza neuraminidase inhibitors oseltamivir and zanamivir have been shown to 
reduce pneumococcal colonization in a mouse model (Trappetti et al. 2009). 
 
In a longitudinal study in Gambia where sampling was performed once every three 
months, HIV-positive women are associated with higher rates of pneumococcal 
colonization determined by pneumococcal-positive cultures (Gill et al. 2008b). 
However, the study could not conclude whether presence of the same serotype in a 
host in consecutive visits is indicative of repeated acquisition, prolonged duration of 
carriage, or new acquisition of pneumococcal strain with the same serotypes. One 
study indicated an association between HIV-positive men and pneumococcal 
persistence in the nasopharynx, (Rodriguez-Barradas et al. 1997). HIV-positive 
individuals are more likely to carry pneumococci non-susceptible to co-trimoxazole, 
possibly due to the use of the drug as a prophylaxis in HIV-positive individuals 
(Rodriguez-Barradas et al. 1997; Gill et al. 2008a). 
 
1.5.4.5 Smoking 
Smoking adults are associated with an increased carriage rate than non-smokers 
exposed to smoking, which in turn showed a higher carriage rate than individuals not 
exposed to smoking (Greenberg et al. 2006). Children of smoking parents showed 
higher overall carriage rates and carriage odds ratio than children not exposed to 
cigarette (Greenberg et al. 2006; Cardozo et al. 2008). Smoking may also affect viral 
infection that enhances secondary bacterial colonization (Murphy 2006). Nonetheless, 
in vitro studies demonstrate that pneumococcal adherence was higher in cells of 
smoking individuals, and exposing non-smoking cells to cigarette-smoke extracts 
reduced pneumococcal binding (El Ahmer et al. 1999).  
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1.5.5 Colonization as an Immunizing Event 
Several studies have shown increases in antibodies specific to capsular and protein 
antigens such as PspA, PsaA, and pneumolysin following pneumococcal colonization, 
(Soininen et al. 2001; McCool et al. 2002; Goldblatt et al. 2005; Weinberger et al. 
2008). Healthy children previously exposed to pneumococci showed an increase in 
type-specific IgA concentration in saliva, suggesting that carriage induces production 
of mucosal antibodies (Simell et al. 2001). In addition, toddlers in Israel (Weinberger 
et al. 2008) and adults in the United Kingdom (Goldblatt et al. 2005) showed 
increases in levels of IgG specific to carried serotypes such as 14 and 23F, and this 
rise is associated with a reduction of odds of reacquisition of the same serotype. 
Through efforts to design a cost-effective vaccine eliciting broad species-wide 
protection, it was revealed that CD4
+
 T-cells provide serotype-independent protection 
from subsequent pneumococcal colonization and rapid clearance from the 
nasopharynx by macrophages, possibly by the expression of IL-17A (Malley et al. 
2005; Malley, Srivastava & Lipsitch 2006; Lu et al. 2008). 
 
1.5.6 The Role of Capsule in Colonization 
During colonization, full encapsulation may hinder exposure of pneumococcal surface 
adhesins important in host epithelial attachment. In natural populations, nontypable 
strains with no apparent mechanism for capsule production do colonize (Hathaway et 
al. 2004; Hanage et al. 2006). Transparent phase variants with reduced amounts of 
capsule polysaccharide are associated with a higher capacity for host attachment in an 
infant rat model, compared to opaque variants with higher capsule expression (Weiser 
et al. 1994). Mutants producing only 20% of capsule had similar concentrations of 
pneumococci in nasal washes to parental strains (Magee & Yother 2001). Biofilm 
formation in a non-capsulated strain M11 enhanced biofilm-forming capacity in vitro, 
compared to capsulated derivatives of M11 (Moscoso, García & López 2006). 
However, strains producing very low amounts of capsule are impaired in biofilm 
production and enhanced mucosal clearance during colonization (Nelson et al. 2007b; 
Domenech, García & Moscoso 2009). The observation that anti-capsular antibodies 
reduces carriage rates (Dagan et al. 2002), and the differing propensities of varying 
serotypes to colonize the nasopharynx, suggest that capsule and its chemical 
structures do play a role in colonization.  
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1.5.7 Inter-Species Competition and Co-Colonization 
Opportunistic pathogens such as H. influenzae, Moraxella catarrhalis, 
Staphylococcus aureus, and other Streptococcus species also colonize the respiratory 
tract. Children can be co-colonized by these species simultaneously at an early age 
with high prevalence (Kwambana et al. 2011). Interspecies competitions thus are 
expected to occur for nutrients and attachment space. In addition, interference 
between species can occur, in which presence of one species protects against the 
colonization of another. Interaction between species in the same ecological niche is 
also influenced by the host responses and presence of inhibitory compounds; co-
colonization with H. influenzae has been shown to enhance pneumococcal 
phagocytosis by the host immune system (Lysenko et al. 2005; Lysenko et al. 2007). 
 
Positive and negative correlations between pneumococcal colonization and that of H. 
influenzae have been reported in in vitro and population-based studies (Lysenko et al. 
2005; Pettigrew et al. 2008; Margolis, Yates & Levin 2010; Kwambana et al. 2011). 
Pneumococcal H2O2 was shown to be toxic for N. meningitidis, M. catarrhalis, and H. 
influenzae (Pericone et al. 2000). Co-existence of S. pneumoniae and H. influenzae 
has been shown to promote biofilm formation, however this was a model of middle 
ear infection (Weimer et al. 2010). The main pneumococcal neuraminidase, NanA is 
able to cleave sialic acid residue from lipopolysaccharides of N. meningitidis and H. 
influenzae strains, rendering these colonizers more vulnerable to host complement 
defences (Shakhnovich, King & Weiser 2002). An inverse relationship between 
carriage rates of S. pneumoniae and S. aureus has been observed (Bogaert et al. 
2004a; Regev-Yochay et al. 2004a). 
 
The effect of pneumococcal vaccination may affect replacements of colonization by 
other species, however thus far observations have been conflicting. With some studies 
showing an increase in prevalence of S. aureus in carriage following a pneumococcal 
vaccination trial (van Gils et al. 2011a), others fail to demonstrate replacements by H. 
influenzae and M. catarrhalis (van Gils et al. 2011b; Dunne et al. 2012).  
 
1.5.8 Intra-Species Competition and Co-Colonization 
Competitive interactions between co-colonizing pneumococci have been shown, and 
may partially explain the emergence of non-vaccine serotypes following PCV7 
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immunization (Lipsitch et al. 2000; Zhang, Auranen & Eichner 2004). Colonization 
by a resident strain can reduce the colonization of a second strain (Lipsitch et al. 
2000). However, this inhibition of acquisition is subject to the concentration of the 
challenge strain. Competitiveness may in part be a serotype-specific property, but 
other serotype-specific properties such as duration of carriage and transmissibility 
need to be considered to assess the success of a strain in co-colonization (Melegaro et 
al. 2007). Recently, a longitudinal study in Finland demonstrated that children 
colonized by a serotype have a 10-fold reduction in acquisition of another serotype, 
compared to acquisition in un-colonized children (Auranen et al. 2010). In contrast, 
once colonized with 2 serotypes, clearance of a serotype is not dependent on 
simultaneous carriage of another serotype.  
 
Some mechanisms that may play a role in intra-species competition include release of 
bacteriocins. Sequence analysis shows sequence variation in the two bacteriocins 
BlpM and BlpN across serotypes may be grouped into two clusters that may play 
roles in competition in vivo (Dawid, Roche & Weiser 2007). In addition, activation of 
the pneumococcal competence pathway leads to the upregulation of genes encoding 
enzymes involved in fratricidal lysis of noncompetent cells (Chapter 5). Hence, 
differential activation of competence and release of such lytic enzymes may 
contribute to the lysis of a strain within the nasopharynx by another. 
 
1.5.9 Pneumococcal Biofilm 
Biofilms are complex sessile communities comprised of extracellular polysaccharides, 
proteins, and nucleic acids. Biofilms generally consist of different species co-
colonizing as a polymicrobial community. Pneumococci adopt a biofilm mode of 
growth during colonization and otitis media (Hall-Stoodley et al. 2006), in which 
different transcription and protein expression profiles compared to planktonic 
pneumococci are reported (Allegrucci et al. 2006; Oggioni et al. 2006; Sanchez et al. 
2011). Biofilm formation involves initial attachment, formation of cellular aggregates, 
and dispersal of single cells to other attachment sites. Mutations causing impaired in 
vitro biofilm formation also impaired colonization in a mouse model (Muñoz-Elías, 
Marcano & Camilli 2008). There is a positive correlation between the formation of an 
extracellular matrix and stability of biofilms during murine colonization (Trappetti et 
al. 2011b). Biofilm formation appears to be a general characteristic of pneumococci 
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from different isolation sites and of different serotypes, although some serotypes (6B, 
14, and 19F) have been shown to be more efficient biofilm formers than others (3 and 
38). (Tapiainen et al. 2010; Camilli, Pantosti & Baldassarri 2011). Drug-susceptible 
strains also tend to form thicker biofilms.  
 
Biofilm growth provides a favorable environment for adaptation and persistence. 
Increased antibiotic resistance is a major characteristic of a biofilm, and different 
mechanisms of this resistance have been proposed, such as reduced diffusion and 
penetration of drugs through the biofilm matrix and into cells, and the reduced growth 
rates of cells within a biofilm
19
 (Donlan 2000). Isolates from a biofilm have been 
documented to possess higher MICs to a variety of antibiotics than those in planktonic 
mode of growth (García-Castillo et al. 2007).  
 
The requirement for extracellular DNA for maintaining biofilm architecture and the 
higher transformation efficiency in biofilm cells, probably mediated by competence 
activation (Chapter 5), may provide a suitable condition for gene exchange (Li et al. 
2001; Moscoso, García & López 2006; Oggioni et al. 2006). The different 
environments within a biofilm also contribute to variations in pneumococcal exposure 
to antibiotics and oxidative stress. These factors may affect genetic transformation 
and mutation, giving rise to phenotypic variants within a biofilm (Pericone et al. 
2002; Prudhomme et al. 2006; Allegrucci & Sauer 2007; Allegrucci & Sauer 2008). 
 
 
1.6 Multiple Pneumococcal Colonization  
Multiple pneumococcal colonization (or co-colonization) is the simultaneous 
colonization of pneumococcal strains. Most of the early reports of co-colonization 
employed culture-based methods and showed differences in its prevalence across 
continents (Chapter 4). More recent approaches in determining genetic diversity 
included sensitive DNA-based methods for serotyping (Chapter 3 and 4), as well as 
strain characterization mainly by PFGE, MLST, and whole-genome sequencing 
(Chapter 4).  
                                                        
19
 Antibiotics such as β-lactams target metabolically active cells which undergo cell division, as they 
target proteins necessary for cell wall synthesis. Therefore, metabolically inactive cells would be 
minimally affected by these drugs. 
 71 
1.6.1 Effects of Vaccination on Co-Colonization 
Two recent studies analyzed the effects of vaccination on co-colonization, one of 
which showed no significant change in the prevalence of multiple colonization for up 
to 3 years (Brugger et al. 2010), while the other showed a significant reduction in co-
colonization rates in the PCV7 era compared to pre-vaccine era (Valente et al. 2012). 
The different observations may be due to the differences in background colonization 
rates, cohort age and characteristics, as well as laboratory methods of detecting co-
colonization. The latter study also demonstrated the effects of herd immunity in 
reducing rates of co-colonization with vaccine serotypes in non-vaccinated 
individuals. After PCV7 administration, both studies showed an increase in 
prevalence of NVT in single or co-colonization. However, due to possibly differences 
in competitiveness of NVTs, some serotypes were more prominent than others in 
single colonization than multiple colonizations in the PCV7 era, indicating that 
composition and relative prevalence of serotypes in co-colonization is not only a 
reflection of exposure to that serotype. The effects of conjugate vaccines in lowering 
co-colonization have significant adaptive consequences, as it may reduce the diversity 
of colonization strains undergoing horizontal transfer of genes encoding advantageous 
traits (Valente et al. 2012). 
 
1.6.2 Horizontal Gene Transfer (HGT) 
Pneumococci are naturally competent for genetic exchange (Chapter 5), and multiple 
pneumococcal colonization facilitates the optimal environment for such exchanges 
between heterogeneous strains by horizontal gene transfer (HGT). Genes encoding 
virulence and colonization factors that showed evidence of HGT include pspA 
(Hollingshead, Becker & Briles 2000), IgA1 protease (Lomholt 1995), pspC (Iannelli, 
Oggioni & Pozzi 2002), and nanA (Dowson et al. 1997; King, Whatmore & Dowson 
2005); these are all surface components subjected to selective pressure from the host 
immune system.  In addition, two crucial properties of the pneumococcus, serotype 
and antibiotic susceptibility, can also be altered by intra- and inter-species HGT of the 
capsulation locus and antibiotic-resistance determinants, respectively, between 
pneumococci and other streptococci (Coffey et al. 1991; Coffey et al. 1998; 
Brueggemann et al. 2007; Croucher et al. 2011).  
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1.6.3 Pneumococcal Supragenome 
Comparisons of multiple pneumococcal strains at the genomic level (either by whole-
genome sequencing or CGH) reveal the extensive heterogeneity in gene content 
among these strains (Dopazo et al. 2001; Hakenbeck et al. 2001; Hoskins et al. 2001;  
Oggioni & Pozzi 2001; Tettelin et al. 2001; Brücker et al. 2004; Obert et al. 2006; 
Shen et al. 2006; Hiller et al. 2007; Dagerhamn et al. 2008; Donati et al. 2010; 
Croucher et al. 2011; Hiller et al. 2011). The gene pool of multiple pneumococci 
therefore exists as a “supragenome” with a size larger than a genome of any single 
strain (Reviewed in (Ehrlich et al. 2005) and (Muzzi & Donati 2011). Using the finite 
supragenome model, which does not assume an endless introduction of new gene 
clusters upon the addition of genomes (therefore a non-open genome) (Hogg et al. 
2007), the pneumococcal supragenome size contains approximately 5,100 clusters, 
compared to a single genome of ~2,400 clusters (Hiller et al. 2007).  
 
The distributed genome hypothesis states that the supragenome consists of a set of 
core genes found in all strains, in addition to accessory (or distributed) genes found in 
a subset of strains, and genes unique to a particular strain (Ehrlich et al. 2005; Shen et 
al. 2005; Hiller et al. 2007). Genome sequence comparison of strains TIGR4 and R6 
revealed that some genes and gene clusters are specific to each of the strains, and 
these unique genes made up 13% of the genome (Brückner et al. 2004). Similarly, 
comparison of TIGR4 and a serotype 3 strain revealed presence of unique gene 
regions (Oggioni & Pozzi 2001). These clusters exhibit mosaic structures with 
atypical GC content, suggestive of non-pneumococcal sequences. Similarly, evidence 
of HGT and microevolution was observed among strains in the nasopharynx of host 
during a respiratory infection (Hiller et al. 2010). Similarities in gene content may not 
be associated with geographical location and serotype, and strains of serotypes 
commonly detected in carriage vary in gene contents and genetic background (Hiller 
et al. 2007). 
 
1.6.4 Supragenome in Other Bacterial Species 
Intra-species genome diversities are also reported for related streptococcal species 
such as S. pyogenes, S. agalactiae, S. mitis, S. thermophilus, S. suis (Tettelin et al. 
2005; Brochet et al. 2006; Lefébure & Stanhope 2007; Denapaite et al. 2010; Donati 
et al. 2010; Johnston et al. 2010; Zhang et al. 2011). Collectively, it is thought that 
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the streptococcal supragenome exceeds 6,000 genes, triple to that of a single genome. 
In addition, other respiratory tract colonizers such as H. influenzae (Shen et al. 2005; 
Hogg et al. 2007), S. aureus (Fitzgerald et al. 2001), and M. catarrhalis (Davie et al. 
2011) also show genomic differences across strains.  
 
The extent of diversity varies between species. For example, the supragenome of 
Bacillus anthracis is small; no new genes are introduced after only 4 genomes (Read 
et al. 2002). Similarly, an aphid endosymbiont, Buchnera aphidicola, also presents no 
novel genes after 4 genomes (Mira et al. 2010). Such closed pan-genomes may be a 
consequence of a restricted and isolated niche in which acquisition of foreign DNA 
material is improbable. In contrast, the opportunistic pathogen Acinetobacter 
baumannii appears to have an open pan-genome associated with its ability to persist 
in multiple host environments such as lungs, urinary tracts, skin, and plastics (Imperi 
et al. 2011). Similarly, the large streptococcal supragenome is associated with the 
different host anatomical sites in which they can be isolated and the wide spectrum of 
diseases they cause in humans and animals. Therefore, differences in supragenome 
sizes between species may reflect on the species’ capacity for gene exchange and 
transformation, as well as its adaptability in different habitats. 
 
1.6.5 Genetic and Genic Heterogeneity as Means of Adaptation 
Distributed genes with known functions encode for transporters, bacteriocins, 
transcription regulators, antibiotic resistance determinants, efflux proteins, metabolic 
enzymes, and cell surface proteins (Brückner et al. 2004; Obert et al. 2006; Hiller et 
al. 2007; Ding et al. 2009; Croucher et al. 2011; Hiller et al. 2011). In addition, other 
distributed clusters are of hypothetical function, some of which may be beneficial 
during invasion or colonization (Obert et al. 2006; Hiller et al. 2007). These 
variations may enable pneumococcus as a species to increase its metabolic 
capabilities and adapt in different niches, which may explain its ability to survive and 
cause infections in multiple host anatomical locations. Genomic comparisons of 
strains of the same multilocus sequence types (STs) sharing identical housekeeping 
gene fragments revealed gene content differences closely related clones, and these 
differences have been shown to be associated with variations in disease potentials in 
animal models (Silva et al. 2006; Hiller et al. 2011). 
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1.6.6 The Significance of Co-Colonization in Adaptation 
Simultaneous colonization of pneumococci of different serotypes as well as with other 
streptococci provides opportunity for intra- and inter-species HGT, enabling the 
acquisition of beneficial properties (Dowson et al. 1990; Dowson et al. 1993; Sibold 
et al. 1994). Multiple colonizations can expand the supragenome of a species by 
introducing accessory, non-core genetic determinants into the population (Shen et al. 
2006; Hiller et al. 2007; Donati et al. 2010). This ultimately would confer the 
population an adaptive advantage for survival in different host environments. Clearly, 
the simultaneously colonization of different strains is required before such HGT 
between strains can take place. Therefore, the extent of multiple colonization is a 
measure of the supragenome and thus the adaptive potential of the organism as a 
population. 
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1.7 Work in This Thesis 
The works in this thesis include the evaluation of phenotypic and genotypic 
diversities of pneumococci from different perspectives, including strain diversity in 
co-colonization events, diversity of the competence-stimulatory peptide, and that of 
the capsular regulatory gene cpsB. The works in this thesis included strains collected 
from Tanzania as well as the United Kingdom, in addition to reference strains kindly 
provided by collaborators. The study was conducted by the Centre for Clinical 
Microbiology of the Royal Free and University College Medical School, University 
College London. 
 
1.7.1 Chapter Three  
Continuous surveillance of prevalent serotypes is crucial in understanding the 
epidemiology of pneumococcal carriage and infections, which aids in assessing 
efficacies of current vaccines and designing future serotype-based vaccines. 
Conventional serotyping methods are costly, time-consuming, and non-specific. 
Current DNA-based methods require the large number of serotype-specific primer 
pairs, while microarray studies are costly, limiting its use in selected laboratories. 
Also, the resolution power of microarrays is also dependent on the serotype-specific 
targets present in the array, whereas a sequence-based method can easily be modified 
to identify and characterize a new serotype. Here, we present a novel single-primer 
PCR and sequence-based method targeting capsular regulatory gene cpsB that can 
correctly identify a high number of serotypes, including those covered in the latest 13-
valent conjugate vaccines. 
 
1.7.2 Chapter Four 
The phenotypic and genotypic diversities were determined for pneumococci 
colonizing in a cohort of healthy Tanzanian children under the age of five in Moshi, 
Tanzania. The selection and systematic characterization of up to 20 colonies per 
colonization event in this study is greater than most previous studies analyzing 
pneumococcal diversity. We characterized two crucial phenotypes, serotype and 
antibiotype. This work also entails genetic characterization by multilocus sequence 
typing (MLST). We demonstrated the co-colonization of multiple serotypes, some of 
which also had different antibiotic susceptibilities. MLST revealed the presence of 
unrelated strains of the same serotype, providing evidence that determining serotype 
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alone is an underestimate of pneumococcal co-colonization diversity. Through this we 
have provided a framework and a starting point for performing whole-genome 
sequencing in estimating the supragenome size of pneumococci within a nasopharynx. 
 
1.7.3 Chapter Five 
Pneumococcal competence is mediated by the competence-stimulatorypathway 
containing a ligand peptide (CSP), which exists in multiple allelic forms. This chapter 
documents a unique discovery of a high prevalence of CSP4 in Tanzania, a rare 
pherotype in the developed world. We provide evidence that the differences in 
proportions of CSP between Tanzania and the United Kingdom is likely to be 
governed by geography rather than disease potentials of different CSP alleles. We 
also demonstrated that most co-colonization events containing multiple strains had 
different CSP alleles, potentially facilitating genetic exchanges between co-colonizing 
strains. 
 
1.7.4 Chapter Six  
It is thought that regulation of capsule expression is crucial to the survival of 
organism, and some serotypes are more commonly encountered than others. We 
hypothesize that serotypes differ in their capacity to regulate capsule production, 
perhaps by the sequence diversity of capsular regulatory genes. With the availability 
of cpsB data from Chapter Three we sought to determine intra-serotype diversity of 
cpsB in a large sample of pneumococci. Irrespective of ST differences, we reveal that 
serotype 6B contains two divergent clusters based on cpsB, compared to serotype 1 
that clusters closely together. Comparison of over 300 sequences shows different 
areas of amino acid conservation and substitutions throughout the length of CpsB, 
while the majority of amino substitutions within serotype 6B occurred between 
globular domains, which might affect the structure and folding of the protein.  
 
1.7.5 Chapter Seven 
While conducting work described in Chapter Five, we encountered a rare CSP6.1 
allele in one of the archived strains from the Royal Free Hospital. Phenotypic and 
MLST suggest its identity as the newly recognized organism Streptococcus 
pseudopneumoniae. To test the hypothesis of CSP6.1 being a common 
pseudopneumococcal CSP, presumptive strains of different streptococcal species were 
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compared in their CSP alleles. We show that CSP6.1 is a common allele in S. 
pseudopneumoniae, and we propose that CSP determination is a potential target in 
differentiation between these closely related organisms.  
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CHAPTER TWO: Materials and Methods 
 
 
2.1 General Overview 
Pneumococcal strain collection and archiving is divided into two sections: studies 
conducted in Tanzania, including nasopharyngeal strain collection and archiving, and 
studies conducted at the Royal Free Hospital (RFH) in London, United Kingdom, 
including reference and invasive strain collection, as well as collection of non-
pneumococcal reference strains. Strains from Tanzania were included in studies 
discussed in Chapters 3, 4, 5, and 6, and strains from the UK were included in works 
discussed in Chapters 3, 5, and 6. Each heading is followed by the location in which 
the studies were conducted. Preparations for growth media and reagents are described 
in Section 2.9. Strains included in this thesis are represented in Appendix Table A1. 
Clinical strains included in the S. pseudopneumoniae study are described in the 
Materials and Methods section in Chapter 7. In addition, non-pneumococcal strains 
provided by collaborators throughout the work of this thesis are indicated in Table 
2.1. 
 
Methods covered in Tanzania were performed by Dr. Ndeky Oriyo, Dr. Sarah Batt, 
and Dr. John Crump, depending on the cohorts as described below. Methods covered 
in the Royal Free Hospital, London was performed by Mr. Marcus Leung, unless 
otherwise described below.  
 
2.2 Pneumococcal Strains from Tanzania 
2.2.1 Pneumococcal Isolates from Carriage Studies 
Pneumococci isolated from Africa were collected from two separate studies. One was 
conducted in Moshi, Tanzania, where a longitudinal analysis of multiple 
pneumococcal carriage in children under the age of 6 was undertaken and headed by 
Dr. Ndeky Oriyo (Oriyo 2011). A separate study in the Huruma Hospital in Kahe, 
Tanzania, investigated the effect of azithromycin treatment for trachoma on induction 
of drug resistance in S. pneumoniae (Batt et al. 2003). This study was headed and 
performed by Dr. Sarah Batt. Strains from Moshi were included in works discussed in 
Chapters 3, 4, 5, and 6. Strains from Kahe were included in works discussed in 
Chapters 3, 5, and 6. Both studies were conducted by the Department of Medical 
 79 
Microbiology (now referred to as the Centre for Clinical Microbiology) of the Royal 
Free Campus UCL Medical School in London. For sections 2.2.3 to 2.2.9, procedures 
for both studies, where they differ, are described separately. 
 
2.2.2 Pneumococcal Isolates from Invasive Studies  
Eighteen invasive strains isolated from Tanzanian children and adults were kindly 
provided by Dr. John Crump (Crump et al. 2011a; Crump et al. 2011b). Antibiotic 
susceptibility data for these strains was provided by Ms. Shanette Nixon of the 
Kilimanjaro Christian Research Institute. Antibiotic susceptibilities were determined 
according to CLSI guidelines by Dr. Shanette Nixon of Kilimanjaro Christian 
Medical College, Moshi, Tanzania. Pneumococci were inoculated onto Dorset’s egg 
medium agar slants (Southern Group Laboratory) and shipped to our London 
laboratory in ambient temperature (Wasas et al. 1998). These strains are included in 
Materials and Methods section of Chapter 5.     
 
2.2.3 Ethical Approval 
Ethical approval for the Tanzania multiple colonization study was initiated, 
implemented and followed-up by Miss Ndekya Oriyo. Approval was granted by the 
Tanganyika Planting Company Limited (TPC) Ethical Committee, under application 
reference number L08E02RB. A copy of the approval letter can be found in Appendix 
Fig. A1. 
 
Ethical approval for the trachoma study was initiated, implemented and followed-up 
by Dr. Sarah Batt. Approval was given by the London School of Hygiene and 
Tropical Medicine (application number 597) and approved by the Ethics Committee 
of the KCMC, and the Tanzanian National Institute of Medical Research. In addition, 
consultation was undertaken with Balozi
20
 village leaders from the study villages 
prior to the study. The Balozi leaders were in agreement with all protocols and with 
their blessing village people were very co-operative. Informed consent was obtained 
from parents or guardians before samples were taken, in the form of signatures or 
fingerprints on a consent form printed in English and Kiswahili.  
 
                                                        
20
  Balozi: Ambassador of a group of 10 houses 
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2.2.4 Demographic Characteristics 
The multiple colonization study was conducted near Moshi, in the Kilimanjaro region 
of Northeastern Tanzania, between January and December 2003 by Dr. Ndeky Oriyo. 
The city has a population of 144,739 (2002 census). The study site is a semi-closed 
community located within a sugar plantation named Tanganyika Plantation Company 
25 km from the town of Moshi (Fig. 2.1). At time of study, the plantation has 
approximately 16,000 hectares of land, with cane cultivation allocated to about 6,100 
hectares. The 2,300 employees (majority of which permanent) and their families who 
lived on the plantation are served by the 60-bed TPC Hospital. The plantation is 
divided into camps and living accommodation is allocated according to occupation 
and income. At time of study the employees earned incomes of £28-50 per month. 
Most of the children in the study were from families with low socioeconomic status in 
Tanzania, and their houses have on average two bedrooms with shared bathroom and 
toilet facilities. The average family size is five members. Electricity is provided in 
residential camps but not in an individual household level. Firewood is used for 
cooking in greater than 90% of the households. Every camp has a small drug 
dispensary. 
 
 
Fig. 2.1 Typical houses within the semi-closed community around the 
Tanganyika Plantation Company.  
 
The trachoma study was conducted by Dr. Sarah Batt in the Huruma Hospital at the 
Ibunoki village, in the Rombo district along the foothills of Mount Kilimanjaro in 
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Northeastern Tanzania between August 2000 and February 2001. Information of the 
Huruma Hospital is available online (Tanzania Volunteers 2011). The hospital serves 
mainly residents of the Ibunoki village but also individuals from other regions of 
Tanzania and neighbouring parts of Kenya. The hospital contained 300 beds and 
offered free healthcare to individuals. 
 
2.2.5 Recruitment Criteria 
Recruitment for the multiple colonization study was organized and supervised by Dr. 
Ndekya Oriyo. The study cohort consisted of healthy children aged between 1 and 5 
years who attended the Mother and Child Health (MCH) Centre at TPC Hospital. 
These children were eligible for the expanded programme of immunisation (EPI) that 
does not include a pneumococcal vaccine. The recruitment criteria for the children 
were that they resided on the plantation, were healthy and had not taken any 
antibiotics over the 3 months prior to recruitment. A questionnaire was completed by 
the clinician with information regarding the child’s gender, age, medical history and 
current antibiotic treatment. It also included a continuing record of the antibiotics and 
other medicines taken within a month of each sampling point. Children that were 
eligible and for whom, informed consent was obtained were screened for 
pneumococcal carriage. Children positive for pneumococcal carriage at baseline in 
January 2003 were swabbed monthly, where possible, for the subsequent 11 months. 
Thus, children with pneumococcal-positive culture in January/February 2003 were 
followed longitudinally until December 2003 (Oriyo 2011). 
 
Recruitment criteria for the trachoma study was designed by Dr. Sarah Batt as 
described (Batt et al. 2003). Briefly, a single oral dose of azithromycin was provided 
to each non-pregnant individual over the age of 5 years and ingestion of the drug was 
supervised as indicated. (Batt et al. 2003). 
 
2.2.6 Specimen Collection 
Specimen collection for the multiple colonization study was supervised by Dr. 
Ndekya Oriyo. Both nasopharyngeal and oropharyngeal swabs were taken to 
accurately detect rate of pneumococcal carriage and diversity of colonizing serotypes 
(Masters et al. 1958; Capeding et al. 1995; Rapola et al. 1997; Watt et al. 2004; 
Charalambous, Oriyo & Gillespie 2008). Both nasopharyngeal and oropharyngeal 
 82 
swabs were taken for the first six months of the study from children by the same 
laboratory assistant. Due to complaints from families regarding the discomfort of 
children when receiving nasopharyngeal swabs, only throat swabs were taken for the 
remaining six months of the study.  
 
Calcium-alginate swabs on a flexible aluminum shaft (Medical Wire and Equipment 
Limited) and cotton tipped swabs (Technical Service Consultants Limited) were used 
for nose and throat swabs, respectively. Nose swabs were inserted into the child’s 
nose and sample was collected by sweeping the roof of the nasal cavity. The throat 
swabs were inserted through the child’s mouth and a sample was collected by 
sweeping the back of his/her tongue. The swab was immediately immersed in 
approximately 1.0 mL of skim milk-tryptone-glucose-glycerol (STGG) medium 
(Section 2.9.4) contained in a 7.0 mL plastic screw-topped bijoux bottle. The shaft of 
the swab was cut with ethanol-flamed, sterilized scissors approximately an inch above 
the swab so that the screw-top lid could be replaced immediately. Inoculated STGG 
medium in cool box were taken to the KCMC, where inoculated culture was 
transferred aseptically without the swab and stored at -70°C.  
 
Single colonies were sub-cultured onto blood agar (purity plate) and pneumococcal 
colonies from purity plates were archived in STGG medium and sent to the RFH in 
London, UK. Upon arrival STGG archives were stored at -70°C until the start of this 
study in October 2008.  
 
In the trachoma study, throat swabs were taken from children under the age of 7 in the 
communities near the Huruma Hospital by Dr. Sarah Batt. Throat swabs were touched 
onto the back of the oropharynx and then immediately dipped into 5 mL SGG (STGG 
without tryptone) medium in bijoux bottles. SGG medium was used instead of the 
charcoal transport media supplied with the throat swab, bypassing the need for culture 
before freezing. Two 1 mL aliquots for each specimen were archived at -70 at KCMC 
in 1.8 mL cryo tubes (Nunc). One aliquot was sent back to the UK and one to be kept 
in Tanzania.  
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2.2.7 Isolation of S. pneumoniae From Primary Swab 
Methods of pneumococcal isolation from primary swabs did not differ between the 
two carriage studies. Isolation was performed by Dr. Ndeky Oriyo or Dr. Sarah Batt 
depending on the cohort. Ten microliters of primary swab sample in STGG (or SGG 
for trachoma study) medium was plated onto a primary blood agar plate containing 5 
μg/mL gentamicin (BAG) to select for pneumococcal growth (Sondag, 1977; 
Dilworth et al. 1975; Sondag et al. 1977). BAG plates were incubated overnight at 
35°C with 5% CO2.  
 
2.2.8 Identification of S. pneumoniae 
For multiple colonization study, pneumococci from primary plate was identified by 
Dr. Ndeky Oriyo based on α-haemolysis, indicated by greenish zone around colony 
growth, and the characteristic greyish draughtsman-like colonies. Up to 10 
presumptive pneumococcal colonies were plated separately on a purity blood agar to 
confirm pneumococcal growth by addition of optochin disc (Oxoid) and bile 
solubility testing. Purity plates were incubated in conditions as described above, and a 
zone of inhibition exceeding 14 mm in diameter (including the disc) was considered 
optochin-sensitive. Zone sizes of 7-13 mm were optochin intermediate-resistant. A 
swab of optochin-sensitive pneumococci from each purity plate was inoculated in 1.0 
mL STGG and archived in -80°C. Only one colony suggestive of pneumococcal 
growth per primary plate was selected for the trachoma study. 
 
2.2.9 Sample Numbering 
For the multiple colonization study, each child in the cohort was given a number. A 
strain is numbered by the child number, the site of isolation (NP, nasopharynx, or OP, 
oropharynx), and the isolate number. For example, 35NP10 represents the 10
th
 
pneumococcal colony isolated from the nasopharynx of child 35. Should 
pneumococci be detected in a children over multiple time points over the duration of 
sample collection (twelve months, one sampling per month), the isolate number is 
followed by the first three letters of the month (e.g. 11OP6 Jan and 11OP6 Jun). 
Strains isolated since July were all from oropharyngeal swabs and hence all were 
named OP. 
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For the trachoma study, each child was given a demographic number, the first two 
digits represents the village, the second two digits the house number, and the digits 
following hyphenation represents the child starting from the eldest. Hence 
pneumococcal strain 1003-2 represents one that was isolated from the second eldest 
child in house 3 of village 10. All samples included in this thesis from the trachoma 
study were taken at the same time point. 
 
2.3 Pneumococcal Strains from the United Kingdom 
Pneumococci isolated from sputum, blood, and CSF collected between the years 
1993-2000 at the RFH Microbiology Department were included in Chapters 3, 5, and 
6. Pneumococci from sites of infection were isolated and purity plated from qualified 
laboratory personnel of the Microbiology Department as described below. 
Pneumococci were archived in STGG after confirmation of pneumococcal isolation 
by phenotypic properties (Section 2.6). 
 
2.3.1 Isolation of S. pneumoniae from Sputum 
Isolation of pneumococci from sputum was performed by qualified laboratory 
personnel of the RFH. Isolates included in the works of this thesis were collected 
between the years 1993-2010, performed as described in the RFH Standard Operating 
Procedure (Royal Free Hospital NHS Trust 2011c). Briefly, using a sterile swab, a 
purulent piece of sputum is selected for dry thin smear preparation. Staining of 
sample was performed using ProDiff method to visualize and compare proportions of 
leukocytes (stain violet) and epithelial cells (stain red) in sample for quality 
assessment. Using low (10X) power objective lens, the number of epithelial cells are 
calculated, and samples with greater than 25 epithelial cells/lower power field are not 
analyzed, as the high number of epithelial cells may indicate sample contamination 
with nasopharyngeal colonizing flora.  
 
For samples with fewer than 25 epithelial cells/lower power field, they are mixed with 
an equal volume of Sputasol and mixture was vortexed for 30 seconds to homogenize 
sample. A 10-μL loopful of digested sample was then plated onto a CBA plate and 
grown overnight as described. Pneumococci were initially identified based on colony 
morphology and α-haemolysis (Section 2.6.2). A colony was then streaked on a purity 
plate and an 5-μg optochin disc (Oxoid) was added and grown overnight as described 
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(Sections 2.2.8 and 2.6.2). Presumptive pneumococci that were optochin-sensitive 
were tested for bile solubility (Section 2.6.3).       
 
2.3.2 Isolation of S. pneumoniae from Blood 
Isolation of pneumococci from blood was performed by qualified laboratory 
personnel of the RFH using the BD BACTEC FX Instrument. Isolates included in the 
works of this thesis were collected between the years 1993-2000, performed as 
described in Standard Operating Procedure (Royal Free Hospital NHS Trust 2011a). 
Briefly, samples are drawn directly from patients into BACTEC culture vials, which 
are subsequently placed into the instrument and incubated at 35°C. Bacterial growth 
is determined based on detection of CO2 in the system. The generated CO2 reacts with 
dye in culture vial and affects amount of light absorbed by fluorescent signal in the 
instrument. When positive growth is indicated, the culture is plated onto CBA 
overnight and pneumococci identified as described above for sputum samples.   
 
2.3.3 Isolation of S. pneumoniae from Cerebrospinal Fluid (CSF) 
Isolation of pneumococci from CSP was performed by qualified laboratory personnel 
of the Royal Free Hospital. Isolates included in the works of this thesis were collected 
between the years 1993-2000, performed as described in Standard Operating 
Procedure (Royal Free Hospital NHS Trust 2011b). Briefly, CSF samples are received 
from the hospital ward in a sterile container and plated onto CBA overnight. 
Identification of pneumococci is performed as described above for sputum samples. 
 
2.4 Pneumococcal Reference Strains 
Twenty-nine pneumococcal strains of known serotypes were received by Prof. 
Stephen Gillespie from GR MICRO prior to the start of the thesis (Appendix Table 
A1). Serotypes for these strains were confirmed by the Health Protection Agency 
(HPA) with the kind assistance of Dr. Karen Broughton, Dr. Siobahn Martin, and Dr. 
Androulla Efstratiou. Reference pneumococcal strains were kindly provided by Dr. 
Bruno Pichon (HPA) and Dr. Jutta Loeffler (Centre for Amyloidosis and Acute Phase 
Proteins, UCL Royal Free Campus). Multilocus sequence typing profiles for HPA 
strains were provided by the HPA. S. pneumoniae ATCC 49619 (serotype 19F) was 
kindly provided by Mrs. Rajita Dasai (RFH). For all but pneumococci received by 
Jutta Loeffler, strains were archived in STGG. Pneumococci provided by Dr. Jutta 
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Loeffler, were archived in Brain Heart Infusion (BHI) medium with 10% glycerol 
were prepared by Dr. Jutta Loeffler. All strains are stored at -80°C. 
 
2.5 Non-Pneumococcal Reference Strains 
Streptococcal strains other than S. pneumoniae were kindly provided by Dr. Anna 
Tymon (Eastman Dental Institute), Dr. Derren Ready of the (Eastman Dental 
Institute, UCL), Mrs. Rajita Dasai (RFH), and Dr. Clare Ling (HPA). Other bacterial 
strains were provided by Mrs. Rajita Dasai (RFH) and Ms. Sarah Thurston 
(Respiratory Medicine, UCL) (Table 2.1). Frozen archives in STGG were prepared as 
described above, except for H. influenzae, where chocolate blood agar (Oxoid) was 
used instead of CBA for overnight incubation
21
. Strains provided by Dr. Derren 
Ready were archived from CBA in frozen medium containing 50% BHI, 30% 
Phosphate Buffered Saline, pH 7.2 (Gibco), and 20% glycerol (Sigma). 
 
Table 2.1. Non-pneumococcal strains provided for works included in this thesis 
 
Species Type Strain Provided by 
Streptococcus anginosus NCTC 10713 Derren Ready (UCL) 
Streptococcus gordonii NCTC 7865 Derren Ready (UCL) 
Streptococcus intermedius NCTC 2227 Derren Ready (UCL) 
Streptococcus mitis NCTC 12261 Derren Ready (UCL) 
Streptococcus mutans   NCTC 10449 Derren Ready (UCL) 
Streptococcus parasanguinis NCTC 55898 Derren Ready (UCL) 
Streptococcus salivarius NCTC 8618 Derren Ready (UCL) 
Streptococcus sanguinis NCTC 7863 Derren Ready (UCL) 
Streptococcus sobrinus NCTC 12279 Derren Ready (UCL) 
Streptococcus cristatus ATCC 51100 Derren Ready (UCL) 
Streptococcus agalactiae ATCC 12401 Rajita Dasai (NHS) 
Streptococcus pseudopneumoniae ATCC BAA-960 Clare Ling (HPA) 
Streptococcus oralis NCTC 11427 Anna Tymon (UCL) 
Haemophilus influenzae ATCC 10211 Rajita Dasai (NHS) 
Staphylococcus aureus ATCC 25923 Rajita Dasai (NHS) 
Klebsiella pneumoniae ATCC 13883 Rajita Dasai (NHS) 
Moraxella catarrhalis ATCC 25238 Sarah Thurston (UCL) 
 
2.6 Identification of S. pneumoniae 
From frozen culture archived in -80°C in freezer in RFH, confirmation of 
pneumococcal identity by α-haemolysis, optochin sensitivity and bile solubility were 
performed. A proportion of pneumococci were also tested for agglutination with 
                                                        
21
  CBA plates are unsatisfactory for growth of H. influenzae, and chocolate blood agar with already-
lysed erythrocytes is more appropriate. 
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anticapsular antibodies. The pneumococcus is generally α-haemolytic, optochin 
sensitive, bile-soluble. Agglutination with anticapsular antibodies depends on the 
presence and type of the capsule. These tests are described below. 
 
2.6.1 α-Haemolysis 
Presumptive pneumococci are indicated by α-haemolysis, seen as a greenish zone 
around colony growth. This can be differentiated from β-haemolysis, where the 
clearing of the agar colour can be seen, and γ-haemolysis, where no colour change is 
observed (Fig. 2.2). α-hemolysis characteristic is not a definitive property of the 
pneumococcus, as it is seen in other streptococcal species
22
 (Rouff & Bisno 2010). 
 
Fig. 2.2. Haemolytic characteristics of Streptococci. Streptococcus pneumoniae is 
α-haemolytic (left), which can be differentiated with β-haemolysis (center), and γ-
haemolysis (right), by their effect on red blood cells on blood agar.  
 
 
2.6.2 Optochin Susceptibility 
For each strain, a 5-μg optochin disc (Oxoid) was placed on purity plate. Optochin-
susceptibility was not tested directly from frozen STGG culture, as glycerol may 
induce optochin-resistance (Robson et al. 2007). Optochin susceptibility is 
determined by the zone of inhibition around the disc (O'Brien et al. 2003). After 
overnight incubation, the strain is considered optochin-susceptible if a zone of 
inhibition exceeds 14 mm, optochin-nonsusceptible if zone of inhibition is 7-14 mm, 
and optochin-resistant if the zone of inhibition is ≤ 7 mm. All but one strain (strain 
N452) included in this study was optochin sensitive based on zone size. Subsequent 
                                                        
22
 α-haemolytic streptococci include but not limited to S. mitis, S. oralis, S. sanguinis, and S. gordonii 
(Rouff & Bisno 2010). 
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phenotypic and genetic characterization suggests N452 belongs to S. 
pseudopneumoniae (Chapter 7). 
 
2.6.3 Bile Solubility 
Two variations of the bile solubility tests, the colony and suspension procedures were 
performed, depending on colony sizes. The colony procedure is preferable when 
pneumococcal colonies are large or mucoid. The suspension procedure is 
recommended when pneumococcal colonies are small (Health Protection Agency 
2011). Both procedures were performed as described below. Reference S. pneumoniae 
strain ATCC 49619, instead of NCTC 12977 as recommended by the HPA, was tested 
in parallel as a control. 
 
2.6.3.1 Colony Bile Test 
A loopful of 2% sodium deoxycholate (Sigma-Aldrich) was placed onto a large or 
mucoid colony on purity plate, and plate was incubated at 35°C with 5% CO2 for 15-
30 mins. A flattening of colony indicates that strains of that colony is bile-soluble, 
and is suggestive of pneumococci. Intact colonies after incubation suggest that strains 
are bile-insoluble. 
 
2.6.3.2 Broth Bile Test 
From purity plate, a loopful of colonies was suspended into 500 μL of 0.9% saline 
(Oxoid) to make a thick suspension. Five hundred microliters of 10% sodium 
deoxycholate (Sigma) was added to the test samples, while 500 μL of saline was 
added to a negative control. Tubes were then placed in 35°C with 5% CO2 for 15-30 
mins. A clearing of the suspension following incubation is indicative of bile-
solubility.  
 
2.6.4 Serotyping Using Anti-Capsular Sera 
Pooled (Pneumotest Kit) and type-specific antisera (Statens Serum Institut, 
Copenhagen) were used for serotyping. Pneumokit includes antisera specific for 
serotypes or serogroups included in the 23-valent polysaccharide vaccine.  
 
Serotyping performed was based on the chessboard method (Sørensen 1993). The kit 
contains 12 pooled antisera (A-F, and H, and P-T), each containing sera specific to a 
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group of serotypes or serogroups. The kit is designed such that a vaccine 
serotype/group will react with one pool from A-F and H and one from P-T. 
Suspension of each sample was to be mixed with each pool individually and 
sequentially, first with pools A-F and H, followed by pools P-T. Pools containing 
serotypes/groups most prevalent in carriage and disease are tested first. Thus, the 
order is A→B→C→H→D→E→F, then P→Q→R→S→T. In brief, a loopful of 
multiple pneumococcal pure colonies was re-suspended in 50 µL of PBS, pH 7.2 
(Gibco). Two µL of the suspension was added to a plain glass slide, and 1 µL of 
pooled antiserum was added adjacent to the drop of suspension. A coverslip was then 
used to mix the two droplets and applied onto the slide, and the slide was then viewed 
under light microscope.  
 
A positive result is indicated by the agglutination of pneumococci under the light 
microscope when mixed with sera of a particular pool. The serotype/group was 
recorded as the type/group reactive to a combination of 2 pools (Table 2.2). For 
example, a sample in which agglutination was found when exposed to pool B and Q 
belongs to serogroup 6. Pneumococci belonging to a serogroup where multiple 
serotypes are present, type-specific antisera were used to identify the serotype of these 
isolates. 
 
 
Table 2.2. Serotypes/groups reactive to antiserum pools included in the 
Pneumotest Kit 
 
Pool A B C D E F H 
P 1 19 7    14 
Q 18 6     23 
R 4 3  9 12   
S 5 8   10 17 15 
T 2  20 11 33 22  
Neg
a 
  Group 1 Group 2 Group 3 Group 4 Group 5 
 
a
  Positive reactions to only one pool of A-F and H are in one of these groups: 
Group 1: Serotypes/groups 24, 31, 40 
Group 2: Serotypes/groups 16, 36, 37 
Group 3: Serotypes 21, 39 
Group 4: Serotypes/groups 27, 32, 41 
Group 5: Serotypes/groups 13, 28 
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2.7 Antibiotic Susceptibility Tests 
2.7.1 Disc Diffusion Test 
The Kirby-Bauer disc diffusion method was performed by Dr. Ndekya Oriyo in 
Tanzania, and was performed to determine susceptibilities to penicillin, amoxicillin, 
co-trimoxazole (25 μg), tetracycline (30 μg), chloramphenicol (30 μg), erythromycin 
(15 μg), and amoxicillin, according to guidelines set out by the Clinical and 
Laboratory Standards Institute (CLSI) (Clinical 2008). An oxacillin disc (1 μg) was 
used to assess penicillin and amoxicillin susceptibilities. To perform disc testing, 
colonies from an overnight-grown CBA plate were picked with a cotton swab and 
inoculated into 0.9% saline to a density equivalent to turbidity of 0.5 McFarland 
standard by comparing with a control 0.5 McFarland standard tube (bioMerieux). A 
cotton swab was immersed into the suspension was then streaked to cover the entire 
area of MHB agar plates. Following streaking antibiotic discs were placed onto MHB 
and plates were incubated as described above. Table 2.3 shows the susceptible, 
intermediate-resistant, and resistant breakdown for each antimicrobial tested. 
 
Table 2.3 Zone diameter interpretive standards for S. pneumoniae according to 
Clinical Laboratory and Standards Institute guidelines 
 
Antimicrobial Sensitive (mm) Intermediate (mm) Resistant (mm) 
Oxacillin (1 μg) ≥ 20 - - 
Co-trimoxazole (25 μg) ≥ 19 16-18 ≤ 15 
Tetracycline (30 μg) ≥ 23 19-22 ≤ 18 
Chloramphenicol (30 μg) ≥ 21 - ≤ 20 
Erythromycin (15 μg) ≥ 21 16-20 ≤ 15 
 
 
2.7.2 Minimum Inhibitory Concentration Determination 
Ε-test was performed by Dr. Ndekya Oriyo in Tanzania and was confirmed by 
Marcus Leung in RFH. For strains non-susceptible to penicillin and co-trimoxazole 
based on disc diffusion, E-test performed with benzylpenicillin and co-trimoxazole 
strips (AB bioMerieux), following CLSI procedures (Clinical and Laboratory 
Standards Institute 2008). S. pneumoniae  ATCC 49619
23
 was included as a control 
strain. An overnight pure culture from CBA was swept and inoculated into 0.9% 
saline (Oxoid) to 0.5 McFarland standard. This turbidity was visually compared with 
                                                        
23
  ATCC 49619 with penicillin and co-trimoxazole MIC of 0.25-1 μg/mL and 0.125-1 μg/mL, 
respectively (Clinical and Laboratory Standards Institute 2008). 
 91 
0.5 MacFarlane control standard (bioMerieux). The inoculated suspension was then 
plated onto MHB agar plate (Oxoid). One E-test strip was placed onto the center of 
each plate. For each strain triplicates were performed (three for penicillin, three for 
co-trimoxazole per strain). MHB containing E-test strips were incubated overnight at 
35°C with 5% CO2. MIC was read on the confluent grown plate the next day, 
measured by the concentration scale of the strip where growth inhibition meets (Fig. 
2.3). In cases where MICs differ within the triplicate by two-fold, the median MIC 
values were indicated in results. For greater than two-fold discrepancies, triplicate 
tests were re-performed. Table 2.4 shows the susceptible, intermediate-resistant, and 
resistant breakpoints for penicillin and co-trimoxazole as interpreted by CLSI 
guidelines (Clinical and Laboratory Standards Institute 2008). 
 
Table 2.4 Minimum Inhibitory Concentration (MIC) interpretive standards for 
S. pneumoniae according to CLSI guidelines 
 
 MIC breakpoints (μg/mL) 
Antimicrobial Sensitive Intermediate Resistant 
Penicillin  
(non-meningitis) 
≤ 0.06 0.12-1.0 ≥ 2.0 
Co-trimoxazole ≤ 0.5 1.0-2.0 ≥ 4.0 
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Fig. 2.3 MIC determination using E-test strips on a confluent growth of 
pneumococci. MIC of a strain is indicated as the concentration scale of the strip 
where growth inhibition meets. The strip shown is the benzylpenicillin E-test strip. 
Arrow indicates the MIC value for this strain. Figure modified from Morand and 
Muhlemann (Morand & Mühlemann 2007). Proceedings of the National Academy of 
Science of the USA allows the use of original figures including one shown above for 
noncommercial and educational use without requesting permission. 
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2.8 Genetic Analysis of Pneumococcal Strains 
The works in this thesis include sequence analysis of capsulation regulatory gene 
cpsB (Chapter 3), housekeeping genes in multilocus sequence typing (Chapters 4 and 
7), gene encoding the competence pathway ligand peptide comC (Chapter 5 and 6), 
and PCR amplification of 16S ribosomal gene from non-pneumococcal organisms 
(Chapter 3). The sections that follow describe the procedures required to extract DNA 
from intact cells, followed by PCR amplification, and sequence analysis. The steps 
described below are standard methodologies applicable to all sequence analysis across 
all gene regions analyzed. For specific procedures, please refer to the materials and 
methods sections in respective chapters. 
 
2.8.1 Standardized DNA Extraction by Heat Lysis Method 
Overnight pneumococcal colonies from purity plates were harvested with a sterile 
loop (Nunc) and inoculated into 50 µL 1X PBS, pH 7.2 (Gibco). Microcentrifuge 
tubes were heated at 95ºC in Accublock Digital Dry Bath (Labnet) for 5 mins to 
induce cell lysis. Suspension was then centrifuged at 10,000 x g for 5 mins. A 1/10 
dilution was made by mixing 10 µL supernatant containing genomic DNA with 90 µL 
PBS (Gibco) or PCR-grade water (Invitrogen). Diluted genomic DNA was stored in 
4ºC for up to six months. 
 
2.8.2 DNA Quantification and Quality Verification 
Purified DNA was quantified using the NanoDrop 2000 Spectrophotometer (Thermo 
Scientific). Briefly, the instrument was first calibrated with either 2 μL of PBS or 
PCR-grade water depending on the elutant of the DNA sample to be assessed. The 
sample loading dock was then cleaned with a tissue wipe and the same volume of 
DNA sample was examined for its concentration and purity as measured by a 
260/280-nm absorbance ratio. A ratio with a range of 1.8-2.0 is considered to be pure.   
  
2.8.3 Standardized Polymerase Chain Reaction (PCR) 
Each PCR reaction contained 50 µL master mix consisting of 5 µL 10X PCR buffer 
(Invitrogen), five µL MgCl2 (Invitrogen), three µL dNTP (Promega), two µL of each 
oligonucleotide primer (Sigma-Aldrich), and 0.3 µL Taq polymerase (Invitrogen), and 
32.7 µL DNase/RNase-free distilled water (Invitrogen). Stock and master mix 
concentrations of PCR components are presented in Table 2.5. 
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Table 2.5. PCR components and stock and master mix concentrations 
 
Component  
(Stock concentration) 
Volume in Master Mix 
(µL) 
Master Mix 
Concentration (in 50 µL) 
PCR Buffer (10X) 5 1 X 
MgCl2 (50 mM) 3 3 mM 
dNTP (5 mM) 3 0.3 mM 
Primers (10 µM) 2 0.4 µM each 
Taq polymerase (5 U/µL) 0.3 0.03 U/µL 
 
Table 2.6 lists primers used for conventional PCR performed in this thesis and the 
amplification extension time for each primer pair. Other than differences between Tm 
and extension time, all PCRs performed had an initial denaturation step at 94 ºC, 
followed by 30 cycles of amplification. Amplification included 30 sec. of 
denaturation at 94 ºC, thirty sec. of annealing, and extension at 72 ºC. A final 4-
minute extension step at 72 ºC is included. For works pertaining to quantitative PCR 
(qPCR) amplification in works of Chapter 7, sequences of primers and quantitative 
PCR (qPCR) probes are included in Section 7.2. 
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Table 2.6 Conventional PCR primers used in works of thesis 
Primer Chapter Sequence (5’ – 3’) Tm(ºC) Size (bp) ET (Sec)a Reference 
aroE-fw 3, 5 GCC TTT GAG GCG ACA GC 50 405 45 (Enright & Spratt 1998) 
aroE-rv 3, 5 TGC AGT TCA (G/A)AA ACA T(A/T)T TCT AA 50 405 45 (Enright & Spratt 1998) 
gdh-fw 3, 5 ATG GAC AAA CCA GC(G/A/T/C) AG(C/T) TT 50 460 45 (Enright & Spratt 1998) 
gdh-rv 3, 5 GCT TGA GGT CCC AT(G/A) CT(G/A/T/C) CC 50 460 45 (Enright & Spratt 1998) 
gki-fw 3, 5 GGC ATT GGA ATG GGA TCA CC 50 483 45 (Enright & Spratt 1998) 
gki-rv 3, 5 TCT CCC GCA GCT GAC AC 50 483 45 (Enright & Spratt 1998) 
recP-fw 3, 5 GCC AAC TCA GGT CAT CCA GG 50 450 45 (Enright & Spratt 1998) 
recP-rv 3, 5 TGC AAC CGT AGC ATT GTA AC 50 450 45 (Enright & Spratt 1998) 
spi-fw 3, 5 TTA TTC CTC CTG ATT CTG TC 50 474 45 (Enright & Spratt 1998) 
spi-rv 3, 5 GTG ATT GGC CAG AAG CGG AA 50 474 45 (Enright & Spratt 1998) 
xpt-fw 3, 5 TTA TTA GAA GAG CGC ATC CT 50 486 45 (Enright & Spratt 1998) 
xpt-rv 3, 5 AGA TCT GCC TCC TTA AAT AC 50 486 45 (Enright & Spratt 1998) 
ddl-fw 3, 5 TGC (C/T)CA AGT TCC TTA TGT GG 50 441 45 (Enright & Spratt 1998) 
ddl-rv 3, 5 CAC TGG TG(G/A) AAA CC(A/T) GGC AT 50 441 45 (Enright & Spratt 1998) 
cpsA-fw 3 GCA GTA CAG CAG TTT GTT GGA CTG ACC 54 160 30 (Pai, Gertz & Beall 2006) 
cpsA-rv 3 GAA TAT TTT CAT TAT CAG TCC CAG TC 54 160 30 (Pai, Gertz & Beall 2006) 
cpsB-fw 3, 6 GCA ATG CCA GAC AGT AAC CTC TAT 65 1061 90 This work 
cpsB-rv 3, 6 CCT GCC TGC AAG TCT TGA TT 65 1061 90 This work 
cps13wzy-fw 3, 6 GAT GGG AAA ATA CGA TAT GCT C 61 309 50 Kong (2005) 
cps13wzy-fw 3, 6 AAC TCC ATG ACA AAA CTC CAG C 61 309 50 Kong (2005) 
cps34I6bh-fw 3, 6 GCT TTT GTA AGA GGA GAT TAT TTT CAC CCA AC 54 408 45 (Pai, Gertz & Beall 2006) 
cps34I6bh-rv 3, 6 CAA TCC GAC TAA GTC TTC AGT AAA AAA CTT TAC 54 408 45 (Pai, Gertz & Beall 2006) 
cps6cwciN-fw 3, 6 TAC CAT GCA GGG TGG AAT GT 55 1800-2000 150 (Park et al. 2007) 
cps6cwciN-rv 3, 6 CCA TCC TTC GAG TAT TGC 55 1800-2000 150 (Park et al. 2007) 
comC-fw 4, 5 GAT AAA ATT CTC TCA ACT GT 54 ~300 30 This work 
comC-rv 4, 5 GGT AAC TGT GAC TAA TAA TT 54 ~300 30 This work 
16slf-fw 6 AGT TTG ATC CTG GGC TCA G 55 ~1300 120 (Woo et al. 2001) 
16slf-rv 6 AGG CCC GGG AAC GTA TTC AC 55 ~1300 120 (Woo et al. 2001) 
  
a
 ET: Extension time 
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2.8.4 Agarose Gel Electrophoresis 
Electrophoresis gel with 1.5% agarose was made by adding 0.45 g of agarose 
(Bioline) to 30 mL 1 x TBE buffer. Mixture was heated in a microwave oven (Sharp 
Electronics) to boiling to melt agarose powder. Ethidium bromide (Fluka) was added 
to a final concentration of 0.05 µg/mL. Each lane contains 3 µL containing PCR 
reaction and loading buffer (Qiagen). Gel bands were visualized in either ImageQuant 
300 (GE Healthcare Life Sciences) or G:BOX (SynGene) gel imaging systems. 
Hyperladder I (Bioline), 100-bp (Invitrogen) or 1000-bp ladders (Invitrogen) were 
used for band size standardizations for all electrophoresis runs depending on reagent 
availability. 
 
2.8.5 PCR Amplicon Purification 
Purification of PCR products was performed using QIAquick PCR Purification Kit 
(Qiagen), according to manufacturer’s instructions. The elutant containing purified 
DNA was stored in -20ºC. 
 
2.8.6 Cycle Sequencing 
The same primers used for PCR amplification were employed for cycle sequencing. 
Each sequence reaction contains 1.8 µL 5X Big Dye Sequencing Buffer (Applied 
Biosystems), two µL of forward or reverse primer, and 0.5 µL of Big Dye Sequence 
Terminator v3.1 (Applied Biosystems). Sterile distilled water (Invitrogen) was added 
to a final volume of 7.5 µL of master mix, followed by the addition of 2.5 µL of 
purified PCR amplicon. Sequencing reactions were added into 96-well plate (Applied 
Biosystems) and were subject to an initial 96 ºC step, followed by 25 cycles of 96 ºC 
for 30 sec., 50 ºC for five sec., and 60 ºC for four mins. Each sample is run in 
quadruplicate: duplicate in the forward direction and duplicate in the reverse 
direction. Completed sequencing reactions were kept at 4ºC until ethanol precipitation 
(see below). Ethanol precipitation was performed no later than 3 days after cycle 
sequencing to ensure fluorescent dye from Big Dye does not dissipate over time.  
 
2.8.7 Ethanol Precipitation 
Ethanol precipitation was performed directly on 96-well plates (Applied Biosystems) 
to cycle-sequenced product to desalt and concentrate amplified single-stranded 
products. Each sequencing reaction (10 µL) was mixed with 90 µL of precipitation 
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solution containing 62.5 µL 95% ethanol (Sigma-Aldrich) with 24.5 µL HPLC water 
(VWR) and 3 µL of sodium acetate, 3M, pH 4.6 (Applied Biochem). Precipitation 
reactions in 96-well plates were centrifuged at 4,000 x g for 45 mins at 4°C in the 
ALC PK120 centrifuge (ALC). The solution was discarded by gently tapping the 96-
well plate upside down to not dislodge invisible DNA pellet. Excess salt in 
precipitation was removed by the addition of 200 µL of 70% ethanol, followed by 
centrifugation of 4,000 x g for 15 mins at 4°C. Ethanol was discarded in the same 
fashion. To remove excess ethanol, the 96-well plate was spun upside-down at 800 x 
g for 1 min at 4°C to remove excess ethanol without removing DNA pellet, and put 
on 95°C hot plate for 10 seconds. Fifteen μL of HiDi formamide 24  (Applied 
Biosystems) was added to each reaction well. Plates containing purified DNA pellets 
were either immediately analyzed on the sequence analyzer (see below) or stored at -
20°C until sequence analysis. Stored plates were processed no later than a week to 
ensure fluorescence signal is sufficient for sequence analysis. 
 
2.8.8 Sequence Analysis 
Sequencing plates were loaded onto Sequence Analyzer 3130 (Applied Biosystems) 
with the 50 cm, four-capillary array set up. Polymer POP-7 (Applied Biosystems) was 
used for sequencing reactions over the course of this thesis. Each set of 4 reactions 
took approximately 60 minutes. Therefore, a full 96-well plate containing 
quadruplicates of 24 samples would take approximately one day to complete. Raw 
data files were automatically converted into .ab1 files that can be analyzed by 
sequence analysis software Bionumerics.   
 
2.8.9 Bionumerics 
Bionumerics software versions 3.0 or 6.5 (Applied Maths) were used to perform 
sequence analysis, sequence trimming, and sequence data storage. Ab1 sequence files 
generated by sequence analyzer were loaded onto Bionumerics interface and multiple 
alignment (from each of four cycle sequencing reactions per sample) was performed 
to generate a consensus sequence. Alignment was analyzed over the length of the 
consensus. Should undefined or overlapping peaks appear within the fragments 
                                                        
24
 Addition of formamide improves sequencing reactions by weakening hydrogen bonding between 
nucleotides (Zhang, Hu & Deisseroth 1991). 
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required for analysis (with MLST loci, cpsB, or comC), sequences were classified as 
of poor quality, and cycle sequencing was repeated from purified PCR products. If 
necessary, plating from frozen culture and PCR were also repeated. During the course 
of this thesis Bionumerics was upgraded to version 6.5. Database was transferred 
from the old version into the new. 
 
2.9 Growth Culture and Media 
2.9.1 Columbia Blood Agar (CBA) 
Blood agar with gentamicin was prepared by Dr. Ndekya Oriyo in Tanzania. CBA 
plates used in London do not contain gentamicin as archived samples were selected 
for pneumococcal growth in Tanzania; CBA plates used in RFH were purchased from 
the manufacturer (Oxoid), and were stored in 4ºC until use. All plates were inoculated 
prior to the expiration date indicated on package. 
 
2.9.2 Mueller Hinton Agar with Horse Blood (MHB) 
MHB plates used in Tanzania was prepared by Dr. Ndekya Oriyo by mixing 38 g of 
Muller-Hinton powder (Oxoid) to 950 mL of distilled water and autoclaved at 121°C. 
MHB plates used in RFH were prepared by the manufacturer (Oxoid), and were 
stored in 4ºC until use. All plates were used prior to the expiration date indicated on 
package. 
 
2.9.3 Brain Heart Infusion (BHI) Broth 
BHI broth was made by dissolving 37 g of BHI (Cosmos Biomedical) in distilled 
water. Broth was autoclaved at 121°C at 15 p.s.i. for 15 minutes.  
 
2.9.4 Skim Milk-Tryptone-Glucose-Glycerol (STGG) Medium 
2.9.4.1 Rationale for its Use 
The requirement for detailed analysis of nasopharyngeal sample calls for the optimal 
recovery of pneumococci following long-term storage. Sampling of such clinical 
samples in the developing world should also provide a transport medium which can 
maintain the viability of the samples (Leach et al. 1997). STGG (skim milk, tryptone, 
glucose, glycerol) medium was designed by Gibson et al. (Gibson & Khoury 1986) as 
a transport medium. This study showed that 97 bacterial species, including S. 
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pneumoniae, stored in STGG was viable for at least 40 months. Similarly, cell count 
was maintained in this medium for at least 3 years with repeated freeze-thaw cycles 
(Kaijalainen et al. 2004). There was no detectable difference in recoveries of 
pneumococci between direct plating and STGG storage at both -70°C and -20°C for at 
least 9 weeks; however long-term storage is preferable at -70°C (O'Brien et al. 2001). 
A recent study by Hare et al. (Hare, Smith-Vaughan & Leach 2011) showed that 
pneumococci in STGG remain viable for up to 12 years. The correlation between 
direct plating and STGG in detecting viable pneumococci even in low cell 
concentration is important for characterization of pneumococci in low abundance 
(Gratten et al. 1994; Brugger et al. 2010). Put together, the transport and long-term 
storage of pneumococci in STGG provides optimal and representative recovery of 
nasopharyngeal sampling, bypassing the requirement for immediate pneumococcal 
identification and characterization following sampling. Thus, a more extensive 
analysis can be performed at a later time without significant loss of viability. 
 
2.9.4.2 STGG Components 
Each component of STGG contributes to the preservation of cells. While skim milk is 
included in STGG to replace glass beads for bacterial agglutination, skim milk alone 
is capable of sustaining viable pneumococci for at least 16 months (Siberry et al. 
2001). Tryptone soya broth is a nutrient source when cells are grown in this medium. 
The inclusion of tryptone to the original SGG (skim milk, glucose and glycerol) 
medium has been demonstrated to extend preservation of pneumococci at higher 
storage temperatures (Charalambous et al. 2003). Glucose provides a protective effect 
to cells from freezing (Gherna 1981), and glycerol is capable of diffusing through the 
cell membrane and also provides cellular protection from freezing. The properties of 
STGG enable a slow cooling rate of 1.5°C/min when stored in -70°C, which allows 
optimal survival and recovery of bacterial organisms during and after long-term 
freezing (Gherna 1981; Gibson & Khoury 1986). 
 
2.9.4.3 STGG Preparation 
Three grams of tryptone soya broth (Oxoid) two grams of skim milk powder (Sigma-
Aldrich), and 0.5 g glucose (Sigma-Aldrich) were added into a 250 mL Pyrex bottle 
(Duran). Ten milliliters of glycerol (Sigma) and 100 mL distilled water was added. 
The mixture was heated to 70°C and stirred with a magnetic stirrer until all 
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components are dissolved. Aliquots containing 1 mL were dispensed into 1.8 mL 
cryo-tubes (Nunc). Tubes were either autoclaved at 15 p.s.i. at 121°C for 10 mins, or 
tyndallized (see section 2.7.4.4). The sterilized medium was stored in 4°C until use. 
Sterile STGG was used within six months of preparation to ensure stability of 
inoculant after sterilization (O'Brien et al. 2001). 
 
2.9.4.4 Tyndallization 
Tyndallization is a process for sterilizing under atmospheric pressure as an alternative 
to autoclaving if such a pressurized sterilization device is not available or the medium 
would be destroyed by high temperature. At times where autoclaving facilities are out 
of service, tyndallization was employed. Utilizing the germination process, bacterial 
spores are killed under repeated boiling. STGG was boiled for 15 minutes, then 
incubated in 37°C with 5% CO2 overnight. The remaining spores that survived the 
boiling process would germinate and become vegetative cells during the overnight 
incubation. This boiling and incubating process was repeated twice to maximize 
elimination of spore-forming contaminants. After tyndallization STGG was stored in 
4°C until use. Immediately prior to the need for long-term storage of bacterial cells, a 
sample of tyndallized STGG was plated onto Columbia blood agar and incubated 
overnight to confirm the absence of contaminants. 
 
2.10 Preparation of Solutions, Buffers, and Other Reagents 
2.10.1 Optochin Discs 
Optochin discs (Oxoid) were stored at 4°C until use. 
 
2.10.2 Bile (Sodium Deoxycholate) 
For the colony solubility method, two percent bile solution was prepared by 
dissolving 0.2 g of sodium deoxycholate (Sigma-Aldrich) into 10 mL sterile distilled 
water. For the broth solubility method, ten percent bile solution was prepared by 
dissolving 1 g of sodium deoxycholate into 10 mL sterile distilled water. Solution was 
stored in 4°C in the dark to keep away from light source. 
 
2.10.3 Working Primer Stocks 
Primers were received from manufacturer in powdered forms (Sigma-Aldrich). Stock 
solution of primers were made with DNase/RNase-free distilled water (Invitrogen) to 
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a concentration of 100 µM and stored at -20°C. Working stocks were made by mixing 
20 µL of 100 µM primer stocks with 180 µL DNase/RNase-free distilled water 
(Invitrogen) to a concentration of 10 µM. Working stocks were stored at 4°C. 
 
2.10.4 dNTP Working Stocks 
Stock dNTPs were supplied by Promega. Separate tubes of dATP, dGTP, dCTP, and 
dTTP were supplied at a concentration of 100 mM. Working stocks were made by 
mixing 50 μL of each dNTP with 800 μL DNase/RNase-free distilled water 
(Invitrogen) to a 1000 μL working stock 5 mM dNTP mix.  
 
2.10.5 Tris-Borate EDTA (TBE) Buffer 
TBE buffer (0.5 X) was prepared by adding 50 mL of 10 X TBE buffer (Gibco) into 
950 mL distilled water to total volume of 1 L. Buffer was stored in room temperature. 
 
2.10.6 PCR Purification Buffers (PB, PE, EB Buffers) 
Buffers for DNA purification (PB, PE, and EB buffers) were included in QIAquick 
DNA Purification Kit (Qiagen). Before use, PE wash buffer was mixed with 275 mL 
99.97% ethanol (Sigma-Aldrich). Buffers were stored in room temperature. 
 
2.10.7 Ethanol 
For 70% ethanol, fourteen milliliters of 99.97% ethanol (Sigma-Aldrich) was added 
with 6 mL HPLC water (VWR). For 95% ethanol, nineteen mL of 99.97% ethanol 
was added with 1 mL HPLC water. Both solutions were stored in room temperature. 
 
2.10.8 Sodium acetate, 3M, pH 4.6  
Sodium acetate, 3M, pH 4.6 (Applied Biochem) was stored in room temperature 
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CHAPTER THREE: Pneumococcal Sequetyping Using a Single 
Primer Pair 
 
 
3.1 Introduction 
3.1.1 Pneumococcal Serotyping 
Serotyping the pneumococcus has been an integral part in both pneumococcal 
research and clinical settings. Serotype-specific serum therapy during the early half of 
the last century required knowledge of the disease-causing serotype (Finland & Sutliff 
1931). More recently, the correct serological identification of Streptococcus 
pneumoniae is crucial in understanding global and regional epidemiological trends, as 
well as determining vaccine efficacies.  Conventional serotyping was based on the 
Quellung reaction or the Neufeld test, invented by Fred Neufeld in 1902, which 
described the change in refractive properties of the pneumococcal capsule upon 
reacting with specific anti-capsular antibodies. In 1931 the Quellung reaction was 
accepted as a method for differentiating capsular types (Austrian 1976), and to this 
day it remains to be the “gold standard” for serological classification of the organism 
because it is relatively easy to perform. 
 
3.1.2 Quellung Reaction 
Conventional Quellung reaction serotyping employs pneumococcal antiserum 
formulated and manufactured by the Statens Serum Institut (Copenhagen) 
(Henrichsen 1979). Polyclonal rabbit antibodies are served for this diagnostic purpose 
and have 4 levels of increasing capsular specificity in serum: 
1) Omniserum reacts with all serotypes at the time of its development. This can 
be used as rapid identification method for pneumococci. 
2) Pooled sera contains up to 12 pools with each pool containing antibodies 
specific to groups of serogroups and serotypes.  
3) Type or group sera are specific to a particular serotype. For a serogroup with 
multiple serotypes, group sera will cross-react with serotypes within a group. 
4) Factor sera are used to differentiate serotypes within a serogroup. 
  
The main serotyping method was modified by Sørensen (Sørensen 1993), enabling 
identification of serotypes/groups of 90-95% of pneumococci isolated from blood and 
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CSF using the chessboard system. The amount of costly sera required for this new 
method was greatly reduced compared to typing schemes involving a high number of 
antisera (Lalitha et al. 1999). The chessboard system involves 7 existing pooled 
antisera (A to H) and 5 new pools (P to T) to identify most serotypes of the PPV23. 
The pooled method was designed so that a serotype/group of the PPV23 serotypes 
would react with one existing pooled antiserum and one new pooled antiserum, and 
that the most commonly encountered serotypes would be identified first.  
 
3.1.3 Disadvantages of the Quellung Reaction 
The Quellung reaction requires technical expertise as agglutination visualization and 
interpretation may be subjective. A particular isolate would also need to be tested 
against a high number of antisera, slowing down identification. Third, a culture step is 
required, therefore culture-negative clinical isolates may not be detected (Azzari et al. 
2008). Fourth, there have been reports documenting anti-pneumococcal antibodies 
reacting with viridans streptococci, leading to false positives (Smith & Washington 
1984; Holmberg et al. 1985). The main disadvantage remains to be the cost of 
antisera. A kit of 12 pooled antisera, one mL each vial, costs £1200 in total, and 
would not be able to differentiate cross-reactive types within a group. To identify 
types within a group, a full set of factor sera would cost approximately £10,000. 
 
3.1.4 Alternative Serological-Based Serotyping Methods 
Most alternative serological-based methods have been developed in the past 3 
decades. Their main attempts were to address the aforementioned shortcomings 
present in conventional serotyping. These methods are summarized in the following 
sections. While some of these methods are promising, very few of them entered 
routine use as they introduce other shortcomings. 
 
3.1.4.1 Microscope Precipitin Test 
The high cost required in the Quellung reaction was recognised as early as 1938, 
when Schaub and Reid (Schaub & Reid 1938) developed the microscope precipitin 
test. This provided improved results when typing pneumococci from cultures, while 
requiring small amounts of serum. At that time this method also bypassed the need for 
test tubes and pipettes.  
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3.1.4.2 Microtiter Plate Agglutination Typing 
An agglutination method performed on microtiter plate was developed to ease routine 
serotyping on large numbers of pneumococci (Kirkman, Fischer & Pagano 1970).  
Culture was pre-treated with formalin to facilitate apparent agglutination with an 
unaided eye upon reaction with a factor serum. This method, however, required 
multiple incubation steps. 
 
3.1.4.3 Capillary Precipitin Typing (CPT) 
CPT was designed also to allow large-scale serotyping involving low amounts of 
immune serum. Type-specific antisera reacted with capsule antigens in glass capillary 
pipettes (Russell et al. 1978). A pipette was dipped into antiserum until capillary 
action drew up serum to 15 mm in length. The pipette was wiped with tissue paper 
and dipped into pneumococcal antigen solution of a similar volume. Pipette was then 
inverted and agglutination is visible for a positive reaction when pipette is placed 
against a black background with a tungsten light bulb or with a florescent light. There 
was 100% agreement between the capillary test and the Quellung reaction. However, 
a positive reaction may take up to 30 minutes to be visible.  
 
3.1.4.4 Counterimmunoelectrophoresis (CIE) 
CIE involves electrophoresis on agarose containing paired wells, a cathode one with 
antigen and the anode with capsular antibodies, and the specific precipitation as they 
converge along the gel. CIE has been applied to capsular antigen detection in sputum, 
blood, urine, and CSF samples (Fossieck, Craig & Paterson 1973; El-Refaie & Dulake 
1975). Multiple cycles of CIE would be performed, first with omniserum, followed by 
group and type antisera, to determine the serotype. Holliday et al. (Holliday 1981) 
subsequently devised a one-step method by employing pneumococcal omniserum 
without the need for group or type antisera. CIE was in wide use for detecting 
antigens from pneumococci causing invasive diseases during the introduction of the 
14-valent pneumococcal vaccine. However, a low proportion of isolates could be 
serotyped. Further analysis indicated that CIE using conventional barbitol buffer was 
incapable of serotyping capsules with neutral charge such as 7F, 7A, 14, 33F, 33A 
and 37, and these types could be correctly identified using m-carboxylphenylboronic 
acid buffer instead (Henrichsen, Berntsson & Kaijser 1980). 
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3.1.4.5 Co-Agglutination (COA) 
In this method, serotype-specific antibodies are bound and stabilised on their F’c 
fragments to protein-A of S. aureus (Kronvall 1973). The antibody-protein-A 
complex is then mixed with the pneumococcal strain on a glass slide (Smart 1986). 
The multiple serotype-specific F’ab regions present allow for the strong amplification 
of the agglutination signal. A positive signal could be visible within seconds. COA 
has been reported to be superior to CIE, being able to identify serotypes with neutral 
charges (Trollfors et al. 1983), is as accurate as Quellung (Smart 1986), and is 
superior to CIE and Quellung in simplicity and speed in serotyping. The chessboard 
system (Section 2.6.4) was also modified for COA typing (Lalitha et al. 1999). 
 
3.1.4.6 Latex Agglutination (LA) 
LA was first employed to detect β-streptococci, and subsequently for capsular typing 
of pneumococci (Browne, Miegel & Stottmeier 1984). In this method, antisera are 
coated with latex particles and are mixed with capsule antigen of an isolate. 
Visualization of agglutination with an unaided eye is indicative of a positive reaction, 
while the presence of a milky suspension suggests a negative reaction (Lafong & 
Crothers 1988). Results from LA was reported to be in agreement to Quellung 
serotyping and coagglutination, and may be a cost-effective alternative for serotyping 
in developing countries (Kaldor, Asznowicz & Dwyer 1988; Lafong & Crothers 
1988; Lalitha et al. 1996). LA may also be applied directly to body fluids (Kaldor, 
Asznowicz & Dwyer 1988; Sridharan et al. 1994). Statens Serum Institut 
(Copenhagen) manufactures latex-coated serotyping kit (Pneumotest-Latex), based on 
the chessboard method (Slotved et al. 2004). This method has been shown to produce 
false-positive results with viridans streptococci (Browne, Miegel & Stottmeier 1984; 
Slotved et al. 2004). 
 
3.1.4.7 Fluorescence Antibody Technic (FAT) 
FAT involves the detection of capsular antigen by rabbit immunoglobulin, and FITC-
conjugated, anti-rabbit goat immunoglobulin. The antigen and antibodies are mixed 
onto films and observed under the fluorescent microscope. While the method may be 
more time-consuming than the Quellung reaction, the main advantage of FAT is that 
fluorescence eases visualization, and it is more sensitive in identifying serotypes in 
various body fluids with low bacterial titre or with small capsules (Wicher et al. 
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1982). However, cross-reactivity with other α- and β-haemolytic streptococci and 
Klebsiella pneumoniae was reported. 
 
3.1.4.8 Dot Blot ELISA Assay (DBEA) 
The DBEA was developed by Fenoll et al. (Fenoll et al. 1997) and was being used 
routinely by the group at the time of their publication in addition to the Quellung test.  
A heavy pneumococcal suspension in saline was spotted onto nitrocellulose 
membranes and dried at room temperature, followed by membrane blocking with 5% 
skim milk in PBS. After washing type or group antiserum was added to the membrane 
and incubated on a shaking platform. Goat anti-rabbit immunoglobulin G conjugated 
with peroxidase is added. When mixed with substrate 4-chloronaphthol, a positive 
reaction is seen as a dark colour surrounded by a halo. This method is reported by the 
group to be specific, rapid, and economical, but identification of types within a 
serogroup may be inconclusive. 
 
3.1.4.9 Immunoblot ELISA Assay (IBEA) 
The IBEA is a variation of DBA in which nitrocellulose membrane is placed directly 
on top of blood agar plate (Bronsdon et al. 2004). This allows for detection of 
multiple serotypes from nasopharyngeal samples, where other serotypes may be low 
in prevalence. Bronsdon et al. (Bronsdon et al. 2004) acknowledges the tedious nature 
of blot analysis and culture, which presents obstacles for rapid diagnostic use and 
skews proportions of co-colonizing serotypes in multiple colonizations.  
 
3.1.4.10 Flow Cytometry Assay 
The assay allows simultaneous detection of up to 15 serotypes, and also enabled to 
differentiation of cross-reactive serotypes (Park, Briles & Nahm 2000). Latex beads 
of variable sizes with red-fluorescent dye were coated with pneumococcal capsule 
antigen. This was then mixed with bacterial lysate in a microplate with rabbit 
pneumococcal antiserum pool P-T from Statens Serum Institut (Copenhagen), along 
with a fluorescein-conjugated anti-rabbit antibody. A correct match is the serotype in 
the lysate that effectively reduces the green fluorescence given by the antibody and 
the antigen-coated latex beads. Despite the small sample size, this method showed 
100% agreement to conventional typing, including cross-reactive types. The serotype 
coverage of this method was later expanded to cover 36 serotypes with incorporation 
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of a multiplex PCR reaction (Yu et al. 2005; Yu et al. 2008), and had been validated 
on clinical samples from different continents (Lin et al. 2006). With the use of 
Luminex
®
 technology, flow cytometry-based serotyping has recently been shown to 
be efficient and rapid in determining most of the known pneumococcal serotypes and 
detection of multiple serotypes (Yu et al. 2011).  
 
3.1.5 DNA-based Serotyping 
Serological methods mentioned above require antigens and antibodies in sufficient 
amounts to enable detection. With the recent advances in molecular biology and 
bioinformatics, DNA-based serotyping methods have been pursued. Molecular 
methods drastically increase sensitivity of serotyping, allowing identification of 
culture-negative pneumococci found in clinical samples (Saha et al. 2008; Tarragó et 
al. 2008). A recent comparison between DNA-based and Quellung serotyping 
revealed that colonisation rates in healthy children may be two-fold greater if 
molecular serotyping method was employed in place of conventional serotyping 
(Ogami et al. 2010). This is also important in the analysis of multiple colonization 
events (Chapter 4), as multiple serotypes can only be detected in culture by sampling 
multiple colonies on agar (Huebner et al. 2000a; Bronsdon et al. 2004) or by 
enrichment liquid broth (Kaltoft et al. 2008). For serotype identification, DNA-based 
typing methods target the serotype-specific genes of the capsular polysaccharide 
synthesis (cps) operon (Kong & Gilbert 2003; Kong et al. 2005; Pai, Gertz & Beall 
2006; Turner et al. 2011). DNA-based methods may be applied directly on clinical 
samples, bypassing a culture step. Compared to culture serotyping, PCR-based 
methods are much less laborious and efficient.  
 
3.1.5.1 Multiplex/Multistep PCR-Based Serotyping Methods 
A plethora of DNA-based serotyping methods targeting serotype-specific genes, as 
the presence of these regions clearly identifies the serotype. These methods are briefly 
summarized below. 
 
3.1.5.2 Multiplex PCR in Determining Nine Common Serotypes  
This method aimed to target serotypes covered in the proposed 11-valent conjugate 
vaccine (Brito, Ramirez & De Lencastre 2003). Multiple primers specific to serotypes 
1, 3, 4, 6B, 14, 18C, 19F, 19A, and 23F were put into six different multiplex PCR 
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reactions. Differentiation of serotypes within serogroup 6 and 18 were shown to be 
problematic, however the use of expensive antibodies can be reduced after serogroup 
determination of these strains. 
 
3.1.5.3 Semiautomated Multiplex PCR 
The study designed by Lawrence et al. (Lawrence et al. 2003) employs eight primer 
pairs to detect serotypes 1, 3, 14, 19F, 23F, and serogroups 6, 19, and 23. Of 93 
pneumococci tested in the study, all within the targeted serotypes and serogroups 
were identified correctly and reproducibly. This method was also species-specific, 
with no amplification products from related streptococci. However, not all primer 
pairs are put into the same reaction, and with an unknown pneumococcus three 
separate multiplex PCR reactions may be required for serotype identification. 
 
3.1.5.4 Combination of cpsA-cpsB polymorphism and serotype-specific wzy and wzx   
Kong and Gilbert (Kong & Gilbert 2003) designed a method that is able to 
differentiate up to 51 serotypes based on sequencing capsular regulatory genes cpsA 
and cpsB, as well as serotype-specific PCRs targeting the polymerase (wzy) and 
flippase (wzx) genes.  The sequencing aspect of this work will be discussed below 
(Section 3.1.5.14), however PCR branch of this method is able to differentiate 12 
different serotypes using more than 20 primer pairs (some serotypes require more 
than one primer pair per gene). PCR alone is not able to differentiate between 
members of serogroup 6, 18 (which can be resolved by the sequencing branch of this 
method), and is problematic differentiating between members of serogroup 33 except 
for 33B. This method eventually expanded to cover all 90 serotypes known at that 
time (Kong et al. 2005) and was tested on a large number of pneumococci (a total of 
708 pneumococci from the two studies). An additional 26 new primer pairs targeting 
the serotype-specific genes enabled differentiation of serotypes in which sequencing 
results were ambiguous. However even with the expanded repertoire of primer pairs, 
members of serotypes 6A and 6B proved difficult to differentiate by this method. 
 
3.1.5.5 Multiplex Nested PCR Detecting Serotypes 3, 14, 19F, 23F 
This method uses dot-blot probe to detect amplification by employing labelled probe-
linked outer and inner primers to enhance detection of pneumococci (Rubin & Rizvi 
2004). This study tested more than 50 serotypes and 28 non-pneumococcal strains, 
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and has proven the method to be specific both at the species and the serotype level 
(for the serotypes targeted). Of the pneumococci correctly serotyped, the sensitivity of 
this method is extremely high (2-10 fg or one bacterial cell from exponential phase), 
which is also shown by the detection of pneumococci in culture-negative samples. 
The major drawback of this method is that only four serotypes are covered. 
 
3.1.5.6 One-Step Multiplex PCR to Detect PCV7 Serotypes 
Serotypes covered in PCV7 can be correctly identified using this method bypassing 
the need multiple PCR reactions (O'Halloran D & Cafferkey 2005). Instead, all seven 
primer pairs are included in this procedure to identify PCV7 types. This method had 
been shown to be applicable to clinical samples from invasive diseases (Azzari et al. 
2008). However, similar to other studies, differentiation between serotypes PCV-
related type 6A and 6B was proved to be difficult. 
 
3.1.5.7 Differentiation of Serotypes 6A and 6B by Pyrosequencing 
Pai et al. (Pai, Limor & Beall 2005) have identified that despite the high homology 
shared between serotypes 6A and 6B, the two types can be differentiated by 
pyrosequencing based on a SNP at codon 195 of the wciP gene, encoding a rhamnosyl 
transferase (Mavroidi et al. 2004). There was 100% congruence between SNP and 
serotype in that region on over 200 pneumococci tested. This method is likely to be 
used alongside with other serotyping method as this method solely differentiates 
between these two serotypes. 
 
3.1.5.8 Multistep Multiplex PCR 
Pai’s group (Pai, Gertz & Beall 2006) also devised a multiplex, multistep PCR 
reaction that can differentiate 17 serotypes, and can be employed directly on clinical 
invasive and carriage samples with higher sensitivity compared to culture methods 
(Azzari et al. 2008; Saha et al. 2008; Antonio et al. 2009; Moore et al. 2010). More 
than 20 primer pairs are included in seven sequential multiplex PCR reactions. The 
order of the reactions was optimized originally by Pai et al. (Pai, Gertz & Beall 2006) 
to allow early detection of serotypes commonly found in the United States (Fig. 3.1). 
However, the ordering of the reactions can be altered to account for geographical 
differences in serotype prevalence (Dias et al. 2007; Morais et al. 2007; Saha et al. 
2008; Iraurgui et al. 2010; Njanpop Lafourcade et al. 2010). Different multiplex 
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reactions could also be combined to decrease workload. With this method, up to three 
serotypes were detected to be simultaneously present in nasopharyngeal secretions 
(Antonio et al. 2009). However, rare serotypes would require repetitive PCR reactions 
before diagnosis, and more than half of known serotypes would still require 
conventional typing, and serotypes 6A and 6B could not be differentiated by this 
method alone, and require the aforementioned pyrosequencing method (Pai, Limor & 
Beall 2005) or conventional serological typing.  
  
Fig. 3.1. Methodology of Multistep/multiplex PCR reaction. Multiplex PCR 
reactions performed sequentially to determine one of 17 serotypes. Method designed 
by Pai et. al. (Pai, Gertz & Beall 2006). Samples with no PCR amplification 
following seven reactions require conventional serotyping. Reaction orders and 
serotype combinations can be modified based on local epidemiology. Figure from Pai 
et al. (Pai, Gertz & Beall 2006). Journal of Clinical Microbiology authorizes the reuse 
of journal material including figure shown for academic purposes 
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3.1.5.9 Multiplex PCR for Pneumococcal Isolated in Otitis Media Patients 
The method designed by Billal et al. (Billal et al. 2006) allows detection of serotypes 
1, 3, 4, 14, 19F, 23F, and the emerging serotype 19A, as well as serogroups 6, 18, 19, 
and 23. However, band sizes produced by this method are similar across serotypes (all 
amplicons within 100-480 bp long, making differentiation of serotypes by this method 
difficult. 
 
3.1.5.10 Reverse-Line Blot Hybridization Serotyping 
The protocol for this method is described thoroughly by Kong et al (Kong & Gilbert 
2006). Previously used to detect serotypes of GBS (Kong, Ma & Gilbert 2005), this 
procedure was then applied to identification of pneumococcal serotypes, targeting 
serotype-specific gene wzy and regulatory gene wze (cpsD). In brief, oligonucleotide 
probes labelled with amine is anchored covalently to a nylon membrane. PCR 
products containing biotin is then hybridized to probes and detected as light emission 
by introducing peroxidase-containing streptavidin and electrochemiluminescence 
substrates (Fig. 3.3). This method was tested to detect serotypes covered in the PPV23 
(Kong et al. 2006), and subsequently expanded its coverage to include all serotypes 
(Zhou et al. 2007). However, cross-reactions were seen for up to 30 different 
serotypes, most of which were seen between types of a serogroup. Nonetheless, this 
method would be able to perform serotyping of over 90% of strains encountered, 
reducing the need and subsequent cost for specific antisera. 
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Fig 3.2. Procedures of reverse-line blot hybridization method targeting 
pneumococcal serotypes based on wzy and wze. A) Amine-containing serotype-
specific oligonucleotide probes covalently bound to nylon membrane. B) Multiplex 
PCR products containing biotin hybridizes to probes. C) Peroxidase-containing 
streptavidin binds to the biotin on PCR products. D) Addition of reagents leads to 
emission of light upon reaction with, which is indication of presence of PCR products. 
Figure from Kong et. al.(Kong & Gilbert 2006) with permission granted from Nature 
Publishing Group via RightsLink Copyright Clearance Center. 
 
3.1.5.11 Multiplex Real-Time PCR 
By targeting different serotype-specific genes, twelve serotypes (1, 3, 4, 5, 6A, 6B, 8, 
14, 15B/C, 19A, 23A, and 23F) can be differentiated by this real-time PCR approach 
with high sensitivity (detection level of 12-24 fg or five to ten bacterial cells per 
reaction) (Tarragó et al. 2008). Culture-negative samples could be detected to contain 
pneumococcal DNA from pleural fluids of children suffering from parapneumonic 
empyema. This method was promising as a tool for detecting pneumococci in cases of 
parapneumonic empyema, which conventional cultural detection methods have 
proven insensitive, but numerous related serotypes within a group (such as serogroups 
7, 9, 18, and 19) could not be differentiated. 
 
3.1.5.12 Restriction Fragment Length Polymorphism (RFLP) 
RFLP serotyping methods involve the cpsAB regulatory region (Lawrence, 2000) or 
the entire cps locus (Batt, 2005). Targeting cpsA and cpsB showed modest association 
between restriction pattern and serotype, with exceptions to a number of serotype 6A 
strains with identical banding patterns to some serotype 6B pneumococci. This 
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method employed multiple restriction enzymes, thus potentially complicating 
analysis. Therefore, this method is superior to conventional typing only from an 
economic point of view. Different sets of restriction patterns were also seen for 
isolates within a serotype (Lawrence, 2000). By including the entire cps region for 
restriction analysis, differences in serotype-specific genes can also be reflected as 
different banding pattern (Batt, 2005). RFLP of entire capsulation locus from dexB to 
aliA using a single endonuclease (HinFI) has revealed 46 restriction patterns that 
correlated well with serotypes with reproducibility. With the exception of serotype 
6B, multiple strains of the same serotype were observed to share over 90% similarity 
in banding patterns when displayed as a dendogram (Batt, 2005). This method may be 
a promising alternative, however amplification of a fragment of up to 30kb is 
technically demanding and time-consuming.      
 
3.1.5.13 Microarray 
Wang et al. (Wang et al. 2007) designed a microarray method using probes targeting 
serotype/group-specific regions in wzy (cpsD in serotype 3) to identify 43 serotypes 
including the 23 included in PPV23. This method was shown to be species-specific 
however closely-related species such as S. mitis and S. oralis were not included in the 
analysis. In another recent study, serotype/group-specific glycosyltransferase genes 
were used as targets for serotyping a small number of pneumococci of PPV23 
serotypes (Tomita et al. 2011a). Unfortunately, vaccine-related serotypes may also be 
identified as a vaccine type, as in the case of a 23A pneumococci being typed as 23F 
by this method. With the availability of Wellcome cps sequences, microarray could be 
used to differentiate the majority of the serotypes, with the ability to detect serotypes 
with low abundance in co-colonization samples (Turner et al. 2011).  
 
Recently, serotype coverage by microarray has been expanded to identify most of the 
93 serotypes known to date. The sensitivity of microarray was also demonstrated to 
be superior to that of culture method, with a higher rate of co-colonization and extent 
of serotype diversity detected within a co-colonization sample (Chapter 4). However, 
the cost of setting up a microarray limits its widespread use, especially in developing 
countries where pneumococcal disease burdens are high. 
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3.1.5.14 Sequencing-Based Serotyping Methods Targeting cpsAB 
The targeting of serotype-specific genes in multiple PCR means that a large number 
of primers would be required for appropriate coverage of serotypes. To enhance 
efficiency and to simplify set-up process, the design of a universal primer would be 
preferable. A sequence-based serotyping method took advantage of the 
polymorphisms within cpsA and cpsB (Jiang, Wang & Reeves 2001; Kong & Gilbert 
2003; Kong et al. 2005). Based on cps sequences of 11 serotypes (1, 2, 4, 6B, 8, 14, 
18C, 19F, 19A, 23F, 33F), a variable region flanked by conserved sequences was 
detected from 950 bp downstream of cpsA to 302 downstream of cpsB. A 
combination of cpsAB sequencing and wzx/wzy-specific PCR was employed for 
pneumococcal serotyping (Kong & Gilbert 2003; Kong et al. 2005). Sequence 
analysis of over 700 cpsAB sequences revealed 138 sequence types between 90 
serotypes, with most of the sequence types associated with a single serotype. The use 
of wzx and wzy-specific PCR assisted in serotyping ambiguous sequence types shared 
by multiple serotypes (e.g. 23F/A) (Kong & Gilbert 2003). Combining cpsAB 
sequencing and serotype-specific PCR, this method could identify 95% of 
pneumococci at least to the serogroup level (Kong et al. 2005). 
 
3.1.5.15 Weaknesses of cpsAB Partial Sequencing 
The sequence-based typing method described above suffers from some drawbacks. 
Similar to previous reports, serotypes 6A and 6B remain to be difficult to 
differentiate. In addition, with the new identification of serotypes 6C and 6D, the 
resolving power of this method to these new serotypes is unknown. Other serotypes 
(10A, 13, 14, 15B, 17F, 18B, 20, 22F, 23F, 23A, 25F, 33F, 33A, 35B, 38, 42) 
provided ambiguous results, and only five of these serotypes (6A, 6B, 18B, 33F, 33A) 
were serogroup-specific. Most importantly, the primer-binding region was located 
based on cps sequences of only 11 serotypes available at the time (Jiang, Wang & 
Reeves 2001). With the recent sequence analysis of cps operon of over 90 serotypes, 
more heterologous primer-binding regions may be identified by aligning cps 
sequences from these serotypes.   
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3.1.6 Aim 
At present, the availability of cps operon sequences of 90 serotypes from Wellcome 
Trust (Bentley et al. 2006), in addition to that of serotypes 6C (Park et al. 2007) and 
6D (Bratcher et al. 2010) allows us to revisit the potential of a sequence-based 
sequetyping system. Specifically, we aim to re-identify a heterologous region across 
all known serotypes, flanked by conserved sequences for binding of a single primer. 
Therefore, our aim is to locate this region using in silico multiple alignment method. 
Upon identification of this region, a common primer pair was tested on reference and 
clinical pneumococcal strains.  
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3.2 Materials and Methods: 
3.2.1 Sequence Alignment of cps of PPV23 Serotypes  
An in silico interrogation was performed by Dr. Kevin Bryson (UCL Bioinformatics) 
on the cps locus sequences made available by the Wellcome Trust (Bentley et al. 
2006). Alignment of cps of pneumococcal serotypes constituting the PPV23 was 
performed to identify 500 to 1100bp variable regions that are bordered by conserved 
primer sites for PCR amplification that could differentiate between serotypes. 
Alignment of cps sequences for the 23 vaccine serotypes was performed using 
MAFFT version 6.624b online interface (http://mafft.cbrc.jp/alignment/server/) using 
the iterative refinement method (NS-i). ClustalX 2.0.10 was used to analyze the 
alignment generated by MAFFT and generate a q-scores file, which contains 
information regarding the conservation of each nucleotide position along the multiple 
alignment; each nucleotide position was scored (i.e. consensus value for each 
nucleotide position) according to its conservation across all the 23 serotype 
sequences. A high conservation score would thus suggest a suitable common primer 
binding site due to its high sequence conservation. The q-scores file was then entered 
into an algorithm (PrimerFinder algorithm) to locate conserved primer-binding sites. 
After identification of an optimal primer pair based on maximum conserved binding 
sites and sequence differentiation between all 23 serotypes, the region to be amplified 
by this primer pair was analyzed in silico for 92 published serotypes (see below). 
 
3.2.2 “Primer Finder” Algorithm for Selecting Optimal Primer-Binding Sites 
The algorithm was developed by Dr. Kevin Bryson to identify potential conserved 
primer-binding sites, as measured from multiple alignment conservation q-score 
measurements generated from ClustalX. The optimal binding sites would be 
conserved across all 23 serotypes, flanking sequences that are unique in all serotypes. 
The PrimerFinder algorithm allows user to set the desired primer length, the amplicon 
length, and the number of nucleotide mismatches allowed on each primer-binding 
site. Thus, the initial primer length was set to 20 nucleotides, the amplicon length was 
set from 500 bp to 1,100 bp, and the number of nucleotide mismatches was set to two 
nucleotides per binding site. The algorithm examined each alignment position in turn 
within the multiple sequence alignment of the cps operon for all 23 sequences, 
searching for putative forward and reverse primers that obey the set values and whose 
amplicon sequence can discriminate the largest number of serotypes.  
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Each alignment position in turn was considered as a putative start site for a forward 
primer (Fig. 3.4, Step 1). The length of the primer was then extended one base pair at 
a time to obtain the longest forward primer while retaining the maximum number of 
matching sequences (Fig. 3.4 Step 2). This was followed by a search for the most 
optimal reverse primer site by searching the downstream alignment positions at a 
distance from 500 to 1100 bp from the upstream primer site. The primer extension 
approach for each putative reverse primer was repeated (Fig. 3.4 Step 3). For each 
putative primer pair examined, the internal amplified sequences across all the 
matching sequences were analyzed (Fig. 3.4 Step 4). Serotypes that could be 
putatively differentiated by unique sequences between the primer pair were then 
recorded. The serotypes with identical sequences in this region were recorded as 
ambiguously identified. The interrogation was repeated until all possible primer pairs 
along the alignment were considered. The results were recorded and ranked by the 
total number of serotypes (in decreasing order) each primer pair could identify.  
 
Fig. 3.3. Schematic representation of searching approach used by Primer Finder 
algorithm. The forward primer is identified within the multiple sequence alignment 
(allowing 2 mismatches per primer and including as many sequences as possible), 
then the search finds a reverse primer between 500 and 1100 bases downstream of the 
first, again satisfying the constraints and also having as much sequence diversity 
within the internal amplicon region. Steps 1 to 4 are described in Materials and 
Methods. 
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The algorithm identified four potential primer-binding sites (Table 3.1) differing in 
amplicon lengths (between ~600 to ~1000 bp) and number of nucleotide variation (1-
3 nucleotides) in amplified region between the 23 in silico-tested serotypes. As primer 
pair 1 provides the longest amplicon and the highest number of nucleotide variations 
between serotypes, this primer pair chosen by Mr. Marcus Leung to be tested on 
bacterial strains for this study (see below). Primers were designed in Primer3 
(http://frodo.wi.mit.edu/primer3/) by using template sequence of strain 519/43 
(serotype 1, accession number CR926497) and the 5’ and 3’ ends of the heterologous 
region identified above as respective primers. Single nucleotides were substituted on 
the non-extending ends of the primers to adjust for similar annealing temperature and 
minimize self-annealing. Sequences for primers used (cps-fw and cps-rv) are indicated 
in Table 2.6. 
 
3.2.3 Bacterial Strains and PCR  
Please refer to Appendix Table A1 for strains included in this study. Conventional 
serotyping using pooled and typed antisera was performed by Mr. Marcus Leung as 
described in Section 2.6.4. Please refer to Table 2.5 for standard PCR master mix. For 
testing species-specificity of sequetyping, an internal control PCR targeting 16S 
ribosomal RNA gene was employed (Woo et al. 2001). The primers and Tm for the 
control PCR are indicated in Table 2.6. Gel electrophoresis, DNA purification, cycle 
sequencing, ethanol precipitation, and sequence analysis were performed as outlined 
in Sections 2.8.3 to 2.8.8.  
 
3.2.4 Interrogation of Query Sequence to GenBank Database 
Raw sequence data were trimmed by Mr. Marcus Leung to include intact cpsB. For a 
given query sequence, the serotype associated with a result sequence bearing the 
highest BLAST bit score was the identified serotype by our novel method. Should the 
sequence with the top BLAST score belong to the same serogroup, the result is 
termed “serogroup-specific.” In cases where multiple serotypes of different 
serogroups share the highest BLAST score, results are treated as “ambiguous.” A 
misidentified result is one where the top BLAST score corresponds to a sequence of a 
different serogroup.  
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Table 3.1. Putative primer pairs identified from alignment of cps from vaccine serotypes 
Pair
a
 Amplicon 
Length 
(bp)
b
 
Primer
c 
Location
d
 Sequence (5’-3’ on coding strand) Minimum number of 
nucleotide differences between 
unique amplicon sequences
a
 
1 1058 Forward 
Reverse 
4414 
5471 
ATGCCAGACAGTAACCTCTAT 
AATCAGGACTTGCAGGCAGG 
3 
2 1056 Forward 
Reverse 
3772 
4827 
CCTATTAGTTCGGTGTCGCGATCAGATGTCAATATC 
AATGATAGTCGTTATGCCTTGAT 
2 
3 832 Forward 
Reverse 
4414 
5245 
ATGCCAGACAGTAACCTCTAT 
ATCAACTAATTTAGGAGAAA 
2 
4 667 Forward 
Reverse 
4805 
5471 
AATGATAGTCGTTATGCCTTGAT 
AATCAGGACTTGCAGGCAGG 
1 
a
 Pair 1 used for in vitro sequetyping due to identification in all 23 serotypes with highest number of nucleotide differences (i.e. all 23 serotypes 
differ by at least three nucleotides) 
b
 In silico anticipated primer pair one of a length of 1058 bp, however primer used in in vitro sequetyping has added three nucleotides to 5’ end 
of forward primer, therefore the actual amplicon length is 1,061 bp 
c
 Pair 2 reverse and Pair 4 forward are identical in location of the coding strand 
d
 Numbers based on nucleotide position on accession number CR926497.
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3.3 Results 
3.3.1 In Silico Identification of Optimal Primer Pair  
In silico evaluation has identified a region with sequence variation between the 23 
vaccine serotypes with a 1,061 bp amplicon that is 1,351 bp downstream of cpsA to 
224 bp downstream of cpsC (nucleotide position 305,125 to 306,185 on the G54 
genome, GenBank accession number NC011072). Subsequent in silico analysis of the 
92 serotype sequences revealed that with each primer binding site set at a mismatch of 
no more than two nucleotides, up to 84 of the 92 serotypes could yield an amplicon 
(Table 3.2). 
 
As some of the amplifiable serotypes share identical interceding sequences (e.g. 
sequences for serotypes 2 and 41A, as well as 7B and 40, Table 3.2), a subset of 54 of 
the 84 amplifiable serotypes would be differentiated by in silico sequence analysis of 
the amplicon (Table 3.2). However, due to the sequencing chemistry, the entire 1,061-
bp region between the primers is unlikely to be sequenced successfully; 
approximately 200 bp at each end may yield suboptimal sequence data. In silico 
analysis was therefore repeated to determine the serotypes that could be sequetyped 
when the central 732 bp region of the cpsB amplicon (Table 3.2). This revealed an 
additional 8 serotypes (6C, 6D, 7F, 7A, 17F, 18B, 18C, 33C) that would not be 
identified by cpsB alone. Of these eight serotypes, three pairs could be sequetyped to 
the correct serogroup, namely, 6C/6D, 7F/7A, and 18B/18C. Serotypes 17F and 33C 
have identical cpsB sequences and were not predicted to be differentiated from each 
other.  
 
Serotypes 25A, 25F and 38 were predicted to be non-amplifiable as the forward 
primer binding site has six mismatches. However, subsequent in silico sequence 
analysis of these three serotypes revealed multiple weaker reverse binding sites with 
at least 10 nucleotide mismatches that are present approximately 2,000 bp 
downstream of the forward primer, situated within the glycosyl transferase, wcyA 
gene. 
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Table 3.2. In silico analysis of pneumococcal serotypes that can be amplified and 
differentiated by sequetyping based on sequence diversity of cpsB.  
 
Serotype 
(n = 92)
b 
Amplification 
possible 
a,c
 
Differentiable by in 
silico analysis 
a, c, d
 
Differentiable by 
cpsB PCR and 
sequencing? 
a, c, d
 
Included in 
in vitro 
testing 
a
 
1 Y Y Y Y 
2 Y (2/41A) (2/41A) N 
3 Y Y Y Y 
4 Y Y Y Y 
5 Y Y Y Y 
6A Y Y Y Y 
6B Y Y Y Y 
6C Y Y (6C/6D) Y 
6D Y Y (6C/6D) N 
7F Y Y (7A/7F) Y 
7A Y Y (7A/7F) N 
7B Y (7B/40) (7B/40) N 
7C Y Y Y Y 
8 Y Y Y Y 
9A Y (9A/9V) (9A/9V) N 
9L Y Y Y N 
9N Y Y Y Y 
9V Y (9V/9A) (9V/9A) Y 
10F Y (10F/10C) (10F/10C) Y 
10A Y Y Y Y 
10B Y Y Y N 
10C Y (10C/10F) (10C/10F) N 
11F N Unknown Unknown N 
11A Y (11A/11D/18F) (11A/11D/18F) Y 
11B Y (11B/11C) (11B/11C) N 
11C Y (11B/11C) (11B/11C) N 
11D Y (11A/11D/18F) (11A/11D/18F) N 
12F Y (12F/44) (12F/44) Y 
12A Y Y Y N 
12B Y Y Y Y 
13 Y (13/20) (13/20) N 
14 Y Y Y Y 
15F Y Y Y N 
15A Y Y Y Y 
15B Y Y Y Y 
15C Y Y Y N 
16F Y Y Y Y 
16A Y Y Y N 
17F Y Y (17F/33C) Y 
17A Y (17A/34) (17A/34) Y 
18F Y (11A/11D/18F) (11A/11D/18F) N 
18A Y Y Y N 
18B Y Y (18B/18C) Y 
18C Y Y (18B/18C) Y 
19F Y Y Y Y 
19A Y Y Y Y 
19B Y Y Y N 
19C Y Y Y N 
20 Y (20/13) (20/13) Y 
21 Y Y Y Y 
22F Y (22F/22A) (22F/22A) Y 
22A Y (22A/22F) (22A/22F) Y 
23F Y Y Y Y 
23A Y Y Y N 
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23B Y Y Y Y 
24F Y Y Y Y 
24A Y Y Y N 
24B Y Y Y Y 
25F N Unknown Unknown N 
25A N Unknown Unknown N 
27 N Unknown Unknown Y 
28F Y Y Y Y 
28A Y Y Y Y 
29 N Unknown Unknown Y 
31 Y Y Y Y 
32F Y (32F/32A) (32F/32A) N 
32A Y (32A/32F) (32A/32F) N 
33F Y (33F/33A/35A) (33F/33A/35A) Y 
33A Y (33A/33F/35A) (33A/33F/35A) N 
33B Y Y Y Y 
33C Y Y (17F/33C) Y 
33D Y Y Y Y 
34 Y (34/17A) (34/17A) Y 
35F Y (35F/47F) (35F/47F) N 
35A Y (35A/33F/33A) (35A/33F/33A) Y 
35B Y (35B/35C) (35B/35C) Y 
35C Y (35C/35B) (35C/35B) N 
36 Y Y Y Y 
37 Y Y Y N 
38 N Unknown Unknown N 
39 N Unknown Unknown N 
40 Y (7B/40) (7B/40) N 
41F Y Y Y N 
41A Y (2/41A) (2/41A) N 
42 Y Y Y N 
43 N Unknown Unknown N 
44 Y (12F/44) (12F/44) N 
45 Y Y Y N 
46 Y Y Y N 
47F Y (35F/47) (35F/47) N 
47A Y Y Y N 
48 Y Y Y N 
Total Y = 84/92 
N = 8/92 
Y=54/92 
Ambiguous = 30/92 
Unknown=8/92 
Y = 46/92 
Ambiguous = 38/92 
Unknown = 8/92 
Y = 48/92 
N = 44 
 
a
 Y = yes, N = no. 
b
 Serotypes of PPV23 and PCV13 are indicated in bold. 
c
 Serotypes that are amplifiable by PCR but give ambiguous results are indicated as 
two or more serotypes having the same top BLAST bit scores. 
d
 Serotypes deemed non-amplifiable in initial in silico analysis are not included in the 
subsequent tests on identifiable serotypes, therefore resolution power is unknown for 
these serotypes. 
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3.3.2 Species Specificity of Sequetyping 
Other bacterial species, including a range of streptococci and common mucosal 
colonizers were selected to test the specificity of the selected pair of primers. An 
amplicon of the expected size of 1,061 bp was detected only in S. pneumoniae ATCC 
49619 (serotype 19F). Amplification of rRNA gene as a positive control in non-
pneumococcal strains confirmed the presence of a DNA template in these samples 
(Table 3.3).  
 
Table 3.3. The specificity of pneumococcal sequetyping against other bacterial  
species 
 
Organism Type Strain
a
 16S rRNA 
gene
b
 
Expected 1,061 bp band
 
Streptococcus pneumoniae  ATCC 49619 + + 
Streptococcus gordonii NCTC 7865 + - 
Streptococcus anginosus NCTC 10713 + - 
Streptococcus intermedius NCTC 2227 + - 
Streptococcus mitis NCTC 12261 + - 
Streptococcus mutans  NCTC 10449 + - 
Streptococcus parasanguinis NCTC 55898 + - 
Streptococcus salivarius NCTC 8618 + - 
Streptococcus sanguinis NCTC 7863 + - 
Streptococcus sobrinus NCTC 12279 + - 
Streptococcus cristatus ATCC 51100 + - 
Streptococcus pseudopneumoniae BAA-960 + - 
Streptococcus oralis NCTC 11427 + - 
Haemophilus influenzae ATCC 10211 + - 
Moraxella catarrhalis ATCC 25238 + - 
Klebsiella pneumoniae ATCC 13883 + - 
Escherichia coli ATCC 51299 + - 
Enterococcus faecalis ATCC 25922 + - 
 
a
 ATCC: American Type Culture Collection; NCTC: National Collection of Type 
Cultures 
b
 16S rRNA gene amplification performed as described in Woo et al. (Woo et al. 
2001) 
 
 
 
3.3.3 Evaluation of the Sequetyping Method Based on cpsB 
The cpsB sequences of 138 pneumococcal strains covering 48 serotypes were tested 
in vitro (Table 3.4). These strains originate from Tanzania and the United Kingdom 
with different genetic backgrounds and anatomical sample sites (Table 3.4). These 
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strains included all of the PPV23 vaccine serotypes (VTs) except for serotype 2. In 
addition, 25 non-vaccine serotypes (NVTs) were tested. Altogether, the study 
evaluated 46 serotypes that were predicted by in silico analysis to generate an 
amplicon, and two serotypes, 27 and 29, that were not predicted to yield an amplicon.  
 
In silico analysis based on the entire cpsB gene predicted that 28 of the serotypes 
tested would be sequetyped, and 20 serotypes tested in this study were predicted 
unlikely to be differentiated (Table 3.2). Of the 138 strains tested 96 (69.6%) were 
correctly sequetyped to the serotype. An additional 26 (18.8%) were sequetyped to 
the serogroup level, and 13 (9.4%) gave ambiguous results. One of 7 strains of 
serotype 19F (11.6402.H) was identified as a serotype 1, but at lower identity (98%) 
than found with the true serotype 1 strains tested. It is worth noting that the correct 
19F identity was a very close second best at 97% identity (Table 3.4). At this 
relatively low percent identity we would express caution and assign it as ambiguous 
and confirm by alternative methods, as all correctly identified strains had ≥ 99% 
identity. In addition a 33C (SG33c) and a 36 (SG36) strain were misidentified (Table 
3.4).  
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Table 3.4. Serotypes and strains included in this study, and sequetyping results 
based on cpsB sequences. 
Serotypea Sequetype Strain 
Sequence 
Typeb 
Country of 
Isolation 
Isolation 
Sourcec 
cpsB 
Accession Number 
1 1 3OP2 Sep 217 Tanzania NP JN642309 
 
1 H0 8114 0126 217 UK BC JN660116 
 1 H0 8212 0279 303 UK BC JN660117 
 1 H0 8078 0043 618 UK BC JN660118 
 1 H0 6274 0473 304 UK BC JN660119 
 1 H0 8228 0507 227 UK BC JN660120 
 1 H0 6196 0204 228 UK BC JN660121 
 1 H0 5122 0138 306 UK BC JN660122 
3 3 H0 9260 0327 180 UK BC JN660145 
 3 12.1690.X 180 UK BC JQ743514 
 3 12.1655.E 180 UK BC JQ743515 
 3 12.1640.H 180 UK BC JQ743516 
 3 12.1409.G 180 UK BC JQ743517 
 3 12.1259.V 180 UK BC JQ743518 
4 4 H0 9146 0234 246 UK BC JN660124 
 
4 H0 8102 0237 246 UK BC JN660125 
 4 H0 7406 0041 246 UK BC JN664256 
 4 11.6349.S 205 UK BC JQ743519 
 4 11.5324.N 246 UK BC JQ743520 
 4 11.4573.Q 246 UK BC JQ743521 
5 5 H0 8034 0160 289 UK BC JN660126 
 5 02-4520 ND UK BC JQ743522 
 5 04-2077 1400 UK BC JQ743523 
 5 07-2667 289 UK BC JQ743524 
 5 10-1351 4840 UK Eye JQ743525 
6A 6A H0 8212 0259 65 UK BC JN660127 
 6A N15 65 UK BC JN680106 
 6A N94 65 UK BC JN680118 
 6A N155 65 UK BC JN680128 
 6A N259 65 UK BC JN680138 
 6A N405 65 UK BC JN680146 
 6A/6B 12.1624.T 396 UK BC JQ743526 
 6A 11.6939.E 2467 UK BC JQ743527 
 6A 11.5544.Z 1876 UK BC JQ743528 
 6A/6B 11.5346.W 327 UK BC JQ743529 
 6A 11.3085.J 65 UK BC JQ743530 
6B 6B H0 8052 0052 176 UK BC JN660128 
 
6B H0 7156 0309 3481 UK BC JN660129 
 
6B 11NP10 Jan 4432 Tanzania NP JN642310 
 
6B 69OP10 4429 Tanzania NP JN642311 
 
6B 35NP1 4157 Tanzania NP JN642312 
 
6B 35NP6 854 Tanzania NP JN642313 
 
6B 3OP7 Sep 4373 Tanzania NP JN642314 
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Serotypea Sequetype Strain 
Sequence 
Typeb 
Country of 
Origin 
Isolation 
Sourcec 
cpsB 
Accession Number 
6B 6B 3NP7 Mar 4368 Tanzania NP JN642315 
6C 6C/D H0 5252 0052 1390 UK BC JN660130 
7C 7C 1003-2 ND Tanzania NP JN642316 
 
7C 2514-1 ND Tanzania NP JN642317 
7F 7F/7A SG07F ND UK C JN660086 
 7F/7A 12.1695.Y 191 UK BC JQ743531 
 7F/7A 12.1675.H 191 UK BC JQ743532 
 7F/7A 12.1666.R 191 UK BC JQ743533 
 7F/7A 12.1426.R 191 UK BC JQ743534 
 7F/7A 12.1299.R 191 UK BC JQ743535 
 7F/7A 12.1276.C 191 UK BC JQ743536 
8 8 H0 8342 0074 53 UK BC JN660132 
 
8 H0 9122 0175 53 UK BC JN660133 
9N 9N H0 7174 0058 66 UK BC JN660134 
 
9N H0 7018 0063 66 UK BC JN660146 
 
9N H0 9080 0083 66 UK BC JN660135 
9V 9V H0 7016 0058 156 UK BC JN660136 
 
9V H0 8156 0265 162 UK BC JN660141 
 9V 11.5715.C 156 UK BC JQ743537 
 9V 11.3601.D 162 UK BC JQ743538 
 9V 11.3021.E 162 UK BC JQ743539 
 9V 11.2143.S 156 UK BC JQ743540 
10A 10A SG10a ND UK C JN660087 
 
10A 21NP1 ND Tanzania NP JN642318 
 
10A 18NP10 852 Tanzania NP JN642319 
10F 10F/10C SG10f ND UK C JN660088 
11A 11A/11D/18F SG11a ND UK C JN660089 
 
11A/11D/18F 29OP10 5752 Tanzania NP JN642320 
12B 12B SG12b ND UK C JN660091 
12F 12B SG12f ND UK C JN660090 
14 14 H0 8208 0041 9 UK BC JN660147 
 
14 H0 8396 0107 124 UK BC JN660142 
 
14 H0 8084 0056 124 UK BC JN660143 
 
14 H0 7442 0047 124 UK BC JN660144 
 14 10-1688 ND UK S JQ743541 
 14 10-2893 ND UK S JQ743542 
15A 15A SG15a ND UK C JN660092 
15B 15B SG15b ND UK C JN660093 
16F 16F SG16f ND UK C JN660094 
17A 34/17A SG17a ND UK C JN660095 
17F 17F/33C H0 9084 0082 392 UK BC JN660140 
 
4/17F/33C/9V 22NP2 4160 Tanzania NP JN642321 
 
17F/33C H0 6092 0119 392 UK BC JN660137 
 17F/33C H0 8334 0064 964 UK BC JN660138 
18B 18B/18C SG18b ND UK C JN660096 
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Serotypea Sequetype Strain 
Sequence 
Typeb 
Country of 
Origin 
Isolation 
Sourcec 
cpsB 
Accession Number 
18C 18B/18C 10.2671.G 113 UK BC JQ743543 
 18B/18C 10.2178.X 113 UK BC JQ743544 
 18B/18C 09.2555.S 113 UK BC JQ743545 
 18B/18C 09.2223.P 638 UK BC JQ743546 
 18B/18C 09.1742.V 2449 UK BC JQ743547 
 18B/18C 09.1153.K 4162 UK BC JQ743548 
19A 19A 35NP1 4162 Tanzania NP JN642322 
 19A H0 9186 0354 199 UK BC JN664257 
 19A 12.1625.M 2081 UK BC JQ743549 
 19A 12.1623.F 461 UK BC JQ743550 
 19A 12.1579.M 450 UK BC JQ743551 
 19A H0 7336 0087 276 UK BC JN664258 
19F 19F ATCC 49619 ND UK C JN642323 
 19F 16OP4 347 Tanzania NP JN642324 
 19F 35NP8 6170 Tanzania BC JN642325 
 19F H0 8112 0101 162 UK BC JN664259 
 19F H0 8242 0108 162 UK BC JN664260 
 19F 11.6554.S ND UK Sputum JQ743552 
 1e 11.6402.H ND UK Sputum JQ743553 
20 20/13 SG20 ND UK C JN660097 
21 21 45OP9 Jan 1145 Tanzania NP JN642326 
 21 7NP4 ND Tanzania NP JQ009436 
22A 22F/22A SG22a ND UK C JN660098 
22F 22F/22A SG22f ND UK C JN660099 
23B 23B SG23b ND UK C JN660100 
 
23B 7OP9 ND Tanzania NP JN642327 
23F 23F SG23f ND UK C JN664261 
 23F 11.4091.H ND UK BC JQ743554 
 23F 11.3056.E 33 UK BC JQ743555 
 23F 11.2827.S 1682 UK BC JQ743556 
 23F 11.2737.T 1682 UK BC JQ743557 
 23F 11.1373.Z 6959 UK BC JQ743558 
24B 24B SG24b ND UK C JN660101 
24F 24B SG24f ND UK C JN660102 
27 27 H0 8432 0293 1475 UK BC JN660139 
28A 28A SG28a ND UK C JN660103 
28F 28A SG28f ND UK C JN660104 
29 29 SG29 ND UK C JN660105 
31 31 SG31 ND UK C JN660106 
33B 33B SG33b ND UK C JN660108 
33Cb 35B/35C SG33c ND UK C JN660109 
33D 33B SG33d ND UK C JN660110 
33F 33A/33F/35A SG33f ND UK C JN660111 
 33A/33F/35A SG33fb ND UK C JN660107 
34 34/17A SG34 ND UK C JN660112 
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Serotypea Sequetype Strain 
Sequence 
Typeb 
Country of 
Origin 
Isolation 
Sourcec 
cpsB 
Accession Number 
35A 35A/33F/33A SG35a ND UK C JN642328 
 35B/35C 16NP10 840 Tanzania NP JN660113 
 35B/35C 55OP3 ND Tanzania NP JQ009437 
35B 35B/35C SG35b ND UK C JN660114 
36 7F/21 SG36 ND UK C JN660115 
 
a
  Serotypes covered in PPV23, PCV7, and PCV13 are in bold. 
b
 ND: no data. 
c
 NP: nasopharynx; BC: blood culture; C: control laboratory strain 
d
 Identical: same results from serotype and sequetype; Serogroup: serogroup-specific 
sequetype result; Ambiguous: correct sequetype shared with another serotype from 
different serogroup; misidentified, sequetype gave top result of a serotype outside of 
the same serogroup. 
e
 11.6402 (19F) sequetyped as serotype 1, with 98% identity (715/732) with the 
variation at the 5’ end of the gene. Note, the correct 19F serotype was identified at 
97% homology. 
 
Of the 23 VTs tested, all strains of 15 serotypes (1, 3, 4, 5, 6A, 6B, 8, 9N, 9V, 10A, 
14, 15B, 19A, 19F, and 23F) were correctly sequetyped (Table 3.4), except for two 
out of 11 strains of 6A that were sequetyped to the serogroup level, and a strain of 
19F that was ambiguous as described above (Table 3.4). An additional four VTs were 
sequetyped to the correct serogroup, where 7F, 12F, 18C, and 22F were sequetyped as 
7F/7A, 12B, 18B/18C, and 22F/22A respectively. Ambiguous results were obtained 
for serotypes 11A, 17F, 20, and 33F. Except for the ambiguous 19F strain, 11.6402.H, 
none of the VTs tested were incorrectly identified. 
Of the 25 NVTs tested, 12 were correctly sequetyped, and 8 additional NVTs were 
serogroup-specific. Three NVTs gave ambiguous results, in addition to the 
misidentified serotypes 33C and 36.  
 
From two to 11 strains of 23 serotypes were tested (1, 3, 4, 5, 6A, 6B, 7C, 7F, 8, 9N, 
9V, 10A, 11A, 14, 17F, 18C, 19A, 19F, 21, 23B, 23F, 33F, 35A), some with different 
multilocus sequence types (Table 3.4). All but serotypes 6A, 11A, 17F, 19F and 35A 
gave correct sequetype for all strains (Table 3.4). Two strains of 6A were sequetyped 
to serogroup, namely 6A/6B (Table 3.4). All strains of 11A gave an ambiguous 
sequetype of 11A/11D/18F (Table 3.4), and all but one of the serotype 17F strains 
gave an ambiguous sequetype of 17F/33C (Table 3.4). The remaining 17F strain also 
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had the top sequetype score for 4/9V/17F/33C (Table 3.4). As described above, a 19F 
strain was identified as serotype 1, but at a relatively low identity of 98% with 17 bp 
differences, that were all within the 5’ end of the gene. Of the three strains of 35A that 
were included in this study two were from Tanzania and one was from the UK. The 
Tanzania strains (16NP10 and 55OP3) were both typed to the serogroup level 
(35B/35C), while the UK strain (SG35a) gave an ambiguous result (35A/33A/33F) 
(Table 3.4).  
 
3.3.4 Comparison Between the Predicted In Silico and Experimental Data. 
All the strains included in the study could be amplified, including serotypes 27 and 29 
that were not predicted to be amplifiable (Table 3.4). These two serotypes were also 
sequetyped correctly.  
 
Of the 28 serotypes in this study that were predicted to be sequetyped, 23 were 
correctly sequetyped. Four of the remaining serotypes (7F, 24F, 28F, and 33D) were 
sequetyped to the correct serogroup, and the serotype 36 strain was identified as 
serotype 7/21 (Table 3.4).  
Twenty serotypes tested were not predicted to be sequetypable. Remarkably, two 
serotype 9V strains were differentiated from 9A, a serotype predicted to have an 
identical cpsB. The remaining serotypes, as predicted, were serogroup specific, 
consistent, or misidentified. The single serotype 6C strain in the study was sequetyped 
to the serotypes 6C or 6D, but not to 6A or 6B. 
 
A breakdown of the serotypes in our study is provided in Table 3.5, according to the 
success of their identifications based on sequetyping. 
 
Table 3.5 Serotypes classified according to sequetyping accuracy 
Correctly Identified Serogroup-Specific Ambiguous Misidentified 
1, 3, 4, 5, 6A, 6B, 7C, 8, 
9N, 9V, 10A, 12B, 14, 15A, 
15B/C, 16F, 19A, 19F, 21, 
23B, 23F, 24B, 27, 28A, 
29, 31, 33B 
6A
b
, 6C, 7F, 10F, 
12F, 18B, 18C, 22A, 
22F, 24F, 28F, 33D, 
35B, 35C 
11A, 17A, 
17F, 20, 33F, 
34, 35A 
19F
b
, 33C, 36 
 
a
 PPV23 serotypes in bold, PCV13 serotypes in red bold. 
b 
Two strains of serotype 6A (12.1624.T and 11.5346.W) were serogroup specific  
(6A/6B), one serotype 19F strain (11.6402.H) was identified as serotype 1.  
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3.4 Discussion 
Two primer-binding sites were located with a novel software script that was predicted 
to generate an amplicon in 84 of 92 serotypes sequences interrogated. Furthermore, 
amplification of this region using a single primer pair on pneumococcal strains 
isolated from different geographical regions and anatomical sites has been shown to 
be successful in identifying a high number of serotypes that included those in the 
latest conjugate vaccine formulation, as well as the current replacement serotypes 
associated with invasive diseases. 
 
3.4.1 Rationale for Designing Sequetyping Method 
Serotyping is conventionally based on the Quellung reaction with anti-capsular sera, 
but this is expensive, labor-intensive, and prone to errors. Large numbers of 
pneumococcal cells are needed, and false reactivity may occur with different 
serotypes and other streptococcal species (Browne, Miegel & Stottmeier 1984; Lee et 
al. 1984; Werno & Murdoch 2008). Immunoblotting methods have been developed 
and have improved sensitivity and specificity but are not used routinely in most 
laboratories (Bogaert et al. 2004b; Bronsdon et al. 2004).  
 
New methods include PCR with multiple primer sets targeting serotype-specific 
regions of cps (Brito, Ramirez & De Lencastre 2003; Kong & Gilbert 2003; Lawrence 
et al. 2003; Rubin & Rizvi 2004; Kong et al. 2005; O'Halloran D & Cafferkey 2005; 
Billal et al. 2006; Pai, Gertz & Beall 2006), but serotype coverage is limited with the 
use of many primers. Microarray methods for serotyping can provide coverage of all 
known serotypes (Wang et al. 2007; Donkor et al. 2011; Tomita et al. 2011a; Turner 
et al. 2011), but its high cost would limit its routine use in resource-poor regions with 
high burdens of disease. A method based on serotype-specific glycosyl transferase 
genes was proposed (Tomita et al. 2011b), but only multiple strains of serogroup 6 
and serotype 19F were tested. Existing methods targeting cps employing either 
multiple restriction enzymes and/or a long PCR fragment making amplification 
difficult and inconsistencies have been described (Lawrence et al. 2000; Batt et al. 
2005).  
 
A sequence-based typing system targeting regulatory region of cps had been proposed 
(Kong & Gilbert 2003; Kong et al. 2005), but a low resolution was seen between 
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cross-reactive serotypes, in addition to a lack of reproducibility in other serotypes. In 
those methodologies, differentiation of cross-reactive serotypes therefore required 
high number of primers to amplify the serotype specific wzy and wzx genes. This low 
resolution may have been due to the limited availability of published sequence data of 
only 11 serotypes at that time (Jiang, Wang & Reeves 2001). 
 
With the recent characterization of the cps locus of 92 serotypes (Bentley et al. 2006; 
Park et al. 2007; Bratcher et al. 2010), and in silico assessment of the capsulation 
region, we have identified a region unique in sequence in many serotypes that is 
flanked by conserved primer binding sites. The region is located at the 5’ end of the 
cps locus, a region previously known to be relatively conserved (Morona, Morona & 
Paton 1997; Morona, Morona & Paton 1999a; Jiang, Wang & Reeves 2001; 
McEllistrem et al. 2004; Bentley et al. 2006). PCR testing using this putative primer 
pair has resulted in the corrected identification of over 88% of pneumococci in our 
collection. It is notable that this region is only amplified in the pneumococcus in this 
study, with no amplification present in members of S. mitis, S. oralis, and S. 
pseudopneumoniae that have traditionally been difficult to differentiate (Arbique et 
al. 2004). However only one strain each was employed to detect specificity.  
 
3.4.2 Sequetyping Identifies PCV13 Serotypes at Least to Serogroup 
All but two of the 13 conjugate vaccine serotypes tested in our study were identified 
to serotype level whilst serotypes 7F and 18C were serogroup-specific. Serotypes 
such as 19A, 6A, and 15B/C are currently among the most prevalent replacement 
NVTs globally since PCV7 vaccination (Singleton et al. 2007; Fenoll et al. 2009; 
Huang et al. 2009; Hanage et al. 2010). These replacement types were correctly 
identified. Serotypes 6C, 19A and 22F (Kaye et al. 2009; Tocheva et al. 2011), which 
are among the common non-PCV7 serotypes causing IPD in the UK, could be 
identified to at least serogroup level. Reviewing previous epidemiological data 
demonstrated that our method should be able to correctly identify more than 76% of 
invasive pneumococcal diseases in the UK to at least serogroup and over 92% of 
penicillin-nonsusceptible clinical isolates (Cooke et al. 2010; Gladstone et al. 2011a). 
Thus, we conclude that this method could be used to reduce the number of strains for 
which conventional serotyping methods were required and make considerable cost 
savings. 
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3.4.3 In Silico Analysis and Experimental Results Discrepancies 
Differences between the predicted in silico analysis data and the experimental 
sequetyping results were observed. Serotypes 27 and 29 that were not predicted to 
produce an amplicon were in fact amplified and sequetyped in vitro. The values 
inputted into the algorithm for locating appropriate PCR primer sites could be a 
possible explanation for this discrepancy. The potential primer-binding site mismatch 
tolerance was set to no more than two nucleotides, but additional primer mismatches 
may allow successful amplification. The threshold number of mismatches for 
successful amplification is not known and is likely to depend on the length and 
sequence of the primers. It is also possible that the locations of the mismatches within 
the primer also govern the success of amplification. Serotypes, 11F, 39, 43 that were 
predicted to be non-amplifiable were amplified in practice. As for serotypes 25A, 
25F, and 38, cps alignment suggested that despite lacking the cpsB gene at the 
proposed location of cps it is possible to amplify a larger fragment (Bentley et al. 
2006; Mavroidi et al. 2007). It is feasible that successful amplification of these 
serotypes may simply require alteration in the thermal cycling conditions without the 
need to employ additional primers. 
 
Discrepancies between the predicted and experimental results where some serotypes 
could be sequetyped despite predictions to the contrary may be due to additional cpsB 
sequences deposited onto GenBank during this study that expanded the database 
available for comparison. As the in silico analysis was based on a representative strain 
of each serotype, strains of different genetic backgrounds may have variant alleles of 
cpsB (Varvio et al. 2009; Elberse et al. 2011).  Indeed, this was true for serotype 9V, 
where sequetyping our strains matched to both serotypes 9A and 9V of the 
representative strains initially interrogated. However, additional 9V strains deposited 
in GenBank during our study matched precisely to our 9V resulting in correct 
identification (van Selm et al. 2002). Conversely, some serotypes could not be 
sequetyped, contrary to the in silico predictions. Additional strains would be required 
to evaluate this method more fully.  
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3.4.4 Reproducibility of Sequetyping Method 
Multiple strains of the same serotype and different STs collected over a period of 
seven years could be identified correctly. All but two of the 11 serotype 6A strains 
tested were correctly typed, which were sequetyped to either 6A or 6B. It has been 
shown that serotype 6A and 6B strains of unrelated genetic backgrounds can have 
identical cpsB sequences (Elberse et al. 2011). A single 19F strain out of 7 could not 
be typed correctly, showing relatively low identity with other serotype 19F sequences 
on the GenBank database. It has been previously reported that intra-serotype sequence 
variations at the cps regulatory region exist (Varvio et al. 2009). Chapter 6 presents 
works comparing differences in intra-serotype variation. 
 
3.4.5 Potential for Creation of Curated cpsB Database 
The data presented are, in part derived from the uncurated GenBank database. The 
implementation of a curated cpsB database may potentially increase the accuracy of 
this method over time, by incorporating sequence data from different laboratories. 
 
3.4.6 Identification of Large Proportion of Clinical Isolates by Sequetyping 
This method is not likely to be able to replace serotyping as some cannot be identified 
and others only to serogroup level.  Reference serotyping will be required for some 
isolates until further refinements are produced.  The majority of the serotypes 
included in the latest vaccines could be identified correctly, with more identifiable at 
the serogroup level. This method could correctly identify some of the most common 
serotypes seen in IPD and carriage, including types of PCV13 and replacement 
serotypes (Fenoll et al. 2009; Huang et al. 2009; Sa-Leao et al. 2009; Jefferies, Tee & 
Clarke 2011). Therefore, the proposed typing method could characterize commonly-
encountered serotypes, thus reducing cost and time compared to conventional 
serological and multiplex-PCR serotyping methods.  
 
As the initial aim of this method is to provide a cost-effective alternative to 
conventional serotyping in resource-poor regions with minimal vaccine coverage, the 
identifiable serotypes are still likely to be common in pneumococcal disease and 
carriage in these regions (Leimkugel et al. 2005; Arifeen et al. 2009; Traore et al. 
2009). Strains with ambiguous sequetype results and those without an amplicon can 
be assessed by conventional serological and other DNA-based methods, most likely 
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targeting the wzy and wzx regions (Kong et al. 2005). While additional in silico 
analysis is required to address the misidentified serotypes such as 33C and 36, these 
two serotypes are not very common and weighs little against the effectiveness of this 
method in identifying prevalent serotypes. The misidentified serotype 19F strains 
showed high identity with a serotype 1 sequence at the 5’ end, and further study is 
needed to determine whether this was due to a recombination event. Thus. it is only 
with more experience of the technique that we can understand the effect of 
recombination events on the accuracy of the method.  
 
3.4.7 Advantages of Sequetyping 
This new sequetyping method has multiple advantages over other previously reported 
serotyping methods. It requires only a single PCR amplification. The reaction set up is 
straightforward, robust and economical requiring only crude genomic DNA from 
heat-lyzed cells. This creates an opportunity for routine laboratories with a PCR and 
sequencing facilities to serotype the majority of pneumococcal strains without the 
need for an expensive set of serological reagents. Excluding the cost of man-hours, 
sequetyping approximately costs $6.60 US per pneumococcus, more economic 
compared to $15 US for serotyping a pneumococcus by the Quellung reaction, as 
derived by Lalitha et al. (Lalitha et al. 1996). Sequetyping is likely to be a cost 
effective alternative to currently available microarray technologies for serotyping. 
More economic methods are present such as multiplex/multistep PCRs, however 
multiple sequential reactions, in addition to the reduced serotype coverage, are likely 
to be time consuming and costly when labor hours are taken into consideration. It is 
worth noting that the indicated sequetyping cost includes culturing on blood agar, and 
a culture free amplification method would reduce sequetyping time and cost. We are 
currently assessing the feasibility of sequetyping directly on clinical samples as well 
as samples known to contain multiple serotypes. 
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3.5 Concluding Remarks 
In conclusion, our single primer sequetyping method is simple to perform, robust and 
economic. It is specific for the pneumococcus and can identify serotypes included in 
the latest conjugate vaccines and a high number of clinically relevant serotypes. It has 
the potential to identify new serotypes that may emerge in the post-vaccine era that 
are nontypable by standard methods. With the emergence of whole-genome data from 
high-throughout next-generation sequencing platforms, sequetyping may prove to be 
a long-lasting typing method by taking advantage of new sequence information, 
modifying its resolution power based on increased knowledge of pneumococcal cps 
sequences. We are currently evaluating our sequetyping method on pneumococcal 
strains of other serotypes to fully assess the coverage of sequetyping. In addition, 
plans are underway to make the in silico primer design algorithm available to other 
laboratory scientists.  
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CHAPTER FOUR: The Adaptive Potential of Streptococcus 
pneumoniae During Colonization 
 
 
4.1 Introduction 
4.1.1 Measurements of Pneumococcal Diversity During Colonization 
Studies investigating co-colonization assess pneumococcal diversity by serotype, 
antibiotic susceptibility, and/or genetic diversity of co-colonizing strains.  
 
4.1.1.1 Co-Colonization of Multiple Serotypes 
Intuitively, the pre-requisite of serotype switching (Section 1.4.4) is the presence of 
multiple serotypes colonizing together. Due to its clinical relevance, particularly in 
the potential effects of serotype replacement upon use of pneumococcal vaccines, 
serotype is the most common marker for describing co-colonization.  A child may 
acquire up to 6 different serotypes sequentially in the span of 2 years (Gray, Converse 
& Dillon 1980), and up to 5 serotypes may be present at a given time (Table 4.1). 
Most initial studies of multiple serotype colonization relied on culture methods, and 
recently numerous DNA-based methods have been employed. These methods will be 
discussed below. 
 
4.1.1.2 Methodologies Used for Detecting Simultaneous Serotype Carriage 
Detecting colonizations with multiple serotypes depends on the methodologies used, 
and insensitive methods may provide an underestimate of multiple carriage and 
carriage in general. The prevalence of multiple colonizations depends on the cohort 
studied, however the wide range in prevalence of multiple carriage may be a 
reflection of the different methodologies employed (Table 4.1). The World Health 
Organization (WHO) has devised a standardized method for detecting pneumococcal 
carriage (O'Brien, Nohynek & Group 2003). However, the majority of studies with 
extensive sampling information do not conform to the WHO protocol (Gladstone et 
al. 2011b). The earliest studies of multiple colonization involved injection of saliva 
samples (Gundel & Okura 1933) into the peritoneum of mice, and serotyping was 
performed in peritoneal samples. The presence of multiple serotypes could be 
detected by this method by re-inoculating the original samples into mice, however 
including in the sample antiserum specific for the previous serotype detected. Mouse 
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inoculation is sensitive for detecting multiple serotypes but it is time-consuming and 
costly (Huebner et al. 2000a). 
 
Current culture-based studies of multiple colonizations include serotyping on 
numerous colonies following plating of nasopharyngeal swabs. Sensitivity of culture-
based methods can be increased by inoculating swabs into an enrichment broth to 
detect additional colonization events and serotypes (Kaltoft et al. 2008). However, 
this may affect the relative proportion of different serotypes in the sample, and is not 
recommended for comparing proportions of different colonizing serotypes. 
Alternatively, immunoblot methods have been employed to detect multiple serotypes 
on agar plates with more than 25 colonies (Bronsdon et al. 2004; O'Brien et al. 2007). 
Molecular methods by means of PCR-amplification of serotype-specific genes 
provide a much more sensitive approach (Billal, 2008), however to achieve maximal 
serotype coverage of able to detect all 93 serotypes present, microarray may be a 
promising alternative (Turner et al. 2011). Different methods of serotyping are 
described in Chapter 3. 
 
4.1.1.3 Serotyping by Colony Characterization on Agar Plates 
While characterizing one colony per sample provides a representation of the prevalent 
serotype in the population, detecting co-colonizing and rare serotypes require 
serotyping additional colonies (Charalambous, Oriyo & Gillespie 2008). Detecting 
colonizations with multiple serotypes depends on the methodologies used; insensitive 
methods selecting low number of colonies or infrequent sampling (in a longitudinal 
study) may affect isolation rates, potentially underestimating pneumococcal carriage 
(Vives et al. 1997; Huebner et al. 2000a). Most culture-based studies of multiple 
colonizations perform serotyping on numerous colonies following plating of 
nasopharyngeal swabs, and additional serotypes may be identified if more colonies 
were characterized. Table 4.1 lists the studies of culture-based multiple colonization 
conducted, and their methodologies.  
 
4.1.1.3.1 Nasal Swab/Wash/Aspirate and Oral Swab in Revealing Serotype Diversity 
Abdullahi et al. (Abdullahi et al. 2007) compared nasal wash and swab for their 
sensitivity of detecting multiple pneumococcal carriage, and concluded that although 
wash was more sensitive in detecting pneumococcal colonization, swabs detected 
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more serotypes colonizing simultaneously. Higher number of serotypes within a 
nasopharynx can also be detected by the swab method (three serotypes by swab 
versus two by wash). There is no difference in swabbing the left or the right nostril. 
Nasal aspirate may be marginally more sensitive than nasal swabbing in detecting 
colonizing pneumococci (Rapola et al. 1997). If nasal secretions are unavailable, 
nasal swab is more sensitive than oral swabs, but sampling from the oropharynx may 
reveal additional colonization events (Masters et al. 1958; Gray, Converse & Dillon 
1980; Capeding et al. 1995; Watt et al. 2004). Charalambous et al. (Charalambous et 
al. 2008) postulate that serotyping pneumococci from both the nose and throat would 
provide more accurate representation of multiple colonization than either site alone. 
 
4.1.1.3.2 Colony Serotyping Based on Morphology or Random Selection 
Hare et al. (Hare et al. 2008) found that selecting colonies randomly for serotyping 
increases likelihood of detecting multiple serotypes compared to serotyping colonies 
based on colony morphology (17% multiple colonization prevalence by random 
selection and 14% by morphology). However, the study also addressed that 
characterization of colonies based on random selection require more colonies to 
achieve comparable rate of multiple carriage as measured by morphology. 
 
4.1.1.3.3 Enrichment Broth 
Serotyping directly from enrichment broth can increase the yield of rarely detected 
serotypes (Kaltoft et al. 2008; Vestrheim et al. 2008a). However, extended 
enrichment incubation time (<6 hours) may result in overgrowth of predominant 
serotypes and masking of other serotypes in the sample (Antonio et al. 2009; 
Carvalho et al. 2010). Masking by predominant serotypes would increase the 
difficulty in detecting rarer serotypes, hence provide an underestimate of multiple 
carriage. 
 
4.1.3.3.4 Binomial Formula in Assessing Sensitivity of Serotyping 
The binomial formula described by Huebner (Huebner et al. 2000a), derived as q
n
 = 
(1-P), where q = 1 - proportion of organisms in co-colonization, n = number of 
colonies characterized, and P = confidence interval, provides a mathematical 
relationship between the number of colonies analyzed and the probability of detecting 
a serotype of a particular prevalence. This formula calculates the amount of colonies 
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required for a serotype of a particular prevalence to be detected with a given 
confidence. For example, to detect serotypes with a proportion of 5% in the 
nasopharynx with 95% confidence, fifty-nine colonies would need to be examined. 
Nearly 300 colonies would be required for serotypes with proportion of 1%. 
Therefore, detecting multiple colonization by selecting colonies may provide an 
underestimate of the serotype diversity within a colonization event unless a large 
number of colonies are selected. Comparison of different methods for detecting 
multiple carriage revealed that serotyping a colony sweep of pneumococci provides 
co-colonization rates comparable to that done with DNA-based methods (Turner et al. 
2011).  
 
4.1.1.3.5 Summary for Culture Methods for Serotyping 
Multiple colonization assessments by means of culturing have been employed 
commonly, however current methods vary in terms of isolation sources and methods, 
number of colonies selected, and the selection criteria for colony characterization. 
Therefore, comparison of co-colonization prevalence between different studies may 
prove difficult. Also, rates of multiple colonization are also likely to be dependent on 
the pneumococcal prevalence of cohort being studied. Risk factors such as young age, 
history of and exposure to smoking, immunosuppression, and other factors likely to 
contribute to increased pneumococcal colonization and transmission may also 
contribute to multiple colonization, however these factors have not been directly 
linked to increased likelihood for multiple colonization. 
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Table 4.1. Selected studies of culture-based serotyping methods for detecting multiple colonizations 
Year Country Age group Detection Method
a
 
Multiple 
Pneumococcal 
Prevalence (%)
b
 
Max No. 
Serotypes 
Detected Reference 
1933 Germany 12-14 yrs Intra-peritoneal injection into mice 74 4 (Gundel & Okura 1933) 
1971 US Families Pharyngeal swab, colony number not specified 1.3 (of pos) 2 (Dowling, Sheehe & 
Feldman 1971) 
1985 Australia Children+Adult Up to 4 colonies per NP swab 5 3 (Hansman et al. 1985). 
1989 PNG 2 wks–12 yrs Up to 50 colonies per nasal aspirate, six per swab 29.5 (of pos) 3 (Gratten et al. 1989). 
1990 PNG <5 yrs Four colonies by morphology 33 4 (Montgomery et al. 1990) 
1994 Australia < 13 yrs Four colonies per aspirate by morphology or randomly 21 (of pos) 3 (Gratten et al. 1994) 
1996 The Gambia < 2 yrs Unknown 23 Unknown (Obaro et al. 1996) 
1997 Finland <7 years CIE and LA on NP/OP swabs/aspirates 16 2 (Rapola et al. 1997) 
2000 SA 1-60 mts 3-5 colonies per NP swab 1.3 2 (Huebner et al. 2000a) 
2000 Israel 1-60 mts Three colonies per swab 2.4 2 (Huebner et al. 2000a) 
2002 Portugal 6-72 mts 6-8 colonies per swab 10.8 2 (Sa-Leao et al. 2002) 
2003 UK 1-24 mts Three colonies per swab 3.3
c
 3 (Meats et al. 2003) 
2004 US < 5 years Immunoblot on agar plate + four colonies per sample 19 2 (Bronsdon et al. 2004) 
2005 UK Children+Adult Two colonies by morphology 0.16 Unknown (Hussain et al. 2005) 
2007 US <2 years Immunoblot on agar plate 8.1 (of pos)
 
3 (O'Brien et al. 2007) 
2008 Australia Children Four colonies, randomly picked or colony morphology 20 3 (Hare et al. 2008) 
2008 Denmark Mean 23-54 mts Enrichment broth  9.9 (of pos) 3 (Kaltoft et al. 2008) 
2008 Kenya < 86 yrs Four colonies based on morphology 3.7 2 (Abdullahi et al. 2008) 
2008 Norway 1-5 yrs Enrichment broth and by plating of up to 16 colonies 9.4 3 (Vestrheim et al. 2008a) 
2009 Denmark < 3 years Enrichment broth from swab 10.9 (of pos) 3 (Auranen et al. 2010) 
2011 Tanzania 1-5 years Throat + nose swabs, up to 20 colonies total 28.5 (of pos)
e
 5 (Leung et al. 2011) 
2011 Thailand < 3 years Two colonies 11.2 2 (Turner et al. 2011) 
   Sweep colony serotyping 43.2 4 (Turner et al. 2011) 
       
 
a
 PNG: Papua New Guinea, SA: South Africa, mts: Months, CIE: Counterimmunoelectrophoresis, LA: Latex Agglutination, NP: Nasopharyngeal, OP: 
Oropharyngeal 
b
 Prevalence calculated as percentage of cohort, unless indicated by “of pos” meaning of pneumococcal-positive subjects 
c
 Rate of co-colonization was not explicitly stated in literature. Text describes that multiple serotypes were found in 80.4% (74/92) of children over a two-year 
period. Presence of simultaneous colonization was seen in Table 4 of literature where only samples with more than six serotypes over two years were shown. The 
percentage of 3.3% is the number of colonization events with multiple serotypes simultaneously from this table divided by the total number of samples, and 
therefore 3.3% may be an underestimate of the true percentage of simultaneous colonization.    
d
 Nasopharyngeal samples taken from children with lower airway infection. 
e
 Works included in this chapter. Co-colonization prevalence calculated as percent of all pneumococcal-positive colonization events rather than swab or individual 
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4.1.1.4 DNA-based Methods for Detecting Serotype Diversity 
DNA-based serotyping methods including multiplex PCR, real-time PCR, and 
microarray have been applied to assess co-colonizing serotypes (Table 4.2). 
Superiority in sensitivity with DNA-based serotyping methods compared to culture 
methods has been demonstrated (Azzari et al. 2008; Tarragó et al. 2008; Carvalho et 
al. 2010). Importantly, the increased sensitivity indicates that detection of rare 
serotypes is made more efficient, as these less-abundant serotypes may play crucial 
roles in the pneumococcal epidemiology following vaccine interventions (see below).  
These methods have also revealed multiple serotypes in cases where conventional 
cultures could not (Billal et al. 2008; Carvalho et al. 2010). With microarray testing 
of multiple colonization, serotype-specific regions from nine different serotypes could 
be detected in a colonization sample, compared to two serotypes if the same sample 
was performed by serotyping two colonies on blood agar plate (Turner et al. 2011). 
Given the costs of antisera, multiplex PCR is a cost-effective alternative to serological 
methods, important in resource-poor laboratory settings with high pneumococcal 
carriage prevalence. 
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Table 4.2. Selected studies of DNA-based serotyping methods for detecting multiple colonizations 
 
 
Year Country Age group Method
a
 Number (+ Serogroups targeted) 
Multiple 
Pneumococcal 
Prevalence (%)
b
 
Maximum 
No. Serotypes 
Reference 
2005 Columbia < 5 yrs mPCR 7 (+ groups 6 and 18) 9% 2 (Moreno et al. 
2005) 
2008 Japan 1-5 yrs mPCR 7 (+ groups 6, 18, 19, 23) 6% 2 (Billal et al. 2008) 
2009 Gambia Children+Adult mPCR 28 (+ 6A/B) 32%
c 
3 (Antonio et al. 
2009) 
2009 Venezuela < 7 yrs mPCR 7 (PCV7 serotypes) 20% 2 (Rivera-Olivero et 
al. 2009) 
2010 Italy unknown mPCR 31 16% 2 (Azzari et al. 2010) 
   Real-Time PCR 31 63% 4 (Azzari et al. 2010) 
2010 Brazil < 3 yrs Real-Time PCR 9 + 7F/A + 9V/A + 10F/10C/33C + serogroup 24) 12% 2 (Carvalho et al. 
2010) 
2011 Switzerland Unknown mPCR+Microarray 91 3.4%/3.7%
d 
3
e 
(Brugger et al. 
2010) 
2011 Gambia < 2 yrs Microarray 91 19% 3 (Donkor et al. 
2011) 
2011 Thailand < 3 yrs Microarray 91 49% 9 (Turner et al. 2011) 
2012 Valente 18-71 mts mPCR+Microarray 91 8%/18%
d
 6 (Valente et al. 
2012) 
a
 mPCR: Multiplex-PCR 
b
 Prevalence calculated as a percentage of cohort, rather than of pneumococcal-positive samples, unless indicated by “of pos” meaning of 
pneumococcal-positive subjects 
c
 Prevalence limited to colonizations detected by the 29 serotypes covered in the study 
d
 Pre-PCV7 Era % / Post-PCV7 Era 
e
 Three distinct strains as detected by plyPCR method, maximum number of serotypes detected unknown 
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4.1.2 Antibiotic Susceptibility Diversity 
Simultaneous colonization of different antibiotic susceptibilities allows for the 
transfer of resistance determinants between pneumococci. Pneumococci that are 
highly competent and hyper-recombinant (based on evidence of mosaic genes in 
concatenated multilocus sequence types) are significantly associated with resistance 
to antimicrobials (Hanage et al. 2009), and associations have been demonstrated 
between commonly colonizing serotypes, frequent recombination, and penicillin 
resistance (Hsieh et al. 2006). Thus, serotypes 6B, 14, and 19F (commonly 
encountered serotypes) were reported to have higher transformation efficiencies 
following competence activation in vitro, and showed higher prevalence of penicillin-
nonsusceptibility. In contrast, serotypes 3 and 18C had the lowest transformation 
efficiencies among the serotypes tested, and all of the pneumococci of these serotypes 
were penicillin susceptible.  
 
A pilot study in Portugal revealed co-colonization with strains of different 
susceptibilities to penicillin, tetracycline, and clindamycin (Sa-Leao et al. 2002). The 
simultaneous colonization of penicillin-susceptible and non-susceptible pneumococci 
has also been reported previously, with two strains of serotype 6B showing a 50-fold 
difference in penicillin minimum inhibitory concentrations (MICs) (Gratten et al. 
1989). Tetracycline and clindamycin nonsusceptibilities can be attributed to 
acquisition of tet(M) and erm(TR) genes, which can be flanked by mobile elements 
subjected to recombinational events (Camilli et al. 2008; Croucher et al. 2011). 
Penicillin resistance has been associated with mosaic pbp genes that are acquired 
horizontally (Section 1.3.2). Co-colonization of strains with different susceptibilities 
therefore potentially facilitates the horizontal spread of drug-nonsusceptible genetic 
determinants.  
 
4.1.3 DNA-based methods and MLST for detecting Pneumococcal Diversity 
Indexing genetic diversity within a co-colonization event has been determined by 
using restriction digest of either a single gene region (plyNCR) (Brugger, Hathaway 
& Mühlemann 2009; Brugger et al. 2010) or whole genome (pulsed-field gel 
electrophoresis, PFGE, (St. Sauver et al. 2000), or sequence analysis of housekeeping 
genes (MLST). MLST in the pneumococcus involves the sequence analysis of seven 
housekeeping gene fragments subjected to neutral selective pressures, and the 
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combination of alleles of these seven loci determines the sequence type (ST) of the 
strain, which is a representation of the strain’s genotype. Indexing variation using 
nucleotide sequence is unambiguous and results can be compared between 
laboratories. MLST is also suitable for typing of transformable species, as a single 
nucleotide change is equally different from a recombination of multiple nucleotide 
alterations. MLST was originally designed for typing within strains of another 
recombinant organism N. meningitidis (Maiden et al. 1998), and was soon designed 
for pneumococcal typing (Enright & Spratt 1998). Characterization of STs has shown 
that strains of the same serotype have different STs (Enright & Spratt 1998; 
Brueggemann et al. 2003; Meats et al. 2003; Inverarity et al. 2010). These 
observations highlight the possibility of underestimating the true diversity of 
pneumococcal colonization by analyzing serotype alone.  
 
4.1.4 Representation of MLST Data: eBURST 
The relationships between strains can be represented by MLST data that can be 
visualized as an eBURST representation of genetic relationship between strains, 
grouping strains sharing 6 of 7 loci into a clonal complex (CC) of related strains (Feil 
et al. 2004). Illustrating genetic relationship between strains by eBURST is 
advantageous over the more traditional methods such as UPGMA when large samples 
are employed in population studies. More importantly, it does not assume 
evolutionary relationship and directionality between strains, which is important in an 
organism such as the pneumococci, where frequent recombination events may disrupt 
evolutionary signals.  
 
4.1.5 Aim 
The aim of works covered in this chapter is to investigate the diversity of colonizing 
pneumococci in healthy Tanzanian children. Two critical phenotypes, serotype and 
antibiotic susceptibility to penicillin and co-trimoxazole, would be determined for 
these pneumococcal strains. In addition, genotyping by MLST would be performed to 
determine the genetic diversity of numerous colonization events, including events 
where co-colonization of pneumococci of multiple phenotypes was present.   
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4.2 Materials and Methods 
Please refer to Appendix Table A1 for list of strains included in this chapter. Please 
refer to Chapter 2 for sample collection (Section 2.2), DNA extraction (Section 2.8.1), 
and standard PCR master mix components (Section 2.8.2). Gel electrophoresis, DNA 
purification, cycle sequencing, sequence reaction purification, and sequence analysis 
steps were performed as described in Sections 2.8.3 to 2.8.8. Antibiotic susceptibility 
and minimum inhibitory concentrations (MICs) for each strain was performed as 
described in Section 2.7. Antibiotypes were defined as different if they had a 
minimum inhibitory concentration (MIC) that varied by at least four-fold. MIC 
determinations were performed on three independent clones of strains within an 
individual colonization event with different antibiotypes.  
 
4.2.1 Multilocus Sequence Typing (MLST)  
Fragments of seven housekeeping genes were selected as described in the work of 
Enright et al. (Enright & Spratt 1998). PCR thermal cycle condition for MLST was an 
initial denaturation step at 95°C for 4 min, followed by 30 cycles of a 95°C 
denaturation step for 30 sec, a 50°C re-annealing step for 30 sec, and an extension 
step at 72°C for 30 sec. Consensus sequences were trimmed to length of respective 
locus fragments as indicated at the MLST database (http://www.mlst.net).  Sequences 
were interrogated on the MLST database, and any novel MLST locus alleles (alleles 
that were previously not present in the database) were submitted to Miss Cynthia 
Bishop (Imperial College London) for curating and chromatogram quality control. In 
strains where the combination of MLST locus alleles were not observed before, the 
allele integers in the order of aroE-gdh-gki-recP-spi-xpt-ddl were also submitted to 
the curator of MLST database, and a novel ST was allocated to these strains. 
 
4.2.2 eBURST 
Genetically related strains are defined as having either six out of seven identical loci 
conserved (single locus variant; SLV), or five out of seven identical loci conserved 
(double locus variant; DLV) (Feil et al. 2004). SLV and DLV pairs were subsequently 
verified by repeating the MLST analysis on at least three independent clones from the 
frozen archives. The chromatograms were independently verified by Dr. Clare Ling. 
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4.3 Results 
4.3.1 General Carriage Epidemiology 
The cohort consisted of 83 healthy children under the age of 6 (mean age 28.7  15.1 
months, SD) residing in an isolated community on a sugar plantation recruited from 
20
th
 January to 7
th
 February, 2003. Children on antibiotics within 3 months prior to 
recruitment were excluded from the study. Of eighty-three children recruited to the 
study, twenty-one children with questionnaire information were colonized by S. 
pneumoniae (carriage rate 25%) and these were followed up at monthly intervals 
where possible. Due to difficulty in follow-up sampling (result of discomfort 
following nasopharyngeal swabbing, children absent on the day of swabbing), on 
average 14 ± 4.4 (67%) of the children were swabbed per month. Each child was 
swabbed on average 7.0 ± 2.6 occasions and was positive for pneumococci on 3.0 ± 
1.2 occasions. A total of 61 pneumococcal colonization episodes were captured. An 
average of 6.7 ± 1.7 (SD) isolates were sub-cultured and characterized per 
colonization event. There had been exposure to antibiotics in the previous month to 
sampling in 44.3% (27/61) of the pneumococcal colonization events. 
 
Of the 61 pneumococcal colonization events in 21 children, seven (11.5%) 
colonization events from 6 children had multiple phenotypes (Table 4.3). All seven 
colonization events had multiple serotypes, and four of these also had multiple 
antibiotypes. All the multiple antibiotypes had penicillin MICs greater than 4 times 
between strains and two also had multiple MICs for Sxt. One child (Child 10) 
experienced two co-colonization events.  
 
Of the 61 pneumococcal colonization events, fifteen were genotyped by multi-locus 
sequence typing (MLST). Five of these colonization events had multiple serotypes 
and antibiotypes, and 10 colonization events were single phenotypes. In total 120 
isolates were phenotyped, and sequence types were determined for 98 (81.7%) of 
them. 
 
4.3.2 Nasopharyngeal Colonization by Multiple Serotypes 
A total of 13 serotypes were detected in this study including 1, 4, 6B, 10A, 11A/D, 
13, 17F, 18B, 19A, 19F, 21, 34, and 35A. A nontypable strain was captured from a 
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single colonization event, based on the failure to agglutinate with pooled antisera and 
the absence of the cpsA and cpsB genes. Of the 7 colonization events with multiple 
serotypes, five colonization events had 2 serotypes, one event had 3, and up to 5 
serotypes (6B, 10A, 19A, 19F, 21) were detected in Child 35 in January (Table 4.3). 
All events were detected in females. The most common serotypes detected within the 
7 multiple phenotype colonization events was 6B (3/7, 33%) followed by 19F (2/7, 
29%) and 35A (2/7, 29%). We investigated the proportions of each serotype co-
colonizing and found that a dominant (as defined in this study as ≥ 80% prevalence 
within a colonization) serotype was found in 3 of the 7 (42.9%) colonization events, 
all of which had two serotypes each (Table 4.3). A dominating serotype was not 
observed for colonization events with more than two serotypes, but serotype 35A 
made up ≤ 10% of the population characterized in Child 16, which carried with 3 
serotypes. 
 
4.3.3 Nasopharyngeal Colonization by Multiple Antibiotypes 
All strains were susceptible to tetracycline, chloramphenicol, erythromycin, and 
amoxicillin, while some strains were non-susceptible to penicillin and co-trimoxazole 
by disc diffusion. We determined the antibiotypes of strains, measured by MICs of 
penicillin and co-trimoxazole, by E-test. Multiple antibiotypes were detected in 4 
colonization events, all of which also had multiple serotypes. All of the 4 events 
differed in penicillin MICs, with a mix of penicillin-susceptible and intermediate-
resistant strains. In addition, two of the four also had multiple Sxt antibiotypes, with 
Child 1 colonized simultaneously by Sxt-susceptible and resistant strains, and Child 3 
in September co-colonized by intermediate and resistant strains. Each of these 4 
colonizations had 2 different antibiotypes. Differences in antibiotypes are associated 
with differences in serotypes; none of the colonizations had a different antibiotype 
within the same serotype. Across different colonization events studied, serotype 6B 
was associated with multiple antibiotypes, differing in both penicillin and Sxt (Table 
4.3, Child 11 January and Child 3 March). In Child 29, serotypes 35A and 6A were 
detected with the same antibiotype for both penicillin and Sxt. In children where 
multiple colonization events were analyzed a number of times (Child 3 and Child 11), 
strains of the same serotypes detected in each child did not change in antibiotypes 
over time.  
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Table 4.3. Serotypes, MICs, and sequence types of pneumococci isolated from healthy Tanzanian children 
Child# Gender 
Baseline Age 
(Months) 
Colonization             
(Sampling Month) 
No. Isolates    
Characterized 
Serotype
a MIC
b 
Sequence   
Type
c
 
Prevalence 
(%) Penicillin Sxt 
          
1 F 18 January/February 6 NT 0.032 0.19 4156 5 (83.3) 
     6B 0.19 8 4429 1 (16.7) 
          
3 F 41 March 3 6B 0.032 0.125 4368 3 (100) 
          
3 F 41 July 5 1 <0.016 <0.002 217 5 (100) 
          
3 F 41 September 8 1 <0.016 <0.002 217 5 (62.5) 
     6B 0.25 6 4373 3 (37.5) 
          
10 F 60 January/February 7 13 0.125 3 ND 1 (14.3) 
     19A 0.125 6 ND 6 (85.7) 
          
10 F 60 March 6 13 0.125 6 4370 6 (100) 
          
10 F 60 April 7 18B <0.016 <0.002 ND 6 (85.7) 
     6B <0.016 <0.002 ND 1 (14.3) 
          
11 F 27 January/February 15 6B 0.19 6 4432 15 (100) 
          
11 F 27 May 8 4 <0.016 <0.002 ND 8 (100) 
          
11 F 27 June 8 6B 0.19 4 4432 8 (100) 
          
16 F 59 April 11 19F 0.19 6 347 6 (54.5) 
     34 0.032 4 4158 4 (36.4) 
     35A 0.25 4 840 1 (9.1) 
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18 F 21 January/February 3 10A 0.125 4 852 3 (100) 
          
22 M 60 January/February 5 17F 0.016 0.125 4160 5 (100) 
          
24 F 25 October 3 19A 0.25 6 4162 3 (100) 
          
29 F 22 November 2 35A 0.25 4 840 1 (50) 
     11A/D 0.38 6 5752 1 (50) 
          
35 F 27 January/February 7 6B 0.125 6 854 1 (14.3) 
      0.125 6 4157 1 (14.3) 
     10A 0.38 6 852 2 (28.6) 
     19A 0.125 2 4162 1 (14.3) 
     19F 0.19 2 6170 1 (14.3) 
     21 0.064 3 1145 1 (14.3) 
          
45 F 47 January/February 9 21 0.094 4 1145 9 (100) 
          
69 M 12 January/February 7 6B 0.19 8 4429 7 (100) 
 
a
 NT: strains were nontypable by pooled sera with no amplification from PCR targeting cpsA (Pai, 2006) and cpsB (Leung, accepted) 
b
 MIC: minimum inhibitory concentrations indicated as the median of triplicate results 
c
 ND: no data 
d
 Events with multiple serotypes in red, multiple antibiotypes in blue for penicillin and orange for co-trimoxazole. 
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4.3.4 Nasopharyngeal Colonization by Multiple STs 
ST was used as a representation of the strain genotype on the 15 colonization events 
analyzed. A total of 18 STs were identified, of which only 7 (ST217, 347, 840, 852, 
854, 1145, and 5752) were STs previously deposited on the MLST database. Searches 
in the MLST database revealed that all of these previously deposited STs included 
strains isolated in Africa (Appendix Table A3). Multiple STs were observed on the 
five multiple phenotype colonization events sequence typed.  Up to 6 STs (852, 854, 
1145, 4157, 4162, and 6170) were detected within a single colonization event from 
Child 35. This event had 5 serotypes (6B, 10A, 19A, 19F, and 21). STs 840, 852, 
1145, and 4162 were found in more than one child where each ST expressed the same 
phenotype (Table 4.3). ST217 was found in Child 3 two months apart (Table 4.3). 
ST4432 was colonizing in Child 11 in Jan/Feb as well as in June (Table 4.3). We 
found multiple STs expressing the same serotype (Table 4.4). Two STs expressing 
serotype 6B was found in Child 35 concomitantly (Table 4.3).  
 
Table 4.4. Serotypes with multiple sequence types 
 
 
Serotype aroE gdh gki recP spi xpt ddl ST Child 
Colonization 
Event 
           
6B 51 66 230 1 6 1 8 4432 11  Jan/Feb 
 51 66 230 1 6 1 8 4432 11 June 
 7 9 1 10 9 1 14 4368 3 March 
 1 5 54 38 15 288 15 4373 3  September 
 51 66 1 1 6 1 108 854 35  Jan/Feb 
 7 9 1 63 9 1 14 4157 35 Jan/Feb 
 51 66 230 1 6 1 6 4429 1  Jan/Feb 
 51 66 230 1 6 1 6 4429 69  Jan/Feb 
19F 12 8 9 3 3 20 57 347 16 April 
 12 8 9 3 6 20 57 6170 35 Jan/Feb 
 
4.3.5 Genetic Relatedness of STs in Cohort 
eBURST was performed to determine the genetic relatedness of the STs characterized 
in our study. eBURST is based on a clonal expansion and diversification model that 
provides a method for inferring clonal relationships from MLST data (Feil et al. 
2004). Genetically-related strains were defined as single (SLV) or double locus 
variants (DLV). All but 7 STs were singletons. Three pairs of SLVs were identified in 
different colonization events from different children (Tables 4.3 and Tables 4.5). 
ST6170 and ST347 (both serotype 19F and the same antibiotype), differed in the spi 
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locus by a single nucleotide (Table 4.5). ST4432 and 4429 (both serotype 6B and the 
same antibiotype) differed in ddl locus by 4 nucleotides (Table 4.5). ST4157 and 
ST4368 (both 6B, but with a different antibiotype for Sxt) differed in the recP locus 
by 3 nucleotides (Tables 4.3 and 4.5). 
 
In the eBURST analysis algorithm double-locus variants (DLVs), as defined by a 
difference of 2 MLST loci out of 7, are only linked to a CC if an intermediate SLV is 
also present in the sample. However, DLVs could belong to the same CC even if the 
SLV intermediate was undetected in our cohort. The eBURST algorithm can also 
identify DLVs. ST854 (serotype 19F) is a DLV of ST4432 (serotype 6B) and ST4429 
(6B), and both vary at the ddl and gki loci by more than 40 nucleotides (Table 4.5). 
All three STs have the same antibiotype (Table 4.3). Allele 108 has 95% identity to 
the ddl fragment of S. mitis (accession numbers EU075717 and EU075693) and S. 
oralis (accession number AJ387988.1). 
 
 
Table 4.5. Allelic variation between single and double locus variants. 
 
Serotype 
SLV 
Variant 
Locus 
Variant 
Alleles 
(A/B) 
Nucleotide Substitutions   
(% identity) 
Sequence 
Type A 
Sequence 
Type B 
19F 347 6170 spi 3/6 1 (99) 
6B 4432 4429 ddl 8/6 4 (99) 
6B 4157 4368 recP 63/10 3 (99) 
      
 DLV 
      
6B 854 4432 ddl 108/8 38 (92) 
   gki 1/230 5 (99) 
6B 854 4429 ddl 108/6 40 (91) 
   gki 1/230 5 (99) 
 
4.3.6 Novel STs and HGT Between Co-Colonizing Strains 
A total of 11 novel STs were detected in this cohort. Some of these STs form part of a 
CC of SLVs found exclusively in Africa, as shown in Appendix Table A3. Given the 
high number of new STs detected in our cohort, we hypothesized that co-colonizing 
strains act as a reservoir for the assortment of housekeeping gene fragments, thus 
creating novel combinations of MLST loci. From a total of 11 novel STs uncovered in 
this study, eight of them were found co-colonizing with other strains. We compared 
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these eight STs to the MLST database to see if our novel STs were SLVs/DLVs of 
pre-existing strains, and whether the varying allele(s) are present among co-colonizing 
strains (i.e. a variant locus may have been acquired from a co-colonizing strain, giving 
rise to an SLV). Three novel STs in our cohort (ST4162, ST4157, ST6170) are related 
to pre-existing STs. All three novel STs were detected within Child 35. Comparison 
of pre-existing, novel and co-colonizing STs shows that HGT of MLST loci from co-
colonizing strains in this child may have likely given rise to the new STs (Table 4.6). 
While in some cases the variant alleles between the SLVs differ by only one or two 
nucleotides (hence the variation is probably explained by mutation), it is highly 
improbable that mutational events alone gave rise to the difference between loci with 
up to 14 nucleotides. Therefore, our results suggest that novel STs such as ST4157, 
ST6170, and ST5752 have possibly acquired variant alleles from co-colonizing strains 
through genetic exchange. 
 
 
Table 4.6. Comparison of housekeeping loci of novel, pre-existing, and co-
colonizing sequence types within Child 35. 
 
  
Case 
ST 
aroE gdh gki recP spi xpt ddl serotype 
1 854 (co-colonizing) 51 66 1 1 6 1 108 6B 
 6170 (co-colonizing) 12 8 9 3 6 20 57 19F 
 4162 (novel) 7 11 74 1 6 112 64 19A 
 5270 (existing) 7 11 74 1 17 112 64 19A 
spi alleles 6 and 17 differ by 2 nucleotides  
          
2 852 (co-colonizing) 16 9 75 3 9 115 5 10A 
 4157 (novel) 7 9 1 63 9 1 14 6B 
 6041 (existing) 7 62 1 63 6 1 14 6C 
gdh alleles 9 and 62 differ by 3 nucleotides; spi allele 9 and 6 differ by 14 nucleotides  
 
3 854 (co-colonizing) 51 66 1 1 6 1 108 6B 
 6170 (novel) 12 8 9 3 6 20 57 19F 
 347 (existing) 12 8 9 3 3 20 57 19F 
spi alleles 6 and 3 differ by 1 nucleotide 
 
4 854 (co-colonizing) 51 66 1 1 6 1 108 6B 
 852 (co-colonizing) 16 9 75 3 9 115 5 10A 
 4162 (co-colonizing) 7 11 74 1 6 112 64 19A 
 6170 (novel) 12 8 9 3 6 20 57 19F 
 5769 (existing) 12 8 9 1 3 20 57 19F 
recP alleles 3 and 1 differ by 3 nucleotides; spi allele 6 and 3 differ by 1 nucleotide 
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4.4 Discussion 
We have determined the pneumococcal strain diversity within a colonized host by 
characterizing a random selection of up to 20 colonies from pneumococcus-positive 
nasopharyngeal samples. Two critical phenotypes, the serotype and antibiotic 
susceptibility as well as ST, were characterized. Our data revealed the extensive and 
so far unrecognized potential for genetic exchange in the nasopharynx of children in 
Tanzania. Nineteen strains were detected in 12% of the colonization episodes with 
extensive serotype, antibiotype and ST heterogeneity within a colonization event that 
had the potential to utilize the supragenome. This included the presence of antibiotic-
susceptible and non-susceptible strains colonizing together. These data are important 
as there are few detailed studies addressing multiple pneumococcal carriage. To our 
knowledge, only a handful of reports in Europe (Sa-Leao et al. 2002; Vestrheim et al. 
2008a) included serotyping, antibiotyping and genotyping data of multiple 
colonizations.  
 
4.4.1 Cohort Characteristics 
This study was conducted on children under the age of 6. Studies from Australia 
(Hansman et al. 1985) and the UK (Hussain et al. 2005) showed that co-colonization 
is more common in children than in adults. Children may have higher rates of co-
colonization mainly because of the higher general colonization seen in this age group, 
facilitating higher rates of transmission between individuals. This cohort of children 
represents a semi-isolated community residing on a sugar plantation without a 
pneumococcal vaccination programme. Thus, our observations provide an insight into 
the diversity of pneumococcal colonization in the absence of pneumococcal 
immunization. Two recent studies have analyzed the effects of pneumococcal 
vaccination on the carriage of multiple serotypes (Brugger et al. 2010; Valente et al. 
2012). In Switzerland, the prevalence of multiple serotype carriage did not alter three 
years after the use of PCV7 (Brugger et al. 2010). In Portugal, where PCV7 coverage 
reaches at least 70%, vaccinated individuals showed significantly lower rates of co-
colonization than non-immunized individuals and that of the pre-vaccine era (Valente 
et al. 2012). These differences may be due to cohort differences (age, healthy or 
infected hosts) and methodologies (with or without culture) used for detecting 
carriage. Conjugate vaccination in developing countries is now being introduced 
(Global Alliance for Vaccines and Immunizations 2012). Thus, should this area be 
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subjected to future vaccination schemes, this data would be critical baseline data for 
studying the impact of vaccination on the ecology of multiple carriage in this region. 
 
4.4.2 Current Work in Relation to Other Co-Colonization Studies 
Many multiple colony carriage studies were limited to serotyping by serological 
methods and used different culture methods (Hansman et al. 1985; Huebner et al. 
2000a; Meats et al. 2003; Bronsdon et al. 2004; O'Brien et al. 2007; Hare et al. 2008; 
Hill et al. 2008; Kaltoft et al. 2008; Auranen et al. 2010). These studies showed large 
variation of co-colonization rates (1.3% to >30%). In this study, we have employed 
random colony selection as it has been shown to reveal higher rate of multiple 
colonization compared to colony selection by morphology (Hare et al. 2008). 
However, randomization in our study referred to a selection of ten colonies per plate, 
instead of picking six colonies and characterizing four of them determined by a 
random number table as described by Hare et al. (Hare 2008). Therefore, a subjective 
experimental bias may be generated. A more systematic and objective method could 
be performed by drawing a 10x10 grid on the underside of the plate, and picking a 
single colony from each column or row of the grid.  
 
In this study, the proportion of episodes with multiple serotypes were detected to be 
within the range published by others, and we have detected up to five serotypes 
colonizing together. We have identified the co-colonization of different strains of a 
serotype, similar to a finding made previously in Bolivian school children (Inverarity 
et al. 2010). This supports that serotyping alone underestimates the diversity of the 
colonizing population of an organism. 
 
Based on the binomial formula (Huebner et al. 2000a), our method would reveal 
serotypes that constitute 14% of the nasopharynx with 95% confidence. However, a 
correlation between the number of colonies characterized and the prevalence of 
multiple strain colonizations cannot be made from these studies as different 
methodologies were used. The cohort studied, colonizing serotypes and their 
durations of carriage are also likely to influence the prevalence of co-colonization and 
the extent of serotype diversity. DNA-based methods by means of PCR-amplification 
and microarrays will enhance sensitivity with optimal serotype detection coverage 
(Billal et al. 2008; Donkor et al. 2011; Turner et al. 2011). Serotyping by colony 
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sweeps may detect comparable levels of multiple colonization as microarray, but 
colony sweep serotyping is problematic in detecting rare colonizers due to the inferior 
sensitivity (Turner et al. 2011). Microarray is also limited to a handful of reference 
laboratories due to its high cost, and is unlikely to be widely implemented in 
developing countries. 
  
4.4.3 Co-Colonization of Antibiotic Susceptible and Non-Susceptible Strains 
An important observation in this study was that 57% (4/7) of multiple colonization 
episodes had mixed antibiotypes illustrating the potential for genetic exchange 
between strains with different drug susceptibility. For example, in four colonization 
episodes there were both penicillin susceptible and non-susceptible strains colonizing 
together. To our knowledge, the simultaneous carriage of penicillin susceptible 
together with non-susceptible strains has previously been reported in two other studies 
(Gratten et al. 1989; Sa-Leao et al. 2002). Two episodes also had simultaneous 
colonization of Sxt susceptible and non-susceptible pneumococci, and to our 
knowledge this has not been previously reported. The spread of penicillin resistance in 
pneumococci has been attributed to the HGT of pbp2x, pbp2b, and pbp1a, 
predominantly through mosaic blocks (Dowson et al. 1989; Laible, Spratt & 
Hakenbeck 1991; Hakenbeck et al. 1998). Similarly, HGT between pneumococci and 
viridans streptococci have been proposed to contribute to non-susceptibility to Sxt 
(Wilén et al. 2009). Therefore, a mixed colonization of antibiotic-susceptible and non-
susceptible strains increases the potential for susceptible strains to acquire resistant 
determinants, enabling them to survive the presence of antimicrobials.  
 
4.4.4 Geographically Distinct STs 
The semi-closed characteristics of the cohort may also explain the high proportion of 
geographically distinct STs detected. Nearly 90% of all STs detected have thus far 
been exclusively found in African strains. However, it is likely that the MLST 
database is not a representation of the true ST diversity of pneumococci in the sub-
Sahara region, as the majority of strain information originates from developed 
countries. Nonetheless, most of the STs detected, including novel STs, are SLVs of 
pre-existing strains detected in Africa. Furthermore, some of these STs in Tanzania 
form a CC of SLVs exclusively detected in the continent (Appendix Table A3).  
Geographically unique STs were also found in Latin America (Reis et al. 2008; 
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Inverarity et al. 2011) and Asia (Jefferies, Tee & Clarke 2011). Similar to our cohort, 
some of these studies were conducted in areas with high-density populations such as 
urban slums and refugee camps. Donkor et al. (Donkor et al. 2011) postulates that 
high prevalence of multiple carriage directly contributes to emergence of novel ST by 
the HGT of allelic variants between co-colonizing strains. Additionally, we propose 
that the extent of diversity within the nasopharynx also influences emergence of novel 
STs. However, this premise assumes that the MLST database for sub-Sahara is an 
accurate representation of the population in this region. At present approximately 70% 
of STs present in the database corresponds to pneumococci in the western world 
(Donkor et al. 2011). Additional genotypic characterization of pneumococci should 
therefore focus on strains isolated in other geographical regions.    
 
4.4.5 Detection of NT Strain 
A NT strain, based on absence of agglutination when mixed with anticapsular 
antibodies, was detected. This strain may be an acapsulate strain, as cpsA-targeting 
primers developed previously (Pai, Gertz & Beall 2006) provided no amplicons. 
However, up to 2% of encapsulated pneumococci may not have cpsA amplified using 
this method. This strain is bile-soluble, and the MLST loci in this strain (alleles of 
ST4156) share 100% homology to pre-existing MLST loci in the database, strongly 
suggesting that this strain is a pneumococcus. NT and acapsulate strains are 
commonly isolated from the nasopharynx, and studies have shown that they are 
genetically-diverse, antimicrobial-nonsusceptible, and may act as potential sources of 
genetic materials encoding adaptive traits (Hauser, Aebi & Mühlemann 2004; Hanage 
et al. 2006; Sá-Leão et al. 2006; Andrade et al. 2010; Marsh et al. 2010; Simões et al. 
2011b). The multi-resistant Norwegian clone ST344 is among the most common NT 
clone in the nasopharynx and infection sites in Europe (Sá-Leão et al. 2006; Simões et 
al. 2011b). ST4156 from this study share no identical allele with ST344. According to 
the MLST database, ST4156 shares 4/7 alleles with numerous encapsulated STs 
(ST4662, 5109, 5228, 6772) found in China and Thailand. As capsule is a barrier to 
genetic transformation, acapsulate strains may be more efficient in DNA uptake 
(Weiser & Kapoor 1999; Pearce, Iannelli & Pozzi 2002). The NT strain (ST4156) 
detected in our study was co-colonizing with an unrelated serotype 6B strain 
(ST4429), sharing only 1/7 loci (aroE). Based on a previous study, high proportions 
of NT and acapsulate strains were found co-colonizing with capsulated strains of 
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different serotypes, indicating that these strains possibly play crucial roles in 
pneumococcal evolution (Brugger et al. 2010). 
 
4.4.5 Novel STs by HGT During Co-Colonization 
A high proportion (58%) of STs detected were novel STs, and the study suggests that 
some of these novel STs may have arisen through HGT during co-colonization; these 
strains are SLVs and DLVs of pre-existing STs but the locus (or loci) that differed 
were found to be carried by co-colonizing strains. It has been postulated that there is a 
greater potential for new STs to arise if the carriage rate of multiple strains is higher 
(Donkor et al. 2011). Although, in this study, the carriage of multiple strains was 
12%, lower than the 19% reported by Donkor’s group, the diversity of strains within 
the multiple colonization events of our cohort was greater, which would also increase 
the potential for generating new STs. While SLVs differing in single nucleotides may 
have evolved by mutational events (Feil, Enright & Spratt 2000; Feil et al. 2004), 
SLVs containing multiple nucleotide differences within a locus are likely to have 
arisen through HGT. It is not known how these new clones would contribute to the 
supragenome pool and pneumococcal evolution over time, as a high proportion of 
detected STs may be transient clones and disappearing due to competition by more 
successful clones (Jefferies et al. 2010a). However, these new STs may adapt to 
stabilize and survive by interaction with co-colonizing strains.  
 
Despite the serotype diversity observed in multiple colonizations our sequence typing 
data did not reveal any evidence of capsule switching at the individual colonization 
episode level as well as the cohort level, as strains of different serotypes also had non-
related STs.   
 
4.4.6 Repeated Colonization of Pneumococcal Strain 
Sequence typing revealed that the same strain (ST4432) of a 6B serotype was isolated 
five months later (January and June) in Child 11, and a new strain of serotype 6B was 
isolated in Child 3 six months later (ST4368 then ST4373). A similar observation was 
made in a previous longitudinal report (Sluijter et al. 1998). In that study, a single 
colony was characterized monthly from the same child, and different strains of the 
same serotypes were detected in the same child at different months, suggesting re-
acquisition. From an immunological perspective, our data on re-acquisition or co-
 158 
acquisition of a different strain with the same serotype may provide further support 
that colonization does not provide complete immunity, and that protective immunity 
to colonization is not solely dependent on capsular polysaccharide (McCool et al. 
2002). This is borne out by the absence of a correlation between a previous 
colonization by serotype 6B and the titer of serotype 6B-specific antibodies 
(Weinberger et al. 2008). Thus, additional surface proteins may elicit protective 
immunity to colonization, and these may be accessory genes that are not present in all 
strains of a particular serotype, or within a CC of related STs, or even within a 
particular ST (Donati et al. 2010). However, caution must be taken for such 
interpretations. The absence of capturing pneumococci in the interceding months that 
indicates re-acquisition is inconclusive as these strains may persist below the level of 
detection by the method employed in this work. The detection limit of the culture 
method employed is likely to be lower than those of DNA-based multiplex PCR and 
microarrays. The latter methods may therefore be used on the original stored URT 
samples to potentially address and provide greater understanding of the pneumococcal 
colonization dynamics of this cohort. 
 
4.5 Concluding Remarks 
The systematic characterization of up to twenty colonies from the nose and throat has 
revealed the presence of multiple strains co-colonizing. These colonization events 
contain pneumococci of different serotypes, antibiotic susceptibility profiles, and 
genetic backgrounds as determined by MLST.  MLST information provided evidence 
indicating assessing serotype diversity alone is an underestimate of true strain 
diversity. A nontypable strain was detected co-colonizing with an encapsulated strain. 
A high proportion of novel STs had been identified, and these novel STs may have 
arisen through horizontal gene transfer with co-colonizing strains.   
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CHAPTER FIVE: Analysis of United Kingdom and Tanzania  
Pherotypes in Carriage and Clinical Strains 
 
 
5.1 Introduction 
5.1.1 Overview of Competence 
S. pneumoniae is naturally competent in acquiring exogenous DNA from their 
immediate environment. This state of competence is induced and regulated in by a 
two-component, quorum-sensing system known as the competence stimulatory 
pathway. It regulates a set of more than 180 genes grouped as early, late, delayed, and 
repressed genes in a coordinated manner based on the time of gene regulation in 
relation to competence activation (Alloing et al. 1998; Peterson et al. 2000; Rimini et 
al. 2000; Dagkessamanskaia et al. 2004; Peterson et al. 2004). 
 
The pathway consists of an ATP-binding cassette (ABC) transporter and accessory 
proteins ComA and ComB, the competence stimulating peptide (CSP, encoded by 
comC), its cognate histidine kinase receptor (ComD), and a response regulator ComE 
(Pestova, Håvarstein & Morrison 1996; Claverys & Havarstein 2002) (Fig. 5.1). CSP 
is thought to be processed and exported by ComAB (Hui & Morrison 1991; Hui, Zhou 
& Morrison 1995). Extracellular accumulation of CSP reaches a strain-specific 
threshold CSP concentration (usually between 1-10 ng/μL), during which competence 
is induced by the binding of CSP to the histidine kinase receptor ComD, leading to the 
autophosphorylation of ComD at the cytoplasmic histidine residue, followed by the 
phosphorylation of the response regulator ComE (ComE-P). Most pneumococci of a 
pherotype can be induced to competence only by the same pherotype, however strains 
with non-cognate receptors have been identified, and some strains may be induced by 
different pherotypes at increased concentrations (Pozzi et al. 1996; Whatmore, Barcus 
& Dowson 1999; Iannelli, Oggioni & Pozzi 2005). 
 
ComE-P recognizes a region of a promoter containing two 9-bp imperfect repeats 
separated by 12 bps (Ween, Gaustad & Håvarstein 1999). Sets of early and late genes 
containing this motif are activated by ComE-P including the comAB and comCDE 
genes themselves. This creates a positive feedback loop in the competence activation 
circuit. ComE-P also upregulates expression of comX, which encodes an alternative 
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sigma factor (Lee & Morrison 1999). ComX associates with the RNA polymerase 
holoenzyme and affects transcription of genes containing promoters with a cin-box 
consensus sequence (TAATACGAATA) (Campbell, Choi & Masure 1998; Lee & 
Morrison 1999; Luo, Li & Morrison 2003; Luo & Morrison 2003). ComX regulates 
the transcription of late genes including ones involved in transformation and 
recombination as well as stress responses, and expression of these late genes increases 
approximately 10 minutes after CSP exposure in vitro (Dagkessamanskaia et al. 
2004). The transient nature of the competence state may be mediated by the 
differential transcriptional responses of ComE depending on its phosphorylation state, 
possibly mediated by a phosphatase targeting ComE-P (Alloing et al. 1998). The 
CiaRH TCS may also regulate the competence property, as inactivation of ciaR was 
associated with an increase in comC expression (Mascher et al. 2003).  
 Fig. 5.1. The competence stimulatory pathway in the pneumococcus. CSP is 
synthesized by comC as a pre-peptide containing a 24-aa leader peptide containing a 
double-glycine motif. The processing, leader cleavage, and export of pre-CSP are 
mediated by the ABC transporter ComAB, releasing the 17-aa mature peptide into the 
extracellular space. As CSP is exported and accumulated, a threshold concentration is 
reached where competence induction is trigger by the binding of CSP to its cognate 
ComD histidine kinase sensor receptor, leading to autophosphorylation of ComD, in 
turn phosphorylating the response regulator ComE, leading to the expression of early 
genes including fratricide immunity protein gene comM, alternative sigma factor gene 
comX, and comW which encodes a protein responsible for the stability and function of 
ComX. When ComX associates with RNA polymerase, transcription of late genes 
with cin-box promoters takes place. Activation of late competence genes affects 
pneumococcal DNA uptake and recombination, biofilm formation, and bacterial 
fratricide. Figure from Johnsborg and Håvarstein. (Johnsborg & Håvarstein 2009) 
with permission granted from FEMS Microbiology Reviews via RightsLink 
Copyright Clearance Center. 
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5.1.2 Role of Competence in Pneumococcal Physiology 
Despite the large number of genes regulated by competence, only 23 are required for 
transformation, suggesting that the competence pathway genes are involved in 
additional aspects of pneumococcal physiology (Peterson et al 2004). Indeed, 
competence induction may be associated with virulence, as pneumococci with 
mutations in early competence genes are attenuated in murine infections in the lungs 
and blood (Bartilson et al. 2001; Lau et al. 2001; Oggioni et al. 2006). Expression 
studies have also linked competence activation to growth arrest and the induction of 
stress response (Dagkessamanskaia et al. 2004). In a murine sepsis model, it was 
shown that the treatment with CSP inhibits pneumococcal growth, and increases 
survival rate of mice (Oggioni et al. 2004). Such observations appeared to be 
dependent on the activation of ComD. 
 
Recently it was discovered that competence induction actively triggers cell lysis and 
DNA release in a subpopulation of non-competent cells, mediated by murein 
hydrolases LytA, LytC (provided by either competent cells or noncompetent target 
cells) and CbpD, and bacteriocin-like peptides (CibAB) (Steinmoen, Knutsen & 
Håvarstein 2002; Steinmoen, Teigen & Håvarstein 2003; Guiral et al. 2005; 
Kausmally et al. 2005; Eldholm et al. 2009; Eldholm et al. 2010). Competent cells 
express an immunity factor, encoded by an early gene, comM, to prevent lysis from its 
own lytic enzymes (Håvarstein et al. 2006a). This process, known as fratricide, 
provides competent cells with sources of external DNA for acquisition, as fratricide 
has been shown to directly enhance DNA uptake (Johnsborg et al. 2008). Acquisition 
of these DNA may provide novel traits with adaptive benefits. Also, fratricide has 
been proposed to act as virulence complementation between co-colonizing strains by 
releasing virulence factors from heterogeneous pneumococci, thereby modulating host 
immune response (Guiral et al. 2005). It is interesting to note that interspecies 
fratricide also occurs, in agreement to the hypothesis that the pneumococcal 
supragenome (Section 1.6.3) may include genes of S. mitis and S. oralis. Activation of 
competence may confer a fitness cost, as comE mutants colonized better than wild 
type strains in rat colonization competition assays (Kowalko & Sebert 2008).  
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5.1.3 Role of Competence in Colonization and Biofilm Formation 
DNA release from competence-mediated fratricide may support the biofilm structure, 
as exogenous DNA is a constituent of biofilm, and treatment of DNase is associated 
with reduced biofilm biomass and impaired biofilm formation (Moscoso, García & 
López 2006; Hall-Stoodley et al. 2008). While no direct mechanism has been 
described for the precise role competence plays in biofilm, cells adopting a biofilm 
mode of growth have increased expression of comA, comE, and comX (Oggioni et al. 
2006). As transformation, fratricide, and biofilm formation are regulated by 
competence, this transient physiological state may provide the appropriate conditions 
for genetic exchange and DNA acquisition during pneumococcal colonization. A 
comparison of three different in vitro models of biofilm growth revealed different 
roles of competence pherotype in biofilm formation: while competence is crucial for 
biofilm maintenance in biofilms studied in microtiter plates, its role in biofilms grown 
in continuous culture is minimal (Trappetti et al. 2011a).  
 
Formation of a biofilm extracellular matrix was recently shown to require the 
expression of LuxS, encoding S-ribosylhomocysteine lyase, and the presence of Fe 
(III). This is concomitant with the upregulation of iron uptake transporter PiuA, the 
early and late competence genes, increase in transformation efficiency, release of 
extracellular DNA, and fratricidal lysis of noncompetent cells (Trappetti et al. 2011c). 
.  
5.1.4 The Role of Competence in Biofilm Formation in Other Streptococci 
The link between competence and biofilm formation in streptococci was first 
identified in S. gordonii, where inactivation of comD by transposon mutagenesis 
rendered mutants defective in biofilm formation (Loo, Corliss & Ganeshkumar 2000). 
Similarly, competence is associated with biofilm formation in S. mutans, a 
predominant causative agent of dental caries. In this sense, competence in S. mutans is 
related to its pathogenicity, because biofilm formation allows for persistence of the 
organism from rapidly changing environmental conditions and physical stress of the 
oral cavity (Li et al. 2001). It is postulated that competence also affects the initial 
stages of biofilm formation in S. mutans, as comD mutants affected in vitro adherence 
to mucin-coated plate surfaces in this organism (Li et al. 2002). In a mechanism 
possibly similar to pneumococcal fratricide, competence induction is associated with 
cell death, chromosomal DNA release and increase in biofilm biomass in S. mutans 
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(Perry, Cvitkovitch & Lévesque 2009) The addition of synthetic CSP was also 
demonstrated to enhance biofilm formation in S. intermedius (Petersen, Pecharki & 
Scheie 2004).  
 
5.1.5 The Competence Stimulatory Peptide – ComC 
As early as the 1960s it was known that competent pneumococci secrete a competence 
factor, of a proteinaceous nature, as exposure of this factor in trypsin abolishes 
competence induction (Tomasz & Hotchkiss 1964).  In 1995, the chemical nature of 
this factor was described by Håvarstein et al. (Håvarstein, Coomaraswamy & 
Morrison 1995). By chromatographic isolation of competent culture supernatants, the 
competence stimulatory peptide (ComC) was purified, and its amino acid sequence 
determined. Nucleotide sequence analysis revealed that ComC is synthesized as a 41-
amino acid pro-peptide containing a 24-aa leader sequence ending with a Gly-Gly 
motif. The leader sequence also contains the bacteriocin processing consensus 
residues with hydrophobic residues at positions -4, -7, -12, and -15. The homology of 
the leader peptide to other double-glycine-containing bacteriocins (Håvarstein, Holo 
& Nes 1994; Dirix et al. 2004), and the identification that ABC transporters process 
and export bacteriocins with double-glycine motifs (Håvarstein, Diep & Nes 1995), 
led to the designation of ComA and ComB as the ABC transporter complex 
responsible for cleavage of leader peptide of CSP and the export of the 17-aa mature 
peptide (Håvarstein, Diep & Nes 1995; Hui, Zhou & Morrison 1995). 
 
5.1.6 Diversity of ComC in the Pneumococcus 
Two major CSP pherotypes, CSP1 and CSP2, were identified (Pozzi et al. 1996). 
Sequence comparison shows that these two alleles differ by eight amino acid changes 
in the mature peptide region. Later studies identified additional rare CSP alleles, with 
up to 7 identified in the natural population (Fig. 5.2) (Ramirez, Morrison & Tomasz 
1997; Whatmore, Barcus & Dowson 1999; Vestrheim et al. 2011). Differences in 
amino acids between these pherotypes include residues that confer biological activity 
(Havarstein 1999; Johnsborg et al. 2006). Also, substitution of residues 4, 7, 8, and 12 
(together form a hydrophobic patch in the ligand) of mature CSP2 peptide to the 
corresponding amino acids in CSP1 shifts the ligand specificity to the receptor 
ComD1, suggesting that these variable amino acid residues mediate receptor 
specificity. Studies investigating the diversities of CSP are listed in Table 5.1. 
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Fig. 5.2 Amino acid alignment of pneumococcal pherotypes. Arrow indicates 
position of double-glycine residues cleaved during CSP export. CSP6.1 was recently 
hypothesized to be a common allele of S. pseudopneumoniae (Chapter 7). Figure from 
Whatmore et al. (Whatmore, Barcus & Dowson 1999).  
 
 
 
  
 165 
Table 5.1. Selected publications describing pneumococcal pherotype diversity 
 
Reference No. 
Strains 
Geographical 
Location 
Colonization 
or Infection 
Pherotype Proportion (%) 
(Pozzi et al. 
1996) 
42 Italy, USA Infection CSP1 
CSP2 
29 (69.0) 
13 (31.0) 
      
(Ramirez, 
Morrison & 
Tomasz 1997) 
50 USA 
South Africa 
South Korea 
Spain 
Croatia 
Iceland 
Hungary 
Czech 
Republic 
 
Both CSP1
 
CSP2.1 
CSP2.2 
CSP3 
24 (48.0) 
16 (32.0) 
9 (18.0) 
1 (2.0) 
(Whatmore, 
Barcus & 
Dowson 1999) 
60 USA 
Spain 
Papua 
New Guinea 
UK 
Kenya 
Czechoslovakia 
Mexico 
France 
 
Unknown CSP1 
CSP2.1 
CSP2.2 
CSP3 
CSP4 
CSP5 
CSP6.1 
29 (48.3) 
20 (33.3) 
7 (11.7) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
(Sa-Leao et al. 
2002) 
8
a 
Portugal Colonization CSP1 5 (62.5) 
    CSP2.1 2 (25.0) 
    CSP2.2 1 (12.5) 
      
(Carrolo et al. 
2009) 
483 Portugal Infection CSP1 
CSP2 
341 (70.6) 
142 (29.4) 
(Cornejo, 
McGee & Rozen 
2010) 
88 Various
b
 Infection CSP1 
CSP2 
65 (73.9) 
23 (26.1) 
      
(Vestrheim et al. 
2011) 
150 Norway Colonization CSP1 94 (62.7) 
    CSP2 56 (37.3) 
 
 
a
 Analyzed co-colonization of multiple pherotypes, but small sample size 
b
 The 88 strains are a sample from a larger collection of strains from South Africa, 
USA, Sweden, Spain, New Zealand, Taiwan, Argentina, Brazil, Hong Kong, and 
France (Yu et al. 2003).   
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ComC is also present in other streptococci (Håvarstein, Hakenbeck & Gaustad 1997; 
Allan et al. 2007; Kilian et al. 2008).  Switching of competence pherotypes has been 
reported to take place between streptococcal species (Håvarstein, Hakenbeck & 
Gaustad 1997; Kilian et al. 2008). The recombination breakpoint extends beyond 
regions of comC and comD mediating pherotype specificity, indicating that strains can 
change both their pherotypes and receptor by this manner without resulting in non-
cognate ligand-receptor pairs. Extensive diversity of ComC between streptococcal 
species has been observed in a recent study (Kilian et al. 2008), where each strain of 
S. mitis and S. pseudopneumoniae analyzed possessed a distinct pherotype. Chapter 7 
describes the pherotype diversity and sequences associated with S. 
pseudopneumoniae. The presence of multiple pherotypes is also detected in S. mutans 
(Allan et al. 2007). In vitro cross-induction of competence was seen with two 
pherotypes of S. sanguinis containing multiple amino acid substitutions in the mature 
CSP peptide (Zhu et al. 2011). The diversity of CSP therefore does not appear to be a 
property exclusive to S. pneumoniae, but a common feature of the Streptococcus 
genus. 
 
5.1.7 Significance of Pherotype Diversity 
The full biological role of pherotype diversity remains to be elucidated. One 
hypothesis argues that pherotypes drive genetic differentiation between strains within 
a species; the release of CSP of one pherotype in most pneumococci will only induce 
competence and hence genetic transformation of the matching pherotype. Strains 
belonging to a given pherotype are significantly associated with other properties such 
as serotypes and antibiotic resistance, and even more so with genetic backgrounds as 
measured by PFGE and MLST (Carrolo et al. 2009; Vestrheim et al. 2011). 
Håvarstein (Håvarstein, Hakenbeck & Gaustad 1997) argues that pherotype 
specificity allows for communication within bacteria of the same pherotype rather 
than between different pherotypes. Indeed, with pherotype-specific competence 
induction, only a subset of cells of the same pherotype would undergo competence 
induction and DNA acquisition at one time in general. As DNA uptake in the S. 
pneumoniae does not require a signal sequence, pherotype specificity may limit 
acquisition of highly divergent sequences, which may be deleterious or have toxic 
effects (Tortosa & Dubnau 1999). Therefore, while acknowledging the phenomenon 
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of inter-pherotype genetic exchange, Carrolo et al. (Carrolo et al. 2009) hypothesizes 
that this is relatively rare compared to intra-pherotype exchanges. 
 
A second hypothesis suggests that recombinational events are not limited to strains 
bearing identical pherotypes, because bacterial fratricide would enable the release of 
DNA from non-competent cells (Cornejo, McGee & Rozen 2010). If genetic 
differentiation occurs as a result of pherotype differences, sequence diversity of 
strains within a pherotype should be less across pherotypes. By comparing MLST 
sequences of CSP1 and CSP2, Cornejo et al. (Cornejo, McGee & Rozen 2010) did not 
find this to be the case. Pneumococcal competence can lead to the lysis of non-
competent pneumococci as well as species of viridans streptococci (Johnsborg et al. 
2008). Therefore, by inducing competence only in a subset of cells of a pherotype, 
gene exchanges between pherotypes may actually be promoted by allowing the lysis 
and DNA uptake of non-competent cells of different pherotypes. 
 
5.1.8 Cross-Activation of Competence by Non-Cognate Pherotypes 
While most competent pneumococci could only be activated by their own CSP allele, 
the work of Pozzi et al. (Pozzi et al. 1996) demonstrated that some strains can be 
activated by both CSP1 and CSP2 in experimental conditions. Cross-activation work 
was also performed on strains expressing comD3 and comD4 in which some of these 
strains were observed to also be activated by the CSP1 ligand at higher CSP 
concentrations (300-1000 ng/mL) (Iannelli, Oggioni & Pozzi 2005). To date, cross-
activation studies have been performed in vitro, but no in vivo results have been 
reported. Similarly, it is not known whether at physiological conditions, the 
concentration of CSP ligands reach a level that enable cross-activation. Should cross-
activation occur in natural populations, understanding the pherotype diversity of co-
colonizing pherotypes would provide additional insight as to the communication 
between and dynamics of co-colonizing strains. To our knowledge, only two studies 
had been conducted to investigate pherotype diversity in co-colonizations (Sa-Leao et 
al. 2002; Vestrheim et al. 2011). 
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5.1.9 Aim 
Multiple pneumococcal pherotypes exist, however there is scant data on the virulence 
of different phenotypes, and the diversity of pherotypes had only been reported in a 
small number of studies. Similarly, information regarding the relationship between 
pherotypes and core genetic backgrounds, and the co-colonization of different 
pherotypes is limited. In this study, the pneumococcal pherotypes from carriage 
(Chapter 4) and invasive strains obtained from Tanzanian children and patients 
respectively were compared with UK strains. Comparison of pherotype prevalences 
between carriage and clinical pneumococci from the UK and Tanzania will allow us 
to determine if differences in proportions of pherotypes are observed between these 
groups, and whether these pherotypes differ in disease potential and geographical 
distribution. Examining pherotype diversity of pneumococci in co-colonization events 
as described in Chapter 4 provides insights as to how these events provide a suitable 
condition for genetic exchanges. 
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5.2 Materials and Methods 
5.2.1 Bacterial Strains 
CSP analysis was performed on a total of 200 pneumococcal strains. Of these 115 
were isolated between the years 1993-2000 from the Royal Free Hospital in London, 
U.K. These included 68 from blood, 14 from the lower respiratory tract, 4 from the 
middle ear, 2 from cerebrospinal fluid, and one from conjunctiva. Twenty-six strains 
were isolated from unknown anatomical sites due to loss of clinical data. Eighty-five 
pneumococci from Tanzania, including 18 invasive strains (Crump et al. 2011a; 
Crump et al. 2011b), and 67 carriage strains from healthy children (Chapter 4). Please 
refer to Appendix Table A1 for strain included in this study.  
 
5.2.2 PCR of comC 
Sequences for primers used (comC-fw and comC-rv), and the annealing temperature 
and extension time of the PCR are indicated in Table 2.6.   
 
5.2.3 Pherotype Characterization by RFLP 
For 39 of the 85 strains from Tanzania, comC amplicon (~300 bp) was subjected to 
restriction analysis by endonuclease BsaXI (New England Biolabs). This was 
performed by Dr. Sarah Batt prior to the commencement of works included in this 
thesis. Upon restriction, the largest band for CSP1, 2, and 4 were expected to be ~150 
bp, ~200 bp, and 300 bp (undigested), respectively, based on in silico restriction on 
NEBcutter (Vincze 2003) using published comC sequences as template (accession 
numbers AJ240789, AJ240785, AJ240765, and AJ240792. Strains typed as CSP2 on 
RFLP was subtyped as CSP2.1 and 2.2 by sequencing. Sequencing was also 
performed on strains with undigested band to confirm pherotype. All strains tested as 
undigested by RFLP were CSP4 by sequencing (see below). 
 
5.2.4 Pherotype Characterization by comC Sequencing 
Gel electrophoresis, DNA purification, cycle sequencing, ethanol precipitation, and 
sequence analysis were performed as outlined in Sections 2.8.3 to 2.8.8. 
 
5.2.5 Statistical Analysis 
Statistical analyses were performed on Graph Prism 5 (GraphPad) and SPSS Version 
20. Fisher’s Exact Test was employed to compare significances of differences in 
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pherotype proportions. Odds ratio for likelihood of pherotypes to be associated with 
geographical region and invasiveness was as calculated. The odd of detecting each 
pherotype in Tanzania relative to the United Kingdom was calculated by: ratio = 
(ad)/(bc), where a is the number of Tanzania strains of the pherotype in question, d is 
the number of United Kingdom of other pherotypes, b is the number of United 
Kingdom strains of the pherotype, and c is the number of Tanzania strains of other 
pherotypes. For disease potential, the odds ratio of disease relative to carriage is 
calculated using the same formula, where a is the number of invasive strains of the 
pherotype in question, d is the number of carriage strains of other pherotypes, b is the 
number of carriage strains of the pherotype, and c is the number of invasive strains of 
other pherotypes. An odds ratio of >1 indicates an increased likelihood for a 
pherotype to be associated with Tanzania (for geography) or disease (disease 
potential), where odds ratio of  <1 indicates a reduced likelihood. 
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5.3 Results 
5.3.1 Pneumococcal pherotypes from the UK and Tanzania 
Pneumococcal pherotypes were determined for 200 strains. Of these, a hundred and 
fifteen were United Kingdom clinical pneumococcal strains, eighteen were Tanzania 
invasive strains, and 67 were Tanzanian nasopharyngeal strains from healthy children 
under 6 years of age (Chapter 4). Four pherotypes were identified, CSP1 77.4% 
(89/115), 13.0% were CSP2.1 (15/115), 5.2% were CSP4 (6/115), and 4.4% were 
CSP2.2 (5/115).  
 
The prevalence of CSP1 (41.2%, 35/85) was significantly lower in Tanzanian strains 
compared with U. K. strains (Table 5.2). Conversely, CSP2.1 (30.6%, 26/85) was also 
significantly more prevalent in Tanzania. CSP2.2 was not detected in Tanzania (Table 
1). The CSP4 pherotype Tanzania (27.1%, 23/85) was greater by more than five-fold. 
A single CSP3 pherotype was also detected in a Tanzanian strain isolated from blood. 
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Table 5.2. Odds ratio for increased likelihood of pherotypes association by geography and disease potential. 
 
 
Variable Pherotype (%) 
CSP1 CSP2.1 CSP2.2 CSP3
b
 CSP4 
Geography      
Tanzania (n=85) 35 (41.2) 26 (30.6) 0 (0) 1 (1.2) 23 (27.1) 
United Kingdom (n=115) 89 (77.4) 15 (13.0) 5 (4.4) 0 (0) 6 (5.2) 
 Tanzania:UK ratio 
95% CI 
0.20 
(0.11-0.38) 
2.94 
(1.44-5.99) 
0.12 
(0.01-2.16) 
4.10 
(0.16-102.0) 
6.74 
(2.60-17.45) 
P-value
a
 < 0.0001 0.0042 0.074 0.43 <0.0001 
      
Disease Potential      
Tanzania Disease (n=18) 9 (50.0) 5 (27.8) 0 (0) 1 (5.6) 3 (16.7) 
Tanzania Carriage (n=67) 26 (38.8) 21 (31.3) 0 (0) 0 (0) 20 (29.9) 
 (Disease:Carriage ratio) 
(95% CI) 
1.58 
(0.55-2.24) 
0.84 
(0.27-2.67) 
Not detected 
in Tanzania 
11.57 
(0.45-296.7) 
0.47 
(0.12-1.81) 
P-value
a
 0.43 1.00 - 0.21 0.37 
 
a
 P-value calculated by two-sided Fisher’s Exact Test. Statistical significance attained when P-value < 0.05. Statistically-significant comparisons 
in bold 
b
 CSP3 not detected in the United Kingdom 
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5.3.2 Pherotype and Antibiotic Susceptibility in Tanzanian Strains 
Analysis of antibiotic susceptibility data for penicillin and co-trimoxazole data that 
was available for 44 Tanzania strains revealed no association between pherotype and 
drug susceptibility (Table 5.3).  
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Table 5.3. Antibiotic susceptibilities of penicillin and co-trimoxazole in Tanzanian strains by pherotype 
 
 CSP1  (% of n=18) CSP2.1 (% of n=12) CSP3 (% of n=1) CSP4 (% of n=13) Total (% of n=44) 
Antibiotic
a
 
Susceptible 
Non-
susceptible Susceptible 
Non-
susceptible Susceptible 
Non-
susceptible Susceptible 
Non-
susceptible Susceptible 
Non-
susceptible 
Penicillin
 12 (67) 6 (33) 3 (25) 9 (75) 1 (100) 0 (0) 4 (31) 9 (69) 20 (45) 24 (55) 
Co-trimoxazole 6 (33) 12 (67) 2 (17) 10 (13) 0 (0) 1 (100) 6 (46) 7 (54) 14 (32) 30 (68) 
 
a
 Penicillin nonsusceptibility determined as minimum inhibitory concentrations ≤0.06 μg/mL using E-test; co-trimoxazole nonsusceptibility 
determined as a zone of inhibition ≥ 19 mm by the Kirby-Bauer disc diffusion method. 
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5.3.3 Invasive disease potential for individual pherotypes 
To ascertain if particular pherotypes are associated with invasive disease, the invasive 
odds ratio for each pherotype was determined on 67 carriage strains and 18 invasive 
strains from Tanzania. No significant association was found (Table 5.2). The 
prevalence of the CSP1 pherotype in U.K. clinical strains is significantly greater than 
that of clinical strains in Tanzania, while significance within clinical strains from the 
two countries was not observed for the other pherotypes (Table 5.4). 
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Table 5.4. Odds ratio for increased likelihood of clinical pherotypes association by geography 
 
 
Country Pherotype (%) 
 CSP1 CSP2.1 CSP2.2 CSP3 CSP4 
      
Tanzania (n=18) 9 (50.0) 5 (27.8) 0 (0) 1 (5.6) 3 (16.7) 
UK (n=115) 89 (77.4) 15 (13.0) 5 (4.4) 0 (0) 6 (5.2) 
Tanzania:UK Ratio 
95% CI 
0.29 
(0.11-0.81) 
2.13 
(0.88-5.15) 
0.54 
(0.029-10.24) 
19.80 
(0.77-505.9) 
3.63 
(0.82-16.08) 
p-value 0.021 0.15 1.00 0.14 0.10 
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5.3.4 Pherotypes of Co-Colonizing Strains 
Previously we identified seven colonization events with multiple pneumococcal 
strains as characterized by serotype and sequence type (ST) by MLST (Chapter 4). 
Pherotype analysis of these co-colonizing strains revealed that all but one event had 
multiple pherotypes (Table 5.5). Most co-colonization events had two pherotypes, 
while three pherotypes were detected in colonizations 2 and 3 (Table 5.5). Within a 
host, strains with the same serotype, but different STs also had different pherotypes 
(e.g. serotype 6B strains associated with CSP2.1 and 4. Strains with different 
serotypes and/or STs were found to be of the same pherotype (e.g. colonizations 3 and 
5, Table 5.5).  
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Table 5.5. The serotypes, pherotypes, sequence types, and MICs of penicillin and 
co-trimoxazole present in Tanzanian colonizing strains  
 
Sample Child (Month)
a 
Serotype
b
 CSP Pherotype 
Sequence Type 
(ST)
 
1 1 NT 4 4156 
  6B 2.1 4429 
2 16 19F 1 347 
  34 2.1 4158 
  35A 4 840 
3 35 6B 2.1 854 
  6B 4 4157 
  10A 1 852 
  21 1 1145 
  19A 2.1 4162 
  19F 1 6170 
4 3 (Sep) 1 1 217 
  6B 4 4373 
5 29 35A 4 840 
  11A 4 5752 
6 10 (Jan) 19A 2.1 4162 
  13 4 4370 
7 10 (Apr) 18C 1 1233 
  6B 4 4368 
8 18 10A 1 852 
9 22 17F 2.1 4160 
10 45 21 1 1145 
11 3 (Jan) 6B 4 4368 
12 3 (Mar) 6B 4 4368 
13 24 19A 2.1 4162 
14 3 (Jul) 1 1 217 
 
a
 The months of colonization event are indicated if a child had multiple co-
colonization events during study period 
b
 NT: nontypable by agglutination and absence of amplification targeting cpsB and 
cpsA (Pai, Gertz & Beall 2006; Leung et al. 2011) 
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5.3.5 Pherotypes of Genetically Related Strains 
An eBURST representation of the co-colonization cohort revealed 18 STs (Fig. 5.3). 
Six of these belong to two pairs of SLVs (ST347 and ST6170 differing at spi by one 
nucleotide, ST4157 and ST4368 differing at recP by three nucleotides) and a pair of 
DLV (ST854 and ST4429 differing at gki and ddl at five and 40 nucleotides 
respectively). Each pair of related STs were associated with the same serotype and 
pherotype (Table 5.5 and Fig. 5.3).  
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Fig. 5.3. eBURST representation of genetic relatedness of STs and pherotypes of related STs detected in multiple colonization. 
Genetically related STs with variation in a single allele (single-locus variants) are connected by solid lines, and those differing in two alleles 
(double-locus variants) are connected by dotted lines. Each pair of related STs encircled and the sharing serotypes and pherotypes indicated. 
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5.4 Discussion 
It is hypothesized that pherotype specificity enables communication between cells 
within a pherotype, and that this may result in genetically distinct clusters of 
pneumococci within pherotypes (Håvarstein, Hakenbeck & Gaustad 1997; Carrolo et 
al. 2009). Cellular communication via the activation of competence stimulatory has 
the potential to propagate genomic plasticity by coordinating genetic transformation 
(Peterson et al. 2004), contributing to biofilm formation (Trappetti et al. 2011a; 
Trappetti et al. 2011c), and enabling the release of DNA from non-competent cells 
through bacterial fratricide (Guiral et al. 2005; Johnsborg et al. 2008; Eldholm et al. 
2009). In this study we have investigated the relationship between pherotypes and 
geography, invasive potential. We also determined the diversity of CSP alleles in co-
colonization events. 
 
5.4.1 Prevalence of CSP4 
This is the first population-based investigation of pherotype distributions between two 
different geographical locations. To date, pherotype CSP4 had only been detected in 
one pneumococcal strain from Papua New Guinea (Whatmore, Barcus & Dowson 
1999). However, we found that the CSP4 pherotype was detected in 5.2% of U.K. 
strains and the prevalence of this pherotype was significantly higher in Tanzania 
(27%). Interestingly, this pherotype was detected in both carriage (30%) and invasive 
(17%) Tanzanian strains. Moreover, CSP4 was found to be associated with multiple 
serotypes and clones in Tanzania, indicating that this pherotype is widely dispersed in 
this region. 
 
The reasons for the greater prevalence of CSP4 in Tanzanian strains compared with 
U.K. strains are unknown. One possibility is that there is limited transmission of these 
strains, as carriage strains were collected from Tanzanian children living in a semi-
closed community on a sugar plantation (Chapter 4). Previous studies by us and 
others have shown that some STs are geographically unique (Reis et al. 2008), 
(Donkor et al. 2011; Inverarity et al. 2011; Leung et al. 2011). The Tanzanian strains 
with the CSP4 pherotype were associated with STs that have not been detected 
elsewhere thus far. Conversely, there was a significantly greater prevalence of the 
CSP1 pherotype in U.K. strains compared with Tanzanian strains. These data indicate 
that differences in the prevalence of pherotypes between the U.K. and Tanzania may 
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be due to geographically unique sequence types. Additional characterization of 
pherotype distribution in sub-Sahara is therefore encouraged.  
 
5.4.2 Association Between Pherotypes and Serotypes, STs, and CCs 
Pneumococci of the same serotype were associated with different pherotypes, and in 
agreement with other studies, genetically related strains as indicated by the same or 
related STs were found to have the same pherotype (Carrolo et al. 2009; Vestrheim et 
al. 2011).  Multiple alleles of another virulence factor, pneumolysin, also appear to be 
clonally distributed, with some alleles postulated to account for strain-specific 
differences in disease potentials (Kirkham et al. 2006; Jefferies et al. 2007b; Jefferies 
et al. 2010b; Harvey et al. 2011). In vitro and in vivo models employing isogenic 
mutants of different CSP variants may increase our understanding of pherotype-
specific invasiveness.  
 
5.4.3 Co-Colonization of Different Pherotypes 
While simultaneous colonization by different pneumococcal strains has been well 
documented (Meats et al. 2003; Vestrheim et al. 2008b; Donkor et al. 2011; Leung et 
al. 2011), there are limited studies on co-colonization by different pneumococcal 
pherotypes (Sa-Leao et al. 2002; Vestrheim et al. 2011). We have identified that six 
of the seven (86%) of multiple colonization events contained mixed pherotypes. This 
is higher than the previous two studies reporting 25% (Sa-Leao et al. 2002) and 47% 
(Vestrheim et al. 2011) of multiple colonizations containing mixed pherotypes. We 
also detected with up to three pherotypes colonizing simultaneously. Under the 
assumption that multiple colonization allows for genetic exchanges between strains, it 
appears that the high prevalence of multiple pherotype colonization supports the 
fratricide hypothesis, where a subpopulation of strains within a colonization event 
could induce competence and acquire DNA from co-colonizing heterogeneous 
pherotypes by cell lysis. However, additional large-scale studies are required to 
further support or disprove the two hypotheses regarding the significance of 
pherotype diversity (Section 5.1.7). It is possible that both hypotheses contribute to 
the evolution and diversification of not only pneumococci but other members of 
streptococci (Section 7.4.5). 
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5.4.4 Pherotype Cross-Talk 
A single CSP3 strain was detected in an invasive strain from Tanzania. Pneumococci 
with comC3 were detected in South Africa (Ramirez, Morrison & Tomasz 1997) and 
Spain (Whatmore, Barcus & Dowson 1999). Interestingly, Iannelli et al. (Iannelli, 
Oggioni & Pozzi 2005) detected comC1 strains in Italy linked to either comD3 or 
comD4 gene, and that pneumococci with comD3 or comD4 could respond to 
increased concentrations (100 ng/mL) of CSP1 and CSP2 in vitro. However, whether 
such CSP concentrations and subsequent cross talks between pherotypes occur in 
physiological conditions are unknown.  
 
It must be noted that factors other than pherotype, such as capsulation, serotype, ions, 
antimicrobials, pH, presence of sugars, and other pneumococcal proteins may also 
affect competence activation and genetic transformability (Yother, McDaniel & Briles 
1986; Hsieh et al. 2006; Prudhomme et al. 2006) reviewed in (Havarstein 1999; 
Claverys & Havarstein 2002; Johnsborg & Håvarstein 2009). In addition, CSP can be 
detected in other oral streptococci, including the newly recognized emerging pathogen 
Streptococcus pseudopneumoniae (Kilian et al. 2008; Leung et al. 2012), and that 
competence-mediated fratricide in pneumococci can trigger DNA release from related 
streptococcal species. Therefore, the effect of multiple pherotype colonization on 
genetic exchange and the adaptation and evolution of S. pneumoniae is likely to be as 
a result of complex interactions between co-colonizing pneumococci, oral 
streptococci, and the host environment. 
 
5.5 Concluding Remarks 
In conclusion, significant geographical differences in the distribution of pherotypes 
were observed. We reported a higher prevalence of CSP4, contrary to previously 
reports. Genetically related strains had the same pherotype as well as the same 
serotype. There was no association found between the pherotype and invasive 
potential. This study revealed that the majority of co-colonizing strains had different 
pherotypes, thus providing an optimum natural condition for genetic exchanges 
between different strains. 
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CHAPTER SIX: Intra-Serotype Diversity of Pneumococcal Capsular 
Regulatory Gene cpsB 
 
 
6.1 Introduction 
6.1.1 Capsule Regulatory Genes 
The first four genes of the cps locus (cpsA, cpsB, cpsC, cpsD) are expressed in all 
serotypes except for 3 and 37. CpsA has been shown to bind to the cps promoter and 
deletion of cpsA reduces capsule production, and higher levels of cpsA expression 
were detected in serotypes associated with invasive diseases (Morona et al. 2000; 
Bender, Cartee & Yother 2003; Hathaway, Bättig & Mühlemann 2007; Hanson, Lowe 
& Neely 2011). CpsD is a cytoplasmic protein-tyrosine kinase with 
autophosphorylating activity, containing Walker A and B ATP-binding domains, and 
a tyrosine-rich C-terminal with two to four [YGX] repeats, both of which appear to be 
crucial for capsule synthesis (Morona et al. 2000; Morona et al. 2003; Morona et al. 
2004). CpsC is proposed to be a membrane protein required for the phosphorylation 
of CpsD and attachment of capsule polysaccharides to the cell wall (Morona et al. 
2000; Bender & Yother 2001; Morona, Morona & Paton 2006; Byrne et al. 2011).  
 
6.1.2 CpsB Phosphotyrosine Phosphatase 
CpsB is a manganese-dependent phosphotyrosine phosphatase that dephosphorylates 
CpsD-P and inhibits transphosphorylation between CpsD molecules, thereby 
activating capsule expression (Morona et al. 2000; Morona et al. 2002; Morona, 
Morona & Paton 2006). While deletion of cpsB resulted in high levels of CpsD-P in 
both strains, Rx1-19F had a rough appearance with decreased CPS, while D39 had a 
smooth appearance with increased CPS (Bender, Cartee & Yother 2003), suggesting 
that possible additional strain-specific factors located outside the cps regulatory 
region may influence the effects of CpsD phosphorylation on CPS production, and the 
role of CpsB in modulating capsule production. Recently, CpsC and CpsD has been 
demonstrated to be crucial for the attachment of capsule material to the cell wall; 
while deletion of cpsB, and hence a build-up of CpsD-P, is associated with decrease 
in total CPS, approximately 1% of these mutants show a mucoid phenotype due to 
additional amino acid substitutions, possibly at the extracellular domain of CpsC, 
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associated with decreased ability to attach CPS to cell wall and cause invasive 
diseases (Morona, Morona & Paton 2006; Byrne et al. 2011). 
 
6.1.3 CpsB Structure 
CpsB is a phosphotyrosine phosphatase initially postulated to modulate capsule 
production in pneumococci (Fig. 6.1). CpsB is a member of the polymerase and 
histidinol phosphate phosphatase (PHP) family and its crystallized structure was the 
first tyrosine phosphatase of this class to be characterized in Gram-positive bacteria 
(Hagelueken et al. 2009). Other members of the PHP family includes capsular 
biosynthesis proteins in Staphylococcus and Bacillus, and subunits within DNA 
polymerases in Helicobacter, Chlamydia, and B. subtilis (Aravind & Koonin 1998). 
CpsB is a 243-aa, 26-kDa protein consisting of 2 triple-stranded β-sheets surrounded 
by eight α-helix rings (Fig. 6.1).  
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Fig. 6.1 Crystal (A) and schematic (B) structures of CpsB. The phosphotyrosine 
phosphatase is composed of eight α-helices and three pairs of β-sheets in parallel. The 
blue and purple spheres represent metal ions required for full enzymatic activity. 
Figure from Hagelueken et. al. (Hagelueken et al. 2009). 
 
CpsB activity was documented to be dependent on the presence of Mn
2+
 (Morona, 
2001), and addition of Mn
2+
, as well as Cu
2+
 and Co
2+ 
ions was associated with up to 
10-fold increase in biological activity (Hagelueken, 2009). The active site contains 3 
metal-binding pockets, which are thought to involve two arginine residues at positions 
139 and 206. When the enzyme is bound to phosphate, there is minimal 
conformational change to the enzyme, except that the metal-binding pockets are 
replaced by the phosphate molecule. Mutants with arginine-to-alanine substitutions to 
position 139 have 95% reduction in CpsB enzymatic activity, suggesting that this 
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residue is crucial for enzymatic function (Hagelueken, 2009). CpsB also contains 
additional conserved motifs containing histidine residues which may be involved in 
stabilization of the metal cations, and mutation of these residues led to increased 
levels of phosphorylated forms of CpsD, associated with a rough phenotype and 
minimal visual differences in morphologies from that of a cpsB-deletion Rx1-
derivative mutant (Morona, 2001). Alignment of homologues of CpsB with other 
Gram-positive species revealed that these motifs, in particular histidine residues 
within these motifs, are conserved (Fig. 6.2) (Morona, 2002). In addition, a series of 
amino acid residues throughout the protein has been thought to line the phosphate 
pocket (Kim, 2011). CpsB has 30% amino acid homology to PHP protein YwqE of 
Bacillus subtilis, which is a phosphotyrosine phosphatase likely to be a regulator of 
exopolysaccharide synthesis (Mijakovic et al. 2003).  
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Fig. 6.2 Alignment of S. pneumoniae CpsB and its homologues across Gram-
positive species. Alignment included members of S. agalactiae, S. salivarius, S. 
thermophilus, S. suis, S. aureus, B. subtilis, and Lactococcus lactis. Members of the 
PHP superfamily proteins contain four conserved motifs indicated by Roman 
numerals. Shaded amino acids indicated conserved positions, including residues in 
asterisks that are thought to be important for catalysis. Figure from Morona et al. 
(Morona et al. 2002). Journal of Bacteriology authorizes the reuse of journal material 
including figure shown for academic purposes 
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6.1.4 Genetic Characteristics of cpsB 
Compared to serotype-specific regions of the cps locus, sequences of regulatory genes 
including cpsB between serotypes are more conserved in that it is present in all 
serotypes. Studies investigating cpsB sequence variation are scarce. While 
understanding the genetic organization of cps locus of serotype 19F, Morona et al. 
(Morona, Morona & Paton 1997) documented the hybridization of cpsB from 18 
serotypes, including serotype 19A, to cps19fB. However, subsequent sequence 
analysis between cps19fB and cps19aB reveals that only a short region within this 
gene shows 100% identity between the two serotypes, while the overall sequence 
similarity of cpsB between is only 82%, suggesting that sequence analysis reveals a 
higher degree of variation in this gene (Morona, Morona & Paton 1999a). Analysis of 
cps19aB reveals the presence of mosaic patterns with blocks of GC% variation 
(Morona, Morona & Paton 1999a); the authors suggest that recombination of short 
fragments into this gene has occurred (Morona, Morona & Paton 1999a).  
 
Sequence analysis of cpsB from 11 serotypes revealed two major classes, with 
sequence variation between the classes up to 27% (Jiang, Wang & Reeves 2001). 
Class I includes serotypes 1, 14, 18C, and 19F, while class II consists of serotypes 2, 
6B, 8, 19A, 23F, and 33F. In contrast to the high sequence variation between the two 
classes, sequence variations between serotypes within the same class do not exceed 
4%. This indicates that the two clusters are well defined with serotypes within each 
cluster highly similar. 
 
In agreement to this, a recent study involving a larger number of serotypes revealed 
the dichotomous divergence of cpsB sequences (Varvio et al. 2009). In this study, the 
clusters are classified blue (class I) and red (class II), with a greater genetic diversity 
within sequences of the blue cluster, suggesting that this cluster is the ancestral group. 
The lower GC content (lower by 5% compared to blue cluster) in the red cluster 
suggests that the cps regulatory genes of these serotypes originate from an external 
gene pool of unknown origin. Serotypes within a serogroup may belong to different 
clusters, indicating that similarity in capsule structure is not correlated with sequence 
similarity in this region. Analysis of epidemiological data shows that class I serotypes 
are more likely to associate with carriage while serotypes in class II are 
predominantly found in IPD (Varvio et al. 2009). However, this finding was based 
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upon a small selected number of cohorts, and the strength of this association has not 
been determined in other studies. Nonetheless, sequence variation at the cps 
regulatory region may play a role in its ability to colonize and cause disease, perhaps 
by modulating the production of capsules. 
 
6.1.5 Aim 
The discrepancies observed between in silico and experimental results in sequetyping 
resolution power as described in Chapter 3 led us to hypothesize that strains within a 
serotype may have different cpsB sequences. While sequence diversity between 
representative strains of serotypes has been analyzed, information regarding sequence 
diversity within a serotype is limited to a minority of serotypes (McEllistrem et al. 
2004; Varvio et al. 2009; Elberse et al. 2011). Variation in cpsB within a serotype 
may allow the greater potential to regulate capsule expression under different 
environmental conditions. 
 
With the availability of a large number of cpsB sequences following the works 
described in Chapter 3, we aimed to compare intra-serotype diversity of cpsB in 
different pneumococcal serotypes. First the cpsB phylogenetic tree published by 
Varvio et al. (Varvio et al. 2009) was expanded by adding cpsB sequences from the 
newly-identified serotypes 6C and 6D, as well as incorporating additional cpsB 
sequences from results obtained in our sequetyping work (Chapter 3) and previously 
published works. The relationships of cpsB variation and STs and CCs were also 
analyzed. 
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6.2 Materials and Methods 
6.2.1 cpsB Sequence Data for Pneumococcal Strains 
Please refer to Appendix Table A1 for strains included in this chapter. Sequence data 
for an additional 172 cpsB sequences were available from the GenBank database. 
Accession numbers for these Genbank entries are available in Appendix Table A2. 
 
6.2.2 Multilocus Sequence Data 
Sequence types (STs) were available for 163 strains in this study. ST data for strains 
from HPA and SHLMPRL were provided by Dr. Bruno Pichon and Dr. Giles 
Edwards, respectively. STs of strains with cpsB sequences from GenBank are 
available in respective publications. ST from Tanzanian strains were from works in 
Chapter 4. MLST was performed on invasive pneumococcal strains from the Royal 
Free Hospital as described in Chapters 2 and 3. eBURST (Feil et al. 2004) was 
performed to illustrate genetic relatedness of all STs included in this study, and to 
identify clonal complexes of related STs differing in one of the seven MLST loci 
(single-locus variants, SLVs). 
 
6.2.3 Multiple Sequence Alignment and Phylogenetic Analysis 
Multiple sequence alignments on cpsB, concatenated MLST sequences (without ddl), 
and translated CpsB amino acid sequences were constructed on MEGA software, 
version 5.05 (Tamura et al. 2011). GC contents were calculated by MEGA. 
Topologies based on cpsB alignments were acquired using the neighbour-joining (NJ) 
and maximum likelihood (ML) methods, with 1,000 bootstrap repetitions for NJ and 
100 bootstrap for ML. NJ analysis, based on matrix of pairwise distance differences, 
is more computationally efficient and was also used by Varvio et al. (Varvio et al. 
2009), but ML, inferring phylogenetic relationship directly from each site in the 
multiple alignment, provides the most probable estimate of phylogenetic relationship 
based on a given evolutionary model. The NJ trees are included in the results section 
of this chapter, whereas the ML trees of the same alignment data are included in the 
appendix. Bootstrap values < 75% are not included in the trees.  
 
The ML trees were constructed using the Tamura-3 Paramete evolutionary model. 
The Tamura 3 parameter model does not assume that each nucleotide substitution 
occurs at the same rate (i.e. unlike the Jukes and Cantor model). Specifically, branch 
192 
 
lengths in ML under this model are calculated based on two separate calculations: 
transversion and transition nucleotide substitutions. Also, the Tamura 3 parameter 
accounts for mutational bias along a nucleotide site on the alignment. It was chosen 
over other models from the MEGA software as providing the most likely 
phylogenetic representation based on the sequence alignment data. 
 
6.2.4 Statistical Analysis for Intra-Serotype Diversity 
The number of polymorphic or segregating sites (S), haplotype diversity (Hd), 
nucleotide diversity (π), and their standard deviations were calculated using DnaSP5 
software for cpsB for strains of serotypes 1, 3, 4, 5, 6A, 6B, 6C, 7F, 8, 9V, 10A, 14, 
15A, 17F, 18C, 19A, 19F, 21, and 23F. For all but serotypes 10A, 15A, and 21, the 
aforementioned parameters were calculated also on concatenated ST data; serotypes 
10A, 15A, and 21 did not have enough ST data on more than one strain. Intra-
serotype Hd corresponds to the likelihood of two sequences to be of different alleles, 
whereas intra-serotype π is the average number of substitution per site. The 
comparison of cpsBπ between serotypes was calculated by one-way ANOVA and 
Tukey’s test for multiple pairwise comparisons of means. As not all strains with cpsB 
had MLST data, cpsBπ was repeated for strains with only MLST information. This is 
to satisfy the calculation of statistical significance between cpsBπ and MLSTπ using 
the paired t-test. It is possible that differences in π were due to differences in π of 
MLST data. Therefore, the ratio of cpsBπ to MLSTπ was calculated for each serotype 
to normalize for MLST differences.   
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6.3 Results 
6.3 1 Multiple Alignment of cpsB of Different Serotypes 
A total of 351 sequences of 92 serotypes were available for analysis. In most 
serotypes, cpsB has a length of 732 bp, encoding for 243 amino acids. Serotype 3 
contained a single nucleotide deletion at nucleotide position 282, leading to a 
frameshift mutation and a premature stop codon at amino acid position 106. The 
sequence of new serotype 11E (Calix et al. 2010) was not available at the time of 
study. Of all 351 sequences, fifty percent of the sequence (367/732 bp) belongs to 
polymorphic sites. 
 
6.3.2 Phylogenetic Tree of cpsB  
A neighbor-joining phylogenetic tree (Fig. 6.3, maximum likelihood tree in Appendix 
Fig. A2, neighbor-joining radial tree with taxon names in Appendix Fig. A3, and 
maximum-likelihood radial tree with taxon names in Appendix Fig. A4) based on 351 
cpsB sequences of 92 serotypes showed a similar two-cluster topology as seen 
previously (Varvio et al. 2009). Three serotypes (serotypes 29, 39, 43 indicated in 
green) showed sequences resembling non-pneumococcal origins in 3’ end of cpsB 
(Varvio et al. 2009), and are indicated in green in Fig. 6.3. Purple serotypes 
correspond to sequences where mosaics of blue and red sequences were detected. 
Serotypes 3 contains a single-nucleotide deletion in this gene, resulting in a premature 
stop codon in amino acid position 94, and capsule synthesis in serotype 37 is not 
dependent on cps locus (Llull et al. 1999). The gene cpsB in serotypes 3 and 37 are 
not expressed and are indicated in black. Serotypes 25A and 38 formed a very 
divergent group that did not cluster with either blue or red sequences. However they 
were considered red serotypes based on the cpsB GC content (35%).  
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Fig. 6.3. Neighbour-joining phylogenetic representation of pneumococcal cpsB sequences.  Red 
and blue colouring was based on study of Varvio et al. (Varvio et al. 2009), where blue represents 
serotypes commonly associated with carriage, and red represents those predominantly found in 
invasive diseases. Serotypes which, according to Varvio et al., had blue-red mosaic within cpsB 
(serotypes 15A, 15F, 23F, 35F, 47A, 47F) are indicated in purple. Serotypes 29, 39, and 43 contained 
mosaic sequences resembling red sequences and other streptococcal sequences, and are indicated in 
green. Serotypes 3 and 37 do not require cpsB for capsule production, and are indicated in black. 
Phylogenetic representation performed on MEGA 5.05 with bootstrapping of 1,000 repetitions, with 
bootstrapping values over 85% indicated. Distances represented as the number of nucleotide 
substitutions per site. A total of 351 sequences were included in analysis. 
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Fig. 6.3 shows that despite the higher number of sequences included, the dichotomous 
topology is preserved from that seen using a single strain per serotype. The presence 
of cpsB of serotype 37 within the blue cluster is expected, as this serotype contains a 
cryptic cps33f locus, a locus in the blue cluster. Serotype 3 strains were grouped into 
the red cluster, and the lower GC% content (~34%) of this serotype is in agreement 
with the red/blue division based on this property. Serotypes 6C and 6D strains 
grouped with some strains of serotype 6B, and only a single nucleotide (T579C) 
accounted for a difference between 6B and 6C/6D. Serotypes 6C and 6D are identical 
at cpsB. 
 
6.3.3 Intra-Serotype Diversity in cpsB 
Nineteen serotypes containing at least five strains each were included to compare 
intra-serotype cpsB diversity (Table 6.1). The number of polymorphic sites, allelic 
variants, GC content variation, haplotype diversity, and nucleotide diversity were 
tabulated for each of these serotypes. One-way ANOVA revealed that differences 
exist in both haplotype and nucleotide diversities between serotypes, and four clusters 
of serotypes can be made based on nucleotide diversity. The highest diversity in 
cluster one is made up of serotypes 19F, 6A, and 6B, followed by cluster two with 
serotypes 14, 21, 19A, 5, 17F, and 3. Cluster 3 with serotypes 1 and 9V show yet 
lower diversity. Serotypes 10A, 15A, 23F, 4, 6C, 8, 18C, and 7F did not show intra-
serotype nucleotide diversity. Serotype 6B was significantly more diverse than all 
serotypes tested, and 6A was also more diverse than other serotypes except 5 and 17F 
(Tukey’s Test, p < 0.05).  
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Table 6.1 Allele and sequence diversity characteristics of cpsB and concatenated MLST sequences for individual serotypes 
 
a 
N = number of strains, S = Polymorphic sites, H = Number of alleles
 
b
 Hd = Haplotype diversity: the likelihood of two strains having different cpsB alleles or ST 
c
 π = Nucleotide diversity: the average number of nucleotide substitutions per site 
d
 Number of strains with MLST information. MLST was not available for all strains included for cpsB analysis. Serotypes 21, 10A, 15A, and 18C did not have enough MLST 
data 
e
 Serotypes with statistically significant variations between cpsB sequences and MLST concatenated sequences by paired t-test (p<0.05) are indicated in bold. Variation of 
cpsB for these strains calculated only for strains with MLST data 
Serotype
α,d,e
 Ν S Η GC% (SD) cpsB Hdb (SD) cpsBπc (SD) No. MLSTd MLST S No. ST MLST Hdb (SD) MLSTπc (SD) cpsBπ/MLSTπ 
6B 31 54 7 41.7 (0.4) 0.70 (0.059) 0.032 (0.0033) 20 84 12 0.91 (0.053) 0.0088 (0.00094) 3.59 
6A 24 12 5 41.8 (0.2) 0.73 (0.059) 0.0045 (0.00058) 22 44 8 0.81 (0.070) 0.0046 (0.00062) 0.98 
5 8 7 2 37.7 (0.1) 0.43 (0.17) 0.0041 (0.0016) 5 34 3 0.70 (0.22) 0.0049 (0.0026) 0.84 
17F 5 7 2 42.3 (0.2) 0.40 (0.24) 0.0039 (0.0023) 4 18 3 0.83 (0.22) 0.0033 (0.0015) 1.17 
19A 22 11 7 37.7 (0.1) 0.54 (0.13) 0.0024 (0.00101) 17 137 14 0.97 (0.032) 0.013 (0.0015) 0.18 
19F 26 27 6 37.7 (0.1) 0.76 (0.059) 0.0018 (0.00044) 14 106 13 0.99 (0.031) 0.012 (0.0014) 0.15 
21 5 2 2 41.4 (0.1) 0.60 (0.18) 0.0016 (0.00048) - - - - - - 
14 12 3 4 37.4 (0.1) 0.64 (0.13) 0.0011 (0.00030) 7 8 2 0.48 (0.17) 0.0014 (0.00050) 0.86 
1 13 2 2 37.7 (0.1) 0.15 (0.13) 0.00042 (0.00034) 12 34 7 0.894 (0.063) 0.0062 (0.00065) 0.067 
3 13 2 3 37.7 (0.1) 0.30 (0.16) 0.00042 (0.00023) 11 0 1 0 (0) 0 (0) - 
9V 14 1 2 42.5 (0.1) 0.14 (0.12) 0.0002 (0.00016) 6 0 1 0 (0) 0 (0) - 
10A 5 0 1 42.3 (0) 0 (0) 0 (0) - - - - - - 
15A 5 0 1 42.1 (0) 0 (0) 0 (0) - - - - - - 
23F 13 0 1 40.7 (0) 0 (0) 0 (0) 9 44 7 0.92 (0.092) 0.0047 (0.0016) N/A 
4 12 0 1 41.9 (0) 0 (0) 0 (0) 7 8 2 0.48 (0.17) 0.0014 (0.00050) N/A 
6C 5 0 1 42.3 (0) 0 (0) 0 (0) 4 34 2 0.50 (0.27) 0.0062 (0.0033) N/A 
8 7 0 1 41.4 (0) 0 (0) 0 (0) 3 0 1 0 (0) 0 (0) - 
7F 8 0 1 37.2 (0) 0 (0) 0 (0) 6 0 1 0 (0) 0 (0) - 
18C 7 1 2 37.3 (0) 0 (0) 0 (0) 6 0 1 0 (0) 0 (0) - 
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The diversity of cpsB within serotypes was compared with that of concatenated 
MLST sequences for strains of known STs. This was performed on eight serotypes, as 
other serotypes did not have sufficient MLST data. ST differences between strains of 
the same serotype were normalized by dividing cpsB π to MLST π. This ratio of cpsB 
nucleotide diversity to MLST diversity is thus a representation of the diversity of this 
gene relative to that of the genetic background. A high ratio would represent diverse 
cpsB given a particular collection of STs. Analysis shows that serotype 6B has the 
highest ratio (3.59), while serotype 1 has the lowest (0.067), with a difference of 
greater than 50-fold.  
 
6.3.4 Relationship between cpsB, Clonal Complexes (CCs) and STs 
To understand cpsB diversity within CCs and STs, a collection of 163 strains with 
MLST data was represented as an eBURST diagram (Fig. 6.4). A total of 89 STs were 
identified, thirty-one of which constituted 14 CCs of related strains.  
 
6.3.4.1 Diversity of cpsB within CCs of Same Serotypes 
Ten of the 14 CCs contained STs of the same serotype, and all but one of these had 
identical cpsB sequences within the CC. CC with ST4429 and 4432 shared one 
polymorphic site.  
 
6.3.4.2 Diversity of cpsB within STs of Same Serotypes 
Five STs with more than five strains each were included to assess for cpsB diversity 
within a ST of the same serotype. STs 65, 176, 180, 191, and 246 were associated 
with serotypes 6A, 6B, 3, 7F, and 4, respectively. Strains within each STs showed 
identical cpsB sequences, except for members of ST180, which showed a single 
polymorphic site between 11 strains. 
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Fig. 6.4. eBURST representation of genetic relatedness between strains with 
known STs in this study. Single-locus variants (SLVs) differing in only one of the 
seven MLST loci are connected by solid lines, forming a clonal complex (CC) of 
related strains. A total of 14 CCs was included in this study. For STs included in 
analysis of intra-CC and intra-ST cpsB diversity, the associated serotypes for each ST 
are indicated in green, followed by the number of strains in parenthesis. Four of the 
14 CCs (CCa, CCb, CCc, CCd) contained different serotypes, and the cpsB diversity 
for these CCs are presented in Table 6.2. 
 
6.3.4.3 Diversity of cpsB within CCs and STs of Different Serotypes 
Four of the 14 CCs contained related strains of different serotypes. Two clonal 
complexes each constituted of serotypes 19A and 19F (CCa and CCb), one CC 
contained members of 9V and 19F (CCc), and one contained STs of 14 and 19A 
(CCd). All four CCs showed extensive polymorphic sites, but mostly when strains of 
different serotypes were compared (Table 6.2). STs of the same serotype within  each 
CC still showed identical cpsB, except for serotype 19A members of ST199, showing 
two polymorphisms. Both ST199 and ST162 contained strains of different serotypes, 
and in both cases polymorphisms were seen only when the different serotypes were 
compared. 
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 Table 6.2 Diversity of cpsB within CCs and STs containing different serotypes 
 
CC S in CC
a 
ST Serotype (N) Intra-ST S 
CCa 134 199 19A (3), 19F (1) 134 between serotypes, 2 within 19A 
  200 19F (1) - 
  876 19F (1) - 
     
CCb 111 416 19A (2) None within 19A 
  3008 19F (1) - 
     
CCc 120 162 9V (3), 19F (2) 120 between serotypes, none within serotypes 
  156 9V (3) 0 
     
CCd 136 9 14 (2) 136 between serotypes, none in serotype 14 
  15 14 (1) - 
  423 19F (1) - 
a
 S: segregation/polymorphic sites 
 
6.3.5 Relatedness of cpsB within and between Serotypes 
A NJ tree was reconstructed including only serotypes with multiple strains to compare 
cpsB diversity within and between serotypes (Fig. 6.5). A ML tree of the same data is 
provided in Appendix Fig. A5. In agreement to the variation seen in haplotype and 
nucleotide diversities, serotypes 6B and 6A contained strains distantly related in terms 
of cpsB sequences. Serotype 6A members grouped into two major clusters and a 
single heterogeneous strain. For serotype 6B, most strains belonged to two divergent 
clusters, one associating with serotype 6A (cluster I), while another clustered closer to 
members of serotype 19A (cluster II). This divergent cluster is 97% identical in cpsB 
to serotype 11A strains, while the identity between the two divergent 6B clusters is 
94%.  
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Fig. 6.5. Neighbor-joining phylogenetic representation of serotypes with more 
than five strains each, colour-coded by serotypes. Serotypes are indicated beside 
clusters of taxa. Bootstrap with replacements was performed with 1,000 repetitions, 
and bootstrap values above 85% ware indicated. Taxa are colour-coded based on 
serotype for ease of visualization. Ruler indicates average number of nucleotide 
differences per site. Phylogenetic analysis performed on MEGA 5.05.  
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6.3.6 Locations of Amino Acid Substitutions Between Serotypes 
The nucleotide polymorphisms detected across all pneumococcal serotypes 
corresponded to 116 amino acid substitutions (47.7% of 243 amino acids in CpsB). 
The locations of these substitutions were determined in reference to known amino 
acids to form secondary structures and those required for catalysis (Morona et al. 
2002; Hagelueken et al. 2009). For this analysis, strains of serotypes 3 and 37 were 
not included, as functional expression of CpsB is not required for these serotypes. A 
plot of substitution along the length of the protein revealed that most non-
conservative substitutions occurred within domains α4 and α7 (Fig. 6.6A). For the 
amino acids thought to be involved in metal- and phosphate-binding (His5, His7, 
Asp14, His42, Glu80, Glu108, His136, Arg139, His194, Asp199, His201, Arg206), 
all but His194 and His201 were conserved in all sequences. Position 194 was 
substituted with a tyrosine residue in a single serotype 19F strain, and His201 was 
substituted with tyrosine in all serotype 6A strains and the serotype 6B strains closely 
related to 6A. 
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Fig. 6.6. Amino acid substitutions along CpsB for all pneumococcal serotypes 
except serotypes 3 and 37 (A) and strains within serotype 6B (B). For both 
histograms, the x-axis refers to amino acid position (total of 243 positions), and the y-
axis refers to proportion in percentage of sequences with amino acid substitutions. 
Blue bars represent conservative substitutions that do not change the polarity and 
acidity of the amino acid, and red bars represent non-conservative substitutions 
leading to a change in polarity and/or acidity of the amino acid. Locations of globular 
domains are indicated as α-helices (purple) amd β-sheets (orange). A total of 338 
sequences were included in Fig. 6.6A and 30 in Fig. 6.6B. 
 
 
6.3.7 Serotype Distributions of α4 and α7 Non-Conservative Substitutions  
Detailed alignments of the α4 (Fig. 6.7A) and α7 (Fig. 6.7B) regions reveal that the 
majority of non-conservative substitutions were detected within the red serotypes, 
with the most common substitutions in positions 112, 114, 117, 121, and 124 in α4 
and positions 211, 212, 218, and 219 in α7. The purple serotypes with mosaics of blue 
and red also show substitutions in those regions. 
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Serotype
112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128
2 D39 N T P Y R D I H S A L S K I L M S
6A 11 3085 N T P Y R D I H S A L S K I L M L
6A 11 5346 N T P Y R D I H S A L N K I L M L
6B 11NP10Jan N T P Y R D I H S A L N K I L M L
6B 2616/39 N T P Y R D I H S A L S K I L M L
6C 52520075 N T P Y R D I H S A L S K I L M L
6D MNZ920 N T P Y R D I H S A L S K I L M L
8 573/62 N T P Y R D I H S A L S K I L M L
9A Wilder N T P Y R D I H S A L S K I L M L
9V N98 N T P Y R D I H S A L S K I L M L
10A 10061/38 N T P Y R D I H S A L S K I L M L
10B 423/82 D T P Y R D I H S A L S K I L M L
10C Gro Norge N T P Y R D I H S A L S K I L M L
10F SG10F N T P Y R D I H S A L S K I L M L
11A 1813/39 N T P Y R D I H S A L I K I L M L
11B 8087/40 N T P Y R D I R S A L S K I L M L
11C Eddy nr. 53 N T P Y R D I R S A L S K I L M L
11D 70/86 N T P Y R D I H S A L I K I L M L
11F 34356 N T P Y R D I H S A L S K I L M L
12A 559/66 N T P Y R D I H S A L S K I L M L
12B SG12B N T P Y R D I H S A L S K I L M L
12F 6312 N T P Y R D I H S A L S K I L M L
17A nr.4704 H T S Y R E I H S A L S K I L M L
17F Rose N T P Y R D I H S A L S K I L M L
18F Gethens N T P Y R D I H S A L I K I L M L
19A TCH8431 N T P Y R D I H S A L S K I L M L
21 N92 N T P Y R D I H S A L S K I L M L
22A 3405/39 N T P Y R D I H S A L S K I L M L
22F SG22F N T P Y R D I H S A L S K I L M L
23B 1031/41 N T P Y R D I H S A L I K I L M L
23B 7OP9 N T P Y R D I H S A L I K I L M S
23B SG23B N T P Y R D I H S A L I K I L M L
24B 2236/42 N T L Y R D I H S A L N K I L M L
24F SG24f N T L Y R D I H S A L N K I L M L
25F 601/62 N T L Y R D I H S A L N K I L M L
27 84320293 N T L Y R D I H S A L S K I L M L
28A 1982/45 N T L Y R D I H S A L S K I L M L
28F 34372 N T L Y R D I H S A L S K I L M L
31 nr.34374 N T P Y R D I H S A L S K I L M L
32A 2813/41 N T P Y R D I H S A L S K I L M L
32F nr.34375 N T P Y R D I H S A L S K I L M L
33A Biehl N T P Y R D I H S A L S K I L M L
33B SG33b N T P Y R D I H S A L S K I L M L
33C SG33c N T P Y R D I H S A L S K I L M L
33D SG33d N T P Y R D I H S A L S K I L M L
33F SG33fb N T P Y R D I H S A L S K I L M L
34 676/74 H T S Y R E I H S A L S K I L M L
35A SG35A N T P Y R D I H S A L S K I L M L
35B SG35B N T P Y R D I H S A L S K I L M L
35C 7765/43 N T P Y R D I H S A L S K I L M L
36 SG36 N T P Y R D I H S A L S K I L M L
37 7077-39 N T P Y R D I H S A L S K I L M L
41A 6803 N T P Y R D I H S A L S K I L M S
41F 8211/40 N T P Y R D I H S A L S K I L M L
42 198/71 N T P Y R D I H S A L S K I L M L
44 Hammer N T P Y R D I H S A L S K I L M L
46 Eddy nr.73 N T P Y R D I H S A L S K I L M L
1 3OP2 H T S Y R Q I H T G L S N I L M L
4 WCH35 N T P Y R D I H S A L S K I L M L
5 Ambrose H T S Y R Q I H T G L S N I L M L
7A 2040/37 H T S Y R Q I H T G L S N I L M L
7B Johnson H T S Y R Q I H T G L S N I L M L
7C 1003-2 N T L Y R D I H S A L N K I L M L
7F SG07f H T S Y R Q I H T G L S N I L M L
9L T9233/128/68 H T S Y R E I H A G L S N I L M L
9N 533/62 H T S Y R E I H A G L S N I L M L
13 34357 H T S Y R E I H A G L S N I L M L
14 10 1688 H T S Y R Q I H T G L S N I L M L
15B 7904/39 N T P Y R D I H S A L S K I L M L
15C 533/62 N T P Y R D I H S A L S K I L M L
16A R105 H T S Y R E I H T G L S N I L M L
16F nr.34361 H T S Y R Q I H T G L S N I L M L
18A 8609/43 H T S Y R Q I H T G L S N I L M L
18B 1033/41 H T S Y R Q I H T G L S N I L M L
18C WCH94 H T S Y R Q I H T G L S N I L M L
19B nr.4594 H T S Y R Q I H T G L S N I L M L
19C 7588/39 N T L Y R D I H N A L S K I L M L
19F SPVA96 H T S Y R Q I H T G L S N I L M L
20 34365 H T S Y R E I H A G L S N I L M L
23A 1196/45 N T P Y R D I H S A L S K I L M L
24A 2748/40 H T S Y R Q I H T G L S N I L M L
24F L N T P Y R D I H S A L S K I L M L
36 1095/39 H T S Y R E I H T G L S N I L M L
40 Colemore H T S Y R Q I H T G L S N I L M L
45 Eddy nr.72 N T P Y R D I H N A L S K I L M L
58 26/63 H T S Y R E I H A G L S N I L M L
15A 389/39 N T P Y R D I H S A L S K I L M L
15F 688/63 N T P Y R D I H S A L N K I L M L
23F UK-577 N T P Y R D I H S A L S K I L M L
29 nr.34373 H T S Y R Q I H T G L S N I L M L
35F 361/39 N I P Y R D I H S A L S K I L M L
39 203/40 H T S Y R Q I H T G L S N I L M L
43 2427/48 H T S Y R E I H T G L S N I L M L
47A L351 H T S Y R Q I H T G L S N I L M L
47F Eddy nr.52 N I P Y R D I H S A L S K I L M L
25A tp25/38 E T S Y R S I H S A L Q Q L L S G
38 9687/39 E T S Y R S I H S A L Q Q L L S G
Amino Acid Position
A 
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Serotypes
210 211 212 213 214 215 216 217 218 219 220 221
2 D39 M A E A Y D L V T Q K Y
6A-KEE6A-Vb M A E A Y D L V T Q K Y
6B 11NP10Jan M A E A Y D L V S Q K Y
6B 2616/39 M A E A Y D L V T Q K Y
6C-KEE6C-Ic M A E A Y D L V T Q K Y
6D MNZ21 M A E A Y D L V T Q K Y
8 573/62 M A E A Y D F V T Q K Y
9A Wilder M A E A Y D L V T Q K Y
9V N98 M A E A Y D L V T Q K Y
10A SG10A M F E A Y S I V A K K Y
10B 423/82 M F E A Y S I V A K K Y
10C Gro Norge M A E A Y D L V S Q K Y
10F SG10F M A E A Y D L V S Q K Y
11A SG11A M A E A Y D L V S Q K Y
11B 8087/40 M A E A Y D L V S Q K Y
11C Eddy nr. 53 M A E A Y D L V S Q K Y
11D 70/86 M A E A Y D L V S Q K Y
11F 34356 M A E A Y D L V T Q K Y
12A 559/66 M A E A Y D L V T Q K Y
12B Gambia 1/81 M A E A Y D L V T Q K Y
12F SG12f M A E A Y D L V T Q K Y
17A nr.4704 M A E A Y D L V T Q K Y
17F Rose M A E A Y D L V T Q K Y
18F Gethens M A E A Y D L V S Q K Y
19A 12 1579 M A E A Y D L V S Q K Y
21 N92 M A E A Y D L V T Q K Y
22A 3405/39 M A E A Y D L V T Q K Y
22F SG22F M A E A Y D L V T Q K Y
23B 1031/41 M A E A Y D L V S Q K Y
24B 2236/42 M Q Q A Y D I I A K K Y
25F 601/62 M Q Q A Y D I I A K K Y
27 84320293 M A E A Y D L V T Q K H
28A SG28A M A E A Y D L V T Q K Y
28F 34372 M A E A Y D L V T Q K Y
31 SG31 M A E A Y D F V T Q K Y
32A 2813/41 M A E A Y D L V T Q K Y
32F nr.34375 M A E A Y D L V T Q K Y
33A Biehl M A E A Y D L V T Q K Y
33B E294 M A E A Y D L V T Q K Y
33C SG33c M A E A Y D L V T Q K Y
33D CSF/79 M A E A Y D L V T Q K Y
33F SG33fb M A E A Y D L V T Q K Y
34 676/74 M A E A Y D L V T Q K Y
35A SG35A M A E A Y D L V T Q K Y
35B 4356/39 M A E A Y D L V T Q K Y
35B SG35B M A E A Y D L V T Q K Y
35C 7765/43 M A E A Y D L V T Q K Y
41A 6803 M A E A Y D L V T Q K Y
41F 8211/40 M A E A Y D L V T Q K Y
42 198/71 M A E A Y D L V T Q K Y
44 Hammer M A E A Y D L V T Q K Y
46 Eddy nr.73 M A E A Y D L V T Q K Y
1 3OP2 M Q Q A Y D I I A K K Y
4 11 4573 M A E A Y D L V T Q K Y
5 M Q Q A Y D I I A K K Y
7A 2040/37 M Q Q A Y D I I A K K Y
7B Johnson M Q Q A Y D I I A K K Y
7C 1003-2 M Q Q A Y D I I A K K Y
7F SG07f M Q Q A Y D I I A K K Y
9L T9233/128/68 M Q Q A Y D I I A K K Y
9N 533/62 M Q Q A Y D I I A K K Y
13 34357 M Q Q A Y D I I A K K Y
14 10 1688 M Q Q A Y D I I A K K Y
15B 7904/39 M Q Q A Y D I I A K K Y
15C 533/62 M Q Q A Y D I I A K K Y
16A R105 M A E A Y D L V T Q K Y
16F SG16F M Q Q A Y D I I A K K Y
18A 8609/43 M Q Q A Y D I I A K K Y
18B 1033/41 M Q Q A Y D I I A K K Y
18C WCH94 M Q Q A Y D I I A K K Y
19B nr.4594 M Q Q A Y D I I A K K Y
19C 7588/39 M Q Q A Y D I I A K K Y
19F 11 6402 M Q Q A Y D I I A K K Y
20 34365 M Q Q A Y D I I A K K Y
23A 1196/45 M Q Q A Y D I I A K K Y
24A 2748/40 M Q Q A Y D I I A K K Y
24F L M Q Q A Y D I I A K K Y
36 1095/39 M A E A Y D L V T Q K Y
36 SG36 M Q Q A Y D I I A K K Y
40 Colemore M Q Q A Y D I I A K K Y
45 Eddy nr.72 M A E A Y D L V T Q K Y
48 656/63 M Q Q A Y D T I A K K Y
15A 389/39 M A E A Y D L V T Q K Y
15F 688/63 M A E A Y D L V T Q K Y
23F UK-577 M A E A Y D L V T Q K Y
29 nr.34373 M K E A Y E L I S K Q Y
35F 361/39 M Q Q A Y D I I A K K Y
39 203/40 I K E A Y E L I S K Q Y
43 2427/48 M K E A Y E L I S K Q Y
47A L351 M A E A Y D L V T Q K Y
47F Eddy nr.52 M Q Q A Y D I I A K K Y
25A tp25/38 M A E A Y E I I S K R Y
38 9687/39 M A E A Y E I I S K R Y
Amino Acid Position
B 
205 
 
Fig. 6.7. Amino acid substitutions in α4 (A) and α7 (B) regions of CpsB. Serotypes 
listed according to their blue/red designation as defined by Varvio et al. (Varvio, 
2009). Serotypes in purple represent those with mosaics of blue and red sequences. 
Serotypes 25A and 38 have divergent sequences but are grouped as red serotypes 
based on low GC content (~35%). Conservative amino acid substitutions indicated as 
blue blocks, and non-conservative in red. 
  
6.3.8 Locations of Amino Acid Substitutions Within Serotype 6B 
Sequences within serotype 6B showed 19 amino acid substitutions, fourteen of which 
occurred in the linker regions (Fig. 6.6B and Table 6.3). In the five substitutions 
within globular domains, only one (20%) had a change in polarity (Arg27Tyr), with 
the remaining four substitutions with the same polarity and acidity. Changes in 
polarity and acidity were more common in substitutions occurring in linker regions 
but this was not significant (p = 0.30 Fisher’s Exact Test). All but one strain in 6B 
cluster I was isolated from hosts with pneumococcal diseases, whereas in cluster II 
both carriage and clinical pneumococci were isolated in similar proportions (Table 
6.4). No apparent association between geography and cpsB clustering was observed. 
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Table 6.3. Location and types of amino acid substitutions across CpsB in strains 
belonging to Clusters I and II of serotype 6B. 
 
Substitution Site Region Amino Acids Acidity and 
Polarity 
27 α1 Threonine 
Alanine 
Neutral, Polar 
Neutral, Non-Polar 
    
89 α3 Aspartic Acid 
Glutamic Acid 
Acidic, Polar 
Acidic, Polar 
    
92 L6 Glutamic Acid 
Glycine 
Acidic, Polar 
Neutral, Non-Polar 
    
93 L6 Lysine 
Asparagine 
Basic, Polar 
Basic, Polar 
    
94 L6 Lysine 
Asparagine 
Basic, Polar 
Basic, Polar 
    
101 L6 Aspartic Acid 
Asparagine 
Acidic, Polar 
Neutral, Polar 
    
123 α4 Serine 
Asparagine 
Neutral, Polar 
Neutral, Polar 
    
142 L9 Valine 
Alanine 
Neutral, Non-Polar 
Neutral, Non-Polar 
    
162 L11 Valine 
Isoleucine 
Neutral, Non-Polar 
Neutral, Non-Polar 
    
170 L11 Proline 
Serine 
Neutral, Non-Polar 
Neutral, Polar 
    
171 L11 Lysine 
Arginine 
Basic, Polar 
Basic, Polar 
    
176 L11 Arginine 
Proline 
Basic, Polar 
Neutral, Non-Polar 
    
190 L12 Glutamine 
Arginine 
Neutral, Polar 
Basic, Polar 
    
194 L12 Histidine 
Tyrosine 
Basic, Polar 
Neutral, Polar 
    
195 L12 Valine 
Isoleucine 
Neutral Non-Polar 
Neutral, Non-Polar 
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203 L12 Leucine 
Valine 
Neutral Non-Polar 
Neutral, Non-Polar 
    
218 α7 Threonine 
Serine 
Neutral, Polar 
Neutral, Polar 
    
224 α8 Alanine 
Glycine 
Neutral, Non-Polar 
Neutral, Non-Polar 
    
239 L14 Methionine 
Arginine 
Neutral, Non-Polar 
Neutral, Non-Polar 
 
 
Table 6.4 Country of isolation of serotype 6B carriage and clinical strains  
according to clustering by cpsB based on amino acid changes as shown 
on Table 6.3 and invasiveness 
 
Strains Country of Origin Carriage/Clinical 
   
Cluster I   
3OP7S Tanzania Carriage 
71560309 United Kingdom Clinical 
80520052 United Kingdom Clinical 
N252 United Kingdom Clinical 
N380 United Kingdom Clinical 
N465 United Kingdom Clinical 
N6 United Kingdom Clinical 
WCH18 Australia Clinical 
KEE-6B-Ia Netherlands Clinical 
KEE-6B-Ib Netherlands Clinical 
KEE-6B-Ic Netherlands Clinical 
KEE-6B-Id Netherlands Clinical 
KEE-6B-Ie Netherlands Clinical 
KEE-6B-If Netherlands Clinical 
KEE-6B-Ig Netherlands Clinical 
KEE-6B-IIa Netherlands Clinical 
KEE-6B-IIb Netherlands Clinical 
   
Cluster II   
11NP10Jan Tanzania Carriage 
35NP1 Tanzania Carriage 
35NP6 Tanzania Carriage 
3NP7Mar Tanzania Carriage 
670-6B Spain Clinical 
69OP10 Tanzania Carriage 
N389 United Kingdom Clinical 
N888b United Kingdom Clinical 
PN94/361 United Kingdom Clinical 
KEE-6B-IIIa Netherlands Clinical 
KEE-6B-IIIb Netherlands Clinical 
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6.4 Discussion 
In Chapter 3, we observed that some strains of a serotype differed in cpsB sequences 
to those of other members of the same serotype deposited onto GenBank. We 
therefore hypothesized that intra-serotype diversity in this region exists for 
pneumococci, and that different serotypes have different extents of cpsB sequence 
variations. Regulation of capsule expression is crucial for pneumococcal persistence 
and survival in different host environments; full encapsulation appears to be 
beneficial for systemic virulence, while reduced expression of capsular 
polysaccharide exposes surface proteins facilitating adherence and biofilm formation 
(Magee & Yother 2001; Hammerschmidt et al. 2005; Moscoso, García & López 
2006). As cpsB has been shown to modulate pneumococcal capsule synthesis 
(Morona et al. 2000; Morona et al. 2002; Morona, Morona & Paton 2006), sequence 
variation in this region within a serotype may result in different strains of a serotype 
to regulate capsule biosynthesis differently, thereby facilitating its success of 
particular serotypes in different environments. While sequence variation in capsular 
regulatory region between serotypes is well known (Morona, Morona & Paton 1997; 
Morona, Morona & Paton 1999a; Morona, Morona & Paton 1999b; Jiang, Wang & 
Reeves 2001; Varvio et al. 2009), it was not until recently that information regarding 
intra-serotype cps sequence diversity of a handful of serotypes is revealed (Mavroidi 
et al. 2004; Bratcher et al. 2011; Elberse et al. 2011). Most of these reports document 
variation at serotype-specific genes. This capsular regulatory gene was selected in this 
study following our assessment of this region as a target for a single-PCR sequence-
based serotyping method (Chapter 3). 
 
6.4.1 Extension of Previous Work 
Varvio et al. (Varvio et al. 2009) included representative strains from pneumococcal 
serotypes (total 90 strains, one per serotype) and observed a dichotomous phylogeny 
for cpsB, cpsC, and cpsD sequences, and this pattern was associated with GC content 
and invasive potential. In this study, by incorporating over 300 cpsB sequences 
covering 92 serotypes, we observe that, while the topology is conserved and GC 
content does not differ extensively within serotypes, intra-serotype sequence 
variations were detected. In terms of evolution, the sub-clustering of serotypes 
suggests the potential for serotypes to undergo sequence variations.  
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6.4.2 Comparison of Diversity Between Serotypes 
Serotypes with multiple cpsB sequences can be compared to detected differences in 
extent of cpsB variation. We demonstrated that some serotypes (6B and 6A) exhibit 
greater diversity than others (1). Serotype 6B, a serotype common in both disease and 
carriage (Sandgren et al. 2004), has been documented to be genetically diverse 
(Robinson et al. 2002). In contrast, up to 90% of serotype 1 strains around five 
continents are associated with six STs (Brueggemann & Spratt 2003). The observed 
cpsB variation may thus be a reflection of the strain differences.  
 
Therefore, to account for sequence variations in the core genes, cpsB diversity was 
normalized against the core genome (as inferred by concatenated MLST sequences) 
differences. The ratio of cpsB to core gene diversity was shown to differ by at least 
50-fold between serotypes 6B and 1, suggesting that these serotypes are undergoing 
different rates of cpsB diversification relative to their core genomes. Phylogenetic 
analysis reveals that strains of serotype 6B are sub-clustered into two groups, which 
are more variable to each other than to members of other serotypes. It may be that 
such differences in cpsB allow serotypes to regulate capsule expression to persist in 
different host environments, and this is in agreement to serotype 6B and 1 being 
common and rarely detected in carriage, respectively. However, serotypes 19F and 
19A, also common in carriage and invasion, showed low rates of cpsB diversification 
compared to the core genes. Of note, serotypes 1 and 19F, indicated as having low 
intra-serotype cpsB variation, have been demonstrated to be relatively resistant to C3 
deposition and opsonophagocytosis compared to serotype 6B, (Melin et al. 2009; 
Melin et al. 2010). 
 
Intriguingly, others have documented the dichotomous division of serotype 6B 
pneumococci based on sequences of serotype-specific genes (Mavroidi et al. 2004; 
Bratcher et al. 2011). Subsequently, extensive variation in cps genes, including those 
at the 5’ end, had been postulated to be evidence of diversification to new serotypes, 
possibly mediated by recombination events (Elberse et al. 2011; Song, Baek & Ko 
2011). As stated by Elberse et al. (Elberse et al. 2011), the divergent serotype 6B may 
represent a new serotype that cross-react with 6B-specific antisera. Sequencing of 
these serotype-specific genes in our serotype 6B collection and characterization of 
capsule structure by NMR would enable comparison between diversity between the 
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capsule regulatory and synthesis regions, and how these variations relate to structural 
differences. 
 
6.4.3 Comparisons of Diversity Between CCs 
Analyzing cpsB differences within CCs revealed that minimal polymorphisms are 
present within a CC if all clones of that CC are of a serotype. However, when STs of 
multiple serotypes were present within a CC, extensive polymorphisms were seen 
between the serotypes. This indicates that cpsB variation is more likely to be 
governed by the serotype than the STs. As it is inferred that STs with different 
serotypes occurred via capsular switching (Enright & Spratt 1998; Jefferies et al. 
2004; Hanage et al. 2011), the observation suggests that cpsB sequences are closely 
linked to capsular phenotype, and cpsB is invariably included in switching events. 
This is in agreement to previous reports of capsular switches with known 
recombination breakpoints (Coffey et al. 1999; Brueggemann et al. 2007). The 
observed association between cpsB sequences and antigenic properties in this study 
therefore indicates that the sequetyping method targeting cpsB described in Chapter 3 
can accurately identify serotypes in most capsular switch recombinants. However, 
analysis of additional sequences are required to validate such claims. 
 
6.4.4 Amino Acid Substitutions in CpsB within and between Serotypes 
Polymorphisms across serotypes revealed that these alterations encode amino acid 
changes, the majority of which occurring in α-helices, notably α4 and α7. The 
substitutions appear to be associated with the blue-red clustering pattern, as most red 
serotypes contained non-conservative changes within these two helices. Based on 
available crystal structures of CpsB (Hagelueken et al. 2009; Kim et al. 2011), these 
helices are situated on the periphery of the enzyme. Most amino acids crucial for 
catalysis are conserved. Therefore, while enzymatic activity of CpsB is confined and 
evolutionarily conserved, different serotypes possess amino acid variations in other 
structural regions of the enzyme. Analysis of sequence variation within serotype 6B 
showed that linker regions constituted the majority of substitutions. While these 
changes may have no effect on enzymatic activity, may be subjected to constant 
changes that allow the protein to evolve new structures, confirmations, and additional 
functions (Tokuriki & Tawfik 2009). Whether these changes lead to differential CpsB 
folding between serotypes is unknown, and structural characterization of these 
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different sequences may be helpful. In addition, whether these changes affect 
enzymatic activity is also not clear; differences in enzymatic activity between these 
different alleles can be determined by phosphatase assays.  
 
6.4.5 Additional Factors Affecting Capsule Production 
Despite the variation in cpsB observed between serotypes, capsule production 
regulation is influenced by other factors. The upstream gene cpsA has been shown to 
bind to the cps promoter and expression of downstream genes and affect capsule 
expression (Morona et al. 2000; Hanson, Lowe & Neely 2011). Although no 
transcriptional control elements have been identified upstream of cps promoter, the 
presence of RUP (Repeat Unit for Pneumococcus) elements upstream of cpsA in some 
serotypes and tts in serotype 37 may act as binding sites for regulatory proteins 
(Hoskins et al. 2001; Llull, Garc  a & López 2001; Moscoso & García 2009). 
Sequence duplications within serotype-specific genes (cps3D, cps8E and tts for 
serotypes 3, 8 and 37, respectively) also contribute to reversible phase variations 
(Waite, Struthers & Dowson 2001; Waite et al. 2003). In addition, transcription of 
capsule genes or production of capsules can also be altered by genes outside the 
capsulation locus, such as the carbohydrate pyrophosphorylase gene galU (Mollerach, 
López & García 1998), phosphoglucomutase gene pgm (Hardy et al. 2001) and the 
carbohydrate catabolic gene regM (Giammarinaro & Paton 2002). Environmental 
factors also influence cps expression; reduction in CPS production has been shown 
for opaque variants in the presence of oxygen (Weiser et al. 2001). 
 
6.5 Concluding Remarks 
Comparison of a large international collection of pneumococcal cpsB sequences 
revealed that serotypes differ in the extent of diversity in this gene important for 
capsule regulation, with serotype 6B being most diverse, up to 50-fold to that of 
serotype 1. Within strains of 6B two divergent clusters were found. Combining MLST 
data, we provided evidence that cpsB sequences are closely associated with the 
phenotype of the strain, even in cases of serotype switching. Amino acids required for 
enzymatic activity remained conserved, while globular domains, especially α4 and α7, 
showed substitution hotspots. However, whether these non-conservative substitutions 
contribute to the enzyme structure, activity, or capsule production remains unknown. 
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CHAPTER SEVEN: Competence Stimulatory Peptide Gene comC as 
a Target for Differentiating Streptococcus pseudopneumoniae from 
Streptococcus pneumoniae and Other Streptococcal Species 
 
 
7.1 Introduction 
7.1.1 Streptococcus pseudopneumoniae 
Streptococcus pseudopneumoniae (the pseudopneumococcus) was recently classified 
as a species distinct from S. pneumoniae (Arbique et al. 2004). The pathogenic 
potential of the pseudopneumococcus has been demonstrated in a murine model, 
where all mice injected peritoneally with clinical isolates of the organism succumbed 
within 36 hours (Harf-Monteil et al. 2006). Although its detection is thought to be 
relatively rare (1 pseudopneumococcal isolate in 120 pneumococcal isolates, (Harf-
Monteil et al. 2006)), pseudopneumococci have been isolated from sputum samples of 
patients with histories of COPD exacerbations (Arbique et al. 2004; Keith et al. 2006; 
Keith & Murdoch 2008; Shahinas et al. 2011; Sistek et al. 2011). In addition, S. 
pseudopneumoniae forms biofilms in vitro and colonizes the nasopharynx (Moscoso, 
García & López 2006; Johnston et al. 2010; Leegaard et al. 2010; Domenech, García 
& Moscoso 2011). Recent genetic and genomic analysis of this organism reveals 
presence of antibiotic-tolerance and resistance genes (Cochetti et al. 2005; Shahinas 
et al. 2011). In addition, non-susceptibilities to a number of antibiotics are common 
(Keith & Murdoch 2008; Simões et al. 2010).  
 
7.1.2 Phenotypic Identification of S. pseudopneumoniae 
Strains of S. pseudopneumoniae, along with S. mitis and S. oralis have often been 
classified previously as “atypical pneumococci,” because of its similarity to S. 
pneumoniae. S. pseudopneumoniae is non-capsulated, α-hemolytic, bile-insoluble, 
and optochin intermediate-resistant in 5% CO2 and optochin susceptible in ambient 
O2 (Arbique et al. 2004). On blood agar pseudopneumococcal colonies appear similar 
to that of noncapsulated pneumococci, with a colony diameter of up to 1 mm (Keith et 
al. 2006). Under the microscope S. pseudopneumoniae also appear in pairs and highly 
similar to appearance to S. pneumoniae (Fig. 5.1).  
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Fig 7.1. Streptococcus pseudopneumoniae Gram-stain. Image taken from sputum 
smear seen under a light microscope at magnification of 100X. Image from Keith et 
al. (Keith et al. 2006). Journal of Clinical Microbiology authorizes the reuse of 
journal material including figure shown for academic purposes. 
  
The pseudopneumococcus reacts positively to the Binax NOW C-polysaccharide-
specific antigen test, therefore it cannot be used for its differentiation from the 
pneumococcus.  
 
7.1.3 Genetic Identification of S. pseudopneumoniae 
The pseudopneumococcus shares ≥ 99.4% identity to S. pneumoniae in 16S rRNA 
gene sequences (Kawamura et al. 1995; Arbique et al. 2004 Leegaard et al. 2010, 
Sistek et al. 2011). Targeting pneumococcal virulence factors in distinguishing the 
pseudopneumococcus is challenging, as a large portion of the core pneumococcal 
genome is detected in S. pseudopneumoniae (Johnston et al. 2010; Leegaard et al 
2010; Simõnes et al. 2010). Current genetic approaches attempting to differentiate S. 
pseudopneumoniae from S. pneumoniae include targeting cpsA, aliB-like ORF2 
region, ply, Spn9802, lytA, sodA, recA, and psaA. All these approaches have been 
proven problematic and require additional analysis (Table 7.1). Sequence analysis of 
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individual housekeeping genes have been shown to be problematic, and multilocus 
sequence analysis (MLSA) may reveal divergence between the two species by 
concatenated gene fragment sequences (Hanage et al. 2005; Hoshino, Fujiwara & 
Kilian 2005; Kilian et al. 2008). However, MLSA may not applicable for routine 
clinical use as the multiple sequencing reactions required for strain identification may 
be relatively time-consuming and costly. 
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Table 7.1 Genetic approaches for S. pseudopneumoniae identification and differentiation from other Streptococci 
 
Target References Comments 
rRNA (Arbique et al. 2004; Leegaard et al. 2010) 
 
>99% identity with S. pneumoniae (Arbique, 2004) 
   
cpsA (Park et al. 2010) Pseudopneumococcus and noncapsulated pneumococci not differentiable 
   
Spn9802 (Abdeldaim et al. 2008; Park et al. 2010) Present in both pneumococcus and pseudopneumococcus Some pneumococci negative for 
target.  
   
lytA (Carvalho et al. 2007) Depending on primers used, template targets from some pseudopneumococci may be amplified 
   
aliB-like ORF2 (Simões et al. 2011b) Pseudopneumococcus and noncapsulated pneumococci not differentiable 
   
recA (Sistek et al. 2011) Clustering of pseudopneumococcal sequences, but may need to be tested on geographically-
distinct strains 
   
sodA (Arbique et al. 2004; Hoshino, Fujiwara & 
Kilian 2005) 
Could not be differentiated from S. pneumoniae 
   
ply (Johnston et al. 2004; Carvalho et al. 2007; 
Abdeldaim et al. 2008) 
Present in pseudopneumococci, but may vary in sequence from pneumococcus 
   
psaA (El Aila et al. 2010) Pseudopneumococcus and pneumococcus differentiable, but may need to be tested on additional 
strains 
   
MLST/MLVA (Hoshino, Fujiwara & Kilian 2005; Kilian et 
al. 2008) 
Clustering by species based on concatenated sequences, but may be time-consuming for routine 
clinical diagnosis and identification  
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7.1.4 Aim 
Currently there is no gold-standard method for differentiating S. pseudopneumoniae 
from S. pneumoniae. However, the correct identification of this organism in clinical 
isolates is crucial to understand the disease potential of this pathogen and evaluate its 
significance in diagnostic practice. A simple, unequivocal method to identify S. 
pseudopneumoniae would be valuable. Here we present the use of sequencing the 
competence gene comC as a promising alternative in identifying the 
pseudopneumococcus. 
 
While determining pherotype diversity in the UK cohort as described in Chapter 5, a 
rare CSP allele 6.1 was detected. Colonies of this strain, N452, appear small on CBA, 
was optochin non-susceptible in CO2 but was susceptible in O2, bile-insoluble, and 
was nontypable by anti-capsular antibodies. These phenotypic traits suggest that this 
strain belongs to S. pseudopneumoniae. MLST was performed on this strain and 
shared 100% identity to S. pseudopneumoniae sequences on all seven housekeeping 
genes. We thus aimed to determine the pherotypes of additional S. pseudopneumoniae 
strains to understand whether CSP6.1 is common in this newly characterized species.  
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7.2 Materials and Methods 
7.2.1 Clinical Specimens and Bacteria 
A total of seventeen clinical specimens of S. pseudopneumoniae, S. pneumoniae, and 
S. oralis were collected at the Royal Free Hospital Microbiology Laboratory between 
the years 1993-2010 (Table 7.2). Sixteen samples were from patients with lower 
respiratory tract (LRT) infections, and a single strain was isolated from normally 
sterile site. Samples were plated on Columbia blood agar (Oxoid, Cambridgeshire) in 
5% CO2 at 35°C in an attempt to cultivate bacteria, and colonies suggestive of 
pneumococci based on morphology and α-haemolysis were tested with optochin 
sensitivity. All pseudopneumococci except strain N452 were processed by Dr. Clare 
Ling. These strains were included in a separate study conducted by Dr. Clare Ling in 
2009 prior to the commencement of the work performed by Mr. Marcus Leung in this 
chapter. Strain N452 was processed by Mr. Marcus Leung. For N452, in addition to 
α-haemolysis, bile solubility and optochin susceptibility in both ambient and 5% CO2 
conditions were performed. 
 
7.2.2 Genomic DNA Extraction for comC Amplification  
Genomic DNA from LRT samples were extracted by Dr. Clare Ling using a modified 
Chelex method as described previously (Walsh, Metzger & Higuchi 1991). The 
supernatant was used as template for DNA amplification. For culture-positive clinical 
specimens, genomic DNA was extracted by using the Wizard Genomic DNA 
Purification Kit (Promega) (by Dr. Clare Ling) or by the heat-lysis method (Section 
2.8.1). 
 
7.2.3 Presumptive Identification of S. pseudopneumoniae 
qPCR for presumptive identification of S. pseudopneumoniae was designed and 
performed by Dr. Clare Ling. Amplifications employing primers and probes specific 
for Spn9802 (Suzuki et al. 2005; Abdeldaim et al. 2008) and lytA (Carvalho et al. 
2007) were performed sequentially to differentiate between S. pneumoniae (Spn9802 
and lytA-positive) and S. pseudopneumoniae (Spn9802-positive, lytA-negative). To 
assess for PCR inhibition, a potato gene internal amplification control (IAC) was 
included in each reaction, using primers targeting regulatory photoreceptor gene phyB 
of Solanum tuberosum (potato) (Nolan et al. 2006). 
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For lytA and Spn9802 qPCR assays, amplification reactions of 25µl were performed 
containing 1x Platinum® Quantitative PCR SuperMix-UDG (Invitrogen), a final 
concentration of 7 mM of MgCl2, primers and probes, 4 x 10
-7
 µM IAC template 
DNA (Sigma-Aldrich), and 5 µl of template DNA (Table 7.3). Negative and positive 
controls were performed for each qPCR assay. Amplification was performed using a 
Rotor-Gene Q (Qiagen) with the following conditions: an initial hold cycle at 95 °C 
for 3 min, followed by 40 cycles of 95 °C for 15 sec and 60 °C for 45 sec. The PCR 
data was acquired at the end of each cycle and analyzed by the instrument software 
(Qiagen). Samples with cycle threshold (CT) value ≤ 35 for the lytA target or Spn9802 
targets were considered positive; samples with no CT value for either the lytA or 
Spn9802 targets, but did have a CT value ≤ 40 for the IAC target were considered 
negative and samples with a no CT  value for either the lytA or Spn9802 targets and no 
CT value for the IAD target were considered inhibited. Samples positive for both lytA 
and Spn9802 were considered to be S. pneumoniae-positives and samples positive for 
Spn9802 and negative for lytA were considered to be presumptive S. 
pseudopneumoniae-positive. All reactions were performed in triplicate.  
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Table 7.2. Streptococcal strains included for this study 
 
Species Strain 
Clinical Accession 
Number
b
 
Source 
Isolation Site
a
 
S. pseudopneumoniae N452 Blood Not deposited This study 
 
RFH504 LRT Not deposited This study 
 
RFH543 LRT Not deposited This study 
 
RFH686 LRT Not deposited This study 
 
RFH687 LRT Not deposited This study 
 
RFH827 LRT Not deposited This study 
 
RFH905 LRT Not deposited This study 
 
RFH999 LRT Not deposited This study 
 
874 Unknown AJ240773 (Whatmore, Barcus & Dowson 1999) 
 
ATCC BAA-960 LRT Not deposited This study 
 
IS7493 LRT YP004769537 (Shahinas et al. 2011) 
 
PT5479 Nasopharynx Not deposited (Simões et al. 2010) 
 
PT5779 Nasopharynx Not deposited (Simões et al. 2010) 
 
SK674 Unknown Not deposited (Kilian et al. 2008) 
S. pneumoniae RFH324 LRT Not deposited This study 
 
RFH410 LRT Not deposited This study 
 
RFH577 LRT Not deposited This study 
 
RFH815 LRT Not deposited This study 
 
RFH864 LRT Not deposited This study 
 
RFH904 LRT Not deposited This study 
 
VA1 Unknown AJ240789 (Whatmore, Barcus & Dowson 1999) 
 
41G Unknown AJ240766 (Whatmore, Barcus & Dowson 1999) 
 
CSP2.1b Nasopharynx Not deposited (Vestrheim et al. 2011) 
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Pn24 Unknown AJ240759 (Whatmore, Barcus & Dowson 1999) 
 
Pn59 Unknown AJ240793 (Whatmore, Barcus & Dowson 1999) 
 
Pn13 Unknown AJ240792 (Whatmore, Barcus & Dowson 1999) 
 
101/87 Unknown AJ240791 (Whatmore, Barcus & Dowson 1999) 
 
SK676 Unknown Not deposited (Kilian et al. 2008) 
S. mitis Col15 Unknown AJ240762 (Whatmore, Barcus & Dowson 1999) 
 
Col16 Unknown AJ240763 (Whatmore, Barcus & Dowson 1999) 
 
NCTC 10712 LRT AJ240795 (Whatmore, Barcus & Dowson 1999) 
 
NCTC 12261 Nasopharynx AJ000875 (Håvarstein, Hakenbeck & Gaustad 1997) 
 
B5 Unknown AJ000871 (Håvarstein, Hakenbeck & Gaustad 1997) 
 
B6 Unknown AJ000865 (Håvarstein, Hakenbeck & Gaustad 1997) 
 
Hu8 Unknown AJ000866 (Håvarstein, Hakenbeck & Gaustad 1997) 
 
SK137 Unknown Not deposited (Kilian et al. 2008) 
 
SK145 Unknown Not deposited (Kilian et al. 2008) 
 
SK262 Unknown Not deposited (Kilian et al. 2008) 
 
SK272 Unknown Not deposited (Kilian et al. 2008) 
 
SK564 Unknown Not deposited (Kilian et al. 2008) 
 
SK596 Unknown Not deposited (Kilian et al. 2008) 
 
SK598 Unknown Not deposited (Kilian et al. 2008) 
 
SK599 Unknown Not deposited (Kilian et al. 2008) 
 
SK601 Unknown Not deposited (Kilian et al. 2008) 
 
SK602 Unknown Not deposited (Kilian et al. 2008) 
 
SK608 Unknown Not deposited (Kilian et al. 2008) 
 
SK609 Unknown Not deposited (Kilian et al. 2008) 
 
SK611 Unknown Not deposited (Kilian et al. 2008) 
 
SK612 Unknown Not deposited (Kilian et al. 2008) 
 
SK614 Unknown Not deposited (Kilian et al. 2008) 
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SK615 Unknown Not deposited (Kilian et al. 2008) 
 
SK667 Unknown Not deposited (Kilian et al. 2008) 
 
SK675 Unknown Not deposited (Kilian et al. 2008) 
S. oralis RFH623 LRT Not deposited This study 
 
RFH831 LRT Not deposited This study 
 
Col19 Unknown AJ240794 (Whatmore, Barcus & Dowson 1999) 
 
NCTC 11427 Nasopharynx AJ000873 (Håvarstein, Hakenbeck & Gaustad 1997) 
 
DSM 20066 Unknown AJ000874 (Håvarstein, Hakenbeck & Gaustad 1997) 
 
SK153 Unknown Not deposited (Kilian et al. 2008) 
 
SK305 Unknown Not deposited (Kilian et al. 2008) 
 
SK34 Unknown Not deposited (Kilian et al. 2008) 
 
SK39 Unknown Not deposited (Kilian et al. 2008) 
 
SK571 Unknown Not deposited (Kilian et al. 2008) 
 
SK597 Unknown Not deposited (Kilian et al. 2008) 
 
SK610 Unknown Not deposited (Kilian et al. 2008) 
 
SK92 Unknown Not deposited (Kilian et al. 2008) 
S. gordonii NCTC 3165 Gum AJ000870 (Håvarstein, Hakenbeck & Gaustad 1997) 
 
NCTC 7865 Endocardium X98110 (Håvarstein et al. 1996) 
 
NCTC 7868 Unknown X98109 (Håvarstein et al. 1996) 
S. infantis SK140 Unknown Not deposited (Kilian et al. 2008) 
 
SK282 Unknown Not deposited (Kilian et al. 2008) 
 
SK283 Unknown Not deposited (Kilian et al. 2008) 
 
SK350 Unknown Not deposited (Kilian et al. 2008) 
S. cristatus NCTC 12479 Unknown AJ000876 (Håvarstein, Hakenbeck & Gaustad 1997) 
S. peroris ATCC 700780 Tooth EFX39822 NCBI genome 
a
 LRT: lower respiratory tract 
b
 Accession numbers only available for GenBank submissions over the length of 200 bp. Those sequences under 200 bp are available in 
respective publications
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Table 7.3. Primers and probes used in this study with final reaction concentrations 
 
Targets
a,b
 
 
 
Forward Primer 
(Final Concentration) 
Reverse Primer 
(Final Concentration) 
Probe 
(Final Concentration)
c 
Size 
(bp) 
Reference 
Spn9802 5’-AGT CGT TCC AAG GTA ACA AGT CT-3’  
(0.3 µM) 
5’ ACC AAC TCG ACC 
ACC TCT TT-3’  
(0.5 µM) 
5’ ROX-TAC ATG TAG GAA 
ACT ATT TTC CTC ACA AA- 
BHQ2-3’ (0.25 µM) 
155 (Abdeldaim et al. 2008) 
      
lytA 5’- ACG CAA TCT AGC AGA TGA AGC A-3’  
(0.2 µM) 
5’-TCG TGC GTT TTA 
ATT CCA GCT -3’  
(0.2 µM) 
5’ YAK-TGC CGA AAA CGC 
TTG ATA CAG GGA G-DB-3’ 
(0.2 µM) 
75 (Carvalho et al. 2007) 
      
IAC 5’-AAC TTG GCT TTA ATG GAC CTC CA-3’ 
(0.25 µM) 
5-ACA TTC ATC CTT 
ACA TGG CAC CA-3  
(0.25 µM) 
5’ Cy5-TGC ACA AGC TAT 
GGA ACA CCA CGT- BBQ-3’ 
(200 nM) 
101 (Nolan et al. 2006) 
      
comC
†
 5’-GAT AAA ATT CTC TCA ACT GT-3’  
(0.4 µM) 
5’-GGT AAC TGT GAC 
TAA TAA TT-3’ (0.4 µM) 
None ~300 This study 
 
a
 IAC: internal amplification control based on method described previously (Nolan, 2006). IAC template amplicon sequence as follows: 5’-AAC 
TTG GCT TTA ATG GAC CTC CAA TTT TGA GTG TGC ACA AGC TAT GGA ACA CCA CGT AAG ACA TAA AAC GGC CAC ATA 
TGG TGC CAT GTA AGG ATG AAT GT-3’ 
b comC was targeted using conventional PCR without a probe 
 
c BHQ: Black Hole Quencher; YAK: Yakima Yellow; DB: Dabcyl; BBQ: Black Berry Quencher
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7.2.4 Amplification and Sequence Analysis of comC  
PCR amplification, purification, cycle sequencing, and sequence analysis were 
performed as described in Sections 2.8.2 to 2.8.8. Primers specific for comC were 
employed for both PCR and cycle sequencing. Please refer to Table 2.6 for primer 
sequences and annealing temperature. 
 
7.2.5 Multilocus Sequence Typing (MLST) 
The primers for MLST used are as described in Table 2.6, with the same reaction 
components and concentrations as indicated in Chapter 4. Sequences were uploaded 
onto GenBank database with accession numbers JQ352770-JQ352776. 
 
7.2.6 Publicly Accessible Sequences of Streptococcal CSP  
Additional streptococcal ComC amino acid sequences were included in this study for 
the construction of a phylogenetic tree (see below). Sequences obtained from previous 
publications with accession numbers are indicated in Table 7.2. Sequences with no 
accession numbers are provided in respective publications.  
 
7.2.7 Construction of a ComC Phylogenetic Tree  
Multiple alignment of comC sequences were constructed and translated to amino acid 
sequences on MEGA version 5.05 (Tamura et al. 2011). For both analyses neighbour-
joining trees were constructed based on amino acid alignment data. Bootstrap support 
of 1,000 repetitions with replacements was performed.  
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7.3 Results 
7.3.1 S. pseudopneumoniae ComC Sequences 
It was possible to identify ComC sequences for nine pseudopneumococcal strains 
where CSP sequences were derived directly from samples submitted to our laboratory 
with LRT and invasive infections. These samples were presumed to contain 
pseudopneumococci based on a Spn9802-positive and lytA-negative qPCR reaction 
(eight strains), bile-insolubility and optochin-variable phenotypic traits (one strain, 
N452), and/or MLST (one strain, N452). The pherotype of control strain ATCC 
BAA-960 was also characterized in this study. Two pherotypes were detected in these 
nine strains, six (N452, RFH504, RFH543, RFH687, RFH905, RFH999) of which 
were associated with CSP6.1.  To avoid confusion with pherotypes of other oral 
streptococci we propose that CSP6.1 be named as CSPps1, where “ps” represents the 
pseudopneumococcus. The three remaining strains, BAA-960, RFH686 RFH827, had 
a ComC sequence that has not been reported before which is identical to CSPps1 in 
size, differing by an alanine  serine substitution at position 12 of the propeptide.  
We propose that this pherotype be classified as CSPps2 (Fig. 7.2). Nucleotide 
sequences of comC for strains characterized in this study are indicated in Table 7.4. 
All strains of a pherotype had the identical nucleotide sequence.  
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CSP6.1   MK-NT--VKLEQFVALKEKDLQKIKGGEMRLPKILRDFIFPRKK 41  
CSP6.3   MK-NT--VKLEQFVSLKEKDLQKIKGGEMRLPKILRDFIFPRKK 41 
-------------------------------------------------------- 
SK674 MKKNTDFAQMKDFQQLNEKELQEIRGGEWRPPYTINNFLFPKRK 44  
SK350    MKKHTGFAQMKDFQELNEKELQEIRGGEWRPMYTINNFLFSKSK 44  
 
 
 
Fig. 7.2. Pherotypes of S. pseudopneumoniae CSP6.1 (CSPps1), CSP6.3 
(CSPps2), and SK674. Mature region of peptide is in bold after the double-glycine. 
CSP6.1 and CSP6.3 differ by a single amino acid at position 12 (alanine in CSP6.1 
and serine in CSP6.3), as shaded in yellow. SK674 is a presumptive 
pseudopneumococcus (Kilian et al. 2008), with an extended ComC compared to 
CSP6.1 and CSP6.3, and shares higher identity to S. infantis SK350. A total of three 
pseudopneumococcal pherotypes were characterized. Differences between SK674 and 
CSP6.1/6.3 present in the mature peptide region are shaded in light blue. Double-
glycine motif shaded in red. 
 
 
 
Table 7.4 Nucleotide sequences of pherotypes characterized in this study. 
 
Pherotype Nucleotide sequence (5’-3’) 
CSP6.1 
(CSPps1) 
atgaaaaaca cagttaaatt ggaacagttt gtagccttga aggaaaaaga cttgcaaaag attaaaggtg 
gggaaatgag acttccaaaa atcctccgtg attttatttt cccaagaaaa aagtaa 
CSP6.3 
(CSPps2) 
atgaaaaaca cagttaaatt agaacagttt gtatctttga aggaaaaaga cttgcaaaag gggaaatgag 
acttccaaaa atcctccgtg attttatttt cccaagaaaa aagtaa 
CSP1 atgaaaaaca cagttaaatt ggaacagttt gtagctttga aggaaaaaga cttacaaaag attaaaggtg 
gggagatgag gttgtcaaaa ttcttccgtg attttatttt acaaagaaaa aagtaa 
CSP6.2 atgaaaaaca cagttaaatt ggaacagttt gtagccttga aggaaaaaga cttgcaggag attaaaggtg 
gggagatgag actgccaaaa atcctccgtg attttatttt cccaagaaaa aagtaa 
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CSP sequences of four strains (IS7493, PT5479, PT5779, and SK674) were available 
from reports in earlier publications (Table 7.2). All but SK674 were identical to 
CSPps1. Thus, more than 70% of the presumptive S. pseudopneumoniae strains in this 
study were associated with CSPps1 (Table 7.5). SK674 has an extended ComC at 54 
amino acids, most similar to a pherotype characterized in Streptococcus infantis 
SK350, with six amino acid substitutions, three of which in the mature peptide region 
(Fig. 7.2). SK674 differ from CSPps1 and CSPps2 in most of the mature peptide 
region, including positions 4, 7, 8, and 11, which had been hypothesized to confer 
competence receptor specificity (Johnsborg et al. 2006). 
 
Table 7.5. Distribution of Pseudopneumococcal Pherotypes 
Pherotype/ 
Strain 
Proportion  
(% of n = 14) 
Strains 
CSPps1 (CSP6.1) 10 (71) N452, RFH504, RFH543, RFH687, 
RFH905, RFH999, IS7493, 874, 
PT5479, PT5779 
CSPps2 (CSP6.3) 3 (21) BAA-960, RFH686, RFH827 
SK674 1 (7) SK674 
 
 
7.3.2 Phylogenetic Analysis of Streptococcal Pherotypes 
A phylogenetic tree constructed from alignment of streptococcal pherotypes shows 
that, by pherotype, streptococci fall into two major groups (Fig. 7.3). S. pneumoniae, 
S. pseudopneumoniae, S. mitis and some S. oralis strains belonged to one group 
(group 1), while a more divergent and loosely-defined group (group 2) consists of 
predominantly S. gordonii, S. infantis, S. peroris, S. cristatus, and most of the 
remaining S. oralis strains. SK674, formerly classified as a pseudopneumococcus 
(Kilian et al. 2008), clustered near members of S. infantis by ComC alignment. All of 
the remaining S. pseudopneumoniae pherotypes are grouped in a separate cluster in 
close relation to other species, notably S. oralis and S. mitis (Fig. 7.3).  
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Fig. 7.3. Neighbour-joining phylogenetic representation of Streptococcal ComC. 
Two clusters of ComC based on amino acid sequence similarities (groups 1 and 2) are 
separated by a curved dotted line. Each pherotype is labelled according to the 
classified species: filled circle, S. pseudopneumoniae; open square, S. pneumoniae; 
filled upward triangle, S. mitis; filled square, S. oralis; open circle, S. gordonii; open 
upward triangle, S. peroris; open diamond, S. infantis, open downward triangle, S. 
cristatus. Groups with asterisk indicate multiple strains of the same pherotype that 
have been compressed for clarity. Numbers of strains with same pherotype are 
indicated in parentheses. Pseudopneumococcal strains of these groups are indicated in 
Table 2. Pneumococcal CSP1 pherotype includes strains VA1, RFH324, RFH410, 
RFH577, RFH815, RFH864, and RFH904. Pneumococcal CSP2.1 pherotype includes 
strains 41G and CSP2.1b. CSP6.2 pherotypes include SK671 (S. mitis), Col19 (S. 
oralis), RFH623 (S. oralis), and RFH831 (S. oralis). Phylogenetic tree was built with 
1,000 bootstrap repetitions with replacement, with support over 80% indicated. Ruler 
indicates amino acid substitutions per site. Tree constructed with MEGA 5.05 
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7.4 Discussion 
7.4.1 CSP6.1 is a Common Pseudopneumococcal Pherotype 
We have characterized pherotypes associated with S. pseudopneumoniae by 
comparing strains available to us, amplifying sequence collected from lower 
respiratory tract and blood samples and collecting publicly available ComC sequences 
for this organism and related streptococcal species. We have shown that CSP6.1 (or 
CSPps1) is the commonest pherotype among S. pseudopneumoniae found in different 
geographical regions. Pherotype CSP6.1 was previously considered to be a rare 
pherotype of an “atypical nontypable pneumococcal” strain 874 based on multilocus 
sequence analysis (Müller-Graf et al. 1999; Whatmore, Barcus & Dowson 1999). Its 
classification as a pneumococcus may stem from its possession of ply and lytA, which 
were once considered suitable genetic markers for the pneumococcus (Müller-Graf et 
al. 1999). However, it is known that these two genes are not specific to S. pneumoniae 
(Whatmore et al. 2000; Neeleman et al. 2004; Johnston et al. 2010), and we have 
been unable to find a report of CSP6.1 being found in a strain unequivocally 
identified as S. pneumoniae. Based on these observations, we hypothesize that strain 
874 is a member of S. pseudopneumoniae. Strain 101/87 associated with CSP5 was 
described as an “atypical pneumococcus” and could not be serotyped by Whatmore et 
al. (Whatmore, Barcus & Dowson 1999). Phylogenetic analysis of CSP sequences in 
this study suggests that CSP5 is most closely related to S. mitis or S. oralis pherotypes 
that cluster together.  Thus, we believe that CSP 6.1 is associated with S. 
pseudopneumoniae and to differentiate pseudopneumococcal pherotypes from ComC 
sequences from other organisms, they be designated CSPps1 instead of CSP6.1. In 
this study we have identified a new pherotype associated with S. pseudopneumoniae 
and have designated these as CSPps2.  S. pseudopneumoniae pherotypes form a 
distinct cluster within those of other oral streptococcal species, suggesting that 
pseudopneumococcal pherotypes could be species-specific and be used as a simple 
diagnostic tool.  
 
7.4.2 Strain SK674 with a Divergent ComC 
In contrast, strain SK674, a S. pseudopneumoniae strain identified based on clustering 
of housekeeping gene sequences (Kilian et al. 2008), clustered closely in ComC 
sequences of S. infantis strains. One might argue that SK674 acquired a divergent 
comC from S. infantis by horizontal gene transfer.  While interspecies transfer of the 
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competence operon has been documented (Håvarstein, Hakenbeck & Gaustad 1997), 
the lack of such an event in a collection of over 200 pneumococcal strains indicates 
that this is relatively rare. SK674 has an estimated genome size of 1.87 Mbp (Kilian et 
al. 2008), comparable to that of other S. infantis strains (1.74-1.88 Mbp), and much 
smaller than the genome size of the pseudopneumococcal strain IS7493 (2.1 Mbp) 
(Shahinas et al. 2011). It seems that the alternative explanation, that SK674 is actually 
a strain of S. infantis is more likely. Additional analysis of SK674, such as DNA-
DNA hybridization and lytA sequence analysis, may shed light as to the true identity 
of this strain.  
 
7.4.3 Competence Gene comC in Genome of IS7493 
The recently characterized genome sequence of S. pseudopneumoniae strain IS7493 
concluded that CSP-mediated induction of fratricide does not take place based on the 
absence of comC in this strain (Shahinas et al. 2011).  We were, however able to 
locate the gene that is identical to CSPps1. Thus, we can conclude that this S. 
pseudopneumoniae strain does contain the necessary gene sequences for production 
of a competence peptide, and that a homologous gene is found in all 
pseudopneumococcal strains analyzed thus far, strengthening the use of this gene as a 
diagnostic marker.  
 
7.4.4 ComC as a Potential Target for Pseudopneumococcal Identification 
S. pseudopneumoniae is usually identified as acapsulate, bile-insoluble, and optochin 
intermediate-resistant in 5% CO2 and optochin susceptible in ambient O2 (Arbique et 
al. 2004), tests that can be difficult to standardize in the laboratory. Identification by 
comC sequencing would allow a rapid method of definitive diagnosis as competence 
ligand gene is conserved across streptococcal species, pseudopneumococcal comC 
sequences appear to provide taxonomic information. One of the limitations of this 
study is the low number of strains, and follow-up studies employing a larger 
collection of S. pseudopneumoniae strains would provide greater understanding to the 
potential of this gene as a species identification target. 
 
A recent report suggested that sequencing recA could differentiate between S. 
pneumoniae from S. pseudopneumoniae (Sistek et al. 2011), but the study was 
performed with a smaller number of pseudopneumococcal strains solely from North 
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America. The detection of homologues of pneumococcal virulence factors in S. 
pseudopneumoniae and the recent detection of pseudopneumococci in carriage with 
antibiotic resistance necessitate its accurate diagnosis as an emerging causative agent 
of diseases (Keith & Murdoch 2008; Johnston et al. 2010). Here we propose that 
pherotyping may be a promising diagnostic alternative based on the clustering of 
pseudopneumococcal pherotypes from different continents.  
 
7.4.5 ComC and Streptococcal Species Diversity  
As most groups of strains within a species communicate in a concerted manner by 
induction of competence by the same CSP allele, pherotype diversification may thus 
be one of the initial steps for speciation. Indeed, studies have indicated that strains of 
S. mitis are no more related to each other than between strains of S. mitis and S. 
pneumoniae based on MLSA, and this is reflected on the great pherotype diversity of 
the former species (Kilian et al. 2008). Similarly, it may be that S. pseudopneumoniae 
acquired, either through genetic drift or horizontal gene transfer, a variant pherotype, 
and had formed an exclusive group in which communication (in this case, competence 
induction) occurred within this small group. This subsequently led to diversification 
of genetic traits elsewhere in the genome. While competence and genetic exchange in 
this emerging pathogen has not been demonstrated in vivo, this divergent species may 
also expand the streptococcal pan-genome by two mechanisms: pseudopneumococcal 
intra-species diversification and horizontal gene exchange between members of the 
pseudopneumococcus and related members of the Mitis streptococcal group.  
 
The establishment of S. pseudopneumoniae as a potential donor and/or recipient in 
inter-species gene exchange is crucial to the greater understanding of this organism’s 
role in the streptococcal supragenome. Co-culture experiments between S. 
pseudopneumoniae and S. pneumoniae and S. mitis with selection marker would 
indicate whether S. pseudopneumoniae participates in genetic exchanges with its close 
bacterial relatives. 
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7.5 Concluding Remarks 
In conclusion, we propose CSP sequence analysis can provide rapid accurate 
differentiation of S. pseudopneumoniae from closely related species S. pneumoniae, S. 
mitis, and S. oralis. With this in mind, we anticipate that some strains currently 
classified as atypical pneumococci can be identified as pseudopneumococci based on 
ComC sequencing. Use of ComC sequencing will simplify the gathering of data to 
understand the disease potential of this organism that may be now emerging as a 
pathogen. To add to this observation, we would encourage other laboratories to 
sequence “atypical pneumococcal” strains to provide the more sequences to confirm 
whether comC may be used as a rapid marker for the identification of this emerging 
pathogen.  
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CHAPTER EIGHT: Final Discussion and Future Work 
 
Works included in this thesis included the design of a novel single-primer PCR and 
sequencing-based sequetyping method to correctly identify serotypes of commonly 
encountered S. pneumoniae strains. Through this we have identified extensive 
sequence variations at the regulatory gene cpsB in both species and serotype level. 
We have employed this method to assist in understanding the adaptive potential of the 
pneumococcal co-colonization in healthy children in Tanzania. Previous works 
analyzing the pneumococcal supragenome have revealed extensive heterogeneity in 
gene content amongst pneumococci, even within a single ST (Shen et al. 2006; Silva 
et al. 2006; Hiller et al. 2007; Dagerhamn et al. 2008; Donati et al. 2010; Hiller et al. 
2010; Croucher et al. 2011; Hiller et al. 2011). Here we have provided a framework 
in understanding the supragenome size within the nasopharynx. We observed that 
most pneumococci in co-colonization events are of different competence pherotypes, 
thus providing evidence that the paediatric upper respiratory tract is an optimum 
environment for pneumococcal gene transfer. We also suggest that CSP6.1, which 
was detected previously as a pherotype of an “atypical pneumococcus,” is a common 
CSP allele of S. pseudopneumoniae.  
 
8.1 Sequetyping of Pneumococci 
The study described the design and application of a novel, single primer pair-based 
serotype identification method. Based on in silico analysis, PCR targeting the 
capsulation regulatory gene cpsB enabled successful species-specific amplification of 
a large number of pneumococcal serotypes; all serotypes in the latest 13-valent 
conjugate vaccines and common replacement serotypes could be identified accurately 
at least to the serogroup level. A recent global assessment of prevalent serotypes 
indicates that the novel method should correctly identify at least 70% of pneumococci 
causing invasive diseases in children under the age of 5 worldwide (Johnson et al. 
2010). Recent epidemiological accounts of invasive serotypes indicate that virtually 
all of invasive pneumococci in Tanzanian children are PCV13 serotypes (Mudhune, 
Wamae & Region 2009; Crump et al. 2011a). Sequetyping is also more economical 
than conventional Quellung serotyping. However, the efficacy of sequetyping has not 
been assessed in all known pneumococcal serotypes; the results presented included 
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only 48 serotypes. In addition, a large number of serotypes contained only a single 
strain, and reproducibility of sequetyping for these serotypes could not be verified. 
There is also the difficulty in detecting multiple colonization events, as sequence data 
would not distinguish respective sequences. 
 
8.1.1 Future Work 
Our research group is currently acquiring additional strains of the remaining serotypes 
not included, and also those with only one strain to access reproducibility of these 
serotypes. Inclusion of additional strains would also address serotypes with 
discrepant in silico and in vitro results, as well as misidentified strains in this study. A 
blind-study is currently undergoing to assess accuracy of sequetyping from 
polymicrobial samples.  
 
8.2 Co-Colonization of S. pneumoniae Strains in Tanzanian Children 
In Chapter 4 we described the multiple colonization in Tanzanian children under the 
age of 6, illustrating the adaptive potential of this organism in the nasopharynx where 
horizontal gene transfer is thought to take place. Characterization of up to twenty 
pneumococcal colonies from nasopharyngeal and orophayngeal swabs of children 
revealed the simultaneous colonization of strains of different serotypes, antibiotic 
susceptibilities, and genetic backgrounds. We also provided direct evidence that 
assessing serotype diversity alone is an underestimate of strain diversity, as 
pneumococci expressing the same capsule may have different STs in the upper 
respiratory tract.  
 
S. pneumoniae is among the most common detectable etiological agents of 
bloodstream (Matee & Matre 2001; Crump et al. 2011a; Crump et al. 2011b; 
Thriemer et al. 2012) and respiratory infections (Uriyo et al. 2006) in Tanzania, and 
high proportions of non-susceptibility to penicillin and co-trimoxazole have been 
reported in this country (Batt et al. 2003; Moyo et al. 2012). The co-colonization of 
strains with different susceptibilities to both drugs is likely to facilitate the spread of 
nonsusceptible pneumococci. 
 
However, the supragenome size within a single host at one time is yet to be 
determined. This is likely to be dependent on the cohort studied and the strain 
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diversity of the nasopharynx, as the supragenome size is likely to increase with 
additional strains. In our study, child 35 was presented with total of six strains co-
colonizing, which according to Hiller’s finite supragenome model increases the gene 
repertoire for HGT within the nasopharynx by 30% (Hiller et al. 2007).  
 
8.2.1 Future Work 
Whole-genome sequencing of strains within child 35, who showed the highest 
number (six) of multiple strains co-colonizing, would provide an approximation of the 
supragenome size available for HGT within a host at one time. The number of core 
genes present in all strains, distributed genes in some strains, and unique genes in 
single strains can be determined, and compared to previous works where 
supragenome as a species in general was assessed. 
 
Due to the limitation of time and resources, MLST was only performed in 
colonization events of multiple phenotypes and of selected single colonization events. 
Although we were unable to detect presence of different strains within single 
colonization events, it is possible that children had been colonized by different strains 
that were identical in serotype and antibiotic susceptibilities. Therefore, the described 
rate of co-colonization is likely to be an underestimate of the cohort. Determining the 
ST of strains in other colonization episodes would provide a more in-depth analysis of 
such colonization events.   
 
Furthermore, comparison of supragenome sizes of single and multiple colonizations is 
of interest. Dagerhamn et al. (Dagerhamn et al. 2008) showed that strains of the same 
or related ST are more likely to share a higher number of genes in their genomes. 
Understanding the supragenome sizes of multiple and single colonizations would 
therefore directly indicate how multiple colonization attributes to pneumococcal 
adaptation.  
 
8.3 Diversity of CSP Alleles in the UK and Tanzania 
We have revealed differences in proportions of pherotype distributions between two 
countries (UK and Tanzania). This is the first report of pherotype diversity in a 
developing nation, and the first to report of a high prevalence of CSP4. It is likely that 
pherotype distributions are governed by geographical differences and STs, as this and 
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other studies have demonstrated the close association between pherotype and clonal 
complexes (Carrolo et al. 2009; Vestrheim et al. 2011). In addition, co-colonization 
events commonly contain strains of different pherotypes, thereby potentially 
facilitating genetic exchanges through competence-mediated fratricide. 
 
8.3.1 Future Work 
The disease potential of CSP4 is not clear. In this study, CSP4 pneumococci were 
detected in both the nasopharynx and blood. Animal models involving strains of 
CSP4 would allow a greater understanding of host-pathogen interaction in this CSP 
allele. It is of interest to point out that Iannelli detected comC1-expressing strains with 
a comD4 receptor, and that this receptor can activate competence at elevated 
concentrations (~30 ng/mL) of CSP1.  
 
8.4 Intra-Serotype Diversity of cpsB 
Comparison of multiple strains of single serotypes revealed that there exist significant 
differences in intra-serotype diversity in cpsB between serotypes. One of the 
limitations of this work is that MLST data was not available for all strains, and 
comparison between more serotypes could not be performed. However, MLST data 
for a number of serotype 6B and serotype 1 strains was available, and we observed 
the differences in intra-serotype diversity of cpsB that is independent of genetic 
relatedness as determined by MLST.  
 
8.4.1 Future Work  
The inclusion of additional serotypes and multiple strains of studied serotypes, which 
is addressed in Section 8.1, would allow the analysis of intra-serotype cpsB diversity 
to be compared between additional serotypes.  
 
Two clusters of divergent serotype 6B strains based on cpsB sequences were 
observed. However, it is important to understand whether the clusters account for 
phenotypic differences, such as the amount of capsule produced and the rate of 
enzymatic activity. In order to perform such a comparison, characterization of the 
remaining genes present in the cps locus is required for these strains, as sequence 
variation may be found elsewhere along cps (Morona, Morona & Paton 1999a; Varvio 
et al. 2009; Elberse et al. 2011). Comparison of capsule production and invasive 
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potential (with the use of animal models) of isogenic mutants differing in the cps 
region between clusters within a given serotype would provide a biological relevance 
to the observed sequence variations. 
 
Amino acid analysis revealed the presence of non-conservative substitution hotspots 
within α4 and α7 globular domains (Hagelueken et al. 2009). However, it is not 
known whether structural changes would entail as a result of these substitutions. 
Structural modeling and phosphatase activity assays between strains of blue and red 
serotypes, or of different sequence clusters within serotype 6B, would provide a 
relationship between between sequence variation and structural differences and 
biological activity.  
 
8.5 ComC as a Target for Identifying the Pseudopneumococcus 
The discovery of an “atypical pneumococcus” associated with CSP6.1 led to its 
phenotypic characterization, and this strain was subsequently identified as S. 
pseudopneumoniae. Analysis of additional pseudopneumococcal strains based on 
presence and absence of Spn9802 and lytA, respectively, provided evidence that 
CSP6.1 is a common pseudopneumococcal pherotype as supposed to a rare 
pneumococcal pherotype as suggested (Whatmore, Barcus & Dowson 1999). A 
greater understanding the diversity of both pseudopneumococcal pherotypes and that 
of the Streptococcus would  
 
8.5.1 Future Work 
The only other CSP6.1 strain detected previously was a nontypable strain (strain 874) 
from Kenya, and intriguingly strain 874 had identical sequences in comA to other 
pneumococci. Therefore, pherotype identification of additional pseudopneumococcal 
strains is encouraged, and analysis of other competence genes would provide 
additional information on the competence machinery of this organism. In addition, 
mixed culture experiments involving pseudopneumococci of different pherotypes, as 
well as different streptococcal species may reveal the role of S. pseudopneumoniae in 
inter-specific genetic exchange and also streptococcal species diversification. 
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Appendix Table A1. Strains used in the works of this thesis               
              
Strain 
Collection 
Strain Name Serotype by 
Conventional 
Typing 
Sequetyping 
with GenBank 
database 
Serotype-
specific 
DNA-PCRa 
comC allele 
(pherotype) 
Allelic 
Profile 
(ST) 
MIC (μg/mL)b         
Pen Sxt Chapter 
3 
Chapter 
4 
Chapter 
5 
Chapter 
6 
Tanzania 
(Multiple 
Colonization 
Study) 
1NP10S NT no PCR NP 4 4156 0.032 0.19     √     
1NP7 NT no PCR NP 4 4156 0.032 0.19   √     
1NP4 NT no PCR NP 4 4156 0.032 0.19     √     
1NP5 NT no PCR NP 4 4156 0.032 0.19   √     
1NP9 NT no PCR NP 4 4156 0.032 0.19     √    
1NP10B 6B 6B NP 2.1 4429 0.19 6     √ √   
11NP8 (Jan/Feb) 6B 6B NP NP 4432 0.19 6     √     
11OP5 (Jan/Feb) 6B 6B NP NP 4432 0.19 6   √     
11OP9 (Jan/Feb) 6B 6B NP NP 4432 0.25 6     √     
11NP5 (Jan/Feb) 6B 6B NP NP 4432 0.19 6   √     
11OP6 (Jan/Feb) 6B 6B NP NP 4432 0.19 8     √     
11OP10 (Jan/Feb) 6B 6B NP NP 4432 0.19 6   √     
11NP2 (Jan/Feb) 6B 6B NP NP 4432 0.19 6     √     
11NP3 (Jan/Feb) 6B 6B NP NP 4432 0.19 6   √     
11NP4 (Jan/Feb) 6B 6B NP NP 4432 0.19 6     √     
11NP6 (Jan/Feb) 6B 6B NP NP 4432 0.19 6   √     
11NP7 (Jan/Feb) 6B 6B NP NP 4432 0.19 6     √     
11NP9 (Jan/Feb) 6B 6B NP NP 4432 0.19 6   √     
11NP10 (Jan/Feb) 6B 6B NP NP 4432 0.19 6   √ √    √ 
11NP1 (Jan/Feb) 6B 6B NP NP 4432 0.19 6   √     
11OP3 (Jan/Feb) 6B 6B NP NP 4432 0.19 6     √     
16OP4 19F 19F NP 1 347 0.19 6   √ √    √ 
16NP1 19F 19F NP 1 347 0.19 6     √     
16NP4 19F 19F NP 1 347 0.19 6     √ √   
16OP5 19F 19F NP 1 347 0.19 6     √     
16OP2 19F 19F NP 1 347 0.19 6   √     
16NP3 19F 19F NP 1 347 0.19 6     √     
16NP5 34 17A/34 34 2.1 4158 0.032 6     √ √   
16NP8 34 17A/34 34 2.1 4158 0.032 6     √     
16NP9 34 17A/34 34 2.1 4158 0.032 6   √     
16NP7 34 17A/34 34 2.1 4158 0.032 6     √     
16NP10 35A 35B/C NP 4 840 0.25 4   √   √ √   √ 
18NP1 10A 10A NP 1 852 0.125 4     √ √   
18NP5 10A 10A NP 1 852 0.125 4   √     
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18NP9 10A 10A NP 1 852 0.125 4     √     
18NP10 10A 10A NP 1 852 0.125 4   √     
22NP4 17F 17F NP 2.1 4160 0.016 0.125     √ √   
22NP7 17F 17F NP 2.1 4160 0.016 0.125   √     
22NP9 17F 17F NP 2.1 4160 0.016 0.125     √     
22NP10 17F 17F NP 2.1 4160 0.016 0.125   √     
22NP2 17F 17F NP 2.1 4160 0.016 0.125   √ √    √ 
35NP4 10A 10A NP 1 852 0.38 6   √   √   
35NP10 19A 19A NP 2.1 4162 0.125 2   √ √   √   √ √ 
35NP9 10A 10A NP 1 852 0.38 6   √     
35NP1 6B 6B NP 4 4157 0.125 6   √ √   √ √ 
35NP2 21/39 21 NP 1 1145 0.064 3   √     
35NP6 6B 6B NP 2.1 854 0.125 6   √ √   √ √ 
35NP8 19F 19F NP 1 6170 0.19 2   √ √   √ √ 
45OP1 21/39 21 NP 1 1145 0.094 4     √ √   
45OP2 21/39 21 NP 1 1145 0.094 4   √     
45OP3 21/39 21 NP 1 1145 0.094 4     √     
45OP4 21/39 21 NP 1 1145 0.094 4   √     
45OP5 21/39 21 NP 1 1145 0.094 4     √     
45OP6 21/39 21 NP 1 1145 0.094 4   √     
45OP7 21/39 21 NP 1 1145 0.094 4     √     
45OP8 21/39 21 NP 1 1145 0.094 4   √     
45OP9 21/39 21 NP 1 1145 0.094 4   √ √     √ 
55OP3 35A 35B/C NP NP NP 0.19 3   √ √     √ 
69OP8 6B 6B NP NP 4429 0.19 8     √     
69OP9 6B 6B NP NP 4429 0.19 8   √     
69OP4 6B 6B NP NP 4429 0.19 8     √     
69OP3 6B 6B NP NP 4429 0.19 8   √     
69OP7 6B 6B NP NP 4429 0.19 8     √     
69OP2 6B 6B NP NP 4429 0.19 8   √     
69OP10 6B 6B NP NP 4429 0.19 8   √ √    √ 
3NP9 (Mar) 6B 6B NP 4 4368 0.032 0.125     √ √   
3NP6 (Mar) 6B 6B NP 4 4368 0.032 0.19     √     
3NP7 (Mar) 6B 6B NP 4 4368 0.047 0.125   √ √     √ √ 
10NP1 (Mar) 13/28 13/20 13 4 4370 0.125 6     √ √   
10NP4 (Mar) 13/28 13/20 13 4 4370 0.125 6   √     
10NP5 (Mar) 13/28 13/20 13 4 4370 0.125 6     √     
10NP7 (Mar) 13/28 13/20 13 4 4370 0.125 6   √     
10NP8 (Mar) 13/28 13/20 13 4 4370 0.125 6     √     
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10NP10 (Mar) 13/28 13/20 13 4 4370 0.125 6     √     
11OP1 (Jun) 6B 6B NP NP 4432 0.19 4   √     
11OP2 (Jun) 6B 6B NP NP 4432 0.19 4     √     
11OP3 (Jun) 6B 6B NP NP 4432 0.19 4   √     
11OP4 (Jun) 6B 6B NP NP 4432 0.19 4     √     
11OP5 (Jun) 6B 6B NP NP 4432 0.19 4   √     
11OP6 (Jun) 6B 6B NP NP 4432 0.19 4     √     
11OP8 (Jun) 6B 6B NP NP 4432 0.19 4   √     
11OP9 (Jun) 6B 6B NP NP 4432 0.19 4     √     
3OP1 (Sep) 1 1 NP 1 217 <0.016 <0.002   √ √   √ √ 
3OP2 (Sep) 1 1 NP 1 217 <0.016 <0.002    √     
3OP3 (Sep) 1 1 NP 1 217 <0.016 <0.002   √     
3OP6 (Sep) 1 1 NP 1 217 <0.016 <0.002     √     
3OP7 (Sep) 6B 6B NP 4 4373 0.25 6   √ √   √ √ 
3OP8 (Sep) 6B 6B NP 4 4373 0.25 6     √     
3OP9 (Sep) 6B 6B NP 4 4373 0.25 6   √     
3OP10 (Sep) 1 1 NP 1 217 S S     √     
21NP1 10A 10A NP NP NP 2 1.5   √ √    √ 
24OP1 19A 19A NP 2.1 4162 0.25 6     √   √   
24OP3 19A 19A NP 2.1 4162 0.25 6   √   √   
24OP5 19A 19A NP 2.1 4162 0.25 6     √     
29OP8 35A 35B/35C NP 4 840 0.25 4   √     
29OP10 11A 11A/D/18F NP 4 5752 0.38 6   √ √   √ √ 
3NP8 (Jan) 6B 6B NP 4 4368 S S   √   √   
3OP1 (Jul) 1 1 NP 1 217 S S     √   √   
3OP2 (Jul) 1 1 NP 1 217 S S   √     
3OP4 (Jul) 1 1 NP 1 217 S S     √     
3OP5 (Jul) 1 1 NP 1 217 S S   √     
3OP6 (Jul) 1 1 NP 1 217 S S     √     
7NP4 21/39 21 NP NP NP 0.38 8   √ √     √ 
7OP9 23B 23B NP NP NP S 1.5   √ √     √ 
10NP2 (Jan/Feb) 19A 19A NP 2.1 4162 0.125 6     √ √   
10NP3 (Jan/Feb) 19A 19A NP 2.1 4162 0.125 6     √     
10NP5 (Jan/Feb) 19A 19A NP 2.1 4162 0.125 6   √     
10NP6 (Jan/Feb) 19A 19A NP 2.1 4162 0.125 6     √     
10OP6 (Jan/Feb) 13/28 13/20 13 4 4370 0.125 3     √ √   
10NP7 (Jan/Feb) 19A 19A NP 2.1 4162 0.125 6     √ √   
10NP9 (Jan/Feb) 19A 19A NP 2.1 4162 0.125 6   √     
10OP1 (Apr) 18C 18B/C NP 1 NP S S     √     
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10OP3 (Apr) 18C 18B/C NP 1 NP S S     √   √   
10OP5 (Apr) 18C 18B/C NP 1 NP S S     √     
10OP6 (Apr) 18C 18B/C NP 1 NP S S   √     
10OP7 (Apr) 18C 18B/C NP 1 NP S S     √     
10OP9 (Apr) 6B 6B NP 4 NP S S     √   √   
10OP10 (Apr) 18C 18B/C NP 1 NP S S     √     
11NP1 (May) 4 4 NP NP NP S S   √     
11NP2 (May) 4 4 NP NP NP S S     √     
11NP3 (May) 4 4 NP NP NP S S   √     
11NP4 (May) 4 4 NP NP NP S S     √     
11NP5 (May) 4 4 NP NP NP S S   √     
11NP6 (May) 4 4 NP NP NP S S     √     
11NP7 (May) 4 4 NP NP NP S S   √     
11NP8 (May) 4 4 NP NP NP S S     √     
Tanzania 
(Trachoma 
Study) 
1003-2 7C 7C NP NP NP NP NP   √       √ 
2514-1 7C 7C NP NP NP NP NP   √     √ 
1804.1 NP NP NP 1 NP NP NP       √   
3205.2 NP NP NP 1 NP NP NP     √   
3207.3 NP NP NP 1 NP NP NP       √   
4407.1 NP NP NP 1 NP NP NP     √   
5411.1 NP NP NP 1 NP NP NP       √   
5711.1 NP NP NP 1 NP NP NP     √   
5802.1 NP NP NP 1 NP NP NP       √   
5907.2 NP NP NP 1 NP NP NP     √   
6611.1 NP NP NP 1 NP NP NP       √   
6901.2 NP NP NP 1 NP NP NP     √   
6903.2 NP NP NP 2.1 NP NP NP       √   
107.1 NP NP NP 4 NP NP NP     √   
112.1 NP NP NP 1 NP NP NP       √   
210.3 NP NP NP 2.1 NP NP NP     √   
505.2 NP NP NP 1 NP NP NP       √   
602.1 NP NP NP 2.1 NP NP NP     √   
607.3 NP NP NP 1 NP NP NP       √   
2711.3 NP NP NP 4 NP NP NP     √   
2801.2 NP NP NP 4 NP NP NP       √   
2810.1 NP NP NP 4 NP NP NP     √   
2907.1 NP NP NP 2.1 NP NP NP       √   
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3612.2 NP NP NP 2.1 NP NP NP       √   
3612.3 NP NP NP 4 NP NP NP     √   
4407.1 NP NP NP 1 NP NP NP       √   
4806.1 NP NP NP 2.1 NP NP NP     √   
5303.2 NP NP NP 2.1 NP NP NP       √   
5605.1 NP NP NP 2.1 NP NP NP       √   
5609.1 NP NP NP 1 NP NP NP     √   
5609.2 NP NP NP 2.1 NP NP NP       √   
5704.2 NP NP NP 2.1 NP NP NP     √   
5711.1 NP NP NP 1 NP NP NP       √   
5803.1 NP NP NP 2.1 NP NP NP       √   
5808.1 NP NP NP 1 NP NP NP     √   
6614.2 NP NP NP 4 NP NP NP       √   
6802.2 NP NP NP 4 NP NP NP     √   
7502.2 NP NP NP 4 NP NP NP       √   
8715.2 NP NP NP 2.1 NP NP NP       √   
8715.4 NP NP NP 2.1 NP NP NP     √   
8802.2 NP NP NP 4 NP NP NP     √   
Tanzania 
Invasive Isolate 
(John Crump) 
JC001 NP NP NP 1 NP 0.125 9     √   
JC002 NP NP NP 1 NP 0.016 20       √   
JC003 NP NP NP 3 NP 0.016 12     √   
JC004 NP NP NP 1 NP 0.016 11       √   
JC005 NP NP NP 1 NP 0.023 20     √   
JC006 NP NP NP 1 NP 0.25 11       √   
JC007 NP NP NP 2.1 NP 0.25 6     √   
JC008 NP NP NP 1 NP 0.016 19       √   
JC009 NP NP NP 2.1 NP 0.25 15     √   
JC010 NP NP NP 2.1 NP 0.19 10       √   
JC011 NP NP NP 4 NP 0.125 13     √   
JC012 NP NP NP 2.1 NP 0.25 17       √   
JC013 NP NP NP 2.1 NP 0.047 23     √   
JC014 NP NP NP 4 NP 0.25 10       √   
JC015 NP NP NP 1 NP 0.016 20     √   
JC016 NP NP NP 1 NP 0.016 5       √   
JC017 NP NP NP 4 NP 0.25 7     √   
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JC018 NP NP NP 1 NP 0.023 20       √   
United 
Kingdom 
Royal Free 
Hospital 
Strains 
N3 NP NP NP 1 NP NP NP     √   
N5 NP NP NP 1 NP NP NP       √   
N6 NP NP NP 1 NP NP NP     √   
N7 NP NP NP 1 NP NP NP       √   
N8 NP NP NP 1 NP NP NP     √   
N9 NP NP NP 1 NP NP NP       √   
N10 NP NP NP 1 NP NP NP     √   
N13 NP NP NP 2.2 NP NP NP       √   
N15 6 6A 6A 2.1 65 NP NP   √      √   √ 
N16 NP NP NP 1 NP NP NP       √   
N18 NP NP NP 1 NP NP NP     √   
N19 NP NP NP 4 NP NP NP       √   
N21 NP NP 6A 2.1 65 NP NP   √    √   
N22 NP NP NP 1 NP NP NP       √   
N27 NP NP NP 1 NP NP NP     √   
N32 NP NP NP 1 NP NP NP       √   
N34 NP NP NP 1 NP NP NP     √   
N36 NP NP NP 1 NP NP NP       √   
N38 NP NP NP 1 NP NP NP     √   
N39 NP NP NP 1 NP NP NP       √   
N40 NP NP NP 1 NP NP NP     √   
N41 NP NP NP 1 NP NP NP       √   
N42 NP NP NP 2.1 NP NP NP     √   
N47 NP NP NP 1 NP NP NP       √   
N48 NP NP NP 1 NP NP NP       √   
N53 NP NP NP 2.1 NP NP NP     √   
N54 NP NP NP 2.1 NP NP NP       √   
N59 NP NP NP 1 NP NP NP     √   
N60 NP NP NP 1 NP NP NP       √   
N63 NP NP NP 1 NP NP NP     √   
N64 NP NP NP 2.2 NP NP NP       √   
N66 NP NP NP 1 NP NP NP     √   
N70 NP NP NP 1 NP NP NP       √   
N73 NP NP NP 1 NP NP NP     √   
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N76 NP NP NP 1 NP NP NP       √   
N78 NP NP NP 2.1 NP NP NP     √   
N79 NP NP NP 1 NP NP NP       √   
N81 NP NP NP 1 NP NP NP     √   
N92 NP NP NP 1 NP NP NP       √   
N93 NP NP NP 1 NP NP NP     √   
N94 6 6A 6A 2.1 65 NP NP   √     √   √ 
N98 NP NP NP 1 NP NP NP    √  
N100 NP NP NP 1 NP NP NP       √   
N105 NP NP NP 1 NP NP NP     √   
N106 NP NP NP 1 NP NP NP       √   
N107 NP NP NP 1 NP NP NP     √   
N123 NP NP NP 1 NP NP NP       √   
N125 NP NP NP 1 NP NP NP     √   
N126 NP NP NP 1 NP NP NP       √   
N128 NP NP NP 1 NP NP NP     √   
N140 NP NP NP 1 NP NP NP       √   
N147 NP NP NP 1 NP NP NP     √   
N150 NP NP NP 1 NP NP NP       √   
N151 NP NP NP 1 NP NP NP     √   
N152 NP NP NP 1 NP NP NP       √   
N155 6 6A 6A 2.1 65 NP NP   √      √   √ 
N158 NP NP NP 1 NP NP NP       √   
N178 NP NP NP 1 NP NP NP     √   
N180 NP NP NP 1 NP NP NP       √   
N182 NP NP NP 1 NP NP NP     √   
N198 NP NP NP 1 NP NP NP       √   
N199 NP NP NP 1 NP NP NP     √   
N201 NP NP NP 1 NP NP NP       √   
N209 NP NP NP 1 NP NP NP     √   
N216 NP NP NP 1 NP NP NP       √   
N217 NP NP NP 1 NP NP NP     √   
N223 NP NP NP 2.1 NP NP NP       √   
N232 NP NP NP 1 NP NP NP     √   
N244 NP NP NP 1 NP NP NP       √   
N252 NP NP NP 1 NP NP NP     √   
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N253 NP NP NP 1 NP NP NP       √   
N258 NP NP NP 1 NP NP NP     √   
N259 6 6A 6A 2.1 65 NP NP   √      √   √ 
N362 NP NP NP 1 NP NP NP     √   
N367 NP NP NP 1 NP NP NP       √   
N369 NP NP NP 1 NP NP NP     √   
N371 NP NP NP 2.2 NP NP NP       √   
N375 NP NP NP 1 NP NP NP     √   
N380 NP NP NP 1 NP NP NP       √   
N381 NP NP NP 2.2 NP NP NP     √   
N384 NP NP NP 1 NP NP NP       √   
N388 NP NP NP 1 NP NP NP     √   
N389 NP NP NP 2.2 NP NP NP       √   
N390 NP NP NP 1 NP NP NP     √   
N391 NP NP NP 1 NP NP NP       √   
N396 NP NP 6A 2.1 65 NP NP     √   
N400 NP NP NP 1 NP NP NP       √   
N404 NP NP NP 1 NP NP NP     √   
N405 6 6A 6A 2.1 65 NP NP   √      √   √ 
N408 NP NP NP 1 NP NP NP     √   
N447 NP NP NP 2.1 NP NP NP       √   
N448 NP NP NP 1 NP NP NP     √   
N449 NP NP NP 1 NP NP NP       √   
N450 NP NP NP 4 NP NP NP     √   
N451 NP NP NP 2.1 NP NP NP       √   
N453 NP NP NP 1 NP NP NP     √   
N454 NP NP NP 1 NP NP NP       √   
N455 NP NP NP 1 NP NP NP     √   
N456 NP NP NP 1 NP NP NP       √   
N457 NP NP NP 1 NP NP NP     √   
N458 NP NP NP 1 NP NP NP       √   
N459 NP NP NP 1 NP NP NP     √   
N460 NP NP NP 1 NP NP NP       √   
N465 NP NP NP 2.1 NP NP NP     √   
N468 NP NP NP 4 NP NP NP       √   
N2526 NP NP NP 1 NP NP NP     √   
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N2552 NP NP NP 1 NP NP NP       √   
N5510 NP NP NP 1 NP NP NP     √   
N21102 NP NP NP 1 NP NP NP       √   
N161236 NP NP NP 1 NP NP NP     √   
N273110 NP NP NP 1 NP NP NP       √   
N888b NP NP NP 1 NP NP NP     √   
10M204493 NP NP NP 4 NP NP NP       √   
10M265301 NP NP NP 4 NP NP NP     √   
10M251479 NP NP NP 4 NP NP NP       √   
ATCC 49619 19F 19F NP NP NP 0.25 0.12/2.4 – 1/19   √   √   √ 
Scotland 
Pneumococcal 
Reference 
Laboratory (Dr. 
Giles Edwards) 
12.1690.X 3 3 NP NP 180 NP NP √     √ 
12.1655.E 3 3 NP NP 180 NP NP   √       √ 
12.1640.H 3 3 NP NP 180 NP NP √     √ 
12.1409.G 3 3 NP NP 180 NP NP   √       √ 
12.1259.V 3 3 NP NP 180 NP NP √     √ 
11.6349.S 4 4 NP NP 205 NP NP   √       √ 
11.5324.N 4 4 NP NP 246 NP NP √     √ 
11.4573.Q 4 4 NP NP 246 NP NP   √       √ 
12.1695.Y 7F 7A/7F NP NP 191 NP NP √     √ 
12.1675.H 7F 7A/7F NP NP 191 NP NP   √       √ 
12.1666.R 7F 7A/7F NP NP 191 NP NP √     √ 
12.1426.R 7F 7A/7F NP NP 191 NP NP   √       √ 
12.1299.R 7F 7A/7F NP NP 191 NP NP √     √ 
12.1276.C 7F 7A/7F NP NP 191 NP NP   √       √ 
11.5715.C 9V 9V NP NP 156 NP NP √     √ 
11.3601.D 9V 9V NP NP 162 NP NP   √       √ 
11.3021.E 9V 9V NP NP 162 NP NP √     √ 
11.2143.S 9V 9V NP NP 156 NP NP   √       √ 
12.1625.M 19A 19A NP NP 2081 NP NP √     √ 
12.1623.F 19A 19A NP NP 416 NP NP   √       √ 
12.1579.M 19A 19A NP NP 450 NP NP √     √ 
10-1688 14 14 NP NP NP NP NP   √       √ 
10-2893 14 14 NP NP NP NP NP √     √ 
11.4091.H 23F 23F NP NP NP NP NP   √       √ 
11.3056.E 23F 23F NP NP 33 NP NP √     √ 
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11.2827.S 23F 23F NP NP 1682 NP NP   √       √ 
11.2737.T 23F 23F NP NP 1682 NP NP √     √ 
11.1373.Z 23F 23F NP NP 6959 NP NP   √       √ 
02-4520 5 5 NP NP NP NP NP √     √ 
04-2077 5 5 NP NP 1400 NP NP   √       √ 
07-2667 5 5 NP NP 289 NP NP √     √ 
10-1351 5 5 NP NP 4840 NP NP   √       √ 
12.1624.T 6A 6A/6B NP NP 396 NP NP √     √ 
11.6939.E 6A 6A NP NP 2467 NP NP   √       √ 
11.5544.Z 6A 6A NP NP 1876 NP NP √     √ 
11.5346.W 6A 6A/6B NP NP 327 NP NP   √       √ 
11.3085.J 6A 6A NP NP 65 NP NP √     √ 
10.2671.G 18C 18B/18C NP NP 113 NP NP   √       √ 
10.2178.X 18C 18B/18C NP NP 113 NP NP √     √ 
09.2555.S 18C 18B/18C NP NP 113 NP NP   √       √ 
09.2223.P 18C 18B/18C NP NP 638 NP NP √     √ 
09.1742.V 18C 18B/18C NP NP 2449 NP NP   √       √ 
09.1153.K 18C 18B/18C NP NP 1361 NP NP √     √ 
11.6554.S 19F 19F NP NP NP NP NP   √       √ 
11.6402.H 19F 1 NP NP NP NP NP √     √ 
GR MICRO SG07f 7F 7F/7A NP NP NP NP NP   √       √ 
SG10a 10A 10A NP NP NP NP NP √     √ 
SG10f 10F 10F/10C NP NP NP NP NP   √       √ 
SG11a 11A 11A/11D/18F NP NP NP NP NP √     √ 
SG12b 12B 12B NP NP NP NP NP   √       √ 
SG12f 12F 12B NP NP NP NP NP √     √ 
SG15a 15A 15A NP NP NP NP NP   √       √ 
SG15b 15B 15B NP NP NP NP NP √     √ 
SG16f 16F 16F NP NP NP NP NP   √       √ 
SG17a 17A 17A/34 NP NP NP NP NP √     √ 
SG18b 18B 18B/18C NP NP NP NP NP   √       √ 
SG20 20 13/20 NP NP NP NP NP √     √ 
SG22a 22A 22A/22F NP NP NP NP NP   √       √ 
SG22f 22F 22A/22F NP NP NP NP NP √     √ 
SG23b 23B 23B NP NP NP NP NP   √       √ 
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SG23f 23F 23B NP NP NP NP NP √     √ 
SG24b 24B 24B NP NP NP NP NP   √       √ 
SG24f 24F 24B NP NP NP NP NP √     √ 
SG28a 28A 28A NP NP NP NP NP   √       √ 
SG28f 28F 28A NP NP NP NP NP √     √ 
SG29 29 29 NP NP NP NP NP   √       √ 
SG31 31 31 NP NP NP NP NP √     √ 
SG33b 33B 33B NP NP NP NP NP   √       √ 
SG33c 33C 35B/35C NP NP NP NP NP √     √ 
SG33d 33D 33B NP NP NP NP NP   √       √ 
SG33f 33F 33A/33F/35A NP NP NP NP NP √     √ 
SG34 34 17A/34 NP NP NP NP NP   √       √ 
SG35a 35A 33A/33F/35A NP NP NP NP NP √     √ 
SG36 36 7F/21 NP NP NP NP NP   √       √ 
Health 
Protection 
Agency, 
Colindale, 
United 
Kingdom (Dr. 
Bruno Pichon, 
Dr. Jutta 
Loeffler) 
H0 8212 0279 1 1 NP NP 217 NP NP √     √ 
H0 8078 4300 1 1 NP NP 303 NP NP   √       √ 
H0 6274 4730 1 1 NP NP 618 NP NP √     √ 
H0 7276 4000 1 1 NP NP 304 NP NP   √       √ 
H0 8092 8700 1 1 NP NP 227 NP NP √     √ 
H0 8282 5540 1 1 NP NP 228 NP NP   √       √ 
H0 8114 1260 1 1 NP NP 306 NP NP √     √ 
H0 8228 5070 1 1 NP NP 306 NP NP   √       √ 
H0 6196 2040 1 1 NP NP 2126 NP NP √     √ 
H0 5122 1380 1 1 NP NP 3446 NP NP   √       √ 
H0 9260 0327 3 3 NP NP 180 NP NP √     √ 
H0 9146 0234 4 4 NP NP 246 NP NP   √       √ 
H0 8102 0037 4 4 NP NP 246 NP NP √     √ 
H0 7406 0041 4 4 NP NP 246 NP NP   √       √ 
H0 8034 0160 5 5 NP NP 289 NP NP √     √ 
H0 8212 0259 6A 6A NP NP 65 NP NP   √       √ 
H0 8052 0052 6B 6B NP NP 176 NP NP √     √ 
H0 7156 0309 6B 6B NP NP 3481 NP NP   √       √ 
H0 5252 0075 6C 6C/6D NP NP 1390 NP NP √     √ 
H0 8342 0074 8 6B NP NP 53 NP NP   √       √ 
H0 9122 0175 8 6B NP NP 53 NP NP √     √ 
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H0 7016 0558 9V 9V NP NP 156 NP NP   √       √ 
H0 8156 0265 9V 9V NP NP 162 NP NP √     √ 
H0 7174 0058 9N 9N NP NP 66 NP NP   √       √ 
H0 7018 0063 9N 9N NP NP 66 NP NP √     √ 
H0 9080 0063 9N 9N NP NP 66 NP NP   √       √ 
H0 8208 0041 14 14 NP NP 9 NP NP √     √ 
H0 8396 0107 14 14 NP NP 124 NP NP   √       √ 
H0 8084 0056 14 14 NP NP 124 NP NP √     √ 
H0 7442 0047 14 14 NP NP 124 NP NP   √       √ 
H0 8334 0064 17F 17F/34 NP NP 964 NP NP √     √ 
H0 9084 0082 17F 17F/34 NP NP 392 NP NP   √       √ 
H0 6092 0119 17F 17F/34 NP NP 392 NP NP √     √ 
H0 9186 0354 19A 19A NP NP 199 NP NP   √       √ 
H0 7336 0087 19A 19A NP NP 276 NP NP √     √ 
H0 8242 0108 19F 19F NP NP 162 NP NP   √       √ 
H0 8112 0101 19F 19F NP NP 162 NP NP √     √ 
H0 8432 0293 27 27 NP NP 1475 NP NP   √       √ 
 
a
 NP: Not Performed 
b
 Tanzanian invasive strains: Co-trimoxazole susceptibility determined by Kirby-Bauer disc diffusion test with the following CLSI guidelines (Clinical and 
Laboratory Standards Institute 2008): susceptible, ≥16 mm, intermediate: 11-15 mm, resistant ≤ 10 mm. 
  
330 
 
Appendix Table 2. Strains included in Multiple Colonization 
Study  
      
Child # (Sample 
Time) 
Serotype Strain ID 
Locus allele number 
Allelic Profile (ST) 
Minimum Inhibitory Concentration (μg/mL) 
aroE ddl gdh gki recP spi xpt Pen Sxt 
1 (Jan/Feb) 
NT, no cps PCR 1NP10S 51 14 8 4 10 9 170 4156 0.032 0.19 
NT, no cps PCR 1NP7 51 14 8 4 10 9 170 4156 0.032 0.19 
NT, no cps PCR 1NP4 51 14 8 4 10 9 170 4156 0.032 0.19 
NT, no cps PCR 1NP5 51 14 8 4 10 9 170 4156 0.032 0.19 
NT, no cps PCR 1NP9 51 14 8 4 10 9 170 4156 0.032 0.125 
6B 1NP10B 51 6 66 230 1 6 1 4429 0.19 8 
11 (Jan/Feb) 
6B 11NP8 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11OP5 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11OP9 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11NP5 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.25 6 
6B 11OP6 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11OP10 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 8 
6B 11NP2 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11NP3 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11NP4 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11NP6 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11NP7 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11NP9 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11NP10 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11NP1 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
6B 11OP3 (Jan/Feb) 51 8 66 230 1 6 1 4432 0.19 6 
16 (April) 
19F 16OP4 12 57 8 9 3 3 20 347 0.19 6 
19F 16NP1 12 57 8 9 3 3 20 347 0.19 6 
19F 16NP4 12 57 8 9 3 3 20 347 0.19 6 
19F 16OP5 12 57 8 9 3 3 20 347 0.19 6 
19F 16OP2 12 57 8 9 3 3 20 347 0.19 6 
19F 16NP3 12 57 8 9 3 3 20 347 0.19 6 
34 16NP5 141 17 5 62 5 9 88 4158 0.032 4 
34 16NP8 141 17 5 62 5 9 88 4158 0.032 4 
6C 16NP9 141 17 5 62 5 9 88 4158 0.032 4 
6C 16NP7 141 17 5 62 5 9 88 4158 0.032 4 
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35A 16NP10 1 9 5 36 3 6 1 840 0.25 4 
18 (Jan/Feb) 
10A 18NP1 16 5 9 75 3 9 115 852 0.125 4 
10A 18NP5 16 5 9 75 3 9 115 852 0.125 4 
10A 18NP9 16 5 9 75 3 9 115 852 0.125 4 
10A 18NP10 16 5 9 75 3 9 115 852 0.125 4 
22 (Jan/Feb) 
17F 22NP4 10 75 16 54 1 15 1 4160 0.016 0.125 
17F 22NP7 10 75 16 54 1 15 1 4160 0.016 0.125 
17F 22NP9 10 75 16 54 1 15 1 4160 0.016 0.125 
17F 22NP10 10 75 16 54 1 15 1 4160 0.016 0.125 
17F 22NP2 10 75 16 54 1 15 1 4160 0.016 0.125 
35 (Jan/Feb) 
10A 35NP4 16 5 9 75 3 9 115 852 0.38 6 
19A 35NP10 7 64 11 74 1 6 112 4162 0.125 2 
10A 35NP9 16 5 9 75 3 9 115 852 0.38 6 
6B 35NP1 7 14 9 1 63 9 1 4157 0.125 6 
21 35NP2 8 15 10 2 16 1 1 1145 0.064 3 
6B 35NP6 51 108 66 1 1 6 1 854 0.125 6 
19F 35NP8 12 57 8 9 3 6 20 6170 0.19 2 
45 (Jan/Feb) 
21 45OP1 8 15 10 2 16 1 1 1145 0.094 4 
21 45OP2 8 15 10 2 16 1 1 1145 0.094 4 
21 45OP3 8 15 10 2 16 1 1 1145 0.094 4 
21 45OP4 8 15 10 2 16 1 1 1145 0.094 4 
21 45OP5 8 15 10 2 16 1 1 1145 0.094 4 
21 45OP6 8 15 10 2 16 1 1 1145 0.094 4 
21 45OP7 8 15 10 2 16 1 1 1145 0.094 4 
21 45OP8 8 15 10 2 16 1 1 1145 0.094 4 
21 45OP9 8 15 10 2 16 1 1 1145 0.094 4 
69 (Jan/Feb) 
6B 69OP8 51 6 66 230 1 6 1 4429 0.19 8 
6B 69OP9 51 6 66 230 1 6 1 4429 0.19 8 
6B 69OP4 51 6 66 230 1 6 1 4429 0.19 8 
6B 69OP3 51 6 66 230 1 6 1 4429 0.19 8 
6B 69OP7 51 6 66 230 1 6 1 4429 0.19 8 
6B 69OP2 51 6 66 230 1 6 1 4429 0.19 8 
6B 69OP10 51 6 66 230 1 6 1 4429 0.19 6 
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3 (March) 
6B 3NP9 (Mar) 7 14 9 1 10 9 1 4368 0.032 0.125 
6B 3NP6 (Mar) 7 14 9 1 10 9 1 4368 0.032 0.19 
6B 3NP7 (Mar) 7 14 9 1 10 9 1 4368 0.047 0.125 
10 (March) 
13 10NP1 1 18 11 74 1 6 177 4370 0.125 6 
13 10NP4 1 18 11 74 1 6 177 4370 0.125 6 
13 10NP5 1 18 11 74 1 6 177 4370 0.125 6 
13 10NP7 1 18 11 74 1 6 177 4370 0.125 6 
13 10NP8 1 18 11 74 1 6 177 4370 0.125 6 
13 10NP10 1 18 11 74 1 6 177 4370 0.125 6 
11 (June) 
6B 11OP1 51 8 66 230 1 6 1 4432 0.19 4 
6B 11OP2 51 8 66 230 1 6 1 4432 0.19 4 
6B 11OP3 51 8 66 230 1 6 1 4432 0.19 4 
6B 11OP4 51 8 66 230 1 6 1 4432 0.19 4 
6B 11OP5 51 8 66 230 1 6 1 4432 0.19 4 
6B 11OP6 51 8 66 230 1 6 1 4432 0.19 4 
6B 11OP8 51 8 66 230 1 6 1 4432 0.19 4 
6B 11OP9 51 8 66 230 1 6 1 4432 0.19 4 
3 (September) 
1 3OP1 10 9 18 4 1 7 19 217 S S 
1 3OP2 10 9 18 4 1 7 19 217 S S 
1 3OP3 10 9 18 4 1 7 19 217 S S 
1 3OP6 10 9 18 4 1 7 19 217 S S 
6B 3OP7 1 15 5 54 38 15 288 4373 0.25 6 
6B 3OP8 1 15 5 54 38 15 288 4373 0.25 6 
6B 3OP9 1 15 5 54 38 15 288 4373 0.25 6 
1 3OP10 10 9 18 4 1 7 19 217 S S 
24 (October) 
19A 24OP1 7 64 11 4 1 6 112 4162 0.25 6 
19A 24OP3 7 64 11 4 1 6 112 4162 0.25 6 
19A 24OP5 7 64 11 4 1 6 112 4162 0.25 4 
29 (November) 
35A 29OP8 1 9 5 36 3 6 1 840 0.25 4 
11A 29OP10 2 1 5 36 3 6 339 5752 0.38 6 
3 (July) 
1 3OP1 (Jul) 10 9 18 4 1 7 19 217 S S 
1 3OP2 (Jul) 10 9 18 4 1 7 19 217 S S 
1 3OP4 (Jul) 10 9 18 4 1 7 19 217 S S 
1 3OP5 (Jul) 10 9 18 4 1 7 19 217 S S 
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1 3OP6 (Jul) 10 9 18 4 1 7 19 217 S S 
10 (Jan/Feb) 
19A 10NP2 7 64 11 4 1 6 112 4162 0.125 6 
19A 10NP3 7 64 11 4 1 6 112 4162 0.125 6 
19A 10NP5 7 64 11 4 1 6 112 4162 0.125 6 
19A 10NP6 7 64 11 4 1 6 112 4162 0.125 6 
13 10OP6 1 18 11 74 1 6 177 4370 0.125 3 
19A 10NP7 7 64 11 4 1 6 112 4162 0.125 6 
19A 10NP9 7 64 11 4 1 6 112 4162 0.125 6 
10 (April) 
18C 10OP1 10 145 11 34 16 15 1 1233 S S 
18C 10OP3 10 145 11 34 16 15 1 1233 S S 
18C 10OP5 10 145 11 34 16 15 1 1233 S S 
18C 10OP6 10 145 11 34 16 15 1 1233 S S 
18C 10OP7 10 145 11 34 16 15 1 1233 S S 
6B 10OP9 7 14 9 1 10 9 1 4368 S S 
18C 10OP10 10 145 11 34 16 15 1 1233 S S 
11 (May) 
4 11NP1 ND ND ND ND ND ND ND ND S S 
4 11NP2 ND ND ND ND ND ND ND ND S S 
4 11NP3 ND ND ND ND ND ND ND ND S S 
4 11NP4 ND ND ND ND ND ND ND ND S S 
4 11NP5 ND ND ND ND ND ND ND ND S S 
4 11NP6 ND ND ND ND ND ND ND ND S S 
4 11NP7 ND ND ND ND ND ND ND ND S S 
4 11NP8 ND ND ND ND ND ND ND ND S S 
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Appendix Table A3. SLVs of STs detected in works included in Chapter 4 and their 
countries of origins as indicated on MLST database 
 
ST Countries 
with ST 
a, b
 
Related STs Countries 
with ST 
a, b
 
4156 Tanzania (N) None - 
4429 Tanzania (N) 854 Kenya 
  4432 Tanzania (N) 
4432 Tanzania (N) 854 Kenya 
  4429 Tanzania (N) 
347 Norway 556 Sweden 
  2715 Kenya 
  5028 Mozambique 
  5029 Kenya 
  5030 Kenya 
  5344 Kenya 
  5360 Kenya 
  5754 Kenya 
  5759 Kenya 
  5762 Kenya 
  5766 Kenya 
  5769 Kenya 
  5771 Kenya 
  5931 Kenya 
  6170 Tanzania (N) 
  6088 Kenya 
  6095 Kenya 
  6111 Kenya 
  6112 Kenya 
  6277 South Africa 
4158 Tanzania (N) None - 
840 Kenya 843 Kenya 
  2052 Uganda 
  5336 Kenya 
  5364 Kenya 
  5377 Kenya 
  5394 Kenya 
  5399 Kenya 
  5722 The Gambia 
  5723 Kenya 
  5724 Kenya 
  5772 Kenya 
  5902 Kenya 
  6315 South Africa 
852 Kenya 5304 Kenya 
  5329 Kenya 
  5876 Kenya 
  6098 Kenya 
4160 Tanzania (N) 216 Spain 
  1146 Kenya 
  1794 US 
   Nigeria 
  3750 Egypt 
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  5008 South Africa 
  5009 India 
  5338 Kenya 
  5952 Kenya 
  6106 Kenya 
4162 Tanzania (N) 847 Kenya 
   The Gambia 
   Spain 
  2124 UK 
   The Gambia 
   Spain 
  3326 The Gambia 
  5270 Kenya 
  5729 The Gambia 
  5730 The Gambia 
  5820 Malaysia 
  5905 Kenya 
  5906 Kenya 
4157 Tanzania (N) 2265 UK 
   Spain 
  4368 Tanzania (N) 
  5949 Kenya 
  5920 Kenya 
  6041 Nepal 
1145 Kenya 193 International
c
 
  375 Norway 
  474 UK 
   Italy 
   Switzerland 
  889 Portugal 
  1358 Portugal 
   Spain 
  1888 UK 
  2357 Portugal 
  2578 Portugal 
  2848 Czech 
Republic 
  3065 US 
  3066 US 
  3124 Turkey 
  3689 Netherlands 
  4021 UK 
  4321 UK 
  4991 Egypt 
4368 Tanzania (N) 2265 UK 
  5949 Kenya 
  5883 Kenya 
  5920 Kenya 
4370 Tanzania (N) 701 Kenya 
  1144 Kenya 
  2069 Uganda 
  5340 Kenya 
  5922 Kenya 
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  6109 Kenya 
  6110 Kenya 
217 International
c
 302 Sweden 
  303 US 
   Ghana 
   Niger 
  612 South Africa 
   Israel 
   Ghana 
  613 Kenya 
  614 Kenya 
  1316 Ghana 
  1322 Ghana 
  1323 Ghana 
  1325 Ghana 
  1327 Ghana 
  1328 Ghana 
  1331 Ghana 
   The Gambia 
  2019 Egypt 
  2034 Egypt 
  2206 Niger 
  2494 South Africa 
  2565 UK 
  2772 Syria 
  2830 Burkina Faso 
  2839 Niger 
  2960 Burkina Faso 
  3079 Australia 
  3081 Oman 
  3570 The Gambia 
  3575 The Gambia 
  3577 The Gambia 
  4755 Ghana 
  4756 Ghana 
  5002 India 
  5011-17 South Africa 
  5189 Thailand 
  5632 Mozambique 
  5633 South Africa 
  5678 South Africa 
  5802 Israel 
  5887 Kenya 
  5916 Kenya 
  5919 Kenya 
  6056 Kenya 
  6137 Kenya 
  6254 Singapore 
4373 Tanzania (N) 5248 Kenya 
5752 Kenya 843 Kenya 
  4984 Mozambique 
  5356 Kenya 
  5768 Kenya 
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  5940 Kenya 
  5933 Kenya 
  5884 Kenya 
6170 Tanzania (N) 347 Norway 
854 Kenya 5770 Kenya 
  5774 Kenya 
 
a 
Countries of origin based on MLST database 
b
 N: novel ST 
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Appendix Table A4. GenBank sequences employed for cpsB multiple sequence 
alignment for works in Chapter 6 
 
Serotype Strain GenBank Accession Number 
1 INV104 FQ312030 
1 P1031 NC012467 
1 Sp03 2672 FQ312039 
1 Sp03 3038 FQ312042 
11A AP200 CP002121 
14 CGSp14 NC010582 
14 INV200 FQ312029 
14 JJA NC012466 
19F Taiwan19F-14 NC012469 
18C WCH94 AF316642  
19A Hungary19A-6 NC010380 
19A KEE19A-Ia JF911512 
19A KEE19A-Ib JF911513 
19A KEE19A-Ic JF911516 
19A KEE19A-Id JF911517 
19A KEE19A-Ie JF911518 
19A KEE19A-If JF911519 
19A KEE19A-Ig JF911521 
19A KEE19A-II JF911514 
19A KEE19A-IIIa JF911511 
19A KEE19A-IIIb JF911520 
19F KEE19F-IIIa JF911522 
19A TCH8431 CP0019931 
19F G54 NC011072 
19F KEE19F-Ia JF911525 
19F KEE19F-Ib JF911526 
19F KEE19F-Ic JF911527 
19F KEE19F-Ie JF911531 
19F KEE19F-IIb JF911529 
19F KEE19F-IIc JF911530 
19F KEE19F-IIIb JF911523 
19F KEE19F-IVa JF911528 
19F NCTC11906 AF030367 
19F PO329 AF030371 
19F SP496 AF030368 
19F SPGA31 AF030370 
19F SPVA92 AF030369 
19F SPVA96 AF030372 
2 D39 CP000410 
23F ATCC700669 FM211187 
23F UK-577 AF030374  
23F SP-264 AF030373 
3 OXC141 FQ312027 
3 Sp99 4038 FQ312041 
3 Sp99 4039 FQ312044 
3 SPN034156 FQ312045 
3 SPN034183 FQ312043 
37 7077-39 AJ131984 
4 TIGR4 AE005672 
4 WCH35 WCH35 
5 NC012468  
5 70585 CP000918 
6A KEE6A-Ia JF911487 
6A KEE6A-IIa JF911488 
6A KEE6A-IIIa JF911489 
6A KEE6A-VI JF911490 
339 
 
6A-KEE6A-Ib JF911496 
6A-KEE6A-IIb JF911488 
6A-KEE6A-IIIb JF911489 
6A-KEE6A-IVa JF911492 
6A-KEE6A-IVb JF911494 
6A-KEE6A-Va JF911491 
6A-KEE6A-Vb JF911495 
6B 670-6B NC014498 
6B PN94/361 AF246897 
6B WCH18 AF316640 
6B-KEE6B-1c JF911501 
6B-KEE6B-Ib JF911500 
6B-KEE6B-Id JF911502 
6B-KEE6B-Ie JF911503 
6B-KEE6B-If JF911506 
6B-KEE6B-Ig JF911508 
6B-KEE6B-IIa JF911499 
6B-KEE6B-IIb JF911505 
6B-KEE6B-IIIa JF911504 
6B-KEE6B-IIIb JF911507 
6B-KEE6B-Ia JF911498 
6C CHPA388 EF538714 
6C-KEE6C-Ia JF911509 
6C-KEE6C-Ib JF911510 
6C-KEE6C-Ic JF911515 
6D MNZ21 HM171374 
6D MNZ920 HM448897 
8 WCH56 AF316641 
1 519/43 CR926497 
10A 10061/38 CR931649 
10B 423/82 CR931650 
10C Gro Norge CR931651 
10F 34355 CR931652 
11A 1813/39 CR931653 
11B 8087/40 CR931654 
11C Eddy nr. 53 CR931655 
11D 70/86 CR931656 
11F 34356 CR931657 
12A 559/66 CR931658 
12B Gambia 1/81 CR931659 
12F 6312 CR931660 
13 34357 CR931661 
14 34359 CR931662 
15A 389/39 CR931663 
15B 7904/39 CR931664 
15C 533/62 CR931665 
15F 688/63 CR931666 
16A R105 CR931667 
16F nr.34361 CR931668 
17A nr.4704 CR931669 
17F Rose CR931670 
18A 8609/43 CR931671 
18B 1033/41 CR931672 
18C 4593/40 CR931673 
18F Gethens CR931674 
19A 141/68 CR931675 
19B nr.4594 CR931676 
19C 7588/39 CR931677 
19F 485/61 CR931678 
2 pN2L CR931633 
20 34365 CR931679 
340 
 
21 546/62 CR931680 
22A 3405/39 CR931681 
22F 1772/40 CR931682 
23A 1196/45 CR931683 
23B 1031/41 CR931684 
23F Dr. Melchior CR931685 
24A 2748/40 CR931686  
24B 2236/42 CR931687 
24F L CR931688 
25A tp 25/38 CR931689  
25F 601/62 CR931690 
27 nr.34371 CR931691 
28A 1982/45 CR931692 
28F 34372 CR931693 
29 nr.34373 CR931694 
3 542/62 CR931634 
31 nr.34374 CR931695 
32A 2813/41 CR931696 
32F nr.34375 CR931697 
33A Biehl CR931698 
33B E294 CR931699 
33C 7098/41 CR931700 
33D CSF/79 CR931701 
33F 3084/37 CR931702 
34 676/74 CR931703 
35A 1936/39 CR931704 
35B 4356/39 CR931705 
35C 7765/43 CR931706 
35F 361/39 CR931707 
36 1095/39 CR931708 
37 264/73 CR931709 
38 9687/39 CR931710 
39 203/40 CR931711 
4 600/62 CR931635 
40 Colemore CR931712 
41A 6803 CR931713 
41F 8211/40 CR931714 
42 198/71 CR931715 
43 2427/48 CR931716 
44 Hammer CR931717 
45 Eddy nr.72 CR931718 
46 Eddy nr.73 CR931719 
47A L351 CR931720 
47F Eddy nr.52 CR931721 
48 656/63 CR931722 
5 Ambrose CR931637 
6A 34351 CR931638 
6B 2616/39 CR931639 
7A 2040/37 CR931640 
7B Johnson CR931641 
7C Sutcliff CR931642 
7F 554/62 CR931643 
8 573/62 CR931644 
9A Wilder CR931645 
9L T9233/128/68 CR931646 
9N 533/62 CR931647 
9V 980/68 CR931648 
 
 
  
341 
 
 Appendix Fig. A1. Ethical approval document granted by TPC 
  
342 
 
 
 
Appendix Fig. A2. Maximum-likelihood phylogenetic representation of pneumococcal cpsB sequences.  
Red and blue colouring was based on study of Varvio et al. (Varvio, 2009), where blue represents serotypes 
commonly associated with carriage, and red represents those predominantly found in invasive diseases. 
Serotypes which, according to Varvio et al., had blue-red mosaic within cpsB (serotypes 15A, 15F, 23F, 35F, 
47A, 47F) are indicated in purple. Serotypes 29, 39, and 43 contained mosaic sequences resembling red 
sequences and other streptococcal sequences, and are indicated in green. Serotypes 3 and 37 do not require 
cpsB for capsule production, and are indicated in black. Phylogenetic representation performed on MEGA 
5.05 with bootstrapping of 100 repetitions. Distances represented as the number of nucleotide substitutions 
per site. A total of 351 sequences were included in analysis. 
 
 
0.1
343 
 
 
Appendix Fig. A3. Neighbour-joining phylogenetic (radial) representation of pneumococcal cpsB sequences.  
Red and blue colouring was based on study of Varvio et al. (Varvio et al. 2009), where blue represents serotypes 
commonly associated with carriage, and red represents those predominantly found in invasive diseases. Serotypes 
which, according to Varvio et al., had blue-red mosaic within cpsB (serotypes 15A, 15F, 23F, 35F, 47A, 47F) are 
indicated in purple. Serotypes 29, 39, and 43 contained mosaic sequences resembling red sequences and other 
streptococcal sequences, and are indicated in green. Serotypes 3 and 37 do not require cpsB for capsule production, 
and are indicated in black. Phylogenetic representation performed on MEGA 5.05 with bootstrapping of 1,000 
repetitions, with bootstrapping values over 85% indicated. Distances represented as the number of nucleotide 
substitutions per site. A total of 351 sequences were included in analysis. 
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Appendix Fig. A4. Maximum-likelihood phylogenetic (radial) representation of pneumococcl cpsB sequences. Red and blue 
colouring was based on study of Varvio et al. (Varvio et al. 2009), where blue represents serotypes commonly associated with 
carriage, and red represents those predominantly found in invasive diseases. Serotypes which,according to Varvio et al., had blue-
red mosaic within cpsB (serotypes 15A, 15F, 23F, 35F, 47A, 47F) are indicated in purple. Serotypes 29, 39, and 43 contained 
mosaic sequences resembling red sequences and other streptococcal sequences, and are indicated in green. Serotypes 3 and 37 do 
not require cpsB for capsule production, and are indicated in black. Phylogenetic representation performed on MEGA 5.05 with 
bootstrapping of 100 repetitions. Distances represented as the number of nucleotide substitutions per site. A total of 351 sequences 
were included in analysis. 
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Appendix Fig. A5. Maximum-likelihood phylogenetic representation of serotypes with more than five 
strains each. Serotypes are indicated beside clusters of taxa. Bootstrap with replacements was performed 
with 100 repetitions, and bootstrap values above 85% ware indicated. Ruler indicates average number of 
nucleotide differences per site. Phylogenetic analysis performed on MEGA 5.05.  
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